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Abstract (German) 
 
KAPITEL 1: STUDIEN ZUR TOTALSYNTHESE VON STEPHADIAMIN 
Diese Dissertation beschreibt unsere Studien zur Synthese des Naturstoffs (+)-Stephadiamin (VI), 
welcher in geringen Mengen 1984 aus Stephania japonica isoliert wurde und das erste Beispiel eines 
Norhasubanan-Alkaloids darstellt. (+)-Stephadiamin (VI) besitzt ein einzigartiges pentazyklisches 
Gerüst mit insgesamt vier stereogenen Zentren, darunter zwei benachbarte α-tertiäre Amine 
(ATAs) sowie ein benzylisches, quartäres Stereozentrum. Das benzylische Stereozentrum wurde 
erfolgreich mithilfe einer decarboxylativen Tsuji-Allylierung ausgehend von Enolcarbonat II 
installiert (elf Schritte von kommerziell erhältlichem Aldehyd I). Dieses Stereozentrum wurde 
anschließend verwendet, um die Einführung aller weiteren Stereozentren des Naturstoffs zu 
dirigieren. Eine neue Kaskadenreaktion wurde entwickelt, um in einem Schritt zwei Fünfringe mit 
zwei Stereozentren, eines davon ein ATA, des pentazyklischen Skeletts von Stephadiamin 
aufzubauen. Die Einführung des dritten benachbarten quartären Stereozentrums stellte sich 
aufgrund des sterischen Anspruchs als sehr schwierig heraus. Dieses Problem wurde letztendlich 
mit einer Tollens-Reaktion gelöst und das entstandene Stereozentrum wurde mit einer Curtius-
Umlagerung in das zweite ATA umgewandelt. Weitere chemische Transformationen führten zu der 
Synthese des TFA-Salzes von Stephadiamin (VI). 
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KAPITEL II: SYNTHESE VON PHOTOCHROMEN 
GALACTOCEREBROSIDEN 
Das zweite Kapitel dieser Dissertation beschreibt die Synthese von photoschaltbaren Derivaten der 
Galactocerebroside α- und β-Galactosylceramid (GalCer). KRN7000 (α-GalCer, VIII) ist ein 
Wirkstoff aus dem Bereich der Immuntherapie und wird für die Anwendung in der Krebstherapie 
untersucht. In Verbindung mit dem Glykoprotein CD1d aktiviert KRN7000 (VIII) natürliche 
Killer-T-Zellen (NKT-Zellen) was zu einer Produktion von unterschiedlichen Zytokinen führt, die 
entweder eine TH1- oder TH2-Immunantwort hervorrufen. Basierend auf Struktur-
Wirkungsbeziehungen haben wir photoschaltbare Analoga (z.B. α-GACe-4, VIII) synthetisiert, um 
die bevorzugte Produktion von entzündungshemmenden Zytokinen (TH1-Zytokine) zu stimulieren. 
Diese funktionalisierten Azobenzole könnten in Zukunft zu einem besseren Verständnis der TH1- 
versus TH2-Zytokinproduktion führen und möglicherweise sogar zur Beeinflussung der TH1/TH2-
Immunantwort mithilfe von Licht verwendet werden. 
 
Zusätzlich haben wir ein photoschaltbares Derivat von β-GalCer, einem Glykosphingolipid (GSL), 
das zum Beispiel in Membranzellen der Schleimhaut vorgefunden wird, hergestellt. In Kooperation 
mit der Schwille-Gruppe haben wir photoschaltbares β-GACe-4 und α-GACe-4 (VIII) in eine lipid 
raft-imitierende unterstützte Lipiddoppelschicht eingebracht. Mithilfe von atomarer 
Kraftmikroskopie (AFM) haben wir ihr Verhalten bei der Bestrahlung mit Licht untersucht. Diese 
Derivate könnten in der Zukunft von Nutzen sein, um die Interaktionen von Proteinen und GSL 
zu untersuchen, beispielsweise der Bindung des rekombinanten HIV-1 Oberflächenproteins gp120 
(rpg120) zu β-GACe-4. 
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Abstract (English) 
 
 
CHAPTER 1: STUDIES TOWARD THE TOTAL SYNTHESIS OF 
STEPHADIAMINE  
This thesis describes our synthetic efforts toward the synthesis of (+)-stephadiamine (VI), which 
was isolated as a minor component of Stephania japonica in 1984 and represents the first example of 
a norhasubanan alkaloid. (+)-Stephadiamine (VI) features a unique pentacyclic skeleton bearing a 
total of four stereogenic centers, including two adjacent α-tertiary amines (ATA) and a benzylic 
quaternary stereocenter. This benzylic stereocenter was successfully set using a decarboxylative 
Tsuji allylation starting from stabilized enol carbonate II (11 steps from aldehyde I). This 
stereocenter was then used to direct the formation of all other stereocenters of the natural product. 
A new cascade reaction was developed to assemble the complex pentacyclic core of 
(+)-stephadiamine (VI), constructing two five-membered rings and two stereocenters (including 
one ATA) in a single step (IV→V). Installation of the third adjacent stereocenter proved to be 
highly challenging due to the steric hindrance associated with this position. We were able to 
overcome this by the use of a Tollens reaction to install a quaternary stereocenter, which was later 
converted to the second ATA of stephadiamine via a Curtius reaction. Additional transformations 
subsequently provided the TFA salt of stephadiamine (VI). 
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CHAPTER II: SYNTHESIS OF PHOTOCHROMIC  
GALACTOCEREBROSIDES  
Chapter two of this thesis describes the synthesis of azo-derivatives of galactocerebrosides, namely 
α- and β-galactosylceramides (GalCer). KRN7000 (α-GalCer, VIII) is an immunotherapy drug 
under investigation for use as a potential treatment for cancer. Associated with the glycoprotein 
CD1d, KRN7000 (VIII) activates natural killer T (NKT) cells, leading to the production of 
different cytokines modulating a TH1/TH2 immune response. Based on structure-relationship 
studies, we designed photoswitchable analogs (e.g., α-GACe-4, VIII) to mainly activate the 
production of pro-inflammatory cytokines (TH1-type cytokines). These functionalized azobenzenes 
may help to improve our understanding of TH1 versus TH2-type cytokine production and we hope 
that they could be used to modulate a TH1/TH2 immune response. 
 
In addition, we prepared photoswitchable analogs of β-GalCer, a common glycosphingolipid that is 
for example expressed on mucosal membrane cells. In collaboration with the Schwille laboratory, 
we incorporated photoswitchable β-GACe-4 and α-GACe-4 (VIII) into a lipid raft-mimicking 
supported lipid bilayer. Using atomic force microscopy (AFM), we characterized their behaviour on 
irradiation with light. Ultimately, these tools could be of use to study binding of proteins to the 
glycosphingolipids (GSLs), for example the interaction of recombinant HIV-1 surface glycoprotein 
gp120 (rgp120).  
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1 Introdution 
1.1 α-Tertiary amines as a retron in alkaloid synthesis* 
1.1.1 Alkaloids bearing α-tertiary amines (ATAs) 
Alkaloids account for some of the most structurally complex and biologically active natural 
products – to date more than 50.000 natural products are known and over 12.000 of these are 
alkaloids.[1] They are famous for their toxic and sometimes psychomimetic, euphoria inducing, 
hallucinogenic and even addictive properties.[2] Consequently, they have been used as both poison 
and medicine and have played an important role in the development of synthetic organic chemistry, 
pharmacology and medicine. 
Alkaloids are produced by practically all phyla of marine and terrestrial organisms at any 
evolutionary level.[3] One of their main functions in plants is for chemical defense against 
herbivores. As such, they benefit their producers in various ways, e.g., as antimicrobials, antifungals, 
antivirals and herbicides.[3–4] Most alkaloids fall into the class of specific modulators and have been 
shaped during evolution so that they can interfere with critical targets within potential enemies by 
mimicking endogenous ligands, hormones or substrates.[3] As a consequence of their structural 
diversity and relatively weak basicity, they interact with a large variety of biological targets, such as 
neuroreceptors, ion channels, DNA/RNA, the cytoskeleton, enzymes involved in ribosomal 
protein biosynthesis and are able to modulate membrane permeability. However, alkaloids do not 
only act as toxic agents. When administered at lower dosages, they sometimes show useful 
pharmacological activities.[5–6] Alkaloid natural products and synthetic analogs have found wide 
medical application, e.g., in relieving pain and spasms, stimulating circulation and respiration, 
reducing blood pressure and killing tumor cells.[3] 
In general, alkaloids can be defined as naturally produced organic nitrogen-containing secondary 
metabolites. Although only a small number of amino acids are involved in their biosynthesis, 
alkaloids encompass enormous structural diversity.[7] By incorporating polyketide and terpenoid 
elements and additional late-stage redox transformations, this structural complexity is increased 
even further. 
Alkaloids are usually classified along biosynthetic criteria, however they can also be categorized 
according to certain structural motifs, e.g., their nitrogen-containing structure (quinolone, 
isoquinoline, piperidine, pyridine, etc.) or the nature of the amine incorporated into the alkaloid. In 
                                                      
* This chapter has been adapted from the review “Synthetic Approaches towards Alkaloids Bearing α-Tertiary Amines” – A. 
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general, there are three different classes of amines (Figure I.1A): primary (one C−N bond), 
secondary (two C−N bonds) and tertiary amines (three C−N bonds). Furthermore, the carbon that 
is bound to the nitrogen, the α-carbon (Figure I.1B), can be classified as α-primary (one additional 
C−C bond), α-secondary (two additional C−C bonds) or α-tertiary (three additional C−C bonds). 
All combinations of these structural motifs, ranging from primary α-primary amines to tertiary α-
tertiary amines, can be found in nature. 
 
Figure I.1 Classification of amines. 
Amongst these motifs, the α-tertiary amine (ATA), i.e. a tetrasubstituted carbon atom surrounded 
by three carbons and one nitrogen, stands out among the structural features frequently found in 
alkaloids.[8–11] An ATA is defined as a nitrogen atom bound to an sp3-hybridized carbon that bears 
three additional C−C bonds, which renders this α-carbon stereogenic and its installation 
synthetically challenging in most alkaloids. In most cases, the nitrogen is sp3-hybridized. However, 
broadening the definition of an ATA, the nitrogen can also be sp2- or sp-hybridized, e.g., an amide 
or isonitrile. This definition highlights the particular C−N bond of a fully substituted carbon, and 
thereby obviates the confusion that is often evoked by the term ‘quaternary stereocenter’, which, 
strictly speaking, corresponds only to a carbon bound to four additional carbon atoms. 
Figure I.2 presents some alkaloids that illustrate this definition and emphasizes that the nitrogen in 
ATAs (highlighted in blue) can show various degrees of substitution. Stephadiamine (I.1) and 
huperzine A (I.2) contain primary ATAs, whereas tetrodotoxin (I.3), histrionicotoxin 283A (HTX 
283A, I.4), amathaspiramide F (I.5) and N-methyl-euphococcinine (I.6) contain secondary ATAs. 
Halichlorine (I.7), himgaline (I.8), stephadiamine (I.1) and porantherine (I.9) contain sterically 
demanding tertiary ATAs. In addition, porantherine (I.9) is an example for an alkaloid featuring a 
twofold ATA. Stephadiamine (I.1) contains two adjacent ATAs, wherein the primary ATA 
additionally contributes to an α-amino acid motif. The dimeric indole alkaloid stephacidin B (I.10) 
contains four ATAs in total, which are incorporated in two bridged diketopiperazine moieties.  
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Figure I.2 Structurally diverse alkaloids that contain the ATA motif. 
Although several methods have been reported for the synthesis of ATAs, only few are commonly 
used in total synthesis. The following chapters therefore provide a brief summary of these synthetic 
methods and discuss their application in total synthesis. 
 
1.1.2 Classification and selected examples of synthetic strategies 
Many approaches have been reported for the synthesis of ATAs, but only a few methods are 
commonly applied in the total synthesis of alkaloids. In this chapter, an overview of these methods 
accompanied by selected examples of applications in natural product synthesis is provided. 
Whenever possible, these methods are classified according to the bond that is formed as well as the 
electronic nature of the transformation (Figure I.3). It should be noted that this “simplified” 
categorization cannot be applied to all methods used in ATA synthesis. 
 
Figure I.3 Classification of methods for the construction of ATAs. 
In recent years, new methods to create ATAs have been developed, such as C−H bond 
azidations[12] and hydroaminations.[13] As they have not yet been employed in the total synthesis of 
alkaloids, they are not featured in this introduction.  
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1.1.2.1 Installation of ATAs v ia  C−C bond formation  
ATAs can either be introduced by a reaction in which a C−C bond or a C−N bond is formed. In 
the case of C−C bond formation, the addition of carbon nucleophiles to electrophilic α-carbons, as 
in activated imines and iminium ions, represents one of the most popular methods to install ATAs 
(Scheme I.1). This class of methods includes Mannich, Strecker and aza-Prins reactions as well as 
1,2-additions of nucleophilic reagents (often organometallic) to C−N double bonds. N-acyliminium 
ions are particularly powerful electrophiles in reactions of this type. Heck reactions involving 
enamines also fall into this category.  
 
Scheme I.1 C−C bond formation involving electrophilic α-carbons. 
There are numerous examples of Mannich reactions for the construction of ATAs. Already in 1959, 
Alder synthesized N-methyl-euphococcinine (I.6) using a Mannich reaction analogous to the 
famous tropinone syntheses of Robinson[14–15] and Schöpf[16] (Scheme I.2a).[17] Starting from 
dihydropyran I.11, ketoaldehyde I.12 was formed under acidic conditions. Ketoaldehyde I.12 was 
then transformed into iminium ion I.13, and addition of 1,3-acetonedicarboxylic acid (I.14) led to 
the formation of N-methyl-euphococcinine (I.6) in a one-pot process.[18–19] This biomimetic 
Mannich strategy was often adopted in other syntheses of euphococcinine and adaline.[20–22] A very 
similar, albeit asymmetric, strategy was used by Davis in 2012 to synthesize structurally related 
azabicyclononane natural products (not shown).[23]  
The construction of ATAs via Mannich reaction is very popular and has found use toward 
structurally very different alkaloids such as asparagamine A (I.148),[24] FR901483,[25–26] and 
gracilamine.[27] Also, Mannich reactions have been the predominant strategy in Lycopodium alkaloid 
synthesis. 
O
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Scheme I.2 Homotropane alkaloid synthesis by Alder (1959), lycopodine synthesis by Heathcock (1982) 
and porantherine synthesis by Corey (1974). 
In 1982, Heathcock established one of the most elegant and groundbreaking routes to lycopodine 
(I.19), which has been adapted multiple times throughout the years towards other Lycopodium 
alkaloids (Scheme I.2b).[28–30] Starting from amino bisacetal I.15, both ketones underwent 
deprotection to give reactive monocyclic intermediate I.16. Condensation of the amino group gave 
iminium ion I.17 which underwent an intramolecular Mannich reaction to furnish tricyclic 
secondary ATA I.18. The formation of two rings and the installation of the ATA thus occurred in a 
one-pot procedure, which mimics the proposed biosynthesis of lycopodine (I.19). Further 
optimization by Heathcock and co-workers resulted in an eight step synthesis – the shortest 
synthesis of this popular synthetic target to date.[30] Using this strategy, lycodine (I.43) and 
lycodoline were also prepared by Heathcock.[30] Synthetic campaigns involving a biomimetic 
Mannich reaction have been used by Evans toward clavolonine (2005)[31] and Fujioka  toward other 
Lycopodium alkaloids (2011).[32] Although the Mannich approach is very elegant, a major 
disadvantage can be long reaction times (up to 18 days as for lycopodine (I.19)), due to the 
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neccessary simultaneous formation of an iminium ion and an enol as depicted in intermediate 
I.17.[30] A solution to this problem was recently offered by Carter, who was able to prepare and 
isolate an imine-containing TBS-enol ether, which formed the respective ATA after treatment with 
zinc triflate (not shown).[33–34]  
In addition to these historically important and famous examples, Mannich reactions have also been 
investigated for structurally different Lycopodium alkaloids. Schumann (1982)[35–37] utilized this classic 
Mannich strategy to access racemic lycodine (I.43), α-obscurine and N-acetylflabellidine (not 
shown).[35–37] In 2010, Sarpong used the same cascade as an opening sequence towards an 
asymmetric synthesis of (+)-complanadine A, a lycodine dimer.[38] In the same year, Shair published 
an approach towards the Lycopodium alkaloid fastigiatine using a transannular Mannich reaction[39–40] 
and in 2014 Takayama achieved a very short synthesis of (−)-lycodine (I.43) and (+)-flabellidine 
using a similar Mannich strategy as the key step (see chapter 1.1.2.3).[41]  
Porantherine (I.9), which is structurally related to the Lycopodium alkaloids, but not a member of the 
family, possess a twofold ATA and only two total syntheses have been reported to date, both of 
which rely on a Mannich reaction to install the ATA motif (Scheme I.2c).[42–43] In 1974, Corey 
published the first synthesis of porantherine (I.9), and the installation of both ATAs involved 
electrophilic α-carbons. The first ATA present in I.9 was set by the addition of an alkyl 
organolithium species to imine I.20, which was then treated with acid to give enamine I.22 (via 
secondary amine I.21). The second ATA was subsequently formed by an acid-catalyzed Mannich 
reaction via iminium ion I.23, yielding bicycle I.24 possessing the twofold ATA. In summary, the 
Mannich reaction and variants thereof constitute one of the most popular strategies in alkaloid 
synthesis to install ATAs.  
The other strategies depicted in Scheme I.1 were not used as exhaustively as the Mannich reaction, 
however there are a few examples of their application in alkaloid total synthesis. The Strecker 
reaction, for example, has been used in Shibasaki’s synthesis of lactacystin (I.51),[44–45] Ohfune’s 
synthesis of manzacidins A (I.100) and C[46] and Myers’ synthesis of avrainvillamide (I.55) and 
stephacidin B (I.10, not shown).[47] A nice example of the Strecker reaction in ATA synthesis is the 
recent synthesis of exochomine (I.29) by Snyder (Scheme I.3a).[48] They were able to form iminium 
ion I.27 by treatment of in situ generated enamine I.26 with TFA (starting from Boc-protected 
piperidine I.25). They then tested the reactivity of the iminium ion I.27 towards different 
nucleophiles, however “virtually every nucleophile probed, such as tributylvinyl tin, allyltrimethylsilane (under 
Sakurai conditions), Grignard reagents, vinyl boronic acids (under Petasis-type conditions), or enolates (prepared both 
in situ and pre-formed), failed to deliver any coupling adduct.“[48] Radical addition to iminium ion I.27 failed 
as well. Addition of KCN was singularly effectiveable to yield ATA I.28. Additional 
transformations finally led to exochomine (I.29). 
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Scheme I.3 Synthesis of exochomine by Snyder (2016), gelsemoxonine by Carreira (2013) and 
cephalotaxine by Nagasaka (2002). 
1,2-Addition of nucleophilic reagents to C−N double bonds was already discussed in Corey’s 
synthesis of porantherine (I.9, Scheme I.2c).[42–43] Furthermore, this general transformation has 
been applied in Ayer’s synthesis of lycopodine (I.19),[49–50] Qin’s synthesis of lundurine A,[51] 
Carreira’s synthesis of gelsemoxonine (I.32)[52] and Nagasaka’s synthesis of cephalotaxine (I.36),[53] 
amongst others. Carreira set the ATA present in I.31 via a diastereoselective propynyllithium 
addition to isoxazoline I.30 (Scheme I.3b). By contrast, Nagasaka made use of a powerful N-
acyliminium ion cyclization in his synthesis of cephalotaxine (I.36, Scheme I.3c).[54] Lactam I.33 
was treated with TiCl4 and AcOH to form an N-acyliminium ion I.34, which was trapped in an 
intramolecular fashion by a β-ketoester to provide ATA I.35 as a mixture of diastereomers (1:4.3, 
cis/trans). Intermediate I.35 was then further transformed to cephalotaxine (I.36). 
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Another reaction in this category is the aza-Sakurai reaction that has been used for example in the 
Danishefsky−Trauner synthesis of halichlorine (I.7) in 1999 (Scheme I.4),[55] which was followed by 
a synthesis of pinnaic acid in 2001 (not shown).[56–57] They made use of Meyers’ lactam I.37 as a 
chiral precursor, which was transformed into the ATA-containing bicycle I.39 using TiCl4 and 
allyltrimethylsilane in an aza-Sakurai reaction (via N-acyliminium ion I.38). Intermediate I.40 could 
be diversified to reach both halichlorine (I.7) and pinnaic acid. 
The Pictet−Spengler reaction, which has been applied in Stork’s synthesis of lycopodine (I.19),[58] 
Inubishi’s synthesis of (±)-3-demethoxyerythratidinone[59] and several Erythrina alkaloid 
syntheses,[60–62] also falls into this category.  
 
Scheme I.4 Synthesis of halichlorine by Danishefsky and Trauner (1999). 
The application of a Heck reaction to set an ATA is rather unusual in alkaloid synthesis, but a few 
examples of this elegant approach have been reported. Tsukano and Hirama used an intramolecular 
Heck reaction of a pyridyl triflate and an ene-carbamate I.41 to furnish the ATA-containing 
pentacyclic core I.42 of lycodine (I.43, Scheme I.5).[63] Sun and Lin furnished the ATA in huperzine 
A (I.2) using an intramolecular Heck reaction of an enamine (not shown).[64] 
 
Scheme I.5 Synthesis of lycodine by Tsukano and Hirama (2010). 
The last reaction in this category is the aza-Prins reaction, which has been used several times in the 
synthesis of ATAs. The Hsung group synthesized cylindricine C (I.48) from the linear precursor 
I.44. Intramolecular condensation to the N-acyliminium ion I.45 set the stage for the nucleophilic 
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attack of a diene to furnish bicyclic ATA I.46 (Scheme I.6).[65–66] Hydrolysis of the formyl group 
then gave allylic alcohol I.47 in 64% yield over two steps. 
 
Scheme I.6 Synthesis of cylindricine C by Hsung (2004). 
By contrast to the previous examples, the α-carbon can also serve as a carbon nucleophile (Scheme 
I.7). However, these reactions are less commonly employed. The alkylation of branched 
nitroalkanes or deprotonated amino acid derivatives falls into this category. In addition, insertions 
into nucleophilic C−H bonds adjacent to a C−N bond can be used for ATA installation. 
 
Scheme I.7 C−C bond formation involving nucleophilic α-carbons. 
The α-alkylation of amino acid derivatives has been used in Corey’s first synthesis of lactacystin 
(I.51) (Scheme I.8a).[67] Starting from cis-oxazolidine derivative I.49, an aldol reaction with 
isobutyraldehyde set the ATA to furnish lactacystin precursor I.50. α-Alkylation has been a popular 
strategy to set the ATA in lactacystin (I.51) and salinosporamides and most syntheses reported to 
date involve an alkylation or aldol reaction of an α-amino acid derivative.[67–75] More recently, Baran 
used Seebach’s method for chirality transfer[76] in the α-alkylation of proline derivative I.52 to 
provide I.53, forging the first ATA of stephacidin A (I.54) in a diastereoselective manner (Scheme 
I.8b).[77] Stephacidin A (I.54) could be further transformed into avrainvillamide (I.55) and 
stephacidin B (I.10). 
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Scheme I.8 Syntheses of lactacystin by Corey (1992), synthesis of prenylated indole alkaloids by Baran 
(2005) and synthesis of amathaspiramide F by Trauner (2002). 
A third example of an α-alkylation of amino acid derivatives in alkaloid total synthesis is Trauner’s 
synthesis of amathaspiramide F (I.5), which was reported in 2002 (Scheme I.8c).[78] Aminal I.56 was 
converted to the corresponding silyl ketene acetal, which then underwent Michael addition to the 
nitro styrene I.57, installing the ATA of I.58 in a diastereoselective manner. Additional 
transformations led to the first synthesis of amathaspiramide F (I.5).   
Carbene insertions are still relatively rare in ATA synthesis, however two examples have been 
reported by Hayes and co-workers. In their synthesis of cephalotaxine (I.36) they applied an 
vinylidene C−H insertion reaction. Derived from ketone I.59, vinylidene I.60 can insert into the 
C−H bond adjacent to the carbamate to furnish spiro[4.4]azanonene I.61, which could be further 
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transformed into cephalotaxine (I.36) (Scheme I.9).[79] Another carbene insertion was reported by 
the same group in their synthesis of lactacystin (I.51).[80]  
 
Scheme I.9 Synthesis of cephalotaxine by Hayes (2008). 
Pericyclic reactions have occasionally been employed to form the C−C bond of an ATA 
(Scheme I.10). This includes Diels−Alder cycloadditions of 1-aminodienes, 2-azadienes, and certain 
aminodienophiles, 1,3-dipolar cycloadditions of nitrones or azomethine ylids as well as [2+2]-
cycloadditions.  
 
Scheme I.10 C−C bond formation involving pericyclic reactions. 
Pericyclic reactions are particularly powerful as they build up a high degree of structural complexity 
in a single transformation. Therefore, pericyclic reactions constitute an effective strategy for the 
construction of sterically demanding ATAs. The Diels−Alder reaction has proven to be very 
effective for the synthesis of Kopsia alkaloids, a family which possesses an ATA incorporated into a 
bicyclo[2.2.2]octane system.[81–89] The Diels−Alder approaches can be categorized as either 
intermolecular[90–93] or intramolecular.[94–98] In 1990, Spino used the intermolecular variant to set the 
ATA in aspidofractinine (I.65) using phenyl vinyl sulfone as a dienophile (Scheme I.11a).[93] Highly 
reactive aminodiene I.63 was formed from compound I.62 by thermal isomerization und 
subsequently underwent cycloaddition with phenyl vinyl sulfone from the sterically more accessible 
convex side to give sulfone I.64, containing the complete carbon skeleton of aspidofractinine 
(I.65).  
Hayes' formal synthesis of (-)-cephalotaxine
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Scheme I.11 Kopsia alkaloid syntheses by Spino (2009) and Magnus (1983). 
By contrast, an intramolecular Diels−Alder approach was chosen by Magnus to construct the ATA 
in both kopsanone (I.68) and 10,22-dioxokopsane (Scheme I.11b).[94–95] A strategically placed 
sulfide I.66 forced the dienophile into close proximity with the diene. The intramolecular 
cycloaddition reaction proceeded at 100 °C and gave kopsanone precursor I.67, which could 
subsequently be transformed into the natural product I.68. This approach was also applied to the 
closely related alkaloids kopsijasmine, kopsine, (‒)-kopsinilam and (‒)-kopsinine (I.87).[96–98] In 
addition, Fuchs applied an intramolecular nitroso-Diels−Alder cycloaddition to assemble the 
carbon skeleton of cephalotaxine (I.36) in 1988[99] and an intramolecular Diels−Alder approach was 
used in Williams’ synthesis of stephacidin A (I.54) and notoamide B in 2007 (not shown).[100] 
1,3-Dipolar cycloadditions have been used even more extensively than Diels−Alder reactions to 
implement ATAs. In 2006, Gin applied an intermolecular 1,3-dipolar cycloaddition in his synthesis 
of cephalotaxine (I.36) making use of phenyl vinyl sulfone as the dipolarophile, which had already 
been utilized as a potent dienophile in Spino’s synthesis of aspidofractinine (I.65) (see 
Scheme I.11a).[101–102] Gin transformed vinylogous amide I.69 into azomethine ylide I.70, which 
then participated in a 1,3-dipolar cycloaddition to yield cephalotaxine precursor I.71 (Scheme 
I.12a).[101–102] The rather unexpected stereochemical outcome of this cycloaddition was confirmed 
by X-ray analysis. 
An intramolecular 1,3-dipolar cycloaddition was applied in Overman’s synthesis of nankakurine A 
(I.75) and nankakurine B (I.76) (Scheme I.12b).[103] Condensation of benzoyl hydrazine I.72 with 
formaldehyde furnished azomethine imine I.73 in situ, which then underwent 1,3-dipolar 
cycloaddition to form tetracyclic pyrazolidine I.74. Following N−N bond cleavage with SmI2, 
pyrazolidine I.74 could be transformed into both nankakurines.[103] 
N
N
H
(+)-aspidofractinine
(I.65)
N
N
I.62
O
N
N
H
O
SO2Ph
I.63
90 °C N
N
H
O
I.64
SO2Ph
a) Spino's synthesis of (+)-aspidofractinine
N
N
H
O
N
N
Ts
I.66
O
PhS N
N
Ts
I.67
PhS
O
100 °C
b) Magnus' synthesis of (±)-kopsanone
(±)-kopsanone
(I.68)
(55%)
(86%)
INTRODUTION 
 
15  
 
Scheme I.12 Synthesis of cephalotaxine by Gin (2006) and synthesis of nankakurines A and B by 
Overman (2010). 
In addition to these examples, 1,3-dipolar cycloadditions have also found application in the 
syntheses of Stemona alkaloids,[104] manzacidines[105–106] and homotropane alkaloids (not shown).[107]  
[2+2]-Cyclizations are much less encountered than [4+2]-cyclizations or 1,3-dipolar cycloadditions 
and have only been applied a few times in ATA synthesis.[108–114] One example by Tsuda features an 
intermolecular photochemical [2+2]-cycloaddition of tricycle I.77 and 2-siloxydiene I.78 in case of 
the synthesis of erysotrine (I.80) (Scheme I.13).[113] The resulting cyclobutane I.79 subsequently 
expanded into the six-membered ring of erysotrine (I.80). 
 
Scheme I.13 Synthesis of erysotrine by Tsuda (1992). 
The last subclass of reactions to form the final C−C bond in an ATA is radical reactions, which are 
relatively rare, but not unprecedented (Scheme I.14). 5-endo-trig and 6-endo-trig cyclizations and 
radical transfer allylations fall into this category. 
a) Gin's synthesis of (-)-cephalotaxine
(-)-cephalotaxine
(I.36)
N
O
O
OMe
HO
HN
O
O
O
TMS
O
O
PivCl, AgOTf
→ TBAT
SO2Ph
N
O
O
PivO
O
O
N
O
O
PivO
SO2Ph
O
O
I.69 I.70 I.71
BnO(H2C)4
HN
Me
H
H
NHBz
(CH2O)n
N
NBz
BnO(H2C)4
N
BnO(HC)4
BzN
I.72 I.73 I.74
b) Overman's synthesis of (+)-nankakurines A and B
N
R
N
nankakurine A (I.75): R = H
nankakurine B (I.76): R = Me
(77%)
(85%)
OMe
MeO
OO
EtOOC
OTMS
NMeO
MeO
OMe
(±)-erysotrine
(I.80)
Tsuda's synthesis of (±)-erysotrine
hν
I.78I.77 I.79
N N
MeO
OMe
O
O
EtOOC
TMSO+
(93%)
INTRODUTION 
 
 16 
 
Scheme I.14 C−C bond formation involving radical reactions. 
A radical bridgehead allylation was applied by Huang to construct the ATA of methoxystemofoline 
(I.83) (Scheme I.15a).[115] Starting from bromide I.81 a Keck allylation using 
1,1′-azobis(cyclohexanecarbonitrile) (ACHN) as a radical initiator and allyltributylstannane provided 
ATA-contaning bicycle I.82 at an early stage of the total synthesis.  
With respect to radical cyclizations to construct ATAs, a transannular 6-endo-trig cyclization was 
applied in Boger’s synthesis of kopsinine (I.87, Scheme I.15b).[116] Xanthate I.84 was treated with 
SmI2 to form primary radical I.85, which then undergoes 6-endo-trig cyclization followed by 
reduction and diastereoselective protonation of the ester enolate to install the ATA of I.86 as a 
single diastereomer. A 5-endo-trig radical cyclization as part of a domino sequence will be discussed 
in detail for Inubushi’s synthesis of stemonamide (I.162) and isostemonamide in section 1.1.2.3 
regarding cascade reactions.[117–118] 
 
Scheme I.15 Synthesis of methoxystemofoline by Huang (2015) and synthesis of kopsinine by Boger 
(2013). 
In summary, a large variety of methods have been developed to furnish the C−C bond of an ATA. 
The most popular reaction in this class of transfomations is the Mannich reaction, which has been 
used multiple times is total synthesis. It should be noted that most Mannich reactions were applied 
in an intramolecular fashion to circumvent the steric hindrance associated with an ATA.  
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1.1.2.2 Installation of the ATA v ia  C−N bond formation  
In case of the C−N bond formation, intramolecular rearrangements that involve an electrophilic 
nitrogen are often used for the installation of ATAs (Scheme I.16). Prominent strategies include 
Curtius, Schmidt, Hofmann, Beckmann, Stieglitz[8]  and Kim’s oxime rearrangement.[119–121] In most 
cases, these reactions can be classified as 1,2-sigmatropic rearrangements. In addition, related 
nucleophilic substitutions using N-haloamines have been applied in the synthesis of ATAs. Apart 
from these rearrangements, an electrophilic nitrogen also occurs in the insertion of nitrenes into 
C−H bonds. 
 
 
Scheme I.16 C−N bond formation involving electrophilic nitrogens. 
The Curtius rearrangement and variants thereof are probably the most popular choice for the 
formation of primary ATAs. As a demonstrative example, it has been applied numerous times in 
syntheses of huperzine A (I.2). The first synthesis of this popular synthetic target was published in 
1989 by Kozikowski (Scheme I.17a).[122] In their synthesis, methyl ester I.88 was hydrolyzed to the 
carboxylic acid, which was transformed into the acyl azide via the acyl chloride. This acyl azide 
subsequently underwent a Curtius rearrangement to the isocyanate, which was trapped by methanol 
to provide methyl carbamate I.89. Double deprotection of intermediate I.89 gave huperzine A 
(I.2). Many huperzine A syntheses and several semi-syntheses were published in the following years 
and most of them feature a racemic or enantiomerically pure carboxylic acid derivative of precursor 
I.88, retaining the Curtius rearrangement as the key step for the ATA formation. [122–132] Curtius 
rearrangements have also been used for the synthesis of other ATA-containing alkaloids, such as 
histrionicotoxins,[133–134] lundurines[135] and amathaspiramides.[136] 
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An example for a Schmidt reaction as part of a cascade can be found in Zhang’s synthesis of 
stemonamide (I.162),[137] which is described in detail in chapter 1.1.2.3. The closely related 
Hofmann rearrangement was applied in Stork’s synthesis of HTX 283A (I.4) to set the ATA 
(Scheme I.17b).[138] Primary amide I.90 was oxidized with [bis(trifluoroacetoxy)iodo]benzene  
(PIFA) leading to alkyl migration and decarboxylation to give ATA I.91. One of the most famous 
applications of the Beckmann rearrangement in alkaloid synthesis appears in the synthesis of 
tetrodotoxin (TTX, I.3) by Kishi in 1972 (Scheme I.17c).[139–142] Mesylated oxime I.93 was 
converted to ATA I.94 in a Beckmann rearrangement at an early stage of the synthesis. Additional 
transformations involving a series of stereoselective redox transformations, ring cleavage and 
installation of the cyclic guanidine led to the first synthesis of TTX (I.3). 
 
Scheme I.17 Kozikowski’s synthesis of huperzine A (1989), Stork’s synthesis of HTX 283A (1990) and 
Kishi’s synthesis of TTX (1972). 
An unusual albeit elegant method for the synthesis of ATAs is the Stieglitz rearrangement. In 1998, 
Grieco made use of this transformation for the synthesis of lycopodine (I.19) (Scheme I.18a).[143] 
N-chloro amine I.95 was treated with silver tetrafluoroborate, and following rearrangement the 
resulting imine was reduced with sodium cyanoborohydride to yield lycopodine (I.19).  
Another unusual approach for the implementation of an ATA was reported in the first total 
synthesis of N-methylwelwitindolinone D isonitrile (I.100) by Rawal in 2011 (Scheme I.18b).[144–146] 
Starting from aldoxime I.96, isothiocyanate I.98 was formed by a rearrangement found by 
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Huisgen.[120–121] This rearrangement proceeds through the intermediacy of a nitrile oxide. 
Desulfuration using Mukaiyama’s oxazaphospholidine I.99 then provided the natural product N-
methylwelwitindolinone D isonitrile (I.100). 
 
Scheme I.18 Grieco’s synthesis of lycopodine (1998), Rawal’s synthesis of N-methylwelwitindolinone D 
isonitrile (2011) and Du Bois’ synthesis of manzacidin A (2002). 
For several years, Du Bois has been developing and applying his signature nitrene insertion for the 
introduction of ATAs, and in 2002, manzacidin A (I.103) and C were prepared using an elegant 
oxidative Rh-catalyzed nitrene insertion starting from sulfamate ester I.101 to yield cyclic sulfamate 
I.102 (Scheme I.18c).[147] Only one year later, Du Bois used a similar strategy to set the ATA in 
tetrodotoxin (TTX, I.3).[148] 
Nucleophilic addition or substitution involving a nucleophilic nitrogen is a common strategy for 
ATA synthesis as well (Scheme I.19). Aza-Michael additions, SN2 and SN2’ reactions and 
haloaminations belong to this category. Carbocations may also be trapped by a nucleophilic 
nitrogen in the aza-Prins and Ritter reactions. In addition, oxidative dearomatizations have been 
used to establish ATAs. 
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Scheme I.19 C−N bond formation involving nucleophilic nitrogens. EWG = electron-withdrawing group. 
The aza-Michael addition is one of the most popular reactions in ATA formation and has been 
applied to many different classes of alkaloids, such as homotropane alkaloids,[149–150] 
histrionicotoxins, [151–153] hasubanan alkaloids,[154–159] indole alkaloids,[160–162] cephalotaxins,[163–164] 
erythrina alkaloids,[165] amathaspiramides,[78] and indolizidine and quinolizidine alkaloids.[166–170]  
 
Scheme I.20 Synthesis of oHTX by Kishi (1975) and synthesis of himgaline by Chackalamannil (2009).  
An example of an aza-Michael addition in alkaloid synthesis is shown in Scheme I.20a – as part of 
Kishi’s synthesis of octahydrohistrionicotoxin (oHTX, I.107) (Scheme I.20a).[151–153] The ATA is set 
by an intramolecular acid-catalyzed addition starting from primary amide I.104. The Michael 
addition yielded a 2:1 mixture of epimeric spirolactams I.105 and I.106. The undesired diastereomer 
I.105 could be epimerized to I.106 on treatment with NaOMe. Further transformations yielded 
oHTX (I.107). Another application of such a 1,4-addition is Chackalamannil’s elegant and 
biomimetic conversion of GB 13 (I.108) into himgaline (I.8) via ketone I.109 under Lewis and 
Brønsted acidic conditions (Scheme I.20b).[171]  
1,4-addition (aza-Michael addition):
EWG
NHR2 EWG N
SN2' reaction:
NHR2
N
H
X
aza-Prins:Ritter reaction:
N CR N
C
HN
OH2O
oxidative dearomatization:
HN
HO
N
O
[O]
N N
N
H
+
NNHR2
Na(OAc)3BH
(-)-himgaline
(I.8)I.109
Sc(OTf)3
HCl
(-)-GB 13
(I.108)
N
OH
OH
N
OH
O
NH
OH
O
b) Chackalamannil's synthesis of (-)-himgaline
a) Kishi's synthesis of (±)-octahydrohistrionicotoxin
O
O
H2N
CSA
HN
O
O
HN
O
O
HN
OH
I.104 I.105 I.106 (±)-oHTX
(I.107)NaOMe
+
(45%)
(60% over
2 steps)
INTRODUTION 
 
21  
Another class of reactions that has been used for the installation of ATAs is nucleophilic 
substitution. Recently, Frontier published a synthesis of tetrapetalone A-Me aglycon (I.112) using a 
palladium-catalyzed Tsuji allylation starting from carbamate I.110 (Scheme I.21a). 
 
Scheme I.21 Synthesis of tetrapetalone A-Me aglycon by Fronier (2014) and synthesis of 8-
deoxyserratinine by Lei (2014). 
The nitrogen of the carbamate trapped the resulting Pd-allyl species and thereby formed the ATA 
I.111 present in tetrapetalone A-Me aglycon (I.112).[172] One of the very rare examples of a SN2 
reaction in ATA formation is Lei’s synthesis of (−)-8-deoxyserratinine (I.116) (Scheme I.21b).[173] 
Tertiary alcohol I.113 was transformed into chloride I.114, which was subsequently displaced by the 
free secondary amine to give tertiary amine I.115, which could be further transformed into (−)-
8-deoxyserratinine (I.116). 
 
Scheme I.22 Synthesis of 3-demethoxyerythratidinone by Ciufolini (2015). 
An additional method cabable of installing ATAs is the oxidative dearomatization of phenols. This 
reaction has found application in Ciufolini’s 3-demethoxyerythratidinone (I.120) synthesis where 
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oxazoline I.117 was oxidized with PIFA to give spiropiperidine I.119. This transformation 
presumably proceeds via intermediate I.118 with subsequent hydrolysis (Scheme I.22).[174–175]  
Pericyclic reactions may also be used to install ATAs (Scheme I.23). In this class of reactions a C−N 
bond is formed emplying methods such as the Overman, the Kazmaier−Claisen, the 3,3-
sigmatropic rearrangements of allylic cyanates and divinyl cyclopropane rearrangements.[8] 
 
 
Scheme I.23 C−N-bond formation using pericyclic reactions. 
Overman rearrangements are frequently used to establish ATAs. Sato and Chida’s synthesis of 
salinosporamide A (I.123) utilizes such a stereoselective rearrangement (Scheme I.24a).[176] For this 
purpose, trichloroacetimidate I.121 was heated to induce 3,3-sigmatropic rearrangement to provide 
trichloroacetamide I.122, as a key intermediate in the synthesis of salinosporamide A (I.123).  
Other pericyclic reactions to form a C−N bond are relatively rare. In Ichikawa’s synthesis of 
manzacidin A (I.103), a rare allyl cyanate to isocyanate rearrangement is applied as the key step 
(Scheme I.24b).[177] For this purpose, carbamate I.124 was converted to allyl cyanate I.125 by 
dehydration, which subsequently underwent rearrangement with [1,3]-chirality transfer. Thus 
obtained isocyanate I.126 was then transformed to manzacidin A (I.100) (via amine I.127).[176].  
Another unusual approach for ATA installation is the use of a divinyl cyclopropane rearrangement. 
In 1999 Kende published the first synthesis of a Stemona alkaloid by employing this transformation 
(Scheme I.24c).[178] The ATA was formed in an elegant process using a Rh-catalyzed 
cyclopropanation of pyrrole I.128 using vinyl diazoester I.129, yielding divinyl cyclopropane I.130. 
Subsequent Cope-like rearrangement afforded bicycle I.131. The natural product isostemofoline 
(I.132) was assembled in several additional steps. 
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Scheme I.24  Synthesis of salinosporamide A by Sato (2011), synthesis of manzacidin A by Ichikawa 
(2012) and synthesis of isostemofoline by Kende (1999). 
The use of radical reactions to form the C−N bond in an ATA is extremely rare (Scheme I.25). 
However one example including a radical 5-exo-trig cyclization of a nitrogen-centered amidyl radical 
as part of a cascade sequence is described in detail in chapter 1.1.2.3 (Scheme I.34). 
 
Scheme I.25 C−N bond formation involving radical reactions. 
In conclusion, Curtius rearrangements and Michael additions are by far the most popular strategies 
to install the C−N bond as the last step in an ATA synthesis. As mentioned previously in the last 
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chapter, intramolecular transformations are applied to avoid issues of sterical hindrance associated 
with an ATA. 
 
1.1.2.3 Cascade reactions for the implementation of α-tertiary amines 
The development of cascade reactions has been a fascinating and expanding branch of organic 
chemistry and has attracted considerable attention from the synthetis community.[179–187] This class 
of reactions is defined as chemical reactions that consist of at least two consecutive transformations 
where the isolation of intermediates is not required or, in some cases, possible.[186] Strictly speaking, 
in cascade reactions no reagents are added after the initial step and the reaction conditions do not 
change throughout the whole sequence, thus distinguishing them from one-pot reactions. 
The advantages of cascade reactions in synthesis include improved step economy as well as 
economies of time, labor, resource management, and waste generation.[179] Cascade reactions can 
therefore be considered under the term “green chemistry“, as they minimize the amount of 
chemical resources, e.g., solvents, chemicals, etc., required for the generation of a product that 
would otherwise have to be made in several individual steps. The development of cascade reactions 
“to provide specific targeted molecules of considerable structural and stereochemical complexity poses a significant 
intellectual challenge and can be one of the most impressive activities in natural product synthesis.“[179]  
In a few cases, cascade reactions have also been developed for the preparation of α-tertiary amines 
toward alkaloid total syntheses. In these cases, the cascade reactions very often occur in an 
intramolecular fashion to circumvent the problem of steric hindrance associated with an ATA. For 
organizational purposes, the examples in this chapter are classified by the last bond that is formed 
and the nature of the transformation that occurs. 
 
Scheme I.26 Synthesis of flabellidine and lycodine by Takayama (2014). 
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There are several impressive examples for cascade reactions in which the C−C bond is formed at an 
electrophilic α-carbon. Most of them involve Mannich reactions, therefore three examples 
showcasing a Mannich cascade are included in this chapter. In 2014, Takayama published a short 
synthesis of (−)-lycodine (I.43) and the first asymmetric synthesis of (+)-flabellidine (I.137) inspired 
by the biosynthetic proposal for Lycopodium alkaloids (Scheme I.26).[41] Based on a suggested 
biosynthesis by the Spenser group,[188–192] they envisaged that the stereochemistry of the methyl 
group at C-15 would control the stereochemistry of an enamine conjugate addition (indicated in 
I.134) and a subsequent Mannich reaction (as in I.135). Linear precursor I.133, featuring a single 
stereocenter, was prepared in eight linear steps. When this precursor was subjected to acidic 
conditions, double Boc-deprotection and double intramolecular condensation occurred to give 
iminium ion I.134. Intramolecular conjugate addition of the enamine to the α,β-unsaturated 
iminium ion gave second iminium ion I.135, which resembles the presumed precursor to most 
lycopodium alkaloids, phlegmarine. Iminium ion I.135 finally underwent a Mannich reaction to 
yield tetracyclic skeleton I.136 with a diastereomeric ratio of 3:1 at C-13 and a yield of 61%. They 
were then able to transform this intermediate into (+)-flabellidine (I.137) (11 steps and 21% overall 
yield) and (−)-lycodine (I.43) (in 11 steps and 15% overall yield). 
 
Scheme I.27 Synthesis of psylloborine A and isopsylloborina A by Snyder (2016). 
A second application of Mannich cascades in ATA synthesis is Synder’s recently published 
synthesis of psylloborine A (I.142) and isopsylloborine A (I.143) (Scheme I.27).[193] In his 
Michael−Mannich cascade, three rings and three stereocenters, including the ATA, are set in one 
transformation. Upon heating to 65 °C in deuterated benzene, secondary amine I.138 was 
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condensed with the ketone to give enamine I.139, which then added to the Michael system and 
furnished hexacyclic I.140, containing two enamines in a yield of 15% over three steps (previous 
cascade reaction and Boc-deprotection not shown). Subsequent Mannich reaction then furnished 
heptacyclic ATA I.141. Reduction of the aryl sulfone with Na−Hg amalgam completed the 
synthesis of psylloborine A (I.142) that could be isomerized to isopsylloborine A (I.143) under 
acidic conditions. 
Another example of a cascade reaction that includes a Mannich reaction is Overman’s famous 
synthesis of asparagamine A (I.148) (Scheme I.28).[24] He applied his signature reaction, the aza-
Cope−Mannich cascade, to construct the scaffold of the stemonamide class of alkaloids. 
Ammonium iodide I.144 was treated with paraformaldehyde to give iminium ion I.145, which 
subsequently underwent a (reversible) charge-accelerated 3,3-sigmatropic rearrangement (aza-Cope 
reaction) to yield iminium ion I.146 that now reacted in an irreversible intramolecular Mannich 
reaction to afford the ATA present in asparagamine A (I.148) in 94% yield. This cascade has been 
proven to be highly applicable to other molecules with ATAs, such as FR901483.[26, 194] Overman 
himself showcased this methodology in a variety of structurally demanding molecules, such as 
strychnine[195] and 16-methoxytabersonine (not shown).[196]  
 
Scheme I.28 Synthesis of asparagamine A by Overman (2003). 
A cascade reaction in which an ATA C−C bond is formed by addition to an electrophilic α-carbon 
is showcased in White’s synthesis of the acetylcholinesterase inhibitor huperzine A (I.2) (Scheme 
I.29).[197] As stated before, the ATA in huperzine A (I.2) has been set via 1,2-sigmatropic 
rearrangements in almost all other synthetic attempts (see chapter 1.1.2.2). In contrast, White 
applied an elegant and highly efficient aza-Prins cyclization/cyclobutane fragmentation for the 
construction of the ATA in the aminobicyclo[3.3.1]nonene scaffold. Ketone I.149 was condensed 
with methyl carbamate to give N-acyliminium ion I.150 that was trapped by an endo-oriented 
isopropenyl group in an aza-Prins reaction. The obtained cyclobutylcarbinyl cation I.151 is highly 
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strained and therefore undergoes a fragmentation to the aminobicyclo[3.3.1]nonene skeleton I.152, 
which could be transformed into huperzine A (I.2) using Kozikowski’s protocol.[122] 
 
Scheme I.29 Synthesis of huperzine A by White (2013). 
ATAs have not only been constructed by additions to electrophilic α-carbons but also by pericyclic 
reactions. A cycloaddition cascade was used in Stockmann and Fuchs’ short racemic synthesis of 
HTX 283A (I.4), a noncompetitive inhibitor of nicotinic acetylcholine receptors (Scheme I.30).[198] 
C2-symmetric ketodinitrile I.153 was prepared in three steps, which included the use of a 
challenging cross-metathesis reaction, and was then allowed to condense with hydroxylamine. 
Subsequent intramolecular aza-Michael addition of the oxime gave nitrone I.154, which underwent 
intramolecular 1,3-dipolar cycloaddition to give isoxazolidine I.155, albeit as the wrong regioisomer. 
Tricyclic ATA I.155 underwent retro-[3+2] cycloaddition upon heating, allowing equilibration to 
the more stable conformer I.156 and the so-called 'Holmes dinitrile' (I.157) after another [3+2] 
cycloaddition. This intermediate had been previously converted into HTX 283A (I.4) by Holmes in 
four steps.[199–200] However, Stockman and Fuchs optimized the last steps of the synthesis and were 
able to synthesize HTX 283A (I.4) in 9 steps and 17% overall yield. Another example of a 
pericyclic cascade reaction to set an ATA is Nicolaou’s synthesis of the veterinary antibiotic 
thiostrepton involving an aza-Diels–Alder dimerization of two identical thiazolidine fragments as 
the first step of their complex cascade sequence (not shown).[201–205]  
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Scheme I.30 Synthesis of HTX 283A by Stockman and Fuchs (2006). 
An example of a free radical cascade reaction to set an ATA can be found in Inubushi’s racemic 
syntheses of stemonamide (I.162), isostemonamide and their reduced derivatives stemonamine and 
isostemonamine (Scheme I.31).[117–118] Reaction of bromide I.158 with tributyltin hydride and 
ACHN effected an initial 7-endo-trig cyclization to give intermediate radical I.159. This radical 
subsequently underwent a 5-endo-trig cyclization to yield a mixture I.160 and I.161. Additional 
transformations of both compounds furnished stemonamide (I.162), alongside some of its 
congeners.  
 
Scheme I.31 Synthesis of stemonamide by Ishibashi (2008). 
The second class of cascade reactions involves C−N bond formation as the last step to install the 
ATA. In Zhang’s synthesis of stemonamide (I.162) and related Stemona alkaloids, a reaction 
sequence that involves an electrophilic nitrogen was applied (Scheme I.32).[137] Starting from α-
hydroxy epoxide I.163 the cascade was initiated by a TiCl4-mediated semipinacol rearrangement to 
give intermediate ketone I.164, which then formed the ATA in an Aubé−Schmidt reaction to yield 
lactam I.166 as a 5:1 mixture of diastereomers (via transition state I.165). Using this strategy, Zhang 
was able to synthesize stemonamide (I.162) and three additional Stemona alkaloids.[137, 206–207] 
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Scheme I.32 Synthesis of stemonamide by Zhang (2011). 
An impressive cascade reaction was implemented in the synthesis of chartelline C (I.172) by Baran 
and co-workers in 2005 (Scheme I.33).[208–209] In their synthesis, indole I.167 was brominated with 
N-bromosuccinimide (NBS) at 185 °C to form tetrabromide I.168. On addition of 18-crown-6 and 
base, γ-lactam I.169 was formed and ATA formation was then the result of a 1,5-shift to give ring-
contracted spiro-β-lactam I.170. Work-up with aqueous sodium chloride solution led to efficient 
halogen exchange at the vinylogous bromoformate to afford desired lactam I.171, which could be 
converted into chartelline C (I.172).  
 
Scheme I.33 Synthesis of chartelline C by Baran (2005). 
A very rare ATA formation involving a nitrogen-centered radical can be found in Zard’s synthesis 
of 13-deoxyserratine (I.178) (Scheme I.34).[210] His synthesis commences with O-benzoyl 
hydroxamic acid derivative I.173, which forms a nitrogen-centered amidyl radical I.174 on 
treatment with n-Bu3SnH and ACN. The radical then participated in sequential 5-exo-trig and 6-
endo-trig cyclizations to furnish α-chlorocarbinyl radical I.175. Hydrogen abstraction from 
n-Bu3SnH gave intermediate I.176, which was further reduced to 13-desoxyserratine precursor 
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I.177 by in situ dechlorination. The yield of 52% for this cascade reaction is impressive as an ATA 
and an adjacent quaternary stereocenter are formed in a single transformation. 
 
Scheme I.34 Synthesis of 13-deoxyserratine by Zard (2002). 
In conclusion, a variety of cascade reactions have been applied in ATA synthesis. However, as 
already elaborated in the preceding chapters, the ATA is mainly set by Mannich or Michael 
additions. This observation not only illustrates the popularity but also the robustness of these 
reactions.  
 
1.1.3 Installation of ATAs in hasubanan alkaloid synthesis 
Due to their beautiful structures and unsual [4.4.3]-propellane core, hasubanan alkaloids have 
received significant attention from the synthetic community and several total syntheses have been 
reported to date.[154–159, 211–219] The first syntheses of hasubanan alkaloids date back to the 1960s and 
1970s, when Inubushi synthesized (±)-cepharamine (I.184),[154–155] (±)-hasubanonine (I.198),[156–157] 
(±)-aknadilactam[156] and (±)-metaphanine (I.214)[158–159] (Scheme I.35). These syntheses all 
commence from precursor I.179, which upon subjection to basic conditions undergoes a cascade 
reaction involving a retro-Michael/aza-Michael addition (I.180→I.181) to furnish common 
tetracyclic precursor I.183 (no yield reported).[220] 
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Scheme I.35 Synthesis of Cepharamine by Inubushi (1969). 
Almost 30 years later, Schultz reported the synthesis of the unnatural enantiomer (+)-cepharamine 
(I.184) using a Hofmann rearrangement to introduce the ATA. Starting from lactone I.185 (Scheme 
I.36a),[212] aminolysis followed by 1,2-rearrangement led to 1,3-oxazinan-2-one I.186 that was 
further derivatized to obtain (+)-cepharamine (I.184). 
 
Scheme I.36 Synthesis of hasubanan alkaloids Schultz (1998) and Castle (2009). 
In 2006, Castle and co-workers published their approach to the rac-hasubanonine core, which 
included an acid-catalyzed conjugate addition as the key step.[221–222] Later, they extended their 
strategy to provide enantiopure (−)-acutumine (I.189) in which the ATA was set in a formal SN2'-
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reaction (Scheme I.36a).[215] From I.187, an allylic cation was generated under Lewis-acidic 
conditions and subsequently intercepted by the secondary amine. Resulting ATA-containing 
pyrrolidine I.188 was then converted into acutumine (I.189). 
In contrast to all other hasubanan syntheses, Reisman installed the ATA in (−)-8-
demethoxyrunanine (I.193) at the very beginning of her synthesis (Scheme I.37a).[217] 
Diastereoselective addition of Grignard reagent I.190 into chiral N-tert-butanesulfinimine I.191 gave 
sulfinamide I.192, which was subsequently converted into (−)-8-demethoxyrunanine (I.193) and a 
number of related alkaloids.  
 
Scheme I.37 Synthesis of hasubanan alkaloids by Reisman (2011) and Herzon (2011). 
In the same year, Herzon published the first enantioselective synthesis of hasubanonine (I.198)  
(Scheme I.37b).[216] Iminoquinone Diels−Alder adduct I.194 was methylated to give iminium ion 
I.195 that was immediately reacted with alkynyllithium I.196, providing ATA I.197. This strategy 
proved to be versatile, as not only (−)-hasubanonine (I.198), but also many other hasubanan 
alkaloids such as (−)-runanine, (−)-delavayine, (+)-periglaucine B and (−)-acutumine (I.189) could 
be prepared with modifications of this strategy.[216, 218–219] 
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In summary, a variety of different methods have been applied to install the ATA in hasubanan 
alkaloids. As in most other alkaloid syntheses, the installation of this structural motif always 
constitutes a key step and requires careful planning when designing a retrosynthesis.  
 
1.2  Hasubanan alkaloids isolated from japonica  species 
1.2.1 Stephania  japoni ca  and its application in Traditional Chinese Medicine (TCM) 
The genus Stephania belongs to the Menispermaceae family, which is native to warmer parts of the 
world. Plants of the genus Stephania are generally slender climbers with peltate and membranous 
leaves.[223] Stephania japonica, a plant belonging to this genus, is native to village margins and open 
forests across Southeast Asia and the Pacific region. The first specimen was discovered in Japan, 
hence the name Stephania japonica.  
It is widely used in traditional Chinese and Taiwanese medicine, where it is known as qian jin teng or 
snakevine.[223–226] The root and stem leaves of the snakevine are believed to have a detoxicating 
effect and remove “heat, wind and dampness”.[227] Extracts of the plant have been used for 
example for the treatment of malaria, dysentery and rheumatic arthralgia.[227] To date, more than 50 
alkaloids have been found in S. japonica,[228] spanning four different natural product classes: 
dibenzylisoquinolines, hasubananes, aporphines and protoberberines.[229] Some of these natural 
products were identified as biologically active (Figure I.4): the bisbenzylisoquinoline isotrilobine 
(I.199) was found to increase the efficiency of doxorubicin in resistant breast cancer cells, and 
cepharanthine (I.200) is already a registered drug for the treatment of pulmonary fibrosis.[230–231]  
 
Figure I.4 The biologically active alkaloids isotrilobine, cepharanthine, protostephanin and longanine 
isolated from Stephania japonica. 
Protostephanin (I.201), which belongs to the family of morphinan alkaloids, is a antihypertensive 
agent[232] and a few members of the hasubanan family bind to the human δ-opioid receptor 
(DOR).[233] In general, activation of opioid receptors results in euphoria, analgesia and decreased 
respiration. The most potent ligand for the δ-opioid receptor from the hasubanan family is 
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longanine (I.202) with a half maximal inhibitory concentration (IC50) value of 700 nM. The 
hasubanan alkaloids tested showed similar binding affinity for both the µ- and δ-opioid receptors, 
with IC50 values ranging from 0.7 to 46 µM, but low affinity for the κ-opioid receptor. However, 
when compared to morphinan opioid ligands, the binding of hasubanan alkaloids is relatively weak, 
probably due to the opposite absolute configuration at the benzylic quaternary stereocenter.[234]  
 
1.2.2 Isolation and structure of (+)-stephadiamine 
The norhasubanan alkaloid (+)-stephadiamine (I.1) was isolated in 1984 by Taga et al. from the 
alcoholic extracts of the common scrambler Stephania japonica and represents a new class of 
alkaloids that is closely related to the hasubanan and morphinan alkaloids.[224] (+)-Stephadiamine 
(I.1) was isolated “with difficulty in 4x10-6% yield from the mother liquor after removal of 
metaphanine,”[224] and thus biological evaluation has not been possible to date. Nevertheless, Taga 
et al. assigned the structure of the novel alkaloid by 1H NMR analysis, mass spectrometry and IR 
spectroscopy. Moreover, it was possible to obtain an X-ray structure of (+)-stephadiamine (I.1) 
(Figure I.5) and its absolute stereochemistry was assigned by the X-ray structure of 
N-(p-bromobenzoyl)-stephadiamine (not shown). From a structural point of view, pentacyclic 
(+)-stephadiamine (I.1) has a unique [3.3.4]-propellane core structure that consists of a 
tetrahydronaphtalene system fused to a cyclopentane and a pyrrolidine.[235] The aza-propellane 
motif is characteristic for hasubanan alkaloids; however, as opposed to the hasubanan alkaloids, the 
cyclohexenone is contracted to a cyclopentane in (+)-stephadiamine (I.1). 
 
Figure I.5 Molecular and X-ray structure of the isolated norhasubanan (+)-stephadiamine (I.1). 
In addition, the cyclopentane and tetrahydronaphtalene systems in (+)-stephadiamine (I.1) are 
further connected by a bridging δ-lactone, which is unique in the hasubanan family of alkaloids. 
Stephadiamine (I.1) features a total of four stereocenters, including two adjacent ATAs and a 
benzylic quaternary center, which are responsible for its cage-like structure. In addition, both ATAs 
are part of a 1,2-cis diamine motif, one of them being primary and the other tertiary. In general, 1,2-
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diamines constitute an unusual structural motif and, to the best of our knowledge, no other alkaloid 
contains two adjacent 1,2-cis ATAs. 
 
1.2.3 Proposed biosynthesis of (+)-stephadiamine 
Morphinan, hasubanan and norhasubanan alkaloids bear a structural similarity that suggests a 
related biosynthetic pathway. The biosynthesis of (−)-morphine (I.211) has been studied in detail 
and is relatively well understood. Dopamine (I.204) and 4-hydroxyphenylacetaldehyde (I.205) are 
formed biosynthetically from the amino acid L-tyrosine (I.203) (Scheme I.38).[236] These building 
blocks then most likely participate in a Pictet−Spengler reaction to furnish (S)-norcoclaurine 
(I.206), which is then oxidized and methylated to (S)-reticuline (I.207). Inversion of the benzylic 
stereocenter transforms (S)-reticuline (I.207) into (R)-reticuline (I.208), which is a key intermediate 
in all morphinan biosyntheses. Subsequent intramolecular o,p-phenol oxidative coupling gives (R)-
salutaridine (I.210) via biradical intermediate I.209, and additional enzyme-catalyzed 
transformations furnish (−)-morphine (I.211).[236]  
 
 
Scheme I.38 Proposed biosynthesis of (−)-morphine (I.211). 
The biosynthesis of the hasubanan alkaloids has not yet been fully elucidated. However, the 
structural resemblance to the morphinan alkaloids suggests a shared biochemical pathway. 
Battersby therefore proposes a biosynthesis that involves oxidized isoquinoline frameworks similar 
to (S)-reticuline (I.207). This proposal was confirmed through feeding experiments of 14C-enriched 
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isoquinolines to S. japonica, the source of (−)-hasubanonine (I.198) (Scheme I.39).[237–240] The 
detected isoquinoline I.212 resembles (R)-reticuline (I.208) and therefore Battersby and co-workers 
proposed a similar biosynthetic pathway for hasubanonine (I.198) as for morphine (I.211). 
Even less is known about the biogenesis of the target compound (+)-stephadiamine (I.1). However, 
due to its strong resemblance to morphinans and hasubanans, it was suggested by Hager et al. that 
L-tyrosine (I.203) is most likely the precursor for (+)-stephadiamine (I.1).[241–242] In this case, the 
skeleton of the natural product would arise from an identical or similar Pictet–Spengler reaction 
and a phenolic coupling. In contrast to the hasubanan alkaloids, a series of ring contractions or 
rearrangements would have to occur to furnish the unique propellane core and δ-lactone of this 
norhasubanan alkaloid.[241–242] A possible biosynthesis could proceed through (−)-metaphanine 
(I.214), another hasubanan alkaloid co-isolated with stephadiamine (I.1) from S. japonica.[243] 
Elaborating on this hypothesis, condensation of NH3 with I.214 to putative key intermediate imine 
I.215 could then be converted to (+)-stephadiamine (I.1) by [1,2]-semipinacol-type rearrangement.†  
 
Scheme I.39 Proposed mechanism for the biosynthesis of (+)-stephadiamine. 
 
  
                                                      
† This biosynthetic proposal has been developed in cooperation with Prof. Dr. W. Steglich. 
COOH
HO NH2
L-tyrosine
(I.203)
N
O
OMe
OMe
O
HO
N
MeO
OMe
O
OMe
OMe
(-)-hasubanonine
(I.198)
NH
MeO
MeO
O
N
OH
O
MeO
MeO
O
N
OH
(+)-stephadiamine
(I.1)
[1,2]
(-)-metaphanine
(I.214)
N
OMe
MeO
O
H
OH2N
HO
N
HO
HO
(-)-morphine
(I.211)
N
OH
OMe
OMe
OH
HO
O2
NADPH
I.212 I.213
I.215
PROJECT OUTLINE 
 
37  
2 Project outline 
2.1 Aims and significance of the project 
Due to their structural complexity and associated synthetic challenges, members of the morphinan 
and hasubanan families have been popular targets for alkaloid total synthesis. However, as stated in 
the previous chapter, no synthetic efforts have been published for the structurally unique 
norhasubanan alkaloid (+)-stephadiamine (I.1), which was isolated more than ten years ago.[244] 
Stephadiamine (I.1) possesses three contiguous fully substituted carbons: two α-tertiary amines 
(ATAs) and a benzylic quaternary carbon. Moreover, the two amines, a primary and a tertiary ATA, 
form a 1,2-cis-diamine, an extremely rare structural motif in nature. As such, stephadiamine (I.1) 
constitutes a significant synthetic challenge with which to apply and develop new synthetic methods 
for the construction of sterically encumbered ATAs. It was therefore the goal of this Ph.D. thesis 
to develop a concise and practical synthetic route to stephadiamine (I.1). In addition, only trace 
amounts of stephadiamine (I.1) were isolated by Taga et al., and therefore investigation of its 
biological activity was not possible. Synthetic stephadiamine (I.1) would allow for its biological 
assessment. From a synthetic point of view, a main task of a synthesis of stephadiamine (I.1) is the 
construction of the highly congested propellane. Synthetic planning was thus guided by this 
challenge. 
In earlier studies by Dominik Hager and Anastasia Hager and those described in the Master’s thesis 
of the author, a route towards the popular hasubanan and morphinan β-tetralone building block 
was optimized and used as a starting point for all synthetic considerations. In all synthetic plans, it 
was envisaged to construct the aza-propellane core via functionalization of the acidic α-position of 
the β-tetralone. It was the first goal of this Ph.D. thesis to develop a strategy for the construction of 
the propellane core of stephadiamine (I.1). At an early point of this project, a cascade reaction was 
developed and optimized, which then became the foundation of all subsequent synthetic planning.  
In this route, the benzylic stereocenter was set using a decarboxylative Tsuji allylation starting from 
a stabilized enol-carbonate. These substrates represent a remaining challenge in asymmetric Pd-
catalyzed allylations. In collaboration with Prof. Brian M. Stoltz of the California Institute of 
Technology we opted to address this challenge and expand the scope of this transformation to 
enable an asymmetric total synthesis of (+)-stephadiamine (I.1). 
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2.2 Initial work 
2.2.1 Retrosynthesis 
Prior to this Ph.D. thesis, the total synthesis of stephadiamine (I.1) was already investigated as part 
of the Ph.D. theses of Dominik Hager and Anastasia Hager and the Master’s thesis of the author. 
The most challenging task in a synthesis of stephadiamine (I.1) is the installation of the two ATAs, 
which are located next to a benzylic quarternary stereocenter. As outlined in chapter 1.1, numerous 
methods for the installation of ATAs have been published in the literature, however for our 
retrosynthesis we envisaged to develop novel 1,2-diamination chemistry. 
For the synthesis of stephadiamine I.1, we envisaged to install the lactone in the last step of the 
synthesis starting from amino acid derivative I.216 (Scheme I.40). This pentacyclic ATA-containing 
precursor I.216 in turn could be accessed from primary amine I.217 via 1,2-diamination. This 
intermediate could in turn be obtained from Michael system I.218 by reduction and reductive aldol 
reaction. The quarternary benzylic stereocenter present in this structure could then be installed in 
an alkylation/Tsuji allylation sequence starting from literature-known β-tetralone I.219. Based on a 
procedure by Yu and co-workers, tetralone I.219 could be prepared by Fujiwara–Moritani reaction 
(palladium-catalyzed aryl C–H olefination) and subsequent Dieckmann cyclization from 
commercially available, albeit very expensive, 2,3-dimethoxyphenylacetic acid (I.223).[245] During 
this Ph.D. thesis, the starting material was prepared from aldehyde I.220 following a literature 
procedure from Detterbeck and Hesse.[246]  
 
Scheme I.40 Previous retrosynthetic analysis for the synthesis of stephadiamine. 
In our retrosynthetic planning, we envisaged that the Tsuji allylation[247–249] would present a handle 
to render the synthesis asymmetric and that this resulting chirality would allow for the 
diastereoselective installation of all other stereocenters. 
 
2.2.2 Initial experimental work 
Prior to the contributions described in this Ph.D. thesis, optimization and characterization of Yu’s 
β-tetralone-synthesis starting from the commercially available acid I.223 were carried out in 
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collaboration with Anastasia Hager and Dominik Hager, two former Ph.D. students in the Trauner 
group. Thus a detailed discussion of this synthesis can be found in their Ph.D. theses.[241–242] The 
following experiments in Scheme I.43 were first carried out by the author during her Master’s thesis 
in the Trauner laboratories. Yields and procedures described in this chapter are optimized 
conditions.  
 
Scheme I.41 Synthesis of the commercially available acid I.223 from inexpensive starting material I.220. 
Following our retrosynthetic strategy, the first goal was the synthesis of commercially available, yet 
prohibitively expensive 2,3-dimethoxyphenylacetic acid (I.223). We therefore followed a short 
synthesis by Detterbeck and Hesse (Scheme I.41).[246] The synthesis started with commercially 
available and inexpensive 2,3-dimethoxybenzaldehyde (I.220). In a four step sequence, the aldehyde 
was reduced with NaBH4 and transformed into chloride I.221 using thionyl chloride. SN2 reaction 
of chloride I.221 with KCN gave nitrile I.222 in good yield. Finally, the desired carboxylic acid 
I.223 was formed by a base-mediated hydrolysis. No chromatographic purification was necessary, 
allowing for the rapid synthesis of large amounts of acid I.223 with a yield of 80% over four steps 
on 50 g scale.  
  
Scheme I.42 Optimized procedure for the synthesis of β-tetralone I.219. 
Prior to this Ph.D work, the large-scale synthesis of dimethoxy β-tetralone I.219 was already 
established in the Trauner group. β-Tetralones themselves are popular intermediates in the 
synthesis of hasubanan and morphinan alkaloids,[250–254] but most reported preparations suffer from 
either low-yielding steps or expensive catalysts and starting materials.[255–259] Therefore, a recently 
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published synthesis[245] of β-tetralone I.219 starting from commercially available 2,3-
dimethoxyphenylacetic acid (I.223) was optimized by Anastasia Hager and Dominik Hager, two 
former Ph.D. students in the Trauner group.[241–242] The sequence commenced with a Fujiwara–
Moritani reaction[260–262] under conditions published by Yu and co-workers.[245] Thus obtained 
enoate I.224 was then hydrogenated and the free carboxylic acid was methylated to give diester 
I.225 in 98% over three steps. Dieckmann condensation followed by subsequent decarboxylation 
then furnished β-tetralone I.219. Using this optimized route, literature-known intermediate was 
synthesized on multi-gram scale in nine steps involving only two chromatographic separations in an 
overall yield of 55% (Scheme I.42).  
      
Scheme I.43 Installation of the benzylic quarternary stereocenter. 
Next, the β-tetralone I.219 was alkylated with bromoacetonitrile under Stork’s conditions[263] in 
78% yield (Scheme I.43). We then investigated the decarboxylative Tsuji allylation starting from 
nitrile I.226. Exposure of ketone I.226 to NaH generated the thermodynamic enolate, which was 
trapped by allyl chloroformate to furnish the corresponding enol carbonate. In the next step, the 
enol carbonate smoothly underwent the desired allylation in the presence of Pd2(dba)3 and PPh3, 
giving α-allylcyclohexanone I.227 in an excellent yield of 84% over two steps. A cross metathesis 
then furnished conjugated ester I.228. Initial attempts to cyclize reductive aldol precursor I.218 
were not successful. Where applicable, further discussion of these results can be found in later 
chapters (e.g., asymmetric decarboxylative Tsuji allylation). 
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3 Results and discussion 
3.1 Implementation of the quaternary benzylic stereocenter 
3.1.1 The Tsuji allylation 
The implementation of quaternary stereogenic centers remains a challenging task due to the steric 
hindrance associated with such a substituted carboatom.[264–272] To transform racemic compounds, 
such as nitrile I.226 into a single enantioenriched product, the racemate has to undergo a 
stereoconvergent transformation.[273] This class of reaction can be categorized into three subclasses:  
1. Stereoablative transformations  
2. Dynamic kinetic resolutions (DKRs) 
3. Dynamic kinetic asymmetric transformations (DyKATs) 
It was shown in previous studies that benzylic quaternary centers could be set via decarboxylative 
Tsuji allylations in an elegant fashion,[248, 274–277] and we already demonstrated that the racemic 
version of this reaction works well to furnish α-allylcyclohexanone I.227 (Chapter 2.2.2). The 
decarboxylative Tsuji allylation belongs to the subclass of stereoablative reactions. Stereoablative 
processes are characterized by the formation of an intermediate that is formed by the irreversible 
deletion of stereoinformation to form a prochiral species (see Figure I.6). This process involves an 
identical or similar reaction rate (kracR = kracS) for the formation of the prochiral species. 
 
Figure I.6 Principle of a steoreoablative enantioconvergent process. 
The prochiral reactive intermediate then interacts with a chiral catalyst to give preferably one of the 
enantiomeric products, due to the different rates of product formation (kR >> kS). In contrast to 
dynamic kinetic resolutions or dynamic kinetic asymmetric transformations, the stereoablative 
process relies on the formation of a prochiral intermediate followed by the irreversible formation –
 rather than by a reversible process – of an enantioenriched product.  
Historically, the Tsuji allylation reaction was discovered as part of a series of palladium-catalyzed 
reactions “in which unstabilized enolates or enol equivalents were transformed into the corresponding allylated 
ketones under essentially neutral reaction conditions” by Tsuji and co-workers in the 1980s.[276] Almost 20 
years later, Stoltz and co-workers developed an asymmetric version of one of these reactions, the 
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so-called decarboxylative Tsuji allylation. By refining the original procedure and utilizing chiral 
phosphine-based ligands (P,N-ligands, PHOX-ligands), they were able to achieve excellent 
enantioselectivities for unstabilized enol carbonates (for structures of ligands see Figure I.7). Only 
one year later the group of Trost demonstrated that their DACH ligands (P,P-ligand) and several 
other C2-symmetric ligands are able to transfer chiral information for more electron-rich enol 
carbonates. The application of these ligands has been further extended to additional highly 
enantioselective variants, which also proceed under mild reaction conditions. The groups of Tsuji, 
Trost, and Stoltz, among others, have studied the mechanism of the decarboxylative Tsuji allylation 
extensively.[247,276,278–279] The proposed 
catalytic cycle for the decarboxylative 
Tsuji allylation is depicted in Scheme 
I.44. Catalytically active Pd(0) 
coordinates to the double bond of 
allyl carbonate I.228 to form a η2 π-
allyl complex (not shown).[280] On 
oxidative addition, an η3 π–allyl 
complex I.229 is formed. Following 
CO2 release and ligand exchange, the 
resultant nucleophilic enolate may 
either be a stabilized enolate ion-
paired with the dissociated π–allyl 
palladium complex (outer sphere 
mechanism via I.230 followed by 
reductive elimination) or bound 
covalently to the allylpalladium(II) 
species (inner sphere mechanism via 7-membered cyclic transition state I.231). In the last step, 
reductive elimination provides α-allylcyclohexanone I.227 with concomitant regeneration of 
catalytically active Pd(0).[277] For the enantiodetermining allylation step, several mechanistic studies 
by the groups of Stoltz and Trost have been published over the years. These studies suggest that 
Trost ligands might favor an outer sphere mechanism,[275] whereas an inner sphere process might 
be preferred by PHOX ligands,[279,281] although both pathways are feasible.[277] For both 
mechanisms, nonpolar aprotic solvents are preferred as they stabilize the inner sphere complex and 
outer sphere complex by promoting tighter ion-pairing, which ultimately leads to higher 
enantiomeric excess (ee).[277]  
Today the Tsuji allylation serves as a powerful tool for the installation of quaternary stereocenters, 
and the methodology has been extended to complex molecules such as intermediates in the 
Scheme I.44 Proposed catalytic cycle of the Tsuji allylation. 
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synthesis of natural products.[282–285] However, the asymmetric introduction of quaternary 
stereocenters starting from enolate-stabilized enolcarbonates is a challenging problem for this 
methodology.[286] Initial experiments conducted during the Master’s thesis of the author proved that 
this strategy could be suitable for an asymmetric total synthesis of (I.1).[287] To this end, reaction of 
I.228 with Trost’s commercially available (S,S)-DACH Phenyl ligand (I.235) provided α-
allylcyclohexanone I.227 in near quantitative yield with 64% enantiomeric eccess (ee) as determined 
by chiral HPLC. Although the absolute stereochemistry was not determined at this stage, Trost’s 
model for the prediction of the stereochemical outcome suggests that this ligand should lead to 
desired (R)-I.227 (model will be discussed in chapter 3.1.2). 
 
Scheme I.45 First conditions tested for an asymmetric Tsuji allylation. 
To further improve the enantioselectivity of this reaction, a screening of ligands and reaction 
conditions was carried out in collaboration with the Stoltz laboratories in Pasadena at the California 
Institute of Technology. In addition, we also set out to determine the absolute stereochemistry of 
the obtained product.  
 
3.1.2 Screening of the decarboxylative Tsuji allylation‡ 
Regarding the Tsuji allylation, several ligands have proven to successfully transfer chiral 
information, such as the P,N-coordinating PHOX-ligands (S)-t-Bu-PHOX (I.232) and 
(S)-CF3-t-Bu-PHOX (I.233), the P,N-coordinating QUINAP ligand (I.234) and P,P-C2-symmetric-
coordinating DACH-ligands such as (R,R)-DACH-Phenyl Trost ligand (I.235), (R,R)-DACH-
Naphthyl Trost ligand (I.236) and (R,R)-ANDEN-Phenyl Trost ligand (I.237, Figure I.7). In initial 
experiments, these ligands were screened at a concentration of 0.030 M and 5 mol% catalyst loading 
in several nonpolar aprotic solvents (see Experimental section, Procedure A, Chapter 8.2). The 
reactions were carried out at 25 °C for 20 h to ensure complete conversion. We do not expect en 
erosion of ee after completion of the reaction, as C–C bond formation is most likely irreversible.  
                                                      
‡ All experiments were carried out by the author in the laboratories of Prof. Brian M. Stoltz at the California Institute of  
  Technology in Pasadena, CA, USA. 
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Figure I.7 Ligands used for the optimization of the asymmetric Tsuji allylation. 
As determined by chiral HPLC, all reactions went to completion within this time period. The ee was 
calculated based on the HPLC traces of crude reaction mixtures.  
Table I.1 Initial ligand screen for the asymmetric decarboxylative Tsuji allylation. 
 
 
Entry Ligand Solvent T (°C) t (h) %ee 
1 (S)-t-Bu-PHOX (I.232) THF 25 20 3 
2 (S)-t-Bu-PHOX (I.232) toluene 25 20 1 
3 (S)-t-Bu-PHOX (I.232) 2:1 hexane/toluene 25 20 6 
4 (S)-CF3-t-Bu-PHOX (I.233) THF 25 20 10 
5 (S)-CF3-t-Bu-PHOX (I.233) toluene 25 20 26 
6 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene 25 20 38 
7 (R,R)-ANDEN-Phenyl Trost (I.237) THF 25 20 22 
8 (R,R)-ANDEN-Phenyl Trost (I.237) toluene 25 20 13 
9 (R,R)-ANDEN-Phenyl Trost (I.237) 2:1 hexane/toluene 25 20 25 
10 (S)-QUINAP (I.234) THF 25 20 14 
11 (S)-QUINAP (I.234) toluene 25 20 3 
12 (S)-QUINAP (I.234) 2:1 hexane/toluene 25 20 11 
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The most popular and commercially available (S)-t-Bu-PHOX ligand (I.232) gave negligible ee 
values (1 to 6%) (Table I.1, entries 1−3) and thereby proved to be an ineffective catalytic system for 
substrate I.228. We then tested the more electron-deficient (S)-CF3-t-Bu-PHOX ligand (I.233), 
which gave a higher ee as to be expected for an enol-stabilized enolcarbonate.[288] In THF, the ee for 
the transformation was 10% (entry 4), but when conducted in the less polar solvent toluene, an ee 
of 26% was obtained (entry 5). The least polar solvent mixture that still gave a homogeneous 
solution of catalyst, 2:1 hexane/toluene, provided an ee of 38% (entry 6). In addition to these two 
PHOX ligands, we also evaluated (R,R)-ANDEN-Phenyl Trost ligand (I.237), which is generally 
the best Trost ligand for this transformation due to its large bite angle. However, this highly 
engineered ligand only gave an ee of 13−25% (entries 7−9), which is worse than our preliminary 
results with the (S,S)-DACH-Phenyl Trost ligand (I.235).[287] Unfortunately (S)-QUINAP ligand 
(I.234) did not provide higher ee values (entries 10−12). 
In addition to these experiments, we also investigated different reaction temperatures for the 
(S)-CF3-t-Bu-PHOX ligand (I.232) (Table I.2, entries 1−4). We noticed that temperature had little 
to no influence on the enantioselectivity. 
Table I.2 Temperature screen for the (S)-CF3-t-Bu-PHOX ligand. 
 
 
Entry Ligand Solvent T (°C) t (h) %ee 
1 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene 20 14 39 
2 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene 0 14 42 
3 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene −15 14 34 
4 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene −60 14 37 
 
In parallel, we also further investigated the (R,R)-ANDEN-Phenyl Trost ligand (I.235), as this 
ligand very often gives the best results in Tsuji allylations. As for the Trost ligands, two different Pd 
sources are commonly used for decarboxylative Tsuji allylations – Pd2(dba)3 and its chloroform 
adduct. We observed that the palladium source does not have a significant impact on ee: in THF, 
the chloroform adduct is 3% better than Pd2(dba)3 (Table I.3, entries 1 and 4),  in toluene the ee was 
identical (entry 2 and 5), and in a mixture of toluene and hexane the chloroform adduct gave a 
slightly higher ee than Pd2(dba)3 (entries 3 and 6).  
Pd2(dba)3 (5 mol%) 
ligand (12.5 %) 
solvent, T, t
OMe
MeO
O
NC
O
OMe
MeO
NC
OO
I.227I.228
RESULTS AND DISCUSSION 
 
 46 
Table I.3 Screen for Pd sources and solvents. 
 
Entry Ligand Pd source solvent T (°C) t (h) %ee 
1 (R,R)-ANDEN-Phenyl Trost (I.237) (12.5 mol%) B (5.0 mol%) THF 25 20 22 
2 (R,R)-ANDEN-Phenyl Trost (I.237) (12.5 mol%) B (5.0 mol%) toluene 25 20 13 
3 (R,R)-ANDEN-Phenyl Trost (I.237) (12.5 mol%) B (5.0 mol%) 2:1 hexane/toluene 25 20 25 
4 (R,R)-ANDEN-Phenyl Trost (I.237) (11.0 mol%) A (5.5 mol%) THF 25 12 25 
5 (R,R)-ANDEN-Phenyl Trost (I.237) (11.0 mol%) A (5.5 mol%) toluene 25 12 13 
6 (R,R)-ANDEN-Phenyl Trost (I.237) (11.0 mol%) A (5.5 mol%) 2:1 hexane/toluene 25 12 27 
 
Since the chloroform adduct appeared slightly better, we used it as the palladium source. We next 
screened three different commercially available Trost ligands, DACH-Phenyl (I.235), 
DACH-Naphthyl (I.236) and ANDEN-Phenyl (I.237). Each one was tested with five different 
solvents or solvent mixtures (DME, MTBE, THF, toluene and hexane/toluene). We found that the 
DACH-Phenyl Trost ligand (I.235) gave similar ee’s in all five solvent systems (Table I.4, entries 
1−5). The highest ee’s (52% and 53%) were obtained in toluene and hexane/toluene (entries 4 and 
5). The DACH-Naphthyl Trost ligand (I.236) yielded worse ee’s overall, however the general trend 
was the same: the ligand works better in apolar solvents than in polar, coordinating solvents (entries 
6−10). The ANDEN-Phenyl Trost ligand (I.237) gave the lowest ee’s of the three Trost ligands 
(entries 11−15). 
Table I.4 Second screen for Trost ligands and solvents. 
 
Entry Ligand Solvent T (°C) t (h) %ee 
1 (R,R)-DACH-Phenyl Trost (I.235) DME 25 12 51 
2 (R,R)-DACH-Phenyl Trost (I.235) MTBE 25 12 46 
3 (R,R)-DACH-Phenyl Trost (I.235) THF 25 12 47 
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Entry Ligand Solvent T (°C) t (h) %ee 
4 (R,R)-DACH-Phenyl Trost (I.235) toluene 25 12 52 
5 (R,R)-DACH-Phenyl Trost (I.235) 2:1 hexane/toluene 25 12 53 
6 (R,R)-DACH-Naphthyl Trost (I.236) DME 25 12 22 
7 (R,R)-DACH-Naphthyl Trost (I.236) MTBE 25 12 24 
8 (R,R)-DACH-Naphthyl Trost (I.236) THF 25 12 24 
9 (R,R)-DACH-Naphthyl Trost (I.236) toluene 25 12 26 
10 (R,R)-DACH-Naphthyl Trost (I.236) 2:1 hexane/toluene 25 12 29 
11 (R,R)-ANDEN-Phenyl Trost (I.237) DME 25 12 6 
12 (R,R)-ANDEN-Phenyl Trost (I.237) MTBE 25 12 24 
13 (R,R)-ANDEN-Phenyl Trost (I.237) THF 25 12 25 
14 (R,R)-ANDEN-Phenyl Trost (I.237) toluene 25 12 13 
15 (R,R)-ANDEN-Phenyl Trost (I.237) 2:1 hexane/toluene 25 12 27 
 
As the most basic DACH-Phenyl Trost ligand (I.235) performs best for enol carbonate I.228, we 
focused on this ligand in all further experiments. We reasoned that by lowering the temperature, we 
would potentially slow down the speed of the reaction, thereby favoring one of the diastereomeric 
transition states.  
Table I.5 Temperature screening for (R,R)-DACH-Phenyl Trost (I.235). 
 
Entry Ligand Solvent T (°C) t (h) %ee 
1 (R,R)-DACH-Phenyl Trost (I.235) THF −15 24 48 
2 (R,R)-DACH-Phenyl Trost (I.235) 2:1 hexane/toluene −15 24 66 
3 (R,R)-DACH-Phenyl Trost (I.235) THF −60 24 46 
4 (R,R)-DACH-Phenyl Trost (I.235) 2:1 hexane/toluene −60 24 55 
5 (R,R)-DACH-Phenyl Trost (I.235) THF −78 24 54 
6 (R,R)-DACH-Phenyl Trost (I.235) 2:1 hexane/toluene −78 24 54 
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Therefore, we investigated different reaction temperatures the Pd2(dba)3 ⋅ CHCl3 in two different 
solvent systems (Table I.5). At −15 °C, 2:1 hexane/toluene gave a significantly higher ee than in 
THF (entries 1 and 2). At −60 °C the difference was diminished (entries 3 and 4) and at −78 °C the 
ee was identical for both solvents (entries 5 and 6). The observation that the ee for reactions in THF 
did not change significantly at decreased temperatures whereas those in toluene and hexane 
decreased is probably due to the decreased solubility of the catalyst in the nonpolar solvent mixture. 
When comparing these results with our initial results from the author’s Master’s thesis 
(Scheme I.45),[287] we obtained lower ee values than originally observed. We reasoned, that there 
might be a purity issue with the palladium source or ligand. And indeed, when we submitted a 
sample of DACH-Phenyl Trost ligand (I.235) to UHPLC, we observed two masses belonging to 
the ligand and its oxidized version. We therefore recrystallized the ligand in the glovebox and 
confirmed the purity by UHPLC. As we also wanted to ensure, that the palladium source is not 
responsible for the drop in ee, we again tested Pd2(dba)3 and its chloroform adduct. Before adding 
the preformed catalyst to the substrate, the solution containing the catalyst was filtered through a 
plug of glass filter paper. Using this procedure, we were able to obtain ee’s of >60% again when 
running the reaction at −10 °C for both palladium sources (Table I.6, entries 1−4).  
Table I.6 Second screen for solvents and different palladium sources. 
 
Entry Ligand Pd source Solvent T (°C) t (h) % ee 
1a) (R,R)-DACH-Phenyl Trost (I.235) A toluene −10 2 60 
2a) (R,R)-DACH-Phenyl Trost (I.235) A 2:1 hexane/toluene −10 2 66 
3a) (R,R)-DACH-Phenyl Trost (I.235) B toluene −10 2 64 
4a) (R,R)-DACH-Phenyl Trost (I.235) B 2:1 hexane/toluene −10 2 59 
a) Tsuji allylation after passage of the preformed catalyst through a plug of glass filter paper; recrystallized ligand used. 
However, the ee’s were still not stable and varied slightly when running the same reaction twice. We 
therefore became interested if the exact ligand to metal ratio would influence the outcome of the 
reaction (Table I.7). When comparing ratios of 1:2, 1:2.2 and 1:4.4 of Pd2(dba)3 to ligand, we 
observed that ratios of 1:2 and 1:2.2 gave ee’s of 64% (entries 1 and 2), but that a ratio of 1:4.4 led 
to a substantial decrease (17% ee, entry 3). We reasoned that excess ligand may possibly be changing 
the coordination at palladium and by some mechanism lower the observed ee.  
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Table I.7 Screening for different Pd2dba3 to ligand ratios. 
 
Entry Ligand Pd2(dba)3 to ligand ratio Solvent T (°C) t (h) %ee 
1a) (R,R)-DACH-Phenyl Trost (I.235) 1.0 : 2.0 toluene −10 2 64 
2a) (R,R)-DACH-Phenyl Trost (I.235) 1.0 : 2.2 toluene −10 2 64 
3a) (R,R)-DACH-Phenyl Trost (I.235) 1.0 : 4.4 toluene −10 2 17 
a) Tsuji allylation after passage of the preformed catalyst through a plug of glass filter paper; recrystallized ligand used. 
To ensure that Pd2(dba)3 itself is not catalytically active, a control experiment was run without 
ligand. Only starting material was recovered, which suggests that no side reactions due to excess 
Pd2(dba)3 are to be expected. As the ratio of Pd2(dba)3 must be kept close to 1:2.2, we decided to 
investigate the influence of reaction concentration as well as catalyst (Table I.8). We started off with 
a concentration of 0.03 M and 5 mol% catalyst loading in toluene and a 2:1 hexane/toluene mixture 
and observed an ee of 64% in toluene and an ee of 59% in the hexane/toluene mixture (entries 1 
and 2). 
Table I.8 Screening conditions for different concentrations and catalyst loadings. 
 
Entry Conc. (M) Pd2(dba)3 Solvent T (°C) t (h) %ee 
1a) 0.03 5 mol% toluene −10 2 64 
2a) 0.03 5 mol% 2:1 hexane/toluene −10 2 59 
3a) 0.01 5 mol% toluene −10 2 66 
4a) 0.01 5 mol% 2:1 hexane/toluene −10 2 58 
5a) 0.001 5 mol% toluene −10 2 66 
6a) 0.001 5 mol% 2:1 hexane/toluene −10 2 62 
7a) 0.03 1 mol% toluene −10 2 60 
8a) 0.03 1 mol% 2:1 hexane/toluene −10 2 66 
a) Tsuji allylation after passage of the preformed catalyst through a plug of glass filter paper; recrystallized ligand used. 
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At a concentration of 0.01 and 0.001 M and 5 mol% catalyst loading the ee increased slightly to 66% 
in toluene. Further dilution proved to be fruitless (entries 3 and 5). In the hexane/toluene mixture, 
we observed the same trend albeit with slightly worse results (entries 4 and 6). Using a substrate 
concentration of 0.03 M with 1% catalyst loading, we observed comparable results (entries 7 and 8).  
After this extensive screening of solvents, temperatures, ligands, palladium sources and reaction 
concentrations, we were interested in the reaction time and the effect of the ligand on the reaction 
time. We therefore set up a kinetic experiment with triphenylphosphine (PPh3) and DACH-Phenyl 
Trost ligand (I.235): both reactions were conducted at −10 °C, and progress was monitored by 
HPLC every 5 minutes (Table I.9). To our surprise, the reaction with the DACH-Phenyl Trost 
ligand (I.235) was completed within 5 min. As we observed an immediate color change upon 
addition of the substrate, we reasoned that the reaction may even be finished within seconds or 
faster. Using triphenylphosphine as ligand, we observed slow but continuous progress of the 
reaction, and after 12 h the starting material had been completely consumed. 
These experiments demonstrate that the nature of the ligand may have a large influence on the 
reaction rate and that the Tsuji allylation of this substrate can be extraordinarily fast. In most 
reported cases, this reaction is performed at room temperature or elevated temperatures.  
Table I.9 Time dependance of the reaction using different ligands. 
 
Entry Ligand Solvent T (°C) t (h) 
1a) (R,R)-DACH-Phenyl Trost (I.235) (11 mol%) toluene −10 <5 min 
2 PPh3 (22 mol%) toluene −10 12 h 
a) Tsuji allylation after passage of the preformed catalyst through a plug of glass filter paper; recrystallized ligand used. 
Taking all results into account, we were wondering if the C−C bond-forming step, at which the 
stereochemical information is transferred, acts as the rate-determining step. Also, if the rate of the 
reaction is close to a diffusion-controlled process, we were curious if this could explain the low ee of 
the reaction, considering it could not be influenced significantly by solvent, temperature or 
concentration.[289] In Mayr’s database, phenyl-substituted allyl-Pd complexes have an electrophilicity 
value of E = −10 and the anion of phenylpropan-2-one has a nucleophilicity value of N = 25[290]  
and a sN parameter of sN = 0.60 (in DMSO).[291] By combining these values in Mayr’s equation [log 
k20°C = sN(N+E)], reaction constants of k = 109 L mol-1 s-2 are obtained, which are close to the 
Pd2(dba)3独CHCl3 
(5.5 mol%), ligand
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diffusion barrier. However, if we now take into account, that substrate I.228 should be more 
reactive than phenylpropan-2-one, we reason, that our reaction could indeed proceed without 
energy barriers and thus lead to relatively low ee values. In most cases (but not always), reactions, 
“which proceed with such high rates do not have activation energies,[and] the corresponding regioselectivities (as well as 
stereoselectivities) cannot be derived from transition-state models”,[292] which could explain our findings.[289, 292–
293] 
At this stage, we set out to determine the absolute stereochemistry of the decarboxylative Tsuji 
allylation using Trost’s model.[294] In this model, the DACH ligand (in the depicted case, the 
(R)-enantiomer) is presented according to the groundstate structure of the ligand-palladium-π-allyl 
complex based on molecular modeling structures. Obtaining a crystal structure of compound I.238 
was not possible due to its instability. In Trost’s model (Figure I.8), the walls represent the “chiral 
space created by the propeller-like array of the phenyl rings; the raised flaps represent the phenyls, which lie in a plane 
approximately parallel to the allyl, while the lowered flaps represent phenyls which are somewhat perpendicular to the 
allyl.[...] If one considers palladium(0) as the nucleophile in the ionization and palladium(II) the leaving group in the 
alkylation reaction, then both ionization and nucleophilic attack should occur at an angle that closely approaches 
180 ° relative to palladium in the π-allyl.“ [294] Due to these reasons, they propose that the favored 
trajectory for the ionization and the following nucleophilic attack would occur via an exo rather than 
an endo mode with respect to the allyl fragment. 
 
Figure I.8 Trost’s model for the stereochemical outcome of the asymmetric Tsuji allylation. 
Using this model, we propose two different orientations of the tetralone enolate, one leading to the 
(S)-stereoisomer and one leading to the (R)-stereoisomer of α-cyclohexanone I.227 (Scheme I.46). 
In the first and favored case, the catalyst approaches the molecule from the Si-face and repulsive 
interactions are minimized. This transition-state would lead to the (S)-stereoisomer when using the 
(R,R)-catalyst. This absolute stereochemistry proved to be correct (see chapter 3.1.4). 
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Scheme I.46 Model for the determination of the absolute stereochemistry using (R,R)-DACH Phenyl Trost. 
In summary, using the decarboxylative Tsuji allylation, we were able to achieve ee’s up to 66% with 
full conversion of the starting enol carbonate. As we were not able to further improve these results, 
we then investigated other methodologies for the installation of the quaternary stereocenter. 
 
3.1.3 Direct allylation of the tetralone§ 
We next investigated direct allylation methodologies related to the decarboxylative Tsuji allylation. 
Trost reported conditions for a direct allylation using allyl palladium(II) chloride dimer ([(𝜂3-
C3H5)PdCl]2), a Trost ligand, allyl acetate as allyl source and Cs2CO3 as base (Table I.10).  
Table I.10 Conditions tested for the direct Tsuji allylation starting from ketone I.226. 
 
Entry Ligand Solvent T (°C) t (h) %ee 
1 (R,R)-DACH-Phenyl Trost (I.235) DME 0 12 7 
2 (R,R)-DACH-Naphthyl Trost (I.236) DME 0 12 5 
3 (R,R)-ANDEN-Phenyl Trost (I.237) DME 0 12 2 
                                                      
§ All experiments were carried out by the author in the laboratories of Prof. Brian Stoltz at the California Institute of  
  Technology in Pasadena, CA, USA. 
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We tested all three commercially available Trost ligands – DACH-Phenyl (I.235), DACH-Naphthyl 
(I.236) and ANDEN-Phenyl (I.237). Although all three gave full conversion, poor enantiomeric 
excess was observed (entries 1−3). 
We thus changed the system completely and envisaged an Ir-catalyzed allylation. Recently, Stoltz 
and co-workers reported an asymmetric allylation of acyclic β-ketoesters.[295] Due to the acidity of 
the α-carbon in tetralone I.228, we believed that this methodology could also be applicable for our 
substrate. At this point, it was important to take into consideration that Ir-catalyzed allylations 
usually lead to branched products. Aware of this, we initially wanted to investigate the general 
applicability of this methodology. The test reaction was carried out using [Ir(cod)Cl]2 (5 mol%), 
ligand I.230 (10 mol%), and 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) in degassed THF. After 
10 minutes, the preformed catalyst was added to a solution of LiOt-Bu and ketone I.228 followed 
by the addition of cinnamyl carbonate. The reaction stirred at 25 °C for 48 h. After this time, the 
reaction was filtered and analysis via chiral HPLC and NMR suggested that a dr of 1:1.3 at the 
benzylic quaternary stereocenter of I.239 was obtained. As these results were not very promising, 
we did not investigate this strategy further.  
 
Scheme I.47 Direct Iridium-catalyzed Tsuji allylation. 
Next we explored the use of an alkylation published by Pfau and D’Angelo, who reported an 
enantioselective synthesis of quaternary carbon centers through alkylation of chiral imines.[296] This 
method was applied in Corey’s synthesis of a benzenoid analogue of glycinoeclepin A.[297] Pfau and 
D’Angelo reported their method for additions to Michael systems but we reasoned that using our 
acidic tetralone, α-allylations could be facilitated as well.  
 
Scheme I.48 Pfau and D’Angelo’s chiral alkylation method. 
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Following Corey’s procedure, tetralone I.226, (R)-α-methylbenzylamine and MgSO4 were heated in 
toluene to 120 °C for 24 h, then allyl bromide was added and the reaction was stirred at 50 °C for 
15 h. Then, THF and acetic acid were added. Unfortunately, only starting material was observed. 
As this reaction did not work, we changed the substrate for the alkylation and attempted the use of 
allylated β-tetralone I.219. Ketone I.243 was prepared in two steps in high yields from tetralone 
I.219 using a racemic decarboxylative Tsuji allylation (Scheme I.49 via enol carbonate I.242).  
 
Scheme I.49 Synthesis of allylcyclohexanone I.243. 
With allylcyclohexanone I.243 in hand, we investigated the previously introduced alkylation method 
via imine I.244 using the electronically different electrophiles bromoacetonitrile, acrylonitrile and 
methylacrylate (Table I.11, entries 1−3). However, only starting material was recovered under all 
reaction conditions. 
Table I.11 Conditions tested for the alkylation of tetralone I.243. 
 
Entry Electrophile Expected product Observation 
1 bromoacetonitrile I.227 no reaction 
2 acrylonitrile I.245 no reaction 
3 methylacrylate I.246 no reaction 
Given that the best results were obtained with the decarboxylative Tsuji allylation, we decided to 
investigate enantiomeric enrichment of the compound, as the yield of the allylation was almost 
quantitative and the product was highly crystalline. Enantiomeric enrichment and separation of the 
enantiomers would also possibly allow for the determination of absolute stereochemistry. 
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3.1.4 Enantiomeric enrichment and determination of the absolute stereochemistry 
Modern organic synthesis focuses on the development of asymmetric methodology for the 
synthesis of chiral compounds, however, as demonstrated in the previous chapters, not all reactions 
can be optimized to provide good enantioselectivities. Also, scale up of an asymmetric 
methodology is not always possible and therefore several methods for the separation of 
enantiomers have been developed. Chiral column chromatography and chiral HPLC are popular 
methods for the separation of enantiomers.[298] We separated the two enantiomers of I.227 by chiral 
HPLC, isolating approximately 150 mg of each enantiomer. Both samples were then crystallized 
individually from chloroform at 0 °C. The absolute stereochemistry, which was previously 
anticipated using Trost’s model, was confirmed by X-ray crystallography.** Although no heavy atom 
was present in the molecule and MoKα radiation was used, stereochemistry could be determined 
due to high-resolution data up to 0.6 Å with a Flack parameter of x = −0.1(2) for the (R)-
enantiomer and x = −0.09(2) for the (S)-enantiomer.  
  
 
 
 
 
 
R-enantiomer 
retention time: 10.96 min 
S-enantiomer 
retention time: 12.37 min 
 
Figure I.9 Determination of the absolute stereochemistry of I.227 by chiral HPLC and X-ray analysis.†† 
 
These findings are in agreement with the structural assignment based on Trost’s model for the 
stereochemical outcome of Tsuji allylations with (R,R)-DACH phenyl Trost ligand (I.235) giving 
mainly (S)-I.227 and (S,S)-DACH phenyl preferentially forming (R)-I.227. As the (R)-enantiomer is 
the desired stereoisomer for (+)-stephadiamine (I.1), we carried out the asymmetric decarboxylative 
Tsuji allylation using (S,S)-DACH phenyl Trost ligand and then investigated the crystallization of 
the resuting (R)-enantiomer. 
                                                      
**  X-Ray analysis was carried out by Dr. Peter Mayer at LMU Munich using MoKα-radiation. If the Flack parameter, which 
is based on the anomalous dispersion effect, is found to be near 0, the absolute structure, which is determined by structure 
refinement, is probably correct. If the value is close to 1, the opposite structure would be correct. If a value of x = 0.5 is 
obtained, the crystal could be either racemic or twinned. 
†† Retention time was determined on a DAICEL CHIRALPAK® IB column (see chapter 8.2). 
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For synthetic purposes, it would be advantageous to separate the enantiomers via crystallization 
rather than by chiral HPLC, so as to obtain large amounts of the desired enantiomer. After some 
experimentation with various solvent mixtures, it was found that best results were obtained when 
(R)-I.227 was recrystallized from a mixture of Et2O:n-heptane (3:10) at 4 °C. Under these 
conditions, an ee of 97% was obtained. HPLC analysis revealed a remaining 1:1 mixture of both 
enantiomers in the mother liquor. The near quantitatively yielding asymmetric decarboxylative Tsuji 
allylation in combination with a single recrystallization thus consitutes a viable method for the 
synthesis of large quantities of either enantiomer, if needed in the future. 
 
3.1.5 List’s organocatalytic version of the direct Tsuji allylation 
In 2016, an organocatalytic direct allylation method was published by List and co-workers.[299] 
Using material that was prepared in our laboratories,‡‡ a collaborator from the List group carried 
out a Pd-catalyzed allylation making use of their powerful asymmetric counteranion-directed 
catalysis (ACDC) methodology.[300] Using the chiral phosphoric acid (S)-H8-TRIP (I.248) in 
combination with Pd2(dba)3 and t-BuXPhos in cyclohexane at 10 °C, they were able to get yields of 
63% (97% based on recovered starting material) with a remarkable er of 97:3 after 96 h reaction 
time. 
  
Scheme I.50 Direct Tsuji allylation of nitrile I.226. 
In additional experiments, higher yields with slightly lower ee’s were obtained when the reaction was 
run at a higher concentration. This method would not only shorten the sequence by one step, as 
compared to the decarboxylative Tsuji allylation, but also furnishes the α-allylcyclohexanone I.227 
with a much higher ee. 
 
  
                                                      
‡‡ All experiments were carried out by Gabriele Pupo in the List laboratories at the Max-Planck-Institute for Kohlenforschung             
   in Mühlheim an der Ruhr, GER. 
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3.2 Metathesis and cascade reaction 
3.2.1 Ester approach 
With allylcyclohexanone I.227 in hand, we investigated the alkene cross metathesis reaction with 
methyl acrylate. Under optimized conditions, I.227 underwent metathesis to give unsaturated ester 
I.218 in 90% yield using Hoveyda−Grubbs catalyst 2nd generation (GH II, I.250) in toluene. It 
should be noted that the yield of this transformation was significantly lower using Grubbs II 
catalyst (G II, I.249), probably due to side reactions of the catalyst with the acrylate ester. It has 
been reported that the tricyclohexylphosphine (PCy3) ligand reacts with acrylates to create a reactive 
carbanion that engages in multiple pathways, e.g., Rauhut−Currier reaction and catalyst 
deactivation.[301]  
 
 
Scheme I.51 Metathesis of I.227 with methyl acrylate. 
Following our retrosynthetic analysis, we screened conditions for the reductive aldol reaction to 
furnish tricyclic intermediate I.252 or the elimination product I.253 (Scheme I.52). Following 
conjugate reduction, we anticipated that the resultant ester enolate would engage the more reactive 
ketone. We expected that ester I.251 could be a major side product of this reaction.§§  
 
Scheme I.52 Strategy for the construction of tricycle I.252 or I.153. 
A variety of hydride sources such as boranes, indium hydrides, rhodium hydrides and copper 
hydrides are typical conditions for this type of transformation,[302] with Stryker’s reagent 
                                                      
§§  An authentic sample of I.251 was obtained by hydrogenation with Pd/C under hydrogen atmosphere; see Scheme I.55. 
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[(PPh3)CuH]6 being the most popular. Therefore, we started our investigations with this hexameric, 
air-sensitive copper hydride complex (Table I.12). 
Table I.12 Conditions tested for the reductive aldol reaction of ester I.218. 
 
Entry Conditionsa) Observation 
1 [PPh3CuH]6 (1.5 eq.), toluene,  −40 °C, 4 h →  sat. NH4Cl mixture of I.251, I.252, I.254 
2 [PPh3CuH]6 (1.5 eq.), toluene,  −40 °C, 4 h →  sat. NH4Cl mixture of I.251, I.252, I.254 
3 [PPh3CuH]6 (0.5 eq.), toluene, −78 °C to −40 °C, 10 h → sat. NH4Cl >50% I.252 
4 [PPh3CuH]6 (0.5 eq.), toluene, 0 °C, 4 h →  sat. NH4Cl 38% I.254b) 
5 [PPh3CuH]6 (0.5 eq.), toluene, r.t., 4 h → sat. NH4Cl 41% I.254b) 
6 [PPh3CuH]6 (0.33 eq.), toluene, r.t., 18 h → sat. NH4Cl 34% I.254b) 
7 [PPh3CuH]6 (0.5 eq.), toluene, r.t., 4 h → 1 M HCl + TMEDA 60% I.254b) 
8 [PPh3CuH]6 (0.5 eq.), toluene, r.t., 4 h → citric acid + TMEDA 47% I.254b) 
9 Cu(OAc)2 (0.5 eq.), TMDS, dppf, THF, r.t. 24 h → 1 M HCl + TMEDA 30% I.254b) 
10 Cu(OAc)2 (0.1 eq.), TMDS, rac-BINAP, THF, r.t. 24 h → 1 M HCl + TMEDA 63% I.218 and 37% I.254 
11 Cu(OAc)2 (0.5 eq.), TMDS, rac-BINAP, THF, r.t. 24 h → 1 M HCl + TMEDA 60% I.254b) 
12 Cu(OAc)2 (1 eq.), TMDS, rac-BINAP, THF, r.t. 24 h → NaH, 0 °C, 2 h complex mixture 
13 L-selectride (1.6 eq.), THF, −78 °C, 1 h → sat. NH4Cl decomposition 
14 Rh(cod)2OTf, PPh3, H2, K2CO3, DCE starting material 
a) All solvents were degassed using standard freeze-pump-thaw techniques (minimum of three cycles) 
b) Material was accompanied by decomposed starting material and I.251 as the major by-product 
In our first experiments, Stryker’s reagent was dissolved in degassed toluene and cooled to −40 °C. 
Enone I.218 was added and after 4 h, all starting material had disappeared, and the reaction was 
stopped by the addition of aqueous saturated NH4Cl solution. NMR analysis indicated the presence 
of at least three different compounds, two of which were 1,4-reduction product I.251 and desired 
nitrile I.252. To our surprise, the third substance was unambiguously identified as lactone I.254 
(Table I.12, entry 1). 
We therefore investigated other conditions for reductive aldol reactions. With Stryker’s reagent in 
toluene at −40 °C for 4 h traces of product I.254 were observed (entry 2). By lowering the amount 
of Stryker’s reagent to 0.5 equivalents and the temperature to −78 °C (slowly warmed to −40 °C) 
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for 10 h, tertiary alcohol I.252 was obtained as the major product (more than 50% by NMR, 
entry 3). When this sample was dried under reduced pressure, we observed slow transformation to 
lactone I.254, indicating that alcohol I.252 is an intermediate en route to lactone I.254. Using the 
same conditions at 0 °C, we isolated lactone I.254 in 38% yield (entry 4) and at room temperature 
the yield raised to 41% (entry 5). Surprisingly, by prolonging the reaction time from 4 h to 18 h, the 
yield dropped to 34% (entry 6). 
Lactone I.254 was often isolated as a green solid, indicating the presence of residual copper. 
Therefore, we changed the work-up procedure to include a tetramethylenediamine (TMEDA) 
wash. In this way, we were able to improve the yield to 60% (entry 7). When citric acid was used, 
the yield dropped to 47% (entry 8). 
 
Scheme I.53 Suggested mechanism for the copper-hydride induced reductive aldol cascade reaction. 
We then investigated in situ formation of copper hydride based on methodology developed by Lam 
an co-workers (entry 9–12).[303] Using copper(II) acetate, 1,1′-bis(diphenylphosphino)ferrocene 
(dppf) and tetramethyldisiloxane (TMDS) in THF, we isolated lactone I.254 in 30% yield (entry 9). 
By changing the ligand to racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) and using 
0.1 eq. copper (II) acetate, we observed starting material I.218 and 47% of the desired lactone I.254 
(entry 10). By using 0.5 eq. copper (II) acetate, the yield increased to 60%, and we observed very 
clean conversion (entry 11). 
For the formation of propellane product I.254, we propose that the addition of a copper hydride,  
formed in situ from Cu(OAc)2, BINAP and TMDS, provides enolate I.255 (Scheme I.53), which 
undergoes an intramolecular aldol reaction to furnish copper-chelate I.256. Following a simple 
aqueous work up, we were able to isolate traces of I.252, which supports our mechanistical 
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hypothesis. Upon addition of TMEDA to the reaction mixture, copper (II) is sequestered, and an 
intramolecular attack of the alkoxide in I.257 to the nitrile, likely due to their close proximity, gives 
imidate I.258. Upon aqueous acidic work-up, this imidate is then hydrolyzed to lactone I.254.  
 
The crystal structure of lactone I.254 revealed a perfect antiperiplanar configuration of the α-
hydrogen next to the ester and the oxygen of the lactone. We therefore reasoned that addition of 
base could lead to a retro-oxa-Michael addition and the thus obtained product could be converted 
to an amide. However, adding sodium hydride (NaH) to the reaction led to a complex reaction 
mixture, which did not contain lactone I.254 or the elimination product I.253 (entry 12). In 
conclusion, both copper hydride sources, Stryker’s reagent and copper (II) acetate in combination 
with silane, yielded lactone I.254 in 60% yield. However, in situ copper hydride formation proved to 
be more reliable and gave cleaner conversion to desired product I.254. 
In addition to these copper hydride-mediated reactions, we also investigated the use of L-selectride 
as a hydride source, however this transformation led to decomposition of the starting material 
(entry 13).[304–305] Using Rh(cod)2OTf, triphenylphosphine and hydrogen, only starting material was 
isolated (entry 14).[306] 
As these yields could not be improved further, we envisaged to install the lactam present in 
stephadiamine I.1 via condensation with methylamine as described by Elworthy et al.[307] In our case, 
however, lactone I.254 could not be opened using methylamine in ethanol, and only hydrolysis of 
the methyl ester was observed when the reaction was carried out in H2O (Scheme I.54). In addition, 
we also tried to trigger a retro-oxa-Michael addition by the addition of LDA at −78 °C and slowly 
warming to room temperature, nevertheless no reaction occurred (not shown). 
 
Scheme I.54 Attempted condensation of lactone I.254 with methylamine. 
We therefore envisaged to carry out the cascade reaction in a stepwise manner and potentially stop 
at the stage of tertiary alcohol I.252 as described by Pinto’s synthesis of gibberellin analogs[308]  and 
Feldman’s synthesis of nordiamantane.[309] Conjugated ester I.218 was hydrogenated using 
palladium on charcoal (Pd/C) under hydrogen atmosphere to give ester I.251 (Scheme I.55). 
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Scheme I.55 Hydrogenation of unsaturated ester I.218. 
When ester I.251 was treated with sodium methoxide (NaOMe, 0.25 eq.) in methanol at moderate 
temperature, we were able to isolate a mixture of starting material and tertiary alcohol I.252 (Table 
I.13, entry 1).[308] This result was particularly interesting for us as we had observed the formation of 
exactly the same compound as an intermediate in the reductive aldol cascade reation. Using 1.2 eq. 
sodium methoxide in methanol at 75 °C, we isolated two new products, which were identified as 
I.260 and its epimer I.261 (entry 2). As this compound now features the azapropellane core of 
stephadiamine (I.1), which we tried to install in previous attempts (see Scheme I.54), we decided to 
keep this reaction as the key step of our synthesis. We optimized the reaction conditions and found 
that the use of freshly prepared NaOMe gave the best results (entries 3−4). Eventually, we were 
able to obtain lactam I.260 in a 99% yield. 
Table I.13 Conditions tested for the aldol reaction of I.251. 
 
Entry 
Scale 
[mmol] Conditions 
I.251 : I.252 : 
I.260+I.261a) 
d.r. of I.260 : 
I.261 
1 0.3 NaOMe (0.25 eq.), MeOH, 20 °C to 70 °C, 12 h 1 : 2 : 0 − 
2 0.3 NaOMe (1.2 eq.), MeOH, 75 °C, 26 h 0 : 0 : >99 4:1 
3 0.3 Na (1.2 eq.), MeOH, 75 °C, 26 h 0 : 0 : >99 9:1 
4 3.2 Na (1.2 eq), 3 Å MS, MeOH, 75 °C, 16 h 0 : 0 : >99 10:1 
a) Ratio was determined by comparison of the methoxy signals in the 1H NMR spectrum of the crude reaction mixture. 
 
Our findings resemble the cascade reaction reported by Inubushi and co-workers for their synthesis 
of cepharamine (see chapter 1.1.3),[154–155] although in our case a [3.3.4]-propellane core with an 
additional stereocenter is constructed from I.251.  
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Mechanistically, we propose that this remarkably efficient transformation proceeds analogously to 
Inubushi’s cascade reaction and the formation of lactone I.254. Initial deprotonation of compound 
I.251 would lead to the formation of enolate I.262. Intramolecular acylation of this compound, 
however, would lead to a bridged and relatively strained intermediate. Most probably, a small amout 
of ester enolate I.263 is formed, which readily undergoes intramolecular aldol reaction with the 
ketone to give tertiary alkoxide I.257. As described before, this alkoxide subsequently adds into the 
proximal nitrile. The formed imidate I.258 then undergoes a retro-oxa Michael reaction under the 
basic reaction conditions to give tricyclic primary carbamate anion I.263. Finally, aza-Michael 
addition and diastereoselective protonation provides lactams I.260 and I.261 in a 10:1 ratio. 
 
Scheme I.56 Proposed mechanism for the formation of lactams I.260 and I.261. 
Lactams I.260 and I.261 have been separated by column chromatography and have been both fully 
characterized. In addition, we were able to obtain crystal structures of both diastereomers (see 
Scheme I.57, Lewis structures are presented according to the crystal structures). 
 
       
Scheme I.57 Crystal structures of diastereomers I.260 and I.261. 
Under all reaction conditions, diastereomer I.260 was obtained as the major diastereomer. At this 
point we envisaged that I.260 could be a precursor for an intramolecular nitrene insertion to install 
NaOMe
MeOH
OMe
MeO
O
NC
O
OMe
H2O
N
OMe
MeO
H
O OMe
H
dr = 10:1
+O
OMe
MeO
O
NC
O
OMe
I.251
I.260I.258
I.262 I.263
I.264
N
OMe
MeO
O
H
H
MeO
O
I.261
+H
I.257
-H
OMe
MeO
O
NC
O
OMe
O
OMe
MeO
N
O OMe
H
O
OMe
MeO
H
O OMe
N
OMe
MeO
MeO
O
HN
O
N
OMe
MeO
H
O OMe
N
OMe
MeO
O
HH
H
MeO
O
O
I.260 I.261
≡≡
RESULTS AND DISCUSSION 
 
63  
the second ATA and we therefore considered that a modified substrate could induce the cascade 
sequence to give I.261 as the major diastereomer. For example increasing the bulk of the ester 
could potentially lead to a diastereomeric ratio in favour of I.261. With this idea in mind, we carried 
out a metathesis starting from α-allylcyclohexanone I.227 using tert-butyl acrylate instead of methyl 
acrylate (Scheme I.58). Unsaturated ester I.265 was hydrogenated to give cascade precursor I.266. 
Using KOt-Bu and the corresponding solvent tert-butanol, cascade product I.267 was readily 
obtained, but again with the same diastereoselectivity.  
  
Scheme I.58 cascade reaction using tert-butyl ester I.266. 
As this approach proved unsuccessful, cascade product I.260 was N-methylated. Under standard 
conditions, epimerization of the diastereomeric center was observed. When I.260 alone was used 
for the N-methylation, a 5:3 mixture of N-methylated cascade products I.259 and I.268 was 
obtained at 55 °C (Scheme I.59).  
 
Scheme I.59 Equilibration of the diastereomeric center in I.260 at 55 °C under basic conditions. 
We reasoned that a large N-substituent, such as a Boc group, would add significant bulk to this 
position and result in the preferential formation of one ester diastereomer upon treatment with 
base. By using standard Boc-protection conditions, however, no reaction occurred. Under forcing 
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conditions using Boc2O, NEt3 and 4-dimethylaminopyridine (DMAP) at 85 °C,[310] N-Boc lactam 
I.269 could be obtained in 42% yield. No formation of I.270 was observed when I.260 was used as 
a single diastereomer (Scheme I.60). Additionally, treatment of I.269 with sodium hydride resulted 
in no change. 
 
Scheme I.60 Boc protection of lactam I.260. 
As attempts to equilibrate the ester did not succeed, cascade product I.260 was N-methylated under 
milder conditions to preserve the diastereomeric ratio of the starting material (Scheme I.61).  
               
Scheme I.61 Methylation of lactam I.260. 
At this point, challenging α-carbomethoxylation of ester I.259 was investigated. Attempted 
formation of silylketene acetal starting from I.259 using LDA and TMSCl did not yield any product 
(not shown). We therefore focused on a direct carboxylation of the α-position using a variety of 
reagents and bases (Table I.14). 
Deprotonation of ester I.259 with LDA at −78 °C followed by addition of Mander’s reagent 
(methyl cyanoformate) did not yield any product (entry 1). Using lithium bis(trimethylsilyl)amide 
(LiHMDS) and Mander’s reagent, clean starting material I.259 was isolated (entry 2). By contrast, 
usage of n-butyllithium (n-BuLi) led to decomposition of the starting material (entry 3). Dimethyl 
carbonate or methyl chloroformate with NaH as a base, led only to epimerization of the starting 
material (up to a ratio of 1:1, entries 4 and 5). These results suggest that sodium hydride is able to 
deprotonate the α-position, but attack into an electrophile seems to be problematic due to the 
steric hinderance around the propellane core. As a control experiment, we checked if hindered 
bases such as LDA were able to deprotonate substrate I.259 at −78 °C. Therefore CD3OD  was 
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added to deuterate the substrate following addition of LDA. However, the α-proton was still fully 
visible in the NMR, suggesting that LDA is too sterically demanding for this substrate (entry 6).  
Table I.14 Conditions tested for the α-acylation of ester I.259. 
 
Entry Conditionsa) Obervation 
1 Mander's reagent, LDA, THF, −78 °C to 20 °C, 32 h starting material reisolated 
2 Mander's reagent, LiHMDS, THF, −78 °C to 20 °C, 32 h starting material reisolated 
3 Mander's reagent, n-BuLi, THF, −78 °C to 20 °C, 32 h decomposition 
4 dimethyl carbonate, NaH, THF, 50 °C, 24 h epimerized starting material 
5 methyl chloroformate, NaH, THF, 50 °C to 70 °C, 24 h epimerized starting material 
6 LDA, THF, −78 °C to CD3OD  no incorporation of deuterium 
 
In addition, we attempted to reduce lactam I.259 chemoselectively to the tertiary amine I.273 in the 
presence of the ester and then investigate the α-carboxylation. Beller’s procedure (Zn(OAc)2, 
(EtO)3SiH, THF, r.t.)[311] gave no reaction, Ru3(CO)12 and TMDS led to decomposition of the 
starting material.[312]   
 
Scheme I.62 Reduction of the lactam to the corresponding tertiary amine I.259. 
As direct reduction was not applicable, the lactam was transformed into thionolactam I.272 using 
Lawesson’s reagent (Scheme I.62). This was then cleanly reduced to the tertiary amine with Raney-
Ni and hydrogen using a protocol that was applied in Boger’s synthesis of vindoline,[313] however, 
subsequent α-carboxylation of ester I.273 proved unsuccessful as well (Table I.15).  
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Table I.15 Conditions tested for the α-carboxylation of ester I.273. 
 
Entry Conditionsa) Obervation 
1 Mander's reagent, NaH, THF, 0 °C to 20 °C, 48 h no reaction 
2 dimethyl carbonate, NaH, THF, 0 °C to 20 °C, 48 h epimerization at α-carbon of I.273 
3 dimethyl carbonate, NaH, toluene, 80 °C, 48 h no reaction 
4 dimethyl carbonate (neat), NaH, 80 °C, 48 h no reaction 
5 dimethyl carbonate, NaOMe, MeOH, 75 °C, 17 h decomposition 
6 methyl chloroformate, NaH, THF, 0 °C to 20 °C, 48 h no reaction 
 
Turning to a different approach, we investigated the possibility to install the lactone following 
benzylic oxidation by an intramolecular carboxylation via intermediate I.276 to circumvent issues 
associated with steric hindrance around the ester moiety. We envisaged a benzylic oxidation to 
access secondary alcohol I.275. O-Acylation to install carbonate I.276 followed by base-mediated 
lactone formation could then furnish compound I.277. 
 
Scheme I.63 Alternative strategy lactone construction. 
For this purpose, a set of oxidations was investigated that could potentially lead to oxidation 
products I.275, I.278 and I.279 (Table I.16). Oxidation with Jones reagent in acetone at 0 °C led to 
decomposition of the starting material (entry 1).[158–159] By contrast, no reaction occurred using 
potassium permanganate and copper(II) sulfate or Pearlman’s catalyst (Pd(OH)2/C) in combination 
with tert-butyl hydroperoxide (TBHP) (entries 2 and 3). Excess ceric ammonium nitrate (CAN) in a 
1:20 mixture of H2O and acetonitrile led to decomposition (entry 4). By contrast, lowering the 
amount of CAN to 2 equivalents and changing the solvent ratio to 1:1, we isolated trace amounts 
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of a compound that was identified as ketone I.278 (by 1H NMR and HRMS, entry 5).*** 
Unfortunately, we were never able to improve the yield to synthetically useful levels. We therefore 
continued testing other methods for the benzylic oxidation (entries 6−8) and eventually found that 
heating I.259 in a mixture of excess DDQ and acetic acid in DCE[314] afforded styrene derivative 
I.280 in 50% yield (entry 8). 
Table I.16 Conditions tested for the benzylic oxidation of propellane I.259. 
 
Entry Conditions Observation 
1 Jones reagent, acetone, 0 °C decomposition 
2 KMnO4/CuSO4, DCM, 50 °C no reaction 
3 Pd(OH)2/C, TBHP, K2CO3, DCM, 4 °C to r.t. no reaction 
4 CAN, 20:1 MeCN/ H2O, r.t. decomposition 
5 CAN, 1:1 MeCN/ H2O, r.t. 
mainly starting material I.259 and traces of 
ketone I.278 
6 TBHP, Co(acac)2, acetone, r.t., 48 h no reaction 
7 DDQ, 1:1 dioxane/acetone, r.t. no reaction 
8 DDQ/AcOH,DCE, 4Å MS, 75 °C, 5 h elimination product I.280 (50% yield) 
 
We envisaged that styrene I.280 could serve as a handle for a Wacker oxidation or a Mukaiyama 
hydration.[315] For the Mukayama hydration, Mn(dpm)3, oxygen and PhSiH3 in methanol did not 
lead to any conversion (Table I.17, entry 1)[316] whereas the use of Co(acac)2 led to a complex 
mixture of compounds (entry 2).[317] Wacker conditions using palladium(II)acetate, para-
benzoquinone (p-BQ), and fluoroboric acid (HBF4) in a mixture of N,N-dimethylacetamide 
(DMA), acetonitrile and H2O also failed to provide any conversion (entry 3).[318] 
                                                      
*** The experiments with CAN as oxidant were carried out by Dr. Hongdong Hao.  
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Table I.17 Conditions tested for the benzylic oxidation of styrene I.280. 
 
Entry Conditions Observation 
1 Mn(dpm)3, PhSiH3, O2, MeOH, r.t. no reaction 
2 Co(acac)2, PhSiH3, O2, THF, r.t. complex mixture 
3 Pd(OAc)2, p-BQ, DMA, MeCN, H2O, aq. HBF4, r.t. no reaction 
 
As it was not possible to install the quaternary stereo center next to the ester functionality, we 
turned our attention to a different approach. 
 
 
3.2.2 Aldehyde approach 
In parallel to the previous approach, the same reactions were investigated with the corresponding 
aldehyde instead of an ester. However, metathesis of substrate I.227 with crotonaldehyde proved to 
be more challenging than the previous metathesis reaction using methyl acrylate (see chapter 3.2.1). 
Using Grubbs II catalyst (I.249) and excess croton aldehyde in toluene at 20 °C, the reaction was 
relatively slow and 49% of I.281 was isolated after 40 h reaction time (Table I.18, entry 1). Using 
10 mol% grubbs II catalyst (I.249) and 10 eq. crotonaldehyde in DCM, the reaction stalled after 
12 h and a yield of 53% was obtained (entry 2). Elevating the temperature to 50 °C did not increase 
the yield of the reaction (entry 3). By changing to Hoveyda−Grubbs II catalyst (I.250) in DCM, the 
yield increased to 75% after 12 h reaction time at room temperature. When the reaction was heated 
to 50 °C, the yield decreased to 69% (entry 5). In addition to Grubbs II (I.249) and 
Hoveyda−Grubbs II catalyst (I.250), we investigated the use of nitro-Grela catalyst (I.282), which 
gave a significantly lower yield (entry 6).  
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Table I.18 Conditons screened for the synthesis of aldehyde I.281. 
  
Entry Conditions a) T t Observation 
1 Grubbs II (5 mol%),  crotonaldehyde (17 eq.), toluene 20 °C 40 h 49% I.281 
2 Grubbs II (10 mol%), crotonaldehyde (10 eq.), DCM 20 °C 12 h 53% I.281 
3 Grubbs II (10 mol%), crotonaldehyde (10 eq.), DCM 50 °C 12 h 52% I.281 
4 Hoveyda−Grubbs II (10 mol%), crotonaldehyde (10 eq.), DCM 20 °C 12 h 75% I.281 
5 Hoveyda−Grubbs II (10 mol%), crotonaldehyde (10 eq.), DCM 50 °C 12 h 69% I.281 
6 nitro-Grela (10 mol%), crotonaldehyde (10 eq.), DCM 20 °C 12 h 42% I.281 
a) Crotonaldehyde was freshly distilled and solvents were degassed prior to usage 
Having secured significant quantities of enal I.281, we then investigated the reductive aldol reaction 
on this substrate. When Stryker’s reagent was used at −40 °C, decomposition of the starting 
material was observed under acidic and basic work-up conditions (Table I.19, entry 1 and 2). 
Krische’s procedure using Rh(cod)2OTf and hydrogen led to a complex reaction mixture, which did 
not contain any of the desired products.[319]  
Table I.19 Conditions tested for the reductive aldol reaction of aldehyde I.281. 
 
Entry Conditionsa) Observation 
1 Stryker's reagent, toluene, −40 °C, 4 h → HCl, TMEDA decomposition 
2 Stryker's reagent, toluene, −40 °C, 4 h → NaOMe, TMEDA decomposition 
3 Rh(cod)2OTf, PPh3, H2 (1 atm), K2CO3, THF, 40 °C, 4 h complex mixture 
a) All solvents were degassed using standard freeze-pump-thaw tequniques (miniumum of three cycles) 
At this point we attempted the same hydrogenation/cyclization sequence for substrate I.281 (see 
chapter 3.2.1). As the cascade reaction occurred with methyl ester I.251 and tert-butyl ester I.266 
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under basic conditions in protic solvent, it was expected that the cascade would also occur with an 
aldehyde instead of an ester. Reduction of the double bond yielded an unstable saturated aldehyde 
(not shown), that was subjected to cascade conditions. The reaction proceeded either at room 
temperature overnight or at 75 °C in 3.5 h and gave 85% conversion to the cascade product I.284.  
 
Scheme I.64 Synthesis of cascade product I.284. 
Using cascade product I.284, we tried the direct amination of the acidic α-position of the aldehyde 
using dibenzyldiazodicarboxylate (DBAD) and proline as an organocatalyst. This method has been 
described for the α-amination of aldehydes and was successfully used for the implementation of 
ATAs in the past.[320–322] However, when applying these conditions to our substrate, only starting 
material I.284 was obtained (Table I.20, entry 1). Diethyl azodicarboxylate (DEAD) proved 
ineffective as well (entry 2). 
We then turned our attention to α-carboxylations rather than α-aminations of aldehyde I.284. 
Using proline and MgSO4 followed by methylchloroformate, a very slow conversion to a new 
product was observed. After 48 h the reaction was stopped and the compound was identified as 
ketone I.285. 
Table I.20 Conditions tested for the α-funtionalization of aldehyde I.284. 
 
Entry Conditionsa) Observation 
1 proline, DBAD, MeCN, 20 °C, 48 h no reaction 
2 proline, DEAD, MgSO4, THF, 20 °C, 48 h no reaction 
3 pyrrolidine, THF, MgSO4 → methyl chloroformate in THF, 48 h formation of ketone I.285 
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We were interested in an explanation for the unexpected formation of ketone I.285 via 
deformylation, as the product could be used for the installation of the ATA (see chapter 1.1.2.1). In 
most examples in the literature, deformylation reactions are mediated by metals.[323] However few 
examples using metal-free deformylations have been reported, such as Yamamoto’s 
nitrosobenzene-mediated C−C bond cleavage[324] and Johnson’s Lewis acid-promoted C−C bond 
cleavage of aziridines.[325] In addition, Chi and co-workers reported a metal-free oxidative C−C 
bond cleavage using amines and oxygen.[326] Adapting their mechanistic proposal, we suggest the 
following mechanism for the observed oxidation (Scheme I.65): the respective amine and aldehyde 
I.284 condense to form enamine I.286, which engages oxygen to form peroxide anion I.287. 
Dioxetane formation to I.288 followed by retro-[2+2] cycloaddition would then give ketone I.285.  
 
Scheme I.65 Plausible mechanism for the deformylation of aldehyde I.284. 
We realized that ketone I.285 could serve as a substrate for a Strecker or Bucherer−Bergs reaction 
to install the second ATA. Prior to additional experiments, we investigated enamine formation in 
deuterated chloroform and deuterated toluene. In both solvents full conversion to the enamine was 
observed after 1 h reaction time. 
To obtain ketone I.285 on a preparative scale, we investigated the use of pyrrolidine (amine A), as 
this amine initially led to the discovery of the reaction product. By applying oxygen (5 bar) in 
toluene to the reaction mixture, we obtained traces of product, which were accompanied by an 
inseparable side product - most likely the formylated amine (Table I.21, entry 1). We envisaged that 
by addition of MgSO4 we would facilitate elimination of H2O, however no product was observed in 
this case (entry 2). Next we turned our attention to p-anisidine (amine B), an amine also used in 
Chi’s methodology.[326] However, no formation of the desired product was observed (entries 3 and 
4). We next screened for more electron-rich anilines such as 3,4-dimethoxyaniline (amine C) and 
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3,4,5-trimethoxyaniline (amine D) (entries 5−12), which more readily form the enamine and oxidize 
more quickly. Although 3,4-dimethoxyaniline was ineffective (entry 5), we observed formation of 
significant amounts of desired ketone I.285 with 3,4,5-trimethoxyaniline: a mixture of starting 
material I.284 and product I.285 was obtained (entry 7) in CHCl3. Finally, by switching to toluene 
as a solvent, we observed complete conversion to the product by 1H NMR. 
Table I.21 Conditions tested for the synthesis of ketone I.284. 
 
Entry Conditionsa) Observation 
1 amine A, toluene, r.t., 1 h → O2 (5 bar), 33 h I.285 and inseparable byproduct 
2 amine A, toluene, MgSO4, r.t., 1 h → O2 (5 bar), 33 h starting material I.284 
3 amine B, toluene, r.t., 1 h → O2 (5 bar), 20.5 h → MeOH, HCl complex reaction mixture 
4 amine B, toluene, r.t., 1 h → O2 (5 bar), 20.5 h → NH4Cl complex reaction mixture 
5 amine C, toluene, r.t., 1 h → O2 (5 bar), 20.5 h complex reaction mixture 
6 amine D, CHCl3, 4 Å MS, r.t., 1 h → O2 (5 bar), 24 h mixture of starting material I.284 and I.285 
7 amine D, toluene, O2, 4 Å MS, r.t., 1 h → O2 (5 bar), 24 h I.285 and inseparable byproduct 
8 amine D, toluene, r.t., 1 h → O2 (5 bar), 20.5 h → NaHCO3 (pH 12) I.285 and inseparable byproduct 
9 amine D, toluene, r.t., 1 h → O2 (5 bar), 20.5 h → NH4Cl I.285  and inseparable byproduct 
10 amine D, toluene, r.t., 1 h → O2 (5 bar), 20.5 h → NH4Cl, dissolved in 1 M HCl 32% I.285 
11 amine D, toluene, 4 Å MS, r.t., 1 h → O2 (5 bar), 24 h → HCl 41% I.285 
12 amine D, r.t., 1 h → O2 (1 bar), TPP, CDCl3, reptile lamp, r.t., 20 min mixture of I.285 and enamine I.286 
13 Cu(OAc)2·H2O, DBU, DMF, O2, 75 °C, 1.5 h decomposition 
14 Cu(OAc)2·H2O, DBU, DMF, O2 (5 bar), r.t., 33 h decomposition 
15 Cu(OAc)2·H2O, DABCO, 2,2′-bipyridine, DMF, O2, 75 °C, 1.5 h decomposition 
 
At this point, a set of different work-up conditions was investigated, as we found that ketone I.285 
was always accompanied by a side product, most likely formylated amine D (entries 8−11). Workup 
with NaHCO3 or NH4Cl gave ketone I.285 accompanied with inseparable side products (entries 8 
and 9). By washing the product with ammonium chloride and stirring the crude reaction mixture in 
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1 M hydrochloric acid followed by column chromatography, we obtained 32% of the clean product 
I.285 (entry 10). By adding hydrochloric acid to the reaction mixture and stirring for another 1 h, 
we obtained a yield of 41% (entry 11). In addition, photocatalytic conditions using the 
photosensitizer tetraphenylporphyrin (TPP) and a reptile lamp as light source did not yield any 
product (entry 12). 
When we were not able to improve the yields further, we investigated Cu-catalyzed conditions 
(entries 13−15). The earliest report of an aldehyde that was converted to a ketone by oxidative C−C 
bond cleavage was published in 1969 by van Rheenen using Cu(OAc)2 and (1,4-
diazabicyclo[2.2.2]octane) (DABCO).[327] Similar to van Rheenen, Nitta et al. published a strategy 
using a different base (1,8-diazabicyclo[5.4.0]undec-7-ene, DBU).[328] Following their procedures, 
the reactions were carried out using a copper catalyst and an amine base (DBU or DABCO) at 
75 °C or room temperature (entries 13−15). Unfortunately, decomposition of the starting material 
was observed in all cases.  
With small amounts of ketone I.285 in hand, we tested the transformation of this functional 
handle. Following a procedure by Reisman and co-workers,[329] we tried to form the chiral 
sulfinimine I.289 using tert-butanesulfinamide and titanium (IV) ethoxide, but only starting material 
was reisolated (Scheme I.66). As ketone I.285 could not be obtained in good yields and its 
condensation to the corresponding sulfinimine was not successful, we went back to investigate the 
α-functionalization of aldehyde I.284. 
 
Scheme I.66 Attempted sulfinimine formation of ketone I.285. 
We assumed that the unprotected lactam could be problematic in the α-fuctionalization of aldehyde 
I.284 and therefore attempted N-methylation or Boc-protection of lactam nitrogen. However, 
using the conditions we had previously established for the derivatization of ester I.260 (see chapter 
3.2.1), no desired product was obtained – probably due to the competing reactivity of the aldehyde 
(Table I.22, entry 1−3). 
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Table I.22 Conditions tested for the functionalization of lactam I.284. 
 
Entry Conditions Observation 
1 MeI, NaH, DMF, 0 °C complex mixture 
2 NaH, Boc2O, DMAP, DMF, 50 °C, 12 h decomposition 
3 NEt3, Boc2O, DMAP, DCM, 20 °C, 12 h decomposition 
 
To prevent undesired reactivity from the aldehyde, we protected the aldehyde as dimethoxyacetal 
I.292 (Scheme I.67). Subsequent N-Methylation then occurred smoothly using iodomethane (MeI) 
and sodium hydride in DMF at elevated temperatures. For the deprotection of this aldehyde I.293 a 
variety of mild methods such as indium(III)triflate in acetone, were applied. Eventually, we found 
that iodine in acetone gave clean conversion to the aldehyde I.290 and all impurities could be 
removed in the work-up process.  
 
 
Scheme I.67 Synthesis of N-methylated cascade product I.290. 
As this sequence was rather lenghthy and involved several unstable intermediates, we investigated 
the reduction of ester I.259 to aldehyde I.290 using diisobutylaluminium hydride (DIBAL-H, Table 
I.23). This transformation needed careful optimization, as sometimes overreduction of the ester to 
the alcohol I.294 (and its epimer) or the amide to the tertiary amine was observed. It was found 
that 2.0 to 3.0 equivalents of DIBAL-H were needed for clean conversion to aldehyde I.290. We 
applied two common work-up methods for DIBAL-H – addition of potassium sodium tartrate and 
the Fieser work-up. Using 2 and 3 equivalents of DIBAL-H in DCM, the reaction was quenched 
after 4 h at −78 °C by the addition of ethyl acetate followed by Rochelle salt (potassium sodium 
tartrate) to form an aluminum tartrate complex (entries 1 and 2). Quenching with NaOH (Fieser 
work-up), led to the formation of unwanted side products (entries 3 and 4). The fully reduced 
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alcohol I.294 could be identified in the reaction mixture amongst other unknown species. Hence, 
the reaction was quenched at –78 °C with ethyl acetate to destroy excess DIBAL-H (entries 5 and 
6). Sodium hydroxide solution was subsequently added at this temperature and the reaction was 
slowly allowed to warm to room temperature. Under these conditions, it was possible to reach 
yields up to 84% of desired aldehyde I.290 after flash column chromatography, critically, over 
DAVISIL® (entry 6).  
Table I.23 Reduction of ester I.259 to aldehyde I.290. 
  
Entry Conditionsa) Work-up Ratioa) [I.259:I.294:side products] 
1 DIBAL-H (2.0 eq.), 4 h EtOAc / Na,K-tartrate [23:77:0] 
2 DIBAL-H (3.0 eq.), 4 h EtOAc / Na,K-tartrate [39:61:0] 
3 DIBAL-H (3.0 eq.), 4 h NaOH [0:25:75] 
4 DIBAL-H (2.0 eq.), 4 h NaOH [0:21:79] 
5 DIBAL-H (2.5 eq.), 2 h EtOAc / NaOH [0:64:36] 
6 DIBAL-H (2.5 eq.), 3 h EtOAc / NaOH 
[0:100:0] 
84% isolated yield 
a) The ratio was determined by 1H NMR by integration of the two methoxy signals of the starting material, the side product and the aldehyde  
 
With clean aldehyde I.290 in hand, we reinvestigated its carboxymethylation (Table I.24). With 
dimethyl chloroformate, methyl carbonate or Mander’s reagent, only decomposition was observed 
(entries 1−3). Additionally, when applying the same α-amination conditions as attempted for 
aldehyde I.290, no reaction occurred (entry 4). 
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Table I.24 Conditions tested for the functionalization of aldehyde I.290. 
 
entry Conditionsa) observation 
1 dimethyl carbonate, LiHMDS, THF decomposition 
2 methyl chloroformate, LiHMDS, THF, −78 °C decomposition 
3 Mander’s reagent, LiHMDS, THF, −78 °C decomposition 
4 pyrrolidine, CDCl3 → DBAD, toluene, 20 °C No reaction 
 
At this juncture, we aspired to make use of previously synthesized dimethyl acetal I.293 and induce 
elimination of MeOH to form reactive enol ether I.296, which could potentially be 
α-functionalized. Following a procedure by Garg and co-workers,[330] substrate I.293 was treated 
with N,N-diisopropylethylamine (Hünig's base, DIPEA) and TMSOTf and the reaction proceed to 
full conversion. (Scheme I.68). Unfortunately, the isolated product was not enol ether I.296, but 
instead demethylated lactam I.292 with the acetal still intact.  
 
Scheme I.68 Attempted elimination of methanol from acetal I.290. 
The demethylation most likely proceeds via intermediate I.297, which undergoes dealkylation 
(Scheme I.69). Although this transformation was not of practical use at this stage, it provided 
insight into the Lewis basicity of this lactam, which we could exploit at a later step in the synthesis 
to selectively convert it into the tertiary amine found in stephadiamine (I.1). 
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Scheme I.69 Possible mechanism for the demethylation of I.293. 
At this point, we took a deeper look into the literature and found that Cook et al. faced a similar 
problem toward the synthesis of sarpagine- and ajmaline alkaloids and state that „numerous efforts 
(aldolizations, alkylations, and acylations) were originally carried out to construct the quaternary carbon center at C-
16, but they were not successful. gratifyingly, it was found that the aldehydic group at C-16 could be converted into 
diol in 85% yield via the Tollens reaction with 37% aqueous formaldehyde (5 equiv) and KOH (10 equiv) in 
methanol.“[331] We reasoned that this approach makes use of a very small base and a small 
electrophile, which may be suited for our system.  
 
Scheme I.70 Cook’s approach for the installation of a quaternary stereo center. 
We thus carried out a Tollens reaction (crossed Cannizzaro reaction) starting from aldehyde I.290, 
and indeed, after 15 h, a new compound was formed. It was identified to be diol I.300, wherein the 
desired prochiral quaternary carbon had been successfully installed. We screened various amounts 
of base and formaldehyde at different temperatures (Table I.25, entries 1−5). Under optimized 
conditions, we were able to obtain diol I.300 with a yield of 73%.  
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Table I.25 Conditions screened for the Tollens reaction. 
 
Entry Conditions Yield 
1 KOH (10 eq.), formaldehyde (25 eq.), r.t., 48 h 46% 
2 KOH (10 eq.), formaldehyde (10 eq.), r.t., 48 h 41% 
3 KOH (5 eq.), formaldehyde (25 eq.), r.t., 48 h 43% 
4 KOH (10 eq.), formaldehyde (25 eq.), 50 °C, 48 h 61% 
5 KOH (10 eq.), formaldehyde (10 eq.), 50 °C, 48 h 73% 
 
With prochiral diol I.300 in hand, we then set out to install the second ATA and the δ-lactone of 
stephadiamine I.1.  
 
3.3 Implementation of the second ATA 
Starting from diol I.300, the next goal was the installation of the second ATA. For this purpose, the 
two hydroxyl groups of I.300 had to be differentiated. Initially we planned a simultaneous 
oxidation of both alcohols to furnish either bisaldehyde I.301 or malonic acid I.302 (Table I.26). 
Oxidation of diol I.300 under Corey−Kim conditions led to decomposition of the starting material 
(entry 1), whereas Swern oxidation led to a complex reaction mixture (entry 2). Using classical 
Ley−Griffith conditions or benzeneseleninic acid anhydride [(PhSeO)2O] in chlorobenzene at 
110 °C, we were able to isolate traces of mono-oxidation products I.304 and I.305 as a 1:1 mixture, 
however, no dialdehyde I.301 could be isolated (entry 3 and 4). These results suggest that the steric 
environment of the two hydroxyl groups and the potential instability of a dialdehyde I.301 
significantly hampered attempts to isolate the desired product.  
In attempts to access malonic acid I.302, Jones oxidation, 2,2,6,6-tetramethylpiperidinyloxyl 
(TEMPO)/(diacetoxyiodo)benzene (BAIB, [PhI(OAc)2]), aqueous Ley−Griffith conditions and 
Corey−Schmidt oxidations were investigated, but decomposition was observed under all conditions 
(entries 5−8). Attempted direct oxidation to ester I.303 using iodine and potassium carbonate in 
methanol did not occur, and only starting material was isolated (entry 9).  
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Table I.26 Oxidation of diol I.300. 
 
Entry Oxidation type Conditionsa) Expected Product Observation 
1 Corey-Kim NCS, DMS, Et3N, DCM, −78 °C I.301 decomposition 
2 Swern DMSO, (COCl)2, Et3N, DCM, −78 °C I.301 complex mixture 
3 Ley−Griffith TPAP, NMO, DCM, 4 Å MS, r.t., 1 h I.301 1:1 mixture of I.304 and I.305 
4 (PhSeO)2O 
(PhSeO)2O (1.0 eq.), chlorobenzene, 
110°C, 30 min I.301 1:1 mixture of I.304 and I.305 
5 Jones CrO3, H2SO4, H2O, acetone, 0 °C I.302 decomposition 
6 TEMPO/BAIB TEMPO/BAIB, MeCN/H2O I.302 decomposition 
7 Ley−Griffith (aq.) TPAP, NMO · H2O, DCM, 0 °C I.302 decarboxylation (by HRMS) 
8 Corey−Schmidt PDC, DMF, r.t. I.302 decomposition 
9 I2/MeOH I2, MeOH, K2CO3, 70 °C I.303 no reaction 
 
As oxidation of the diol was not feasible, we opted for differentiation of the diol by benzylic 
etherification as described by Cook (Scheme I.71).[332]  
 
Scheme I.71 Cook’s differentiation of diol I.306. 
First, we investigated the use of DDQ in THF at 65 °C and observed traces of benzylic ether I.308 
(entry 1). Using DDQ in a mixture of DMF and THF led to no reaction (entry 2) whereas DDQ in 
THF with 3Å MS at either room temperature or 65 °C led to decomposition of the starting material 
or
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(entries 3 and 4). Performing the reaction under O2 atmosphere also led to decomposition of the 
starting material I.300 (entry 5). We then went back to the reaction conditions that were found for 
the installation of a benzylic double bond (see chapter 3.2.1, Table I.16), namely DDQ and acetic 
acid in DCE at 75 °C (entry 6). Under these conditions, desired cyclic ether I.308 was obtained 
71% yield. 
Table I.27 Conditions tested for the oxidative functionalization of diol I.300. 
 
 
Entry Conditions Observation 
1 DDQ (5.9 eq.), THF, 65°C, 1 h traces of cyclic ether I.308 
2 DDQ (8.7 eq.), THF/DMF (8:2), 65°C, 2 h starting material I.300 
3 DDQ (5.9 eq.), THF, 3 Å MS, rt, 14 h decomposition 
4 DDQ (5.9 eq.), THF, 3 Å MS, 65°C 4.5 h decomposition 
5 DDQ (5.9 eq.), O2 (1 bar), THF, 3 Å MS, rt, 1 h decomposition 
6 DDQ (10 eq.), AcOH (10 eq.), DCE, 3 Å MS, 75 °C, 5 h cyclic ether I.308 (71%) 
 
Having successfully differentiated the two alcohols, we next had to transform intermediate I.308 
into carboxylic acid I.309. At the beginning, conditions for the direct oxidation to the carboxylic 
acid I.310 were tested (Table I.28). RuCl3/NaIO4 primarily gave aldehyde I.310 after 1.5 h reaction 
time and acid I.309 after 12 h, albeit in low yields (entries 1 and 2). Using tetrapropylammonium 
perruthenate (TPAP) and N-methylmorpholine-N-oxide monohydrate (NMO· H2O), varying 
mixtures of aldehyde I.310 and carboxylic acid I.309 were observed after 1, 5 and 12 h (entries 
3−5). Even when H2O was added and the reaction heated to 40 °C, a mixture of aldehyde I.309 
and carboxylic acid I.310 was obtained (entries 6 and 7). At this point, we decided to pursue a 
stepwise oxidation of the primary alcohol I.308 and application of classic Ley−Griffith conditions, 
namely catalytic TPAP and NMO in DCM, which provided aldehyde I.310 (entry 8).  
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Table I.28 Conditions tested for the oxidation of alcohol I.308. 
     
Entry Conditions Observation 
1 RuCl3, NaIO4, MeCN:CCl4:H2O 2:2:3, r.t., 1.5 h mainly I.310 
2 RuCl3, NaIO4, MeCN:CCl4:H2O 2:2:3, r.t., 12 h acid I.309, low yields 
3 TPAP, NMO · H2O, MeCN, r.t., 1 h aldehyde I.310 (traces) 
4 TPAP, NMO · H2O, MeCN, r.t., 5 h mix of I.309 and I.310 
5 TPAP, NMO · H2O, MeCN, r.t., 12 h mix of I.309 and I.310 
6 TPAP, NMO · H2O, MeCN/H2O, r.t., 12 h mix of I.309 and I.310 
7 TPAP, NMO · H2O, MeCN/H2O, 40 °C, 12 h mix of I.309 and I.310 
8 TPAP, NMO, DCM, 4Å MS, r.t., 1 h aldehyde I.310 (70%) 
 
With aldehyde I.310 in hand, we applied Pinnick−Lindgren conditions with 2-methyl-2-butene as 
scavenger for hypochlorous acid (HOCl). This transformation again occurred in near quantitative 
yield and provided carboxylic acid I.309, which could be used in the next step without 
chromatographic purification.  
 
Scheme I.72 Synthesis of acid I.309. 
Next, we investigated the Curtius rearrangement for the installation of the second ATA starting 
from carboxylic acid I.309 (Scheme I.73). As stated before, 1,2-sigmatropic rearrangements are 
arguably the most popular choice for the synthesis of primary ATAs in sterically demanding 
environments (see chapter 1.1.2.2). First, we used diphenylphosphoryl azide (DPPA) and 
triethylamine in benzene to form the carboxylic azide (for mechanism see Scheme I.16). The 
reaction was then heated to 100 °C to facilitate rearrangement to the isocyanate. tert-Butanol was 
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added with the intention to obtain the Boc-protected ATA, but only isocyanate I.311 could be 
isolated.  
 
 
Scheme I.73 Installation of the second ATA using a Curtius rearrangement. Cbz = carboxybenzyl. 
We reasoned that tert-butanol is sterically too demanding for this substrate and therefore added 
methanol instead. This gave methyl carbamate I.312 in 81% yield.[129] Additionally, it was possible 
to obtain Cbz-protected amine I.313 using BnOH. With both ATAs of stephadiamine (I.1) now 
installed, we turned our attention to the remaining δ-lactone (see chapter 3.4). 
 
 
3.4 Installation of the lactone 
With ATAs I.312 and I.313 in hand, our next goal in the synthesis of stephadiamine (I.1) was the 
installation of the δ-lactone, the final ring of the molecule. Starting from Cbz-protected amine 
I.313, we first envisaged to install the δ-lactone via a direct C−H oxidation. Although this 
transformation requires relatively harsh oxidative conditions, there are several precedents in the 
literature, e.g., in Thomson’s synthesis of maoecrystal V (I.314),[333] Zhang’s synthesis of 
jiadifenolide (I.315),[334] Wu’s synthesis of artemisinin (I.316),[335] Piva’s synthesis of amphiasterin 
B4 (I.317) (Figure I.10),[336] Vanderwal’s formal synthesis of 7,20-diisocyanoadociane[337] and 
Senter’s studies of ring systems similar to ophiobolins and ceroplastins (not shown).[338] 
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Figure I.10 Natural products with lactones installed via late-stage oxidation of a cyclic ether. 
Most of these late-stage oxidations have been applied in terpenoid total synthesis and none of the 
natural products depicted contain either an (electron-rich) aromatic ring or a nitrogen atom. When 
surveying the literature, numerous reports concerning directed and undirected C−H oxidations can 
be found over the last few years. Again, however, the number of reports for molecules that contain 
an aromatic ring and/or nitrogen atoms is very limited. An example of a C−H oxidation of 
morphine derivative I.318 in the presence of an electron-poor aromatic ring and a tertiary amine to 
the respective ketone I.319 and alcohol I.320 can be found in Christina White’s remote oxidation 
of aliphatic C−H Bonds using the White−Chen catalysts I.321 or I.322 (Scheme I.74). It comes as 
no surprise that in order to showcase her oxidative C−H activation methodology on alkaloid-like 
structures, she exchanged the “natural” methoxy group for a strongly electron-withdrawing triflate 
to reduce the electron density in the aromatic ring.[339–340]  
 
Scheme I.74 White’s C−H oxidation of nitrogen-containing molecules. 
We started off with the most commonly employed set of oxidation conditions including ruthenium 
tetroxide (RuO4), chromium trioxide (CrO3) and potassium permanganate (KMnO4) (Table I.29). 
With RuCl3 in combination with NaIO4 or KMnO4 only decomposition of the starting material was 
observed (entries 1 and 2). By contrast, RuCl3 with BAIB did not lead to any reaction (entry 3). 
Next, we investigated CrO3 as an oxidant (entries 4–7). Jones oxidation led to a complex reaction 
mixture (entry 4), whereas when CrO3 in combination with 2,4-dimethylpyrazole was used, only 
starting material was observed (entry 5). The same result was obtained using CrO3 in combination 
with acetic acid at 50 °C (entry 6). However, if the temperature was raised to 75°C, decomposition 
of the starting material was observed (entry 7). Next, we applied KMnO4 in combination with 
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FeCl3 and Cu(OTf)2,[341] but in both cases only decomposition was observed (entries 8 and 9). 
Finally, we investigated the White−Chen catalyst, which has already seen applications in the 
oxidative C−H funtionalization of alkaloids (entry 10).[339, 342] Under these conditions, 
decomposition was observed − probably due to the electron rich nature of the aromatic core.  
Table I.29 Conditions tested for the oxidation of cyclic ether I.313 to lactol I.323 or lactone I.324. 
 
Entry Conditions Observation 
1 RuCl3, NaIO4, MeCN, CCl4, H2O decomposition 
2 RuCl3, KMnO4, MeCN, H2O, 0 °C to r.t. decomposition 
3 RuCl3, PhI(OAc)2, MeCN, CCl4, H2O, 0 °C to r.t. starting material 
4 Jones reagent, acetone, 0 °C to r.t. complex mixture 
5 CrO3, 2,4-dimethylpyrazole, DCM, 0 °C to r.t. starting material 
6 AcOH, CrO3, DCM, 50 °C, 12 h starting material 
7 AcOH, CrO3, DCE, 75 °C, 12 h decomposition 
8 KMnO4, FeCl3, acetone, 0 °C to r.t. decomposition 
9 KMnO4, Cu(OTf)2, acetone, 0 °C to r.t. decomposition 
10 White−Chen catalyst, AcOH, H2O2, MeCN, r.t., 25 min decomposition 
11 DMDO, acetone, 0 °C to 20 °C no reaction 
 
As none of the conditions listed in Table I.29 led to a productive result, we stopped investigating 
the direct oxidation of the ether to the lactone and decided to cleave and oxidize the C−O bond 
followed by ring closure. The reductive opening of benzylic ethers is a relatively common 
transformation that can be achieved via hydrogenation or Lewis acid activation.[343] Initially, we 
tested PtO2 and Pd/C in combination with hydrogen (1 bar), but only deprotection of the amine 
was detected (Table I.30, entries 1 and 2). Then, we applied Et3SiH in TFA/DCM,[344–345] TFA and 
AcOH/DCM at room temperature, but in every case only starting material was recovered (entry 
3−6). All three conditions were also investigated at elevated temperature (reaction was slowly 
warmed to 75 °C) without success. 
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Table I.30 Conditions tested for the hydrogenation of the benzylic C−O bond. 
 
Entry Starting material Conditions Observation 
1 I.313 PtO2, H2, AcOH, r.t., 1.5 h Cbz-deprotection of compound I.313 
2 I.313 Pd/C, H2, MeOH, r.t., 15 h Cbz-deprotection of compound I.313 
3 I.312 TFA, Et3SiH, DCM, r.t., 12 h no reaction 
4 I.313 TFA, Et3SiH, DCM, r.t., 12 h no reaction 
5 I.313 TFA, Et3SiH, r.t., 12 h no reaction 
6 I.313 AcOH, Et3SiH, 50 °C, 12 h no reaction 
 
As this approach proved unsuccessful, different conditions were investigated to enable the 
elimination of the benzyl ether to give alcohol I.327 (Table I.31). Heating ether I.313 under basic 
or acidic conditions was unproductive (entries 1 and 2), as well as attempted thermal elimination in 
DMF or toluene at temperatures up to 120 °C (entries 3 and 4). No reaction occurred either with 
TMSOTf, TBSOTf, TMSCl or BF3 · OEt2 from −78 °C to room temperature (entries 5−8). Given 
these results, we surmised that the elimination was a reversible process and therefore used BF3 · 
OEt2 in combination with either trifluoroacetic anhydride (TFAA, entry 9) or Ac2O (entry 10) to 
trap the eliminated alkoxide I.327. And indeed, a mixture of elimination products oxazolidinone 
I.328 and oxazolidinone I.329 were obtained (entry 10). Attempts to optimize the formation of 
oxazolidinone I.329 by utilizing different polar solvents, such as nitromethane, 
hexafluoroisopropanol (HFIP) and dioxane, were all met with either decomposition or re-isolation 
of starting material (entries 11−13). 
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Table I.31 Conditions tested for the Lewis-acid assisted elimination of benzyl ether I.313. 
 
 
Entry Conditions Observation 
1 NaOH, MeOH, 85 °C, 12 h no reaction 
2 CSA, MeOH, 85 °C, 12 h no reaction 
3 DMF, 120 °C, 24 h no reaction 
4 toluene, 120 °C, 24 h no reaction 
5 TBSOTf2 NEt3, DCM, −78 °C to 20 °C no reaction 
6 TMSOTf2, NEt3, DCM, −78 °C to 20 °C no reaction 
7 TMSCl, NEt3, DCM, −78 °C to 20 °C no reaction 
8 BF3·OEt2, Et3SiH, DCM, r.t., 12 h no reaction 
9 BF3·OEt2, TFAA, r.t., 12 h decomposition 
10 BF3·OEt2, Ac2O, r.t., 24 h mixture of I.328 and I.329 
11 BF3·OEt2, MeNO2, r.t. to 50 °C, 12 h no reaction 
12 BF3·OEt2, HFIP, 0 °C to r.t., 12 h decomposition 
13 BF3·OEt2, dioxane, 0 °C to r.t., 12 h decomposition 
 
We therefore focused on the optimization of the reaction conditions used in entry 10. It was found 
that a 3:1 mixture of Ac2O to BF3·OEt2 at 0 °C gave the cleanest conversion to oxazolidinone I.329 
(Scheme I.75). In some cases, acetylated oxazolidinone I.328 was obtained as a side product. This, 
however, could be transformed into oxazolidinone I.329 using In(OTf)3 and methanol. 
 
Scheme I.75 Conversion of ether I.313 to oxazolidinone I.329 (opposite enantiomer depicted). 
N
OMe
MeO
O
O
H
CbzHN
N
OMe
MeO
O
AcN
O
O
N
OMe
MeO
O
HN
O
O
I.328 I.329I.313
N
OMe
MeO
O
OH
CbzHN
I.327
conditions
BF3Ƅ2(W$F2
s&ȾUWK
I.313
N
OMe
MeO
O
O
H
CbzHN
N
OMe
MeO
O
HN O
O
(98%)
I.329
≡
RESULTS AND DISCUSSION 
 
87  
Oxazolidinone I.329 was then Boc-protected to give compound I.330 in 81% yield and then 
hydrolyzed using Cs2CO3 in methanol to give alcohol I.331 in 83% yield (Scheme I.76). 
 
Scheme I.76 Boc-protectiong and selective oxazolidinone hydrolysis. 
To install the lactone, we needed to oxidize aminoalcohol I.331 to aldehyde I.332 or carboxylic acid 
I.333. Direct oxidation to acid I.333 was investigated first. Using classic Jones oxidation conditions, 
TEMPO/BAIB or Corey−Schmidt conditions decomposition was observed (Table I.32, entries 
1−3). Using aqueous Ley−Griffith conditions, oxidation to aldehyde I.332 was observed, along with 
significant decomposition of the material (entry 4). We therefore opted for a stepwise oxidation to 
the carboxylic acid I.333 via aldehyde I.332. Swern oxidation led to a complex reaction mixture 
(entry 5), but Ley−Griffith oxidation gave clean conversion to the desired aldehyde in near 
quantitative yield with no chromatographic purification needed (entry 6). 
Table I.32 Conditions tested for the oxidation of I.331. 
 
 
Entry Oxidation type Conditionsa) Expected Product Observation 
1 Jones CrO3, H2SO4, H2O, acetone, 0 °C I.333 decomposition 
2 TEMPO/BAIB TEMPO/BAIB, phosphate buffer pH = 6.3, MeCN/H2O I.333 decomposition 
3 Corey−Schmidt PDC, DMF, r.t. I.333 decomposition 
4 aq. Ley−Griffith TPAP/NMO, H2O/MeCN/CCl4 I.333 oxidation to I.332, then slow decomposition 
5 Swern DMSO, (COCl)2, Et3N, DCM, −78 °C I.332 complex mixture 
6 Ley−Griffith TPAP, NMO · H2O, DCM, r.t., 1 h I.332 clean product, 96% 
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For the oxidation of aldehyde I.332 to carboxylic acid I.333, we first applied classic 
Pinnick−Lindgren conditions (Table I.33, entries 1−3). Using sodium chlorite with phosphate 
buffer in a mixture of tert-butanol/H2O and 2-methyl-2-butene as scavenger, the formation of a 
side product was observed whose structure could unambiguously be assigned as I.338 using HRMS 
and 2D NMR techniques. This same compound was found, when sodium chlorite with phosphate 
buffer in a mixture of tert-butanol/H2O and hydrogen peroxide as scavenger was used. 
Reproducing this side reaction proved to be challenging and decomposition was often observed. 
From a mechanistic standpoint, we expected oxidation of the aldehyde to acid I.336 would occur 
with concomitant formation of HOCl, which is usually trapped by the scavenger (Scheme I.77). 
However, due to the very electron rich nature of the styrene, HOCl reacted, forming chloronium 
ion I.337. This intermediate could then be trapped by the carboxylic acid to form chlorolactone 
I.338.  
 
Scheme I.77 Hypothetical mechanism for the formation of chlorolactone I.338. 
Following this mechanistic hypothesis, we next investigated an oxidation under Pinnick−Lindgren 
conditions without addition of external scavenger. Under these conditions, we observed traces of 
the desired chlorolactone I.338, but mainly another compound was formed, which was identified as 
oxazolidinone I.340 by HRMS and 2D NMR (entry 3). Under these conditions, the formation of 
chloronium ion I.339 appears to be faster than the oxidation to acid I.336. Intermediate I.339 is 
presumably trapped by the aldehyde, which is in turn trapped by the Boc-group to form 
oxazolidinone I.340 (mechanism A, Scheme I.78). In an alternative mechanism, a chlorohydrin 
could be formed directly from styrene I.332 and the resulting hydroxyl group of I.341 could add to 
the aldehyde, which in turn would form oxazolidinone I.340 following extrusion of tert-butanol 
(mechanism B, Scheme I.78). 
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Scheme I.78 Possible mechanism for formation of oxazolidinone I.340. 
To investigate reactivity further, we subjected aldehyde I.332 to iodine and potassium hydroxide 
(KOH) in acetonitrile and H2O (Table I.33, entry 4). As expected, oxazolidinone I.342 was formed 
and, again, the reaction could proceed either via mechanism A or B. We then applied less basic 
conditions by using potassium carbonate in a mixture of tert-butanol and H2O and this time no 
reaction was observed (entry 5). In the last experiment in this series, we subjected aldehyde I.332 to 
iodine in dry acetonitrile and stirred the reaction mixture in the dark at room temperature (entry 6). 
Although no H2O or base was added, the reaction went to completion within 24 h and 
oxazolidinone I.342 was isolated in 91% yield. This reaction strongly supports that, at least for the 
iodine-mediated reactions, the mechanism occurs most likely via mechanism A. Although these 
studies gave us valuable insight into the reactivity of styrene I.332, oxazolidinone I.342 did not 
prove to be a viable intermediate for the synthesis of stephadiamine (I.1). 
Therefore, we applied a few additional oxidation conditions in attempt to obtain carboxylic acid 
I.336. Pyridinium chlorochromate (PCC) in DMF only led to decomposition of the starting 
material (entry 7). When Bobbitt’s salt [4-(cetylamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium 
tetrafluoroborate] was used in stoichiometric quantities, complete decomposition of the starting 
material was observed (entry 8), whereas with catalytic 2-azaadamantane-N-oxyl (AZADO) or 1-
methyl-2-azaadamantane-N-oxyl (Me-AZADO), each with sodium chlorite as the terminal oxidant, 
no reaction occurred and starting material was reisolated (entries 9 and 10). Silver(II) oxide (Ag2O) 
and aqueous NaOH also proved to be ineffective (entry 11). 
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Table I.33 Oxidation of aldehyde I.332. 
 
Entry Conditionsa) Observation 
1 NaClO2, NaH2PO4, 2-methyl-2-butene, t-BuOH, H2O traces of I.338 
2 NaClO2, NaH2PO4, H2O2, t-BuOH, H2O traces of I.338 
3 NaClO2, NaH2PO4, t-BuOH, H2O I.340 and traces of I.338 
4 I2, KOH, MeCN/H2O I.342 
5 I2, K2CO3, H2O, t-BuOH, r.t., 24 h no reaction 
6 I2, MeCN, r.t., 24 h I.342 (91%) 
7 PCC, DMF, r.t., 15 h decomposition 
8 Bobbitt’s salt [4-(acetylamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium tetrafluoroborate] decomposition 
9 AZADO, DCM, NaOAc buffer, NaClO2, 15 h no reaction 
10 Me-AZADO, DCM, NaOAc buffer, NaClO2, 15 h no reaction 
11 Ag2O, NaOH, H2O, r.t., 4 h no reaction 
 
As oxidation of I.332 to carboxylic acid I.333 was not possible without ring closure, we opted for 
an intermediate containing a less electrophilic carbonyl carbon, namely methyl ester I.343. Ester 
I.343 was easily obtained from aldehyde I.332 with ten equivalents of iodine in methanol in the 
dark.[49, 346] This transformation was clean and starting material was consumed within 15 min at 
room temperature. 
 
Scheme I.79 Oxidation to the methyl ester I.346. 
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The ester could not be hydrolyzed under standard conditions, such as sodium hydroxide in aqueous 
methanol (entry 1, Table I.34). The same lack of reactivity was observed with TMSOK in THF, 
LiOH in aqueous THF or LiI in pyridine at elevated temperatures (entries 2−4). 
Table I.34 Conditions tested for the hydrolysis of ester I.343. 
 
Entry Conditionsa) Observation 
1 NaOH, MeOH, H2O, 80 °C, 12 h no reaction 
2 TMSOK, THF, 50 °C, 12 h no reaction 
3 LiOH, THF, H2O, r.t. to 50°C, 15 h no reaction 
4 LiI, pyridine, 130 °C, 2 h no reaction 
 
As these attempts proved to be ineffective, we next tried to close the lactone directly starting from 
ester I.343 (Table I.35). Using triflic acid in deuterated chloroform, a complex reaction mixture was 
obtained that contained at least three different unidentifiable compounds by 1H NMR (entry 1). 
Using p-toluenesulfonic acid (p-TSA) at elevated temperatures failed to convert any of the starting 
material (entry 2). 
Inspired by our previous results, iodolactonization of ester I.343 was investigated. This type of 
reaction is relatively rare, but a few examples and studies have been published over the years. First, 
we applied standard conditions using iodine in acetonitrile and H2O at 0 °C with warming, but to 
no avail (entry 3). Iodine in acetonitrile at room temperature, led only to deprotected starting 
material I.349 (entry 4). 
 
Scheme I.80 Proposed mechanism for the formation of bromolactone I.346. 
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Then, we attempted to close the lactone using a related approach via the intermediacy of a 
halohydrin.[347] Bromohydrin formation should occur stereoselectively due to facial blocking of the 
ester of I.343. We reasoned that bromonium ion I.344 chould be opened by H2O from the β-face 
and that resultant alcohol I.345 could then directly form δ-lactone I.346. 
To test this hypothesis, we reacted compound I.346 with NBS in a mixture of THF and H2O in the 
dark (entry 5). After 1.5 hours at this temperature and another 1.5 h at room temperature, starting 
material had disappeared, and we observed two new compounds by 1H NMR, one of which 
showed key signals that were analogous to chlorolactone I.338. HRMS (ESI) indicated the 
formation of bromohydrin I.345 and bromolactone I.346. After stirring this mixture in methanol 
for 30 min at room temperature, I.345 was converted into bromolactone I.346, suggesting that 
I.345 is an intermediate in the formation of I.346. This, however, does not exclude the possibility 
of a direct lactonization of methyl ester I.343. Using the same conditions but with N-
iodosuccinimide (NIS) in place of NBS, no reaction occurred, and starting material was recovered 
(entry 6). 
Table I.35 Conditions tested for the cyclization of ester I.343 to lactone I.346, I.347 or I.348. 
 
Entry Conditionsa) Observation 
1 TfOH, CDCl3, complex mixture 
2 p-TSA, DCE, 50 °C to 80 °C, 24 h no reaction 
3 I2, MeCN, H2O, 0 °C to r.t. no reaction 
4 I2, MeCN, 0 °C to r.t. formation of I.349 by HRMS 
5 NBS, THF:H2O (1:1) then MeOH I.346 (82%) 
6 NIS, THF:H2O (1:1) no reaction 
 
In summary, the synthesis of the δ-lactone proved to be highly challenging, but bromolactone I.349 
was installed in six steps starting from Curtius product I.313. 
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3.5 Completion of the synthesis 
With bromolactone I.346 in hand, the remaining steps in the synthesis of stephadiamine I.1 were 
the reduction of the lactam to a tertiary amine, removal of the secondary bromide and Boc-
deprotection. In order to reduce the lactam and the secondary bromide in a single step, we 
transformed lactam I.346 into thionolactam I.350.††† Then, two Nickel-based reductions were 
applied: Raney-nickel and nickel(II)chloride/sodium borohydride (Table I.36). Unfortunately, no 
product could be isolated in both cases, although the mass of the desired amine I.251 was present 
by HRMS (ESI). We reasoned that nickel might be strongly coordinated to the 1,2-cis-diamine, and 
thus investigated different work-up protocols. Caddick described for his reduction of nitriles using 
nickel(II)chloride/sodium borohydride that the introduction of complexing amines during work-up 
significantly improved the isolation of their Boc protected amine.[348] We attempted to address this 
by filtration of the reaction through celite and work-up with ethylenediaminetetraacetic acid 
(EDTA), however, no product was isolated. 
Table I.36 Conditions tested for the reduction on I.346. 
 
 
Entry Conditions Observation 
1 Raney-Nickel, H2, MeOH, r.t., 4 h decomposition, HRMS indicates presence of I.351 
2 NiCl2 · 6 H2O, NaBH4, MeOH, 0 °C, 30 min. decomposition, HRMS indicates presence of I.351 
 
As reduction of the thionolactam did not give us any productive results, we investigated the direct 
reduction of the lactam to the tertiary amine in the presence of the lactone. The most common 
method to reduce lactams to tertiary amines is reduction with LiAlH4, however due to the presence 
of a lactone and a Boc-group, a different method for chemoselective reduction had to be applied. 
In most cases, boranes are used for the chemoselective reduction of lactams in the presence of 
lactones, esters and ketones.[349–351] We therefore first investigated the use of borane dimethyl 
sulfide (BH3· Me2S) for the reduction of lactam I.346. Using three equivalents of BH3· Me2S in 
THF at room temperature, clean starting material was recovered (Table I.37, entry 1). When ten 
equivalents were used, we observed a complex reaction mixture by 1H NMR and HRMS (ESI), 
indicating overreduction to amino acid derivative I.354 (entry 2).  
                                                      
†††  Thionolactam I.350 could not be obtained as a clean compound. Structure was tentatively assigned by 1H NMR, 2D 
NMR and HRMS-ESI. 
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Following this, we attempted the use of Vaska’s complex [Ir (CO)(PPh3)2Cl], which was recently 
used by Chida in his synthesis of neostenine[352] and Dixon’s construction of the strychnine 
core.[353]. In both cases, the chemoselective reduction of the lactam in presence of lactones, esters 
and ketones was achieved with high selectivities in excellent yield. First, we followed Chida’s 
procedure using Ir(CO)(PPh3)2Cl, 1,1,3,3-tetramethyldisiloxane (TMDS) in DCM at room 
temperature.[352] In principle, after reduction to the hemiaminal, the amine should condense to the 
iminium ion under acidic conditions and be further reduced in situ. Following this procedure, we 
observed the formation of two new compounds. By HRMS (ESI) these compounds were identified 
as a mixture of lactam I.351 and enamine I.353. To our surprise, the secondary bromide was 
reduced during this process. Due to the presence of enamine I.353, reasoned that an additional 
reductant might be needed and thus we attempted Dixon’s procedure.[353] First, the enamine was 
formed under the same conditions and then methanol followed by NaCNBH3 and acetic acid was 
added. After stirring the reaction mixture for 12 h, decomposition of the starting material was 
observed. 
Table I.37 Conditions tested for the reduction of lactam I.349. 
 
 
Entry Conditions Observation 
1 BH3 · Me2S (3 eq.), THF, r.t., 24 h no reaction 
2 BH3 · Me2S (10 eq.), THF, r.t., 24 h decomposition, HRMS indicates formation of I.354 
3 Ir(CO)(PPh3)2Cl (20mol%), TMDS (10 eq), DCM, r.t., 1.5 h → TFA, 2 h I.351 and I.353, as indicated by HRMS 
4 Ir(CO)(PPh3)Cl2 (20mol%), TMDS (10 eq), DCM, r.t., 1 h → MeOH, NaBH3CN, AcOH, 12 h 
decomposition 
 
After these initial results, we suspected that the secondary bromide might be causing unwanted side 
reactions. We therefore decided to first focus on the selective reduction of the secondary bromide 
(Table I.38). Reductive debromination using Raney-Nickel in methanol under a hydrogen 
atmosphere led to decomposition of the material (entry 1).[354] By applying Pd/C in ethyl acetate 
under H2 atmosphere, we reisolated starting material (entry 2). Changing the solvent composition 
from 9:1 ethyl acetate/MeOH to pure methanol resulted in either clean recovery of starting 
material (10% methanol) or a mixture of two reduction products (100% MeOH) (entries 3 and 4). 
HRMS indicated the formation of the desired debrominated compound I.355 and hydrogenolysis 
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product, acid I.356. As all test reactions were carried out on a 1 mg scale, we decided that the 
reactivity of Pd/C and hydrogen at this scale was not easily controllable, and turned our attention 
to radical debrominations.  
Table I.38 Conditions tested for the dehalogenation of bromolactone I.349. 
 
 
Entry Conditions Observation 
1 Ra-Ni, H2, MeOH, r.t., 4 h decomposition 
2 Pd/C, H2, EtOAc, r.t., 15 h no reaction 
3 Pd/C, H2, 9:1 EtOAc:MeOH, r.t., 15 h no reaction 
4 Pd/C, H2, MeOH, r.t., 15 h I.355 and I.356 
5b) [Ir(ppy)2(dtbbpy)]PF6, DIPEA, MeCN, CFL, 60 °C, 24 h inconclusive 
6b) Bu3SnH (3 eq), ACHN, toluene, 110°C, 24 h no reaction 
7b) Bu3SnH (10 eq), AIBN, benzene, 90°C, 3 h clean formation of I.355 
8a)b) NHC-BH3 (10 eq), ACHN, benzene, 90°C, 3 h I.355 and side product 
a) NHC-BH
3
 was prepared by Antonio Rizzo (AK Trauner) 
b) Reaction mixture was degassed in three freeze-pump-thaw cycles prior to heating 
 
Using photoredox catalysis (entry 5),[355] compound I.346, [Ir(ppy)2(dtbbpy)]PF6 and excess DIPEA 
in deuterated acetonitrile were heated to 60 °C and illuminated using a compact fluorescence bulb 
(CFL). After 24 h, all starting material was consumed. A single product was visible by NMR, 
however the chemical shift of the aromatic and benzylic signals were not consistent with I.355, 
despite confirmation of its mass (HRMS-ESI). Next, we investigated classic radical debromination 
conditions. With one equivalent tributyltinhydride (Bu3SnH) and the radical initiator ACHN in 
toluene at 110 °C, no reaction occurred and starting material was recovered (entry 6).[356] Using 
excess Bu3SnH and azobis(isobutyronitrile) (AIBN) in benzene, we observed full consumption of 
starting material after 3 h at 90 °C (entry 7). similar observation was made when ten equivalents of 
1,3-dimethylimidazol-2-ylidene borane (NHC-BH3, I.357),[354] was used in combination with AIBN 
in benzene. Although the reaction using NHC-BH3 I.357 is less toxic, we decided to continue 
exploring the reaction with tributyltinhydride, because the reaction was much cleaner by NMR 
analysis. Column chromatography using 1:9 K2CO3/SiO2 as stationary phase proved efficient for 
the removal of tin byproducts and cleanly provided debrominated lactone I.355.[357] The structure 
of I.355 was unambiguously confirmed by X-ray crystallography.  
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Figure I.11 Crystal structure of lactone I.355. 
Next, we reinvestigated conditions for the reduction of the N-methyl lactam present in I.355 
(Table I.39). Although Ir(CO)(PPh3)2Cl appeared promising in experiments with bromolactone 
I.346, no reaction was observed to occur on this debrominated congener (entry 1). Using ten 
equivalents of BH3· Me2S in THF at room temperature, however, we obtained a ratio ca. 2:1 ratio 
of starting material I.355 to desired tertiary ATA I.351 (entry 2). At elevated temperatures with 
BH3· Me2S, decomposition of the starting material was observed (entry 3). To our surprise, 
increasing the loading of BH3· Me2S did not improve conversion of starting lactam (entries 4 and 
5). Finally, when BH3· Me2S was used as a co-solvent with THF as a 1:1 solution, decomposition of 
the starting material was observed (entry 6).‡‡‡ 
Table I.39 Conditions tested for the reduction of lactam I.351. 
 
 
Entry Conditions Observationa) 
1 Ir(CO)(PPh3)2Cl (20 mol%), TMDS (10 eq.), DCM, r.t., 1.5 h → TFA, 2 h no reaction 
2 BH3 · Me2S (10 eq.), THF, r.t., 24 h 68% I.355 : 32% I.351 
3 BH3 · Me2S (10 eq.), THF, 50 °C., 24 h decomposition 
4 BH3 · Me2S (20 eq.), THF, r.t., 24 h 62% I.355 : 38% I.351 
5 BH3 · Me2S (50 eq.), THF, r.t., 24 h 61% I.355 : 29% I.351 
6 1:1 BH3 · Me2S/THF, r.t., 24 h decomposition 
a) Ratio of I.355 to I.351 was determined by the ratio of the N-Me groups in the 1H NMR spectrum. 
 
                                                      
‡‡‡ Tertiary amine I.351 could not be obtained as a clean compound. Structure was tentatively assigned by 1H NMR and 
and HRMS-ESI. 
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With trace quantities of lactone I.351 in hand, we investigated the final step of the synthesis: Boc-
deprotection of the primary ATA. Using a mixture of TFA and DCM at 0 °C, we obtained the TFA 
salt of stephadiamine (I.1), as substantiated by HRMS-ESI (calc: C19H24O4N2+ : 345.1809 [M+H]+; 
found 345.1811 [M+H]+).  
 
Scheme I.81 Final Boc-deprotection to stephadiamine.  
The 1H NMR (CD3OD ) of stephadiamine (I.1)・TFA is depicted in Figure I.12. Isolation of 
stephadiamine (I.1) as its free base is currently under investigation. 
 
 
Figure I.12 1H NMR of stephadiamine (TFA salt) in CD3OD . Signals found for stephadiamine (as TFA salt)  
1H NMR (400 MHz, Methanol-d4) δ= 7.15 (d, J = 8.4 Hz,  1H, Ar-H), 7.03 (d, J = 8.2 Hz, 1H, Ar-H), 5.57 
(s, 1H,  benzylic H), 3.87 (s, 5H, OMe), 3.86 (s, 4H, OMe), 2.53  (s, 3H, NMe) ppm.  Reported signals for 
stephadiamine (free base):  1H NMR (CDCl3) δ = 7.00 (d, J = 8.0 Hz, 1 H, Ar-H), 6.80  (d, J = 8.0 Hz, Ar-
H), 5.39 (dd, J = 4.3, 2.0 Hz, 1H,  benzylic H), 3.87 (6 H, OMe), 2.54 (s, 3H, N–Me) ppm. 
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4 Summary and outlook 
In summary, progress toward the total synthesis of the hasubanan alkaloid stephadiamine (I.1) has 
been detailed in this thesis. Enol carbonate I.228 was synthesized in seven steps starting from 2,3-
dimethoxyphenylacetic acid (I.223) following a literature procedure that we optimized (Scheme 
I.82). It is worthy to note that this sequence commenced with a carboxylate-directed Fujiwara–
Moritani reaction carried out on 10 g scale in near-quantitative yields. Enol carbonate I.228 served 
as a substrate for a racemic Tsuji allylation, which set the quaternary position in I.227 in excellent 
yield. 
 
Scheme I.82 Synthesis of stephadiamine (I.1)・TFA. 
A new cascade reaction was developed to assemble the complex pentacyclic core of (+)-
stephadiamine (I.1), constructing two five-membered rings and two stereocenters (including one 
ATA) in a single step (I.251→I.260). In this high-yielding transformation, the benzylic quaternary 
stereocenter directed the formation of all other stereocenters of the natural product. Establishment 
of the third contiguous fully substituted carbon proved highly challenging. Ultimately, a Tollens 
reaction (crossed Cannizzaro reaction, I.259→I.300) was used to install a quaternary stereocenter 
that was later converted to the second ATA of stephadiamine via Curtius reaction. In eleven 
additional steps, ether I.313 was transformed into lactone I.355, whose structure was 
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unambiguously confirmed by X-ray crystallography. Lactone I.358 was chemoselectively reduced to 
the corresponding tertiary ATA and further converted to the TFA salt of stephadiamine (I.1). 
Overall, racemic stephadiamine (I.1)・TFA was prepared in 27 steps from commercially available 
acid I.223 and isolation of the free base of stephadiamine (I.1) is currently under investigation.  
With an established route toward the natural product in hand, we sought to render the 
decarboxylative Tsuji-allylation asymmetric to access (+)-stephadiamine (I.1) (Scheme I.83). 
Although the racemic reaction proceeded in near quantitative yield, this substrate represents a 
significant challenge for asymmetric Pd-catalyzed allylation reactions. 
 
Scheme I.83 Decarboxylative Tsuji allylations. 
We opted to address this challenge and expand the scope of this transformation in collaboration 
with Prof. Brian M. Stoltz of the California Institute of Technology. After intensive optimization, 
we obtained allylcyclohexanone (R)-I.227 with 66% ee and 97% yield. Subsequent recrystallization 
of enantioenriched material increased the optical purity to 98% ee. Separation of the enantiomers 
using chiral HPLC allowed for the confirmation of absolute stereochemistry by X-ray analysis. In 
collaboration with the group of Prof. Benjamin List of Max-Planck-Institute in Mühlheim an der 
Ruhr, we were able to further improve the ee of the reaction by applying their recently reported Pd-
catalyzed allylation chemistry using (R)-H8-TRIP as chiral ligand. 
Future experiments include optimization of the reduction of lactam I.358 to tertiary amine I.354 
and the development of a protocol to access the free base of stephadiamine (I.1). Following these 
optimizations, the reaction sequence could be carried out with (R)-I.227 for an asymmetric 
synthesis of (+)-stephadiamine (I.1). The enantiopure material could then be used to investigate the 
biological activity of this unique norhasubanan alkaloid. In addition, tetralone I.227 is a common 
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structural motif in morphinan and hasubanan alkaloids. Ultimately, the developed approach to 
access either enantiopure (R)- or (S)-I.227 could therefore be used in the asymmetric synthesis of 
related natural products or related drug derivatives. 
  
 
 
CHAPTER II 
 
 
SYNTHESIS OF PHOTOCHROMIC 
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5 Introduction 
5.1 Sphingolipids, ceramides and cerebrosides 
5.1.1 General classification and biological relevance 
Sphingolipids play an important role in membrane biology as well as signaling and regulation within 
cells. They are a structurally diverse class of lipids, which are defined by their amino-alcohol 
backbone that consists of eighteen carbons.[358] These lipids are most often synthesized in the 
endoplasmatic reticulum (ER) from cytosolic serine and palmitoyl coenzyme A (CoA) and are then 
further derivatized. Their simplest members, sphingosine (II.1) phytosphingosine (II.2) and 
dihydrosphingosine (II.3) serve as templates upon which more complexity is generated by 
derivatization of their alcohol and amine moieties (Figure II.1). Acylation of these backbones with 
structurally diverse acyl-CoA molecules through the action of distinct ceramide synthases generates 
molecules defined as ceramide (II.4), phytoceramide (II.5), or dihydroceramide (II.6), respevtively. 
 
Figure II.1 Structures of sphingosines and ceramides.  
In addition, glycosylation of the ceramide with one or more sugar residues produces the large class 
of glycosphingolipids (GSL), which differ in the type of sphingosine, the sugar moiety and the acyl 
chain composition. So far, more than 300 different oligosaccharide chains and more than 60 
different sphingoid bases have been characterized, creating thousands of different GSL 
structures.[359] These microdomains, also called lipid rafts, are composed of specific lipid species 
and are thought to be a way that cells organize proteins within the plane of the membrane. GSLs 
can form hydrogen-bond/hydrophobic interactions with sphingomyelin and cholesterol (Chol), 
which can be observed as segregated microdomains in supported membrane systems. 
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A subclass of GSLs are the cerebrosides, which are glycosylated with glucose or galactose at the 
anomeric position.[360] The glucosphingolipids are generated from the enzyme glucosylceramide 
synthase (GCS), whereas galactosphingolipids are produced by the evolutionarily dissimilar enzyme 
galactosylceramide synthase (GalCerS).[358] Biologically, cerebrosides in cellular membranes can act 
as surface antigens, and they play an important role in cell signaling, agglutination, communication 
and development. 
However, many details in cerebroside function and signaling are not fully elucidated and  
“understanding the function of all the existing glycosphingolipids and sphingomyelin species will be a major 
undertaking in the future since the tools to study and measure these species are only beginning to be developed.”[358] 
Such a method to elucidate and manipulate lipid signaling with the spatiotemporal precision of light 
is photopharmacology.  
 
5.1.2 The synthetic α-galactosylceramide KRN7000 
α-Galactosylceramides are a class of molecules that contain acylated spingosines bound to galactose 
via an α-glycosidic bond. The most prominent member of this class of compounds is the synthetic 
agelasphin derivative KRN7000 (II.7, Figure II.2) − a synthetic cerebroside containing a 
phytospingosine backbone. The corresponding structure-activity relationship studies have been 
carried out with extracts from the Japanese marine sponge Agelas mauritianius.[361]  
 
Figure II.2 The synthetic α-galactosylceramide KRN7000 (II.7). 
KRN7000 (II.7) activates natural killer T (NKT) cells, a subpopulation of the T lymphocyte family, 
when associated with the glycoprotein CD1d and thereby triggers an immune response.[362] When 
the binary complex, which consists of KRN7000 bound to CD1d, interacts with the NKT cell 
receptor (TCR), it forms the active ternary complex. This binding event leads to the production of 
cytokines, which modulate an immune response. There are many families of cytokines, e.g., 
chemokines, interferons (IFNs), interleukins (IL), tumour necrosis factors (TNF) and colony-
stimulating factors (CSF), which are classified according to their biological activities: A TH1 (T 
helper 1) response is triggered by pro-inflammatory cytokines such as interferon-γ (IFN-γ). The 
downstream effects associated with these cytokines involve the activation of specific immune cells 
(NK cells, macrophages and antigen-specific cytotoxic T-lymphocytes, etc.) to antagonize tumors 
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and infections. By contrast, a TH2 response is provided by immunomodulatory cytokines such as 
interleukin 4 (IL-4). These lead to the activation of lymphocytes and the production of antibodies, 
which are produced for the treatment of autoimmune diseases.[362] In conclusion, TH1- and TH2-
inducing cytokines are immunomodulatory agents that balance between humoral and cell-based 
immune responses by orchestrating the maturation, growth, and responsiveness of the cells 
involved in the immune defense system.  
In the case of activation by KRN7000 (II.7), TH1- and TH2-type cytokines can antagonize each 
other’s biological functions, which is called “cytokine antagonism effect”.[363–364] Due to this effect, 
clinical application of KRN7000 (II.7) is not possible to date. Therefore, numerous derivatives of 
KRN7000 (II.7), which vary on all positions of the molecule, have been synthesized to map a 
structure-activity relationship and thereby selectively induce either TH1 or TH2-type cytokine 
production.[362] As a summary of these investigations, it was postulated that the TH1 immune 
response is favored by a “a stable glycoside bond, a rigid conformation of the spacer between the D-galactose and 
ceramide parts, the presence of aromatic rings or long lipid chains, the installation of a small hydrophobic molecule on 
the C6 sugar position or a carbocyclic ring instead of the D-galactose moiety.”[362] For example, Tsuji, Wong and 
co-workers found that attachment of an aromatic group to N-acyl chain greatly enhances 
IFN-γ/IL-4 secretion, most likely through the alteration of glycolipid/CD1d complex stability.[365] 
Moreover, their phenylated derivatives provided very potent NKT cell agonists that exhibit a 
stronger TH1 cytokine response than KRN7000 (II.7) itself. 
While several factors are involved in shifting the cytokine profile, the stability of the binary 
complex may be an important element. It has been found that after treatment of mice with 
KRN7000 (II.7), the level of IL-4 level is at a maximum after two hours, while the IFN-γ peaks 
after twelve hours,[366–367] therefore suggesting that IFN-γ production requires longer TCR 
stimulation. Therefore a bias towards TH1 response could be achieved by prolonged stimulation of 
TCRs on NKT cells through a stabilization of the glycolipid/CD1d complexes.[365] 
We thus envisaged that these binding events could possibly be modulated by photoswitchable 
derivatives of KRN7000 (II.7), which are based on an azo-extension[368] of the derivatives 
introduced by Tsuji, Wong and co-workers. Ideally, one isomer would bind stronger to the 
complex, therefore switching between binding modes with the spaciotemporal precision of light 
could illuminate the importance of binding strength and times.  
 
5.1.3 β-Galactosylceramide in HIV research 
The cluster of differentiation 4 (CD4) is the main cellular host-associated receptor for the human 
immunodeficiency virus (HIV). However, several CD4-negative cell lines are prone to infection 
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with certain HIV strains. These results suggest, that there might be alternate modes of viral 
infection.[369] The GSL β-GalCer (II.3) is expressed on mucosal membrane cells that do not express 
CD4. Several studies have shown that an alternative pathway of HIV infection occurs in these cells 
through virus-glycoprotein 120 (gp120) interactions with β-GalCer (II.3).[369–370] Mechanistically, β-
GalCer (II.3) acts as an anchor and assists in the capture and uptake of the virus but, by contrast to 
entry receptors, does not enable membrane fusion.[371] 
 
Figure II.3 Structure of β-galactosylceramide. 
Using total internal reflection fluorescence (TIRF) spectroscopy, Saavedra et. al. found that a 
carbohydrate on the ceramide is required for recombinant HIV-1 surface glycoprotein gp120 
(rgp120) recognition.[372] At high rgp120 concentrations (25−220 nM), the carbohydrate bound to 
the ceramide plays a limited role. But at lower concentrations (<20 nM), rgp120 binds to β-GalCer 
(II.3) with an affinity constant of 109 M-1. This is a relatively strong interaction in comparison to 
other protein-receptor interactions at membrane surfaces and resembles the strength of the binding 
of gp120 to the surface cell receptor CD4,[373] which is the initial binding event in the primary HIV 
infection pathway. It was furthermore found, that the selectivity for rgp120 depends on the 
chemical structure of the sugar group rather than the ceramide moiety.[372] The region on gp120 
that recognizes β-GalCer (II.3) is structurally distinct from the binding site for CD4. Therefore it 
could be addressed by targeted drug delivery, however, “understanding the molecular events that are 
responsible for HIV recognition of GalCer is a critical step in developing this dual ligand approach to preventing 
HIV entry into host cells.”[372] For this case, photopharmacology could give insights into the molecular 
events that are responsible for HIV recognition of β-GalCer (II.3). 
 
5.2 Photopharmacology 
Photopharmacology is an attempt to control biological function with synthetic photochemical tools 
that translate a light stimulus into a reversible cellular response.[368] These light-responsive tools 
contain an azobenzene photoswitch that allows for reversible control over the molecular 
configuration. On irradiation with light of a specific wavelength, azobenzenes isomerize from trans 
to cis, and vice versa (Figure II.4). Due to this change of conformation and polarity, its efficacy at the 
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target receptor can be fine-tuned using the light stimulus. This enables control over cell signaling 
with the high spatiotemporal precision of light.  
 
Figure II.4 Conformational change of azobenzene on irradiation with light. λoptimal‐cis is the wavelength at 
which the cis-content in the photostationary state is maximized. 
Photoswitches can be bound to their target through noncovalent interactions (photochromic 
ligands, PCLs), or be covalently attached through a linker (photoswitchable tethered ligands, PTLs). 
Both have been coined photoswitchable ligands or photopharmaceuticals, and have found 
application in the modulation of various biological targets. These include ion channels, G-protein 
coupled receptors (GPCRs), transporters, enzymes, and elements of the cytoskeleton.[374–376]  
The properties of azobenzenes are highly tuneable, and can be designed as required for the specific 
target and biological assay. A standard azobenzene is generally irradiated with 365 nm light, leading 
to a photostationary stage containing approximatley 95% cis-isomer. This cis-azobenzene is bistable, 
and spontaneously relaxes back to the trans-form thermally (t1/2 = 2 days), or on irradiation with 
visible light (e.g., 450 nm).[368] By contrast, red-shifted tetra-ortho-chloro azobenzenes undergo 
isomerization to the cis-configuration at a wavelength of 560 nm (green light).[377] For the design of 
azobenzenes, two main approaches are generally employed: azologization and azo-extension 
(Figure II.5). [368] 
 
Figure II.5 Strategies for the design of photoswitchable derivatives based on common drug structures. 
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In the azologization approach, azobenzenes (“azosters”) can mimic structural motifs such as 
stilbenes, (heterocyclic)N-aryl benzamides, benzyl phenyl ethers, benzyl anilines, and 1,2-diaryl 
ethanes, which are commonly found in drugs or drug candidates. This approach has for example 
been applied for the azologs of MG-624 (azocholine)[378] and glimiperide (JB253).[379] In the second 
approach, the azo-extension, an azobenzene moiety is extended outside the boundary of the parent 
drug. This strategy for the synthesis of photoswitchable analogs can easily be applied, knowning the 
structure-reactivity tables for the given drug. Examples for this approach include azo-propofols[380] 
and a photoswitchable version of capsazepine.[381] 
Another strategy to design photoswitchable molecules involves the incorporation of nonpolar 
azobenzene moieties into lipophilicic structures. This approach will be detailed in the following 
chapter 5.3. 
 
5.3 Photoswitchable lipids and ceramides 
In 2015, Trauner and co-workers presented a series of photoswitchable fatty acids (FAAzos) 
incorporating an azobenzene photoswitch along the fatty acid chain.[382] They demonstrated that in 
the trans-form the FAAzos resemble long, saturated fatty acids, whereas in their cis-form they 
behave like highly bent fatty acids such as arachidonic acid (II.9). For example, photoswitchable 
analogs of capsaicin (azo-capsaicin derivatives, AzCAs) were prepared, which were able to target 
the vanilloid receptor 1 (TRPV1), a non-selective cation channel, on irradiation with UV-A light. 
This publication a seminal report of the fusion of photopharmacology with lipid signalling, and 
thereby set the groundwork for following studies of photolipids.[377, 383–384]  
 
Figure II.6 Photoswitchable fatty acids (FAAzos). 
In 2016, the Trauner and Schwille groups, together reported that photoswitchable ceramides enable 
optical control of lipid rafts within synthetic membranes.[384] Three different photoswitchable 
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ceramides (ACes), which varied in the position of the azobenzene in the N-acyl chain, were used to 
manipulate lipid domains in raft-mimicking supported lipid bilayers (SLBs). These effects were 
visualized by combined atomic force and confocal fluorescence microscopy.  
 
Figure II.7 Photoswitchable ceramide ACe-1. 
In their studies, ACes in the trans-configuration, such as trans-ACe-1 (II.11), behaved similar to 
ceramides in the raft mimicking SLBs, where the azobenzene moiety on the N-acyl chain did not 
influence its interaction with the liquid-ordered (L0) domains. On irradiation and thus isomerization 
to cis-ACe-1 (cis-II.11) a conformational change was induced “in the fatty acid structure from a less bent 
(similar to saturated C18:0), to more bent acyl chain (similar to unsaturated C18:1), respectively, allowing us to 
locally and effectively control the degree of lipid saturation within the bilayer.“[384]  
 
5.4 Aims and significance of the project 
Photoswitchable lipids have already found some application in photopharmacology in the last two 
years. In first reports, photoswitchable fatty acids (FAAzos) proved that on illumination with light a 
conformational change is induced, allows fine-tuning of the lipids biophysical properties. As the 
application for simple fatty acids, ceramides, diacylglycerols and vanilloids has already been 
showcased, we now wish to broaden the application to glycosphingolipids, namely 
galactosylceramides, to study their biological and biophysical properties. 
α-Galactosylceramides, especially the synthetic derivative KRN7000 (II.7), can activate natural 
killer T (NKT) cells when associated with the glycoprotein CD1d. This effect leads to the 
production of different cytokines modulating a TH1/TH2 immune response. A large number of 
derivatives have been synthesized to selectively induce either TH1 or TH2-type cytokine production. 
Based on these studies, we designed a photoswitchable analog of KRN7000 (II.7) to activate 
mainly the production of pro-inflammatory cytokines (TH1-type cytokines). These functionalized 
azobenzenes may help us to manipulate the binding time of the lipid to the receptor, and allow us 
to control the procudtion of cytokines. 
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Moreover, we were interested in assessing the biophysical properties of photoswitchable α- and β-
galactosylceramides incorporated into lipid raft mimicking SLBs. By using a similar approach as the 
one described in our joint effort with the Schwille group[384] based on atomic force (AFM) and 
fluorescence confocal microscopy, we hope to investigate the behavior of these photoswitchable 
cerebrosides on phase-separated model membranes in comparison with their ceramide 
counterparts.  
Ultimately, photowitchable cerebrosides could be of use to study binding of proteins to the GSLs, 
for example the interaction of recombinant HIV-1 surface glycoprotein gp120 (rgp120) with a 
photoswitchable analog of β-GalCer (II.8). 
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6 Photoswitchable derivatives of 
Galactosylceramides 
6.1 Development of photochromic derivatives of α-galactosylceramide 
6.1.1 Design and retrosynthesis of the photochromic ligands 
Based on previous structure-relationship studies on KRN7000 (II.7) and related derivatives, we 
attempted to install the azobenzene moiety in the N-acyl chain of the ceramide. Using these tools, 
we sought to place cytokine production, biased toward TH1 or TH2 type, under the control of light. 
Tsuji, Wong and co-workers observed that derivatives incorporating fatty acids which were 
truncated and arylated with chain length of n = 0−4 were very potent, and also exhibited a stronger 
TH1 cytokine response than KRN7000 (II.7) itself (Figure II.8).[365] Modeling studies suggested, 
that the introduction of a terminal phenyl group promotes additional specific interactions between 
the phenyl groups and the aromatic amino acids Tyr73 and Trp40 in the CD1d hydrophobic 
groove, thereby stabilizing the binary complex.  
 
 
Figure II.8 KRN7000 derivatives, which preferentially induce TH1 cytokine production. 
The most challenging part in the synthesis of galactosylceramides is the formation of a selective α- 
or β-glycosidic bond. α-Gal linkages can be formed under thermodynamic conditions (anomeric 
effect), in appropriate solvents (etheral solvent effect), and/or by using a non-participating 
protecting group at the C2 hydroxyl group.[385] For the synthesis of α-galactosylceramide 
derivatives, we followed the synthetic procedure published by M. Tsuji, C.-H. Wong and co-
workers.[365] 
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Figure II.9 Incorporation of an azobenzene into KRN7000. 
We planned to install the fatty acid azobenzene (FAAzo) in the last steps of the synthesis leading to 
acetyl protected glycoside II.13 (Figure II.9), that can be traced back to benzyl- and benzylidene-
protected glycoside II.14. This use of protection groups is important for the compatibility with the 
azobenzene moiety. Typical deprotection conditions for benzyl- and benzylidene-groups involve 
hydrogenation conditions (such as Pd/C under H2 atmosphere), which would lead to concurrent 
hydrogenation of the azobenzene.  
 
Scheme II.1 Retrosynthesis for photoswitchable α-galactosylceramide derivatives. 
Glycoside II.14 could be obtained from an α-selective glycosylation starting from literature-known 
protected galactose II.15.[386] In turn, galactose II.15 can be derived from commercially available β-
D-galactose pentaacetate (II.17), and protected phytosphingosine II.16 that can be synthesized 
from commercially available phytosphingosine (II.18).[387] This strategy has the advantage that it 
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allows for a late stage introduction of the FAAazos, allowing us to rapidly synthesize a number of 
α-galactosyl azo ceramides (GACes) with different photoswitchable chains. 
 
6.1.2 Synthesis of α-galactosylceramide derivatives 
Following our retrosynthetic considerations, commercially available β- D-galactose pentaacetate 
(II.17) was thiolated at the anomeric center and fully deprotected under Zemplén conditions.[388] 
Protection of the hydroxyl groups at C4 and C5 with a benzylidene protecting group afforded 
galactose acetal II.19 in 90% yield over 3 steps. Benzyl protection of the remaining two hydroxyl 
groups led to fully protected galactose II.20 in 85% yield. Next, the thioacetal was hydrolysed using 
NBS in acetone and H2O, which led to an inseparable mixture of α- and β-galactose derivative 
II.21. The hydroxyl group at C2 was activated as a trichloroacetimidate II.15 using 
trichloroacetonitrile and DBU in DCM in an excellent yield of 98%. 
 
Scheme II.2 Synthesis of protected galactose trichloroacetimidate II.15. 
For the synthesis of the protected sphingosine building block II.16, we commenced our synthesis 
with commercially available phytosphingosine (II.18). This was first Boc-protected and tritylated 
yielding diol II.22 in 83% over two steps. The remaining two alcohols were protected with benzoyl 
chloride leading to fully protected sphingosine II.23 in 93% yield. Deprotection of the primary 
alcohol with p-TSA furnished the sphingosine building block II.16 in 91% yield.  
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Scheme II.3 Synthesis of sphingosine building block II.16. 
With both building blocks in hand, we set out to investigate glycosylation conditions (Scheme II.4). 
After some optimization, glycosylation promoted by TMSOTf in a mixture of ethanol and THF led 
to glycoside II.14 in 46% yield and an excellent α-selectivity (no β-glycoside was isolated). The α-
glycosidic bond was confirmed by a proton−proton coupling of J = 3.6 Hz between the equatorial 
anomeric proton to the adjacent axial proton. 
 
Scheme II.4 Synthesis and derivatization of galactosyl ceramides. 
The protected glycoside II.14 was then hydrogenated using Pd/C in ethanol and EtOAc and re-
protected in a mixture of acetic anhydride and catalytic DMAP in pyridine. The obtained acetyl-
protected glycoside II.13 was then Boc-deprotected using TFA and DCM and the FAAzo (e.g. 
FAAzo-4) was attached to the glycoside in an amide coupling using (2-(1H-benzotriazol-1-yl)-
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1,1,3,3-tetramethyluronium-hexafluorophosphat) (HBTU) and N-methylmorpholine (NMM) as 
coupling agents in 92% over two steps. A final global deprotection of II.24 yielded α-GalCer-4 
(II.12) in 86% yield.  
Using the same strategy, we were able to synthesize three derivatives, which vary in the position of 
the azobenzene - α-GACe-1 (II.25), α-GACe-3 (II.26) and α-GACe-4 (II.12, Scheme II.5). In 
addition, we were able to attach tetrachloro-FAAzo-4 to the glycoside yielding the redshifted α-
galactosyl ceramide (GRACe) α-GRACe-4 (II.27). 
 
Scheme II.5 Photoswitchable galactosyl ceramide derivatives. 
In collaboration with the group of Prof. Dr. Anja Hoffmann-Röder, we synthesized a second set of 
compounds incorporating a 6-fluoro group into galactose. Tashiro et al. reported that a fluorine in 
the C6-position induced large production of TH1-type cytokines such as IFN-γ.[389] Fluorine is 
bioisoster albeit more hydrophobic in comparison with a hydroxyl group.[390–391] It is believed that 
6F-galactose derivatives could therefore form a more rigid binary complex with CD1d than 
KRN7000 (II.7), which possesses the hydrophilic 6-hydroxyl group. 
For a second set of compounds, Andreas Baumann (Ph.D. student, Hoffmann-Röder group) 
repeated the sequence using a 6F-galactose building block II.28 to synthesize glycoside II.29 in 
64% yield (Scheme II.6).§§§ Exchange of the protecting groups via hydrogenation and acetylation 
gave acetylated glycoside II.30 in 61%. Boc-deprotection and amide coupling using FAAzo-4 
yielded fully protected 6F-GACe II.31 in 89% yield and a global deprotection gave the target 
compound α-6F-GACe-4 (II.32).  
                                                      
§§§ 6F-galactose building block II.28 and glycoside II.29 were prepared by Andreas Baumann (PhD student in the  
     group of Prof. Dr. Anja Hoffmann-Röder, LMU München, Germany). 
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Scheme II.6 Synthesis and derivatization of 6F’-galactosyl ceramides. 
Using this strategy, we were able to synthesize three derivatives in total using different FAAzos for 
the amide coupling: α-6F-GACe-1 (II.33), α-6F-GACe-4 (II.32) and the red-shifted α-6F-GRACe-
4 (II.34, Scheme II.7). 
 
Scheme II.7 Photoswitchable 6F-galactosyl ceramide derivatives. 
As a control for biophysical studies in model membranes, we additionally synthesized a 
photoswitchable phytoceramide derivative (PACe-1, II.35), analogous to the already-published 
photoswitchable D-erythro-ceramide ACe-1 (Scheme II.8).[384] 
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Scheme II.8 Synthesis of PACe-1 (II.35). 
In summary, we were able to synthesize seven α-GalCer derivatives of phytoceramide and the 
photoswitchable phytoceramide PACe-1 (II.35), which can now be used for biophysical 
characterizations on SLBs and for immunoassays.  
 
6.2 Development of photochromic derivatives of β-galactosylceramide 
6.2.1 Design of the photochromic ligand 
“Galactosylceramide” (β-GalCer, II.8) generally describes an N-acylated D-erythro-sphingosine 
(often simplified as “sphingosine” (II.1)), which is connected to a galactose headgroup via a β-
glycosidic bond. We therefore planned on building our synthesis on the commercially available 
building blocks galactose and D-erythro-sphingosine (II.1).  
 
Scheme II.9 Azalogization of β-galactosyl ceramide. 
We decided to attach the photoswitchable ceramide ACe-1 to galactose via a β-glycosylation to 
create photoswitchable β-GalCer (II.8, Scheme II.9). By using combined atomic force and confocal 
fluorescence microscopy, Frank et al. have already proven that ACe-1 enables reversible switching 
of lipid domains in raft-mimicking SLBs.[384] We hypothesized that this effect would be preserved, 
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if galactose was attached to ACe-1. For the synthesis of photoswitchable β-GalCer, we envisaged to 
follow a similar strategy as for α-GalCer derivatives. However, to obtain β-selectivity in the 
glycosylation step, we exchanged the non-participating protecting groups on the galactose for β-
directing acetyl groups. In addition, it has been demonstrated that the nature of the protecting 
group on the sphingosine (benzoyl, TBS, benzyl) and the choice of the amide precursor (azide, 
protected alcohol, amide) greatly influences the nucleophilicity of the sphingosine part (acceptor 
character).[362] For the synthesis of β-GalCer derivatives, in most cases azide precursors are used.[392] 
Azides do not coordinate to the primary alcohol and thereby the nucleophilicity of the sphingosine 
is greatly enhanced. 
 
6.2.2 Synthesis of a β-galactosylceramide derivative 
Following these retrosynthetic considerations, acetylated galactose II.38 was deprotected and the 
thus obtained alcohol was activated as a trichloroacetimidate II.39 (Scheme II.10). 
 
 
Scheme II.10 Synthesis of acetylated and activated galactose. 
For the synthesis of azidosphingosin II.40, we started off with D-erythro-sphingosine (II.1, Scheme 
II.11). Azidation with freshly prepared triflylazide catalyzed by copper yielded azidosphingosine 
II.40. Protection of the primary alcohol II.40, followed by protection of the free secondary alcohol 
II.41 and deprotection of the primary alcohol II.42 afforded the protected sphingosine II.43 in 
excellent yield.  
 
Scheme II.11 Synthesis of sphingosine II.43. 
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Glycosylation of azidosphingosine II.43 with trichloroacetimidate II.39 yielded protected glycoside 
II.44 in 92% yield and excellent β-selectivity (Scheme II.12). Staudinger reduction using PBu3 and 
subsequent amide coupling with FAAzo-4 using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimid 
(EDCI) gave fully protected β-GACe II.45. Final deprotection of the benzoyl and acetyl groups 
furnished β-GalCer-4 (II.37) in 74% yield. 
 
Scheme II.12 Synthesis of photoswitchable β-galactosylceramide. 
Characterization of β-GalCer-4 (II.37) on irradiation revelaled that this compound behaved exactly 
as its FAAzo parent compounds (Figure II.10). 
 
Figure II.10 UV Vis spectrum of β-GalCer-4 (II.37). 
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6.3 Biophysical characterization of α-GACe and β-GACe 
The biophysical characterization of α-GACe-4 (II.12), β-GACe-4 (II.37) and respective 
photoswitchable ceramides PACe-1 (II.35) and ACe-1 (II.11) within raft-mimicking SLBs is being 
carried out by our collaborators from the group of Prof. Dr. Petra Schwille; more precisely by Dr. 
Henri G. Franquelim (postdoctoral researcher) and Samuel Leitao (visiting student). As this project 
is still under progression, for the sake of clarity only the most significant preliminary results will be 
discussed.  
Here, different amounts of photoswitchable cerebroside were incorporated into lipid bilayers 
composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), Chol and N-stearoyl-D-erythro-
sphingosylphosphorylcholine (C18-SM), as previously described.[384] Analysis of the liquid-
disordered (Ld) to liquid-ordered (Lo) phases within these model membranes, deposited on freshly-
cleaved mica (muscovite), was carried out using AFM and confocal fluorescence microscopy.  First, 
we observed that the changes induced within the membrane domains on irradiation increased with 
the amount of photoswitchable cerebroside or ceramide that was incorporated into the SLB (Figure 
II.11).  
 
Figure II.11 Transformation of raft-mimicking lipid domains directly after UV-A irradiation. 
Fluorescence confocal images of SLBs containing DOPC:Chol:SM:Azo-βGalCer and DOPC:Chol:SM:Azo-
β-GalCer (10:6.7:X:Y, mol. ratios + 0.1 mol.% Atto655-DOPE). Atto655-DOPE (red fluorescence) is marker 
for liquid-disordered (Ld) domains. Raft-mimicking liquid-ordered (Lo) domains correspond to dark regions 
on images. Directly after irradiation with λ = 365 nm, membranes containing higher content of photolipids 
displayed increased lipid mixing within Lo domains. Scale-bars: 20 µm. 
Using AFM, we could clearly observe that the percentage of Ld to Lo domains could be altered on 
irradiation of all four compounds, which is in accordance with the already published results for 
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ACe-1 (II.11, Figure II.12).[384] In both cases, the membranes became more disordered on 
isomerization to the cis-form. 
 
Figure II.12 Proportions of Ld-Lo domains within raft-mimicking SLBs containing 
photoswitchable ceramides can be altered by light. High-speed AFM images of SLBs containing 
DOPC:Chol:SM:photolipid (10:6.7:5:5, mol. ratios). Lo domains correspond to taller (brighter) regions. 
Directly after irradiation with λ = 365 nm, Lo content was reduced, as fluid Ld “lakes” appeared inside Lo 
domains. In contrast, after irradiation with λ = 470 nm, Lo content increased and transient Lo islands were 
observed. 
In addition, we were interested if incorporation and photoisomerization of α-GACe-4 (II.12) and 
β-GACe-4 (II.37) into the SLBs would affect the properties of the Lo domains. The change in 
height of the rafts was measured, which directly correlates with the line tension at the lipid phase 
boundaries.[393] It was found that switching the cerebrosides from trans- to cis-isomers by irradiation, 
the difference in height between the Lo-Ld domains increased in a reversible manner (Figure II.13). 
C18-SM, which predominantly remains in the Lo domains independently of the light switch, are few 
picometers larger than their photoswitchable sphingolipid analogues, since they do not have an 
azobenzene incorporated into their acyl chain. This height change therefore additionally suggests 
that the photoswitchable derivatives shift into the Ld domains on isomerization to cis. On 
irradiation with blue light, this phenomenon can be reversed. In control experiments, PACe-1 
(II.35) and ACe-1 (II.11) behaved exactly as their glycosylated counterparts. However, as they lack 
the sugar head group, their overall height was lower.  
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Figure II.13: Ld-Lo height difference within raft-mimicking SLBs containing photoswitchable 
ceramides can be altered by light. Lipid domain heights of SLBs containing DOPC:Chol:SM:photolipid 
(10:6.7:5:5, mol. ratios) were recovered from AFM images. Directly after irradiation with λ = 365 nm, the 
height of the domains increased. In contrast, upon irradiation with λ = 470 nm, the lipid domains retained 
their basal height (similar to dark state). In the absence of photolipids (control experiments with lipid bilayers 
composed of DOPC:Chol:SM (10:6.7:10), left) no significant changes in domain height were observed on 
irradiation. 
With this biophysical characterization of α-GACe-4 (II.12) and β-GACe-4 (II.37) in hand, we next 
wanted to investigate the binding of gp120 to β-GACe-4 (II.37) incorporated into an SLB 
displaying a raft-mimicking lipid mixture. Unfortunately, we observed in initial experiments that 
gp120 creates holes in the SLBs, due to the high affinity of gp120 to the highly-negatively charged 
mica surface. In the future, we will use a non-supported membrane model system, e.g., β-GACe-4 
(II.37) incorporated into freestanding giant unilamellar lipid vesicles, as this will remove the artefact 
caused by the solid support. 
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7 Summary and outlook 
In summary, we developed a divergent route for the synthesis of photoswitchable α-GalCer 
derivatives. Starting from commercially available phytoceramide (II.18) and β-D-galactose 
pentaacetate (II.17), their protected derivatives II.16 and II.15 were prepared in four and six steps 
(Scheme II.13), respectively. α-Glycosylation under thermodynamic conditions led to the formation 
of protected glycoside II.14, which could be transformed into glycoside II.13 by exchange of 
protecting groups and deprotection of the Boc group. Amide coupling to the respective 
photoswitchable lipid and a global deprotection under Zemplén conditions furnished a total of four 
photoswitchable α-GalCer derivatives in 15 steps (twelve steps in the longest linear sequence). The 
late-stage derivatization allowed for the rapid synthesis of multiple derivatives. 
 
Scheme II.13 Synthetic route for six photoswitchable α-GalCer derivatives. 
Using a similar approach, three 6F-derivatives were prepared (Scheme II.14). Protected 
phytoceramide (II.16) was glycosylated with protected 6F-β-D-galactose (II.28) to yield protected 
glycoside II.29. Three additional steps furnished glycoside II.30, which was coupled to the 
respective photoswitchable lipids. global deprotection under Zemplén conditions[388] gave three 
photoswitchable 6F-α-GalCer derivatives. In addition to these cerebrosides, we synthesized the 
photoswitchable phytoceramide (PACe-1, II.35) as a control for the biophysical membrane studies 
(not shown). 
 
 
Scheme II.14 Synthetic route for three photoswitchable 6F-α-GalCer derivatives. 
For the synthesis of β-GalCer-4 (II.36), glycosylation of protected D-erythro-sphingosine (II.1) with 
trichloroacetimidate II.39 yielded protected glycoside II.44, which was transformed into β-GalCer-
4 (II.36) in three additional steps (Scheme II.15). As in the synthesis of α-GalCer derivatives, this 
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divergent route including a late-stage derivatization would allow for the rapid synthesis of multiple 
derivatives. 
 
Scheme II.15 Synthesis of the photoswitchable β-GalCer-4 (II.36). 
All cerebrosides and the photoswitchable ceramide PACe-1 (II.35) were characterized using UV-
Vis and behave like their FAAzo counterparts.  
α-GACe-4 (II.12) and β-GACe-4 (II.36), alongside the respective photoswitchable ceramides 
PACe-1 (II.35) and ACe-1 (II.11) as controls, were characterized in raft-mimicking SLBs using 
combined atomic force and confocal fluorescence microscopy. However, our ultimate goal was 
their application as tools for binding studies of proteins to the GSLs, for example the interaction of 
recombinant HIV-1 surface glycoprotein gp120 (rgp120) with a photoswitchable analog of β-
GalCer (II.8). To date, these investigations were not successful due to unspecific interactions of 
gp120 with the mica substrate used in these experiments. In the future, we would like to 
incorporate β-GalCer-4 (II.8) into lipid vesicles to circumvent these surface-induced problems. 
Using fluorescently-labeled gp120, we could potentially investigate the binding and localization 
(upon photo-isomerization) of gp120 to such vesicles. 
In addition, we would like to continue our protein-binding studies in raft-mimicking SLBs 
containing photoswitchable GLS. There are several sphingolipid-binding proteins [394] and bacterial 
toxins[395] that enter the cell via initial binding to lipid rafts and “bacteria and toxins are tools of choice to 
study raft dynamics and lateral sorting of raft-associated proteins as they have been to elucidate other basic 
intracellular functional pathways. Future challenges include the compositional and functional characterization of 
different raft sub-classes both at the plasma membrane and intracellularly and their role in infection. The 
immunological tuning by raft-dependent signaling will also be of great interest.“[395] For a number of bacteria, it 
has been shown that the modification or disruption of lipid rafts, for example by Chol-depleting 
drugs, inhibits either binding or internalization or both.[396] Therefore, we would like to study the 
binding behavior of raft-mimicking SLBs containing photoswitchable GLS to lipid-raft-binding 
proteins in the liquid-ordered (L0) or the liquid-disordered (Ld) phase by changing the conformation 
of photoswitchable β-GalCer (II.8) on irradiation with light.  
Additionally, we are interested in the application of our photoswitchable KRN7000 derivatives in 
immunoassays, as we hope that these azobenzenes could be used to modulate a TH1/TH2 immune 
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response. All photoswitchable derivatives are currently under investigation in the laboratory of our 
collaboration partner Moriya Tsuji, M.D., Ph.D. at Rockefeller University, NY, USA and initial 
experiments are already underway. 
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8 Experimental  
8.1 Methods and equipment 
Unless otherwise noted, all reactions were magnetically stirred and performed under an atmosphere 
of inert gas (Ar or N2) using standard Schlenk techniques. The reactions were carried out in oven-
dried glassware (200 °C oven temperature). External bath temperatures were used to record all 
reaction mixture temperatures. Diethyl ether (Et2O) and tetrahydrofuran (THF) were distilled prior 
to use under an atmosphere of N2 from sodium and benzophenone, triethylamine (NEt3) from 
calcium hydride. N,N-dimethylformamide (DMF), toluene and methanol (MeOH) were purchased 
from Acros Organics as 'extra dry' reagents under inert gas atmosphere and over molecular sieves. 
Solvents for flash column chromatography and crystallization experiments were purchased in 
technical grade and distilled under reduced pressure prior to use. Degassed solvents were degassed 
under N2 atmosphere by using either three successive freeze-pump-thaw cycles or by purging the 
solvent for 30 min with N2. Petroleum ether (PE) refers to fractions of iso-hexanes which boil 
between 40 and 80 °C. All other reagents were purchased from commercial sources and used 
without further purification. 
Chromatography. Analytical thin-layer chromatography (TLC) was performed on pre-coated glass 
plates (silica gel 60 F254) from Merck, and visualized by exposure to ultraviolet light (UV, 254 nm) 
and by staining with aqueous acidic ceric ammonium molybdate(IV) (CAM) solution. Flash column 
chromatography was performed using Merck silica gel (40−63 µm particle size). 
NMR Spectroscopy. Proton nuclear magnetic resonance (1H NMR) spectra were recorded in 
5 mm tubes on a Varian 300, Varian 400, Inova 400 or Varian 600 spectrometer in deuterated 
solvents at room temperature. Chemical shifts (δ scale) are expressed in parts per million (ppm) and 
are calibrated using residual protic solvent as an internal reference (CHCl3: δ = 7.26 ppm).[397] Data 
for 1H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling 
constants (Hz), integration). Couplings are expressed as: s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet or combinations thereof. Carbon nuclear magnetic resonance (13C 
NMR) spectra were recorded at 75, 100 and 150 MHz, respectively. Carbon chemical shifts (δ scale) 
are also expressed in parts per million (ppm) and are referenced to the central carbon resonances of 
the solvents (CDCl3: δ = 77.16 ppm). In order to assign the 1H and 13C NMR spectra, a range of 
2D NMR experiments (COSY, HSQC, HMBC, NOESY) were used as appropriate. The numbering 
of the proton and carbon atoms does not correspond to the IUPAC nomenclature. Diastereotopic 
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protons in the 1H NMR spectra are referenced with a and b, nomenclature is arbitrarily and does 
not correspond to the spin system. 
High performance liquid chromatography (HPLC). HPLC was performed with HPLC grade 
solvents and deionized H2O that was purified on a TKA MicroPure H2O purification system. All 
solvents were degassed with helium gas prior to use. Unless noticed otherwise, all experiments were 
carried out at room temperature. 
Analytical HPLC spectra were recorded on a ultra-high performance liquid chromatography 
(UHPLC) system from the Agilent 1260 Infinity series (1260 degasser, 1260 Binary Pump VL, 1260 
ALS auto sampler, 1260 TCC thermostated column compartment, 1260 DAD diode array 
detector), which was computer-controlled through Agilent ChemStation software.  
Chiral HPLC spectra were recorded on a high performance liquid chromatography (HPLC) system 
from the Shimadzu 20A series (DGU-20A3R degasser, LC-20AD Binary Pump VL, SIL-20AHT 
autosampler, CTO-20A thermostated column compartment, SPD-M20A DAD diode array 
detector), which was computer controlled through Shimadzu LabSolutions Software (Version 5.42 
SP5). Enantiomeric excess (ee) was calculated by using the following equation; m1 refers to the 
integral of the major peak and m2 to the integral of the minor peak: 
𝑒𝑒 =   𝑚! −𝑚!𝑚!  +  𝑚!  ∙ 100% 
High-resolution mass spectrometry (HRMS). A Varian MAT CH7A mass spectrometer was 
used to obtain high-resolution electron ionization (EI) mass. High-resolution electronspray (ESI) 
mass spectra were recorded on a Varian MAT 711 MS spectrometer operation in either positive or 
negative ionization modes. 
Infrared spectroscopy (IR).  Infrared spectra (IR) were recorded on a Perkin Elmer Spectrum 
BX II (FTIR System) equipped with an attenuated total reflection (ATR) measuring unit. IR data is 
reported in frequency of absorption (cm‒1). The IR bands are characterized as: w = weak, 
m = medium, s = strong, br = broad, or combinations thereof.  
Melting points (mp). Melting points were measured on a Büchi Melting Point B-540 or SRS 
MPA120 EZ-Melt apparatus and are uncorrected. 
Optical rotation. Perkin-Elmer 241 or Krüss P8000-T polarimeter were used to measure optical 
rotation at the Sodium D-line (589 nm) at the given temperature (T in °C) and concentrations (c in 
g/100 mL) using spectroscopic grade solvents. The measurements were carried out in a cell with a 
path length (d) of 0.5 dm. Specific rotations were calculated using the following equation: 
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α ! = α𝑐 ∙ 𝑑  10!! ∙ deg ∙ cm!g  
8.2 Experimental data of chapter I 
(2,3-Dimethoxyphenyl)methanol (I.221) 
 
2,3-Dimethoxybenzaldehyde (I.220, 50.0 g, 301 mmol, 1.0 eq.) was dissolved in MeOH (250 mL) 
and the mixture was cooled to 0 °C. NaBH4 (6.72 g, 178 mmol, 0.6 eq.) was slowly added and the 
reaction mixture was allowed to warm to room temperature. After 2 h, the solvent was removed 
under reduced pressure and the residue was dissolved in H2O (500 mL). The solution was extracted 
with DCM (3 × 500 mL) and the combined organic layers were washed with saturated aqueous 
NaCl solution (750 mL). The organic layer was dried (MgSO4) and concentrated under reduced 
pressure to give (2,3-dimethoxyphenyl)methanol (I.221) as a yellow oil, which was used in the next 
step without further purification. 
Rf = 0.54 [PE/EtOAc, 1:1]. 
1H NMR (400 MHz, CDCl3): δ = 7.05 (dd, J = 7.9, 7.9 Hz, 1H, H-5), 6.91 (m, 2H, H-4 
and H-6), 4.70 (s, 2H, H-7), 3.89 (s, 3H, H-8), 3.87 (s, 3H, H-9), 2.20 (s, 1H, O-
H) ppm.  
13C NMR (101 MHz, CDCl3): δ = 152.5 (C-3), 147.0 (C-2), 134.6 (C-1), 124.2 (C-5), 120.6 (C-6), 
112.2 (C-4), 61.6 (C-7), 60.9 (C-7), 55.8 (C-9) ppm.  
IR (ATR): ṽ = 3400 (m), 2938 (m), 2835 (m), 2360 (vw), 1981 (vw), 1587 (m), 1481 (vs), 1430 (m), 
1363 (w), 1272 (s), 1224 (s), 1172 (m), 1082 (s), 1039 (s), 1007 (s), 898 (w), 805 (w), 778 (m), 750 
(m), 707 (m) cm-1.  
HRMS (EI): calcd. for C9H12O3:  168.0786 [M]+ 
found:    168.0781 [M]+. 
 
The analytical data matched those previously described in the literature.[246] 
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1-(Chloromethyl)-2,3-dimethoxybenzene (I.359) 
 
 (2,3-Dimethoxyphenyl)methanol (I.221, 50.6 g, 301 mmol, 1.0 eq.) was dissolved in CHCl3 
(300 mL) and pyridine (9.50 mL, 119 mmol, 0.4 eq.) was added. Thionylchloride (40.8 mL, 
562 mmol, 1.9 eq.) was slowly added to the reaction mixture and an external ice bath was used to 
keep the reaction at room temperature. After 45 min., the reaction was cooled to 0 °C and H2O 
(200 mL) was added slowly. The reaction mixture was extracted with DCM (3 × 500 mL). 
Afterwards the combined organic layers were washed with H2O (500 mL) and saturated aqueous 
NaHCO3 (500 mL), dried (MgSO4) and concentrated under reduced pressure to give 1-
(chloromethyl)-2,3-dimethoxybenzene (I.359) as a yellow oil, which was used in the next step 
without further purification 
Rf = 0.59 [PE/EtOAc, 6:1].  
1H NMR (400 MHz, CDCl3): δ = 7.05 (dd, J = 7.9, 7.9 Hz, 1H, H-5), 6.98 (dd, J = 7.8, 
1.7 Hz, 1H, H-6), 6.90 (dd, J = 8.0, 1.6 Hz, 1H, H-4), 4.65 (s, 2H, H-7), 3.93 (s, 3H, H-
8), 3.87 (s, 3H, H-9) ppm.  
13C NMR (101 MHz, CDCl3): δ = 152.8 (C-3), 147.4 (C-2), 131.6 (C-1), 124.2 (C-5), 122.2 (C-6), 
113.0 (C-4), 61.2 (C-8), 55.8 (C-9), 41.1 (C-7) ppm. 
IR (ATR): ṽ = 3002 (w), 2967 (w), 2939 (w), 2836 (w), 2360 (w), 2340 (w), 1991 (vw), 1972(vw), 
1916 (vw), 1588 (m), 1483 (s), 1464 (m), 1430 (m), 1310 (m), 1272 (vs), 1228 (m),1178 (w), 1189 
(w), 1151 (w), 1078 (s), 1005 (s), 943 (w), 807 (w), 790 (w), 748 (m), 698 (m), 668 (w) cm-1. 
HRMS (EI): calcd. for C9H11ClO2:   186.0448 [M]+ 
found:    186.0446 [M]+. 
The analytical data matched those previously described in the literature.[246] 
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2-(2,3-Dimethoxyphenyl)acetonitrile (I.222) 
. 
KCN (23.8 g, 366 mmol, 1.2 eq. in H2O (50 mL) was heated to 50 °C and 1-(chloromethyl)-2,3-
dimethoxybenzene (I.359, 56.0 g, 301 mmol, 1.0 eq.) in EtOH (100 mL) was added. The mixture 
was heated to 90 °C for 1 h. The reaction mixture was then poured into iced-cold H2O (500 mL) 
and the aqueous layer was extracted with DCM (3 × 500 mL). The combined organic layers were 
washed with saturated aqueous NaCl solution (300 mL) and dried (MgSO4). The organic layer was 
concentrated under reduced pressure and the crude nitrile I.222 was used without further 
purification in the next step.  
Rf = 0.50 [PE/EtOAc, 3:1].  
1H NMR (400 MHz, CDCl3): δ = 7.06 (dd, J = 8.0 Hz, 8.0 Hz, 1H, H-5), 6.96 (dd, 
J = 7.7, 1.6 Hz, 1H, H-6), 6.91 (dd, J = 8.2, 1.5 Hz, 1H, H-4), 3.91 (s, 3H, H-9), 3.88 
(s, 3H, H-10), 3.72 (s, 2H, H-7) ppm.  
13C NMR (101 MHz, CDCl3) δ = 152.7 (C-3), 146.7 (C-2), 124.3 (C-6), 124.2 (C-1), 
121.0 (C-5), 118.2 (C-7), 112.6 (C-4), 60.6 (C-9), 55.8 (C-10), 18.6 (C-7) ppm.  
IR (ATR): ṽ = 2940 (w), 2837 (w), 2361 (m), 2341 (w), 2178 (vw), 2160 (vw), 2098 (vw), 2017 (vw), 
1973 (vw), 1726 (vw), 1588 (m), 1485 (vs), 1432 (m), 1275 (s), 1225 (m), 1170 (w), 1074 (s), 1004 
(s), 773 (m), 750 (m), 710 (w), 668 (vw) cm-1. 
HRMS (EI): calcd. for C10H11NO2:   177.0790 [M]+ 
found:     177.0782 [M]+. 
The analytical data matched those previously described in the literature.[246] 
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2,3-Dimethoxyphenylacetic acid (I.223) 
 
The crude 2-(2,3-dimethoxyphenyl)acetonitrile I.222 (53.0 g, 301 mmol, 1 eq.) was suspended in 
H2O (220 mL) and 2 N aqueous NaOH (890 mL). The reaction mixture was heated to 100 °C for 
10 h. The suspension was washed with Et2O (500 mL) and the organic layer was discarded. The 
aqueous layer was acidified with conc. HCl to pH = 1 and extracted with EtOAc (3 × 1000 mL). 
The combined organic layers were washed with saturated aqueous NaCl solution (1000 mL) and 
dried (MgSO4). The concentration of the organic layers under reduced pressure afforded carboxylic 
acid I.223 (49.6 g, 253 mmol, 84% over 4 steps) as a white powder. 
Rf = 0.17 [PE/EtOAc, 3:1 + 1% AcOH]. 
mp: 78 – 80 °C 
1H NMR (400 MHz, CDCl3): δ = 7.02 (dd, J = 8.0, 8.0 Hz, 1H, H-5), 6.87 (dd, 
J = 8.3, 1.5 Hz, 1H, H-4), 6.83 (dd, J = 7.6, 1.5 Hz, 1H, H-6), 3.86 (s, 6H, H-9, H-
10), 3.70 (s, 2H, H-7) ppm.  
13C NMR (101 MHz, CDCl3): δ = 175.6 (C-8), 152.7 (C-2 or C-3), 147.1 (C-2 or C-
3), 127.6 (C-1), 124.1 (C-5), 122.6 (C-6), 112.0 (C-4), 60.6 (C-9 or C-10), 55.7 (C-9 or C-10), 35.6 
(C-7) ppm.  
IR (ATR): ṽ = 2943 (m), 2839 (m), 2362 (m), 2167 (w), 2159 (w), 2047 (w), 2020 (w), 1991 (w), 
1972 (w), 1920 (w), 1710 (vs), 1587 (m), 1484 (vs), 1273 (s), 1230 (s), 1170 (m), 1081 (s), 1005 (m), 
748 (m), 668 (m)  cm-1. 
HRMS (EI): calcd. for C10H12O4:  196.0736 [M]+ 
found:     196.0730 [M]+. 
The analytical data matched those previously described in the literature.[246] 
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(E)-2-(6-(3-(t e r t-Butoxy)-3-oxoprop-1-en-1-yl)-2,3-dimethoxyphenyl)-acetic acid (I.224) 
 
An autoclave apparatus was charged with a suspension of 2,3-dimethoxyphenylacetic acid (I.223, 
10.0 g, 51.0 mmol, 1.0 eq.), Pd(OAc)2 (1.15 g, 5.10 mmol, 10 mol%), para-benzoquinone (276 mg, 
1.28 mmol, 5 mol%), tert-butyl acrylate (22.4 mL, 153 mmol, 3.0 eq.) and dry KHCO3 (10.2 g, 
102 mmol, 2.0 eq.) in dry tert-amylalcohol (100 mL). The apparatus was purged with O2 five times 
and the reaction mixture stirred under O2 atmosphere (3 bar) at 85 °C for 96 h. After cooling to 
room temperature, aqueous HCl (2 M, 150 mL) was added, the aqueous layer was extracted with 
Et2O (3 × 200 mL) and the combined organic layers were dried (MgSO4). All solid material was 
removed by filtration through a pad of Celite®, which was washed with Et2O (100 mL). The filtrate 
was concentrated under reduced pressure and the crude α,β-unsaturated ester I.224 was used 
immediately in the next step. 
For analytical purposes, a sample of the crude product was purified by flash column 
chromatography [PE/EtOAc 3:1 + 1% AcOH] to give α,β-unsaturated ester I.224 as a white solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[PE/EtOAc 20:1] at 0 °C. 
Rf = 0.20 [PE/EtOAc, 3:1 + 1% AcOH].  
mp: 115 – 117 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.73 (d, J = 15.7 Hz, 1H, H-7), 7.34 (d, 
J = 8.7 Hz, 1H, H-5), 6.87 (d, J = 8.7 Hz, 1H, H-4), 6.20 (d, J = 15.6 Hz, 1H, 
H-8), 3.88 (s, 3H, H-15), 3.87 (s, 2H, H-12), 3.83 (s, 3H, H-14), 1.51 (s, 9H, H-
11) ppm. 
13C NMR (75 MHz, CDCl3): δ = 176.1 (C-13), 166.1 (C-9), 153.4 (C-3), 147.3 (C-2), 139.9 (C-7), 
127.4 (C-1), 127.2 (C-6), 122.4 (C-5), 120.5 (C-8), 111.4 (C-4), 80.3 (C-10), 60.4 (C-15), 55.5 (C-14), 
31.4 (C-12), 28.0 (C-11) ppm.  
IR (ATR): ṽ = 2983 (w), 1734 (m), 1700 (s), 1671 (m), 1626 (m), 1594 (m), 1494 (s), 1452 (s), 
1255 (m), 1145 (s), 1078 (s), 970 (m) cm‒1. 
I.223
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t-butyl acrylate, t-amylalcohol 
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HRMS (EI): calcd. for C17H22O6+:   322.1411 [M]+  
found:     322.1400 [M]+. 
The analytical data matched those previously described in the literature.[241-242, 245]  
 
t e r t-Butyl 3-(3,4-dimethoxy-2-(2-methoxy-2-oxoethyl)phenyl)propanoate (I.225) 
 
To a solution of  α,β-unsaturated ester I.224 (assumed 51.0 mmol, 1.0 eq) in MeOH (300 mL) was 
added Pd/C (10% Pd on activated charcoal; 10 wt%, 2.00 g). The flask was purged with H2 five 
times and stirred under H2 atmosphere (1 atm) at room temperature for 16 h. The catalyst was 
removed by filtration through a pad of Celite® which was washed with MeOH (200 mL). 
Afterwards, the filtrate was concentrated under reduced pressure. For the esterification of the crude 
product, two different protocols were used (procedure A and procedure B). 
Procedure A: The crude saturated ester was immediately redissolved in toluene/MeOH (7:1, 
314 mL). The mixture was cooled to 0 °C and a solution of TMSCHN2 (2.0 M in hexanes, 30.6 mL, 
61.2 mmol, 1.2 eq.) was added dropwise. After stirring for 15 min at 0 °C, the reaction mixture was 
allowed to warm to room temperature and stirred for additional 40 min. The reaction was 
quenched with AcOH (15 mL), diluted with saturated aqueous NaHCO3 (600 mL) and extracted 
with EtOAc (3 × 400 mL). The combined organic layers were washed with saturated aqueous NaCl 
solution (500 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column 
chromatography [PE/EtOAc, 19:1 to 4:1] afforded methyl ester I.225 (14.5 g, 42.8 mmol, 84% 
over 3 steps) as a colorless oil. 
Procedure B: The crude saturated ester was immediately redissolved in DMF (250 mL) and 
K2CO3 (21.2 g, 152 mmol, 3 eq.) was added to the stirring solution. The reaction mixture was 
cooled to 0 °C and MeI (4.13 mL, 66.3 mmol, 1.3 eq.) was added slowly. After 3 h DMF was 
partially removed under reduced pressure and Et2O (200 mL) was added. The organic phase was 
washed with saturated aqueous NH4Cl solution (200 mL) and extracted with Et2O (3 × 200 mL). 
The combined organic layers were washed with saturated aqueous NaCl solution (500 mL), dried 
(MgSO4) and concentrated under reduced pressure. Flash column chromatography [PE/EtOAc 
19:1 to 4:1] afforded methyl ester I.225 (16.9 g, 50.0 mmol, 98% over three steps) as a colorless oil. 
MeOOC
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MeO
I.225
1) Pd/C (10%), H2, MeOH
2) TMSCHN2, toluene/MeOH, 
     7:1 or MeI, K2CO3, DMF
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Rf = 0.51 [PE/EtOAc, 3:1]. 
 1H NMR (300 MHz, CDCl3): δ = 6.90 (d, J = 8.5 Hz, 1H, H-5), 6.80 (d, 
J = 8.5 Hz, 1H, H-4), 3.84 (s, 3H, H-16), 3.81 (s, 3H, H-15), 3.75 (s, 2H, H-
12), 3.69 (s, 3H, H-14), 2.82 (dd, J = 9.1, 6.8 Hz, 2H, H-7), 2.49–2.40 (m, 2H, 
H-8), 1.43 (s, 9H, H-11) ppm.  
13C NMR (75 MHz, CDCl3): δ = 172.3 (2C, C-9, C-13), 151.0 (C-3), 147.6 
(C-2), 132.1 (C-6), 127.1 (C-1), 124.1 (C-5), 111.2 (C-4), 80.6 (C-10), 60.5 (C-15), 55.7 (C-16), 51.9 
(C-14), 36.3 (C-8), 32.0 (C-12), 28.1 (C-11), 27.4 (C-7) ppm.  
IR (ATR): ṽ = 2976 (w), 2940 (w), 2837 (w), 1726 (s), 1605 (w), 1572 (w), 1492 (s), 1366 (m), 1275 
(s), 1227 (m), 1145 (s), 1083 (s), 753 (s) cm‒1. 
HRMS (ESI): calcd. for C18H26O6+:   338.1724 [M+H]+  
found:       338.1718 [M+H]+. 
The analytical data matched those previously described in the literature.[241-242, 245]  
 
7,8-Dimethoxy-1,2,3,4-tetrahydronaphtalen-2-one (I.219)  
 
To a solution of diester I.225 (16.9 g, 50.0 mmol, 1.0 eq.) in Et2O (750 mL) was added potassium 
tert-butoxide (7.29 g, 65.0 mmol, 1.3 eq.) over a period of 15 min and the resulting mixture was 
stirred at room temperature for 30 min. The reaction was cooled to 0 °C and aqueous HCl (1 M, 
20 mL) was added slowly. The mixture was allowed to warm to room temperature and the aqueous 
layer was extracted with DCM (3 × 400 mL). The combined organic layers were washed with 
saturated aqueous NaCl solution (500 mL), dried (MgSO4) and concentrated under reduced 
pressure. The crude product was immediately redissolved in concentrated AcOH (360 mL) and 
concentrated HCl (90 mL), stirred for 3 h at 110 °C and then cooled to 0 °C. The reaction was 
neutralized with aqueous 2 M NaOH and the mixture was extracted with Et2O (3 × 500 mL) and 
DCM (2 × 500 mL). The combined organic layers were dried (MgSO4) and concentrated under 
reduced pressure. Flash column chromatography [PE/EtOAc, 9:1 to 3:1] afforded 7,8-dimethoxy-
1,2,3,4-tetrahydronaphtalen-2-one (I.219, 6.74 g, 32.7 mmol, 65% over 2 steps) as a colorless solid. 
1) KOt-Bu, Et2O
2) AcOH/HCl, 110 °C
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Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 0 °C. 
Rf = 0.43 [PE/EtOAc, 3:1]. 
mp: 75 – 76 °C.  
 1H NMR (300 MHz, CDCl3): δ = 6.93 (d, J = 8.3 Hz, 1H, H-5), 6.79 (d, J = 8.3 Hz, 1H, H-4), 
3.86 (s, 3H, H-12), 3.81 (s, 3H, H-11), 3.60 (s, 2H, H-10), 3.05–2.96 (m, 2H, H-7), 
2.59–2.49 (m, 2H, H-8) ppm. 
13C NMR (75 MHz, CDCl3): δ = 210.8 (C-9), 151.5 (C-3), 146.6 (C-2), 129.8 (C-6), 
127.7 (C-1), 123.2 (C-5), 111.1 (C-4), 60.8 (C-11), 56.3 (C-12), 39.1 (C-8), 38.9 (C-10), 
28.5 (C-7) ppm. 
IR (ATR): ṽ = 2998 (w), 2944 (w), 2836 (w), 1702 (s), 1604 (w), 1582 (w), 1492 (s), 1458 (m), 1428 
(m), 1350 (m), 1307 (m) 1273 (s) cm‒1.  
HRMS (ESI): calcd. for C12H14O3+:   206.0937 [M+H]+  
found:       206.0942 [M+H]+. 
The analytical data matched those previously described in the literature.[241-242, 245] 
 
2-(7,8-Dimethoxy-2-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile (I.226) 
 
To a solution of β-tetralone I.219 (10.3 g, 44.2 mmol, 1.0 eq.) and a small amount of dry MgSO4 in 
toluene (260 mL) was added pyrrolidine (4.7 mL, 57.4 mmol, 1.3 eq.) and the reaction was stirred at 
100 °C for 24 h. The mixture was allowed to cool to room temperature, bromoacetonitrile 
(4.92 mL, 70.7 mmol, 1.6 eq.) was added and the reaction was stirred at 100 °C for an additional 
28 h. The reaction was quenched with H2O (300 mL) at room temperature, extracted with EtOAc 
(3 × 300 mL) and DCM (300 mL) and the combined organic layers were washed with saturated 
aqueous NaCl solution (400 mL), dried (MgSO4) and concentrated under reduced pressure. Flash 
column chromatography [PE/EtOAc, 9:1 to 6:1] afforded 2-(7,8-dimethoxy-2-oxo-1,2,3,4-
tetrahydronaphthalen-1-yl)acetonitrile (I.226, 9.62 g, 39.2 mmol, 89%) as colorless crystals. 
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Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 0 °C. 
Rf = 0.25 [PE/EtOAc, 3:1].  
mp: 77–79 °C. 
 1H NMR (300 MHz, CDCl3): δ = 6.94 (d, J = 8.3 Hz, 1H, H-5), 6.88 (d, 
J = 8.4 Hz, 1H, H-4), 3.90 (s, 3H, H-13), 3.88 (s, 3H, H-14), 3.83 (dd, J = 4.5, 
5.8 Hz, 1H, H-10), 3.34–3.15 (m, 2H, H-7a, H-11a), 2.95–2.89 (m, 2H, H-7b, H-
11b), 2.85–2.74 (m, 1H, H-8a), 2.0 (dddd, J = 15.2, 13.6, 6.1, 0.5 Hz, 1H, H-
8b) ppm.  
13C NMR (100 MHz, CDCl3) δ = 209.0 (C-9), 150.6 (C-3), 146.5 (C-2), 129.5 (C-6), 127.5 (C-1), 
123.1 (C-5), 117.7 (C-12), 112.1 (C-4), 60.4 (C-13), 55.5 (C-14), 43.2 (C-10), 39.1 (C-8), 26.9 (C-7), 
20.2 (C-11) ppm. 
IR (ATR): ṽ = 3006 (w), 2974 (w), 2940 (w), 2918 (w), 2837 (w), 2244 (m), 1716 (s), 1606 (m), 1581 
(m), 1494 (s), 1456 (s), 1421 (s), 1347 (m), 1308 (m), 1279 (s), 1246 (m), 1220 (s), 1156 (m), 1091 (s), 
999 (s) cm‒1. 
HRMS (ESI): calcd. for C14H15O3N+:  245.1046 [M+H]+  
found:     245.1047 [M+H]+. 
 
Allyl (1-(cyanomethyl)-7,8-dimethoxy-3,4-dihydronaphthalen-2-yl) carbonate (I.228) 
 
To a solution of nitrile I.226 (5.00 g, 20.4 mmol, 1.0 eq.) in THF (250 mL) was added sodium 
hydride (60 wt% in mineral oil, 898 mg, 22.4 mmol, 1.1 eq.) at 0 °C and the mixture was stirred for 
1 h. Allyl chloroformate (10 v% in THF, 2.39 mL in 23.9 mL THF, 2.70 g, 22.4 mol, 1.0 eq.) was 
added and the reaction was stirred at 0 °C for an additional 30 min. The reaction was quenched 
with H2O (50 mL) at 0 °C, extracted with EtOAc (3 × 100 mL) and the combined organic layers 
were washed with saturated aqueous NaCl solution (100 mL), dried (MgSO4) and concentrated 
NaH, THF, 0 °C, 1 h → allyl 
chloroformate, 0 °C, 30 min
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under reduced pressure. Flash column chromatography [PE/EtOAc, 8:1] afforded carbonate I.228 
(6.18 g, 18.8 mmol, 92%) as a colorless oil. 
Rf = 0.41 [PE/EtOAc, 3:1].  
 1H NMR (400 MHz, CDCl3): δ = 6.85 (d, J = 8.2 Hz, 1H, H-5), 6.75 (d, 
J = 8.2 Hz, 1H, H-4), 5.98 (ddt, J = 17.1, 10.4, 5.9 Hz, 1H, H-17), 5.43 (dq, 
1H, J = 17.2, 1.5 Hz, H-18a), 5.34 (dq, J = 10.4, 1.2 Hz, H-18b), 4.75–4.71 
(m, 2H, H-16), 3.90 (s, 3H, H-13), 3.85 (s, 3H, H-14), 3.70 (s, 2H, H-11), 
2.84–2.78 (m, 2H, H-7), 2.54–2.47 (m, 2H, H-8) ppm.  
13C NMR (101 MHz, CDCl3): δ = 151.5 (C-3), 151.4 (C-15), 151.0 (C-9), 146.3 (C-2), 130.4 (C-17), 
128.1 (C-6), 125.2 (C-1), 122.1 (C-5), 119.3 (C-18), 117.6 (C-12), 113.5 (C-10), 111.1 (C-4), 69.1 (C-
16), 61.2 (C-13), 55.5 (C-14), 28.2 (C-7), 26.6 (C-8), 16.3 (C-11) ppm. 
IR (ATR): ṽ = 3319 (w), 3197 (w), 2942(m), 2836 (w), 22.51 (w), 1756 (s), 1661 (m), 1573 (w), 1477 
(m), 1418 (m), 1261 (s), 1241 (s), 1206 (s), 1183 (s), 980 (m) cm‒1. 
HRMS (ESI): calcd. for C18H19O5N+:   329.1258 [M+H]+  
found:     329.1255 [M+H]+. 
 
2-(1-Allyl-7,8-dimethoxy-2-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile (I.227) 
 
Tris(dibenzylideneacetone)dipalladium(0) (428 mg, 0.468 mmol, 2.5 mol%) and PPh3 (307 mg, 
1.17 mmol, 6.25 mol%) were dissolved in degassed toluene (550 mL) and stirred until the reaction 
color turned from dark red to orange/yellow (approximately 30 min.). A solution of carbonate 
I.228 (6.17 g, 18.7 mmol, 1.0 eq.) dissolved in degassed toluene (50 mL) was added to the 
preformed catalyst and the reaction was stirred at room temperature for 16 h prior to concentrating 
the reaction mixture under reduced pressure. Flash column chromatography [PE/EtOAc, 9:1] 
afforded 2-(1-allyl-7,8-dimethoxy-2-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile (I.227, 
5.02 g, 17.6 mmol, 94%) as a colorless solid. 
Pd2(dba)3, PPh3
toluene, r.t., 16 h
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Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 20 °C. 
Rf = 0.41 [PE/EtOAc, 3:1]. 
mp: 70–71 °C. 
1H NMR (600 MHz, CDCl3): δ = 6.92–6.85 (m, 2H, H-4, H-5 ), 5.39 (dddd, 
J = 17.0, 10.1, 9.0, 5.9 Hz, 1H, H-16), 5.00–4.94 (m, 2H, H-17), 3.97 (s, 3H, H-
13), 3.88 (s, 3H, H-14), 3.29 (d, J = 16.4 Hz, 1H, H-11a), 3.13 (d, J = 16.3 Hz, 
1H, H-11b), 3.05 (dddd, J = 15.8, 9.7, 6.0, 0.6 Hz, 1H, H-7a), 3.01–2.94 (m, 1H, 
H-7b), 2.90 (ddt, J = 13.7, 5.8, 1.5 Hz, 1H, H-15a), 2.76–2.64 (m, 2H, H-8), 2.71 
(m, 1H, H-15b) ppm.  
13C NMR (150 MHz, CDCl3): δ = 210.3 (C-9), 151.2 (C-3), 147.5 (C-2), 132.3 (C-16), 129.6 (C-6), 
129.1 (C-1), 123.2 (C-5), 118.8 (C-17), 117.6 (C-12), 112.3 (C-4), 60.2 (C-13), 55.5 (C-14), 53.6 (C-
10), 42.4 (C-15), 38.8 (C-8), 28.0 (C-7), 24.5 (C-11) ppm.  
IR (ATR): ṽ = 2941 (m), 2839 (w), 1715 (s), 1601 (w), 1576 (w), 1486 (s), 1454 (m), 1415 (w), 1346 
(w), 1275 (s) cm‒1. 
HRMS (ESI): calcd. for C17H20O3N+:   286.1438 [M+H]+  
found:     286.1435 [M+H]+. 
 
To obtain enantiomerically enriched material, experiments with chiral ligands were carried out using 
procedures A−E and using the following HPLC parameters to determine the ee: 
Chiral HPLC:    Retention time (R)-I.227: 10.438 min 
Retention time (S)-I.227: 12.365 min. 
Column:  DAICEL CHIRALPAK® IB 
Flow rate:  1 mL/min  
Mobile phase:  n-hept:iso-prop 97.5:2.5 (v/v) 
Temperature:  20 °C 
Wavelenghth:  198 nm. 
(R)-I.227: [α]D = +0.40 (c = 1, DCM). 
(S)-I.227: [α]D = −0.38 (c = 1, DMC).  
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Procedure A: The reaction was carried out at a concentration of 0.030 M in a glovebox under 
nitrogen atmosphere. Tris(dibenzylideneacetone)dipalladium(0) (1.50 µmol, 5 mol%) and a ligand 
(3.75 µmol, 12.5 mol%) were dissolved in dry, degassed solvent and the catalyst stirred for 30 min 
at 25 °C. A solution of carbonate I.228 (10.0 mg, 30.0 µmol, 1 eq.) in solvent was added to the 
preformed catalyst and the reaction was stirred at a set temperature T, prior to dilution of the 
sample with hexanes and ether, filtration over silica and analysis of the %ee by chiral HPLC. 
 
Entry Ligand Solvent T (°C) t (h) %ee 
1 (S)-t-Bu-PHOX (I.232) THF 25 20 3 
2 (S)-t-Bu-PHOX (I.232) toluene 25 20 1 
3 (S)-t-Bu-PHOX (I.232) 2:1 hexane/toluene 25 20 6 
4 (S)-CF3-t-Bu-PHOX (I.233) THF 25 20 10 
5 (S)-CF3-t-Bu-PHOX (I.233) toluene 25 20 26 
6 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene 25 20 38 
7 (R,R)-ANDEN-Phenyl Trost (I.237) THF 25 20 22 
8 (R,R)-ANDEN-Phenyl Trost (I.237) toluene 25 20 13 
9 (R,R)-ANDEN-Phenyl Trost (I.237) 2:1 hexane/toluene 25 20 25 
10 (S)-QUINAP (I.234) THF 25 20 14 
11 (S)-QUINAP (I.234) toluene 25 20 3 
12 (S)-QUINAP (I.234) 2:1 hexane/toluene 25 20 11 
13 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene 20 14 39 
14 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene 0 14 42 
15 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene −15 14 34 
16 (S)-CF3-t-Bu-PHOX (I.233) 2:1 hexane/toluene −60 14 37 
 
Procedure B: The reaction was carried out at a concentration of 0.030 M in a glovebox under 
nitrogen atmosphere. To tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (1.65 µmol, 
5.5 mol%) or tris(dibenzylideneacetone)dipalladium(0) (1.65 µmol, 5.5 mol%) and a ligand 
(3.30 µmol, 11.0 mol%) a dry, degassed solvent was added and the catalyst stirred for 30 min at 
25 °C. A solution of carbonate I.228 (10.0 mg, 30.0 µmol, 1 eq.) in solvent was added to the 
Pd2(dba)3 (5 mol%) 
ligand (12.5 %) 
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preformed catalyst and the reaction was stirred at the designated temperature for the designated 
time, prior to dilution of the sample with hexanes and ether and analysis of the %ee by chiral 
HPLC. 
 
Entry Ligand Pd source Solvent T (°C) t (h) %ee 
1 (R,R)-DACH-Phenyl Trost (I.235) A DME 25 12 51 
2 (R,R)-DACH-Phenyl Trost (I.235) A MTBE 25 12 46 
3 (R,R)-DACH-Phenyl Trost (I.235) A THF 25 12 47 
4 (R,R)-DACH-Phenyl Trost (I.235) A toluene 25 12 52 
5 (R,R)-DACH-Phenyl Trost (I.235) A 2:1 hexane/toluene 25 12 53 
6 (R,R)-DACH-Naphthyl Trost (I.236) A DME 25 12 22 
7 (R,R)-DACH-Naphthyl Trost (I.236) A MTBE 25 12 24 
8 (R,R)-DACH-Naphthyl Trost (I.236) A THF 25 12 24 
9 (R,R)-DACH-Naphthyl Trost (I.236) A toluene 25 12 26 
10 (R,R)-DACH-Naphthyl Trost (I.236) A 2:1 hexane/toluene 25 12 29 
11 (R,R)-ANDEN-Phenyl Trost (I.237) A DME 25 12 6 
12 (R,R)-ANDEN-Phenyl Trost (I.237) A MTBE 25 12 24 
13 (R,R)-ANDEN-Phenyl Trost (I.237) A THF 25 12 25 
14 (R,R)-ANDEN-Phenyl Trost (I.237) A toluene 25 12 13 
15 (R,R)-ANDEN-Phenyl Trost (I.237) A 2:1 hexane/toluene 25 12 27 
16 (R,R)-DACH-Phenyl Trost (I.235) A THF −15 24 48 
17 (R,R)-DACH-Phenyl Trost (I.235) A 2:1 hexane/toluene −15 24 66 
18 (R,R)-DACH-Phenyl Trost (I.235) A THF −60 24 46 
19 (R,R)-DACH-Phenyl Trost (I.235) A 2:1 hexane/toluene −60 24 55 
20 (R,R)-DACH-Phenyl Trost (I.235) A THF −78 24 54 
21 (R,R)-DACH-Phenyl Trost (I.235) A 2:1 hexane/toluene −78 24 54 
22a) (R,R)-DACH-Phenyl Trost (I.235) A toluene −10 2 60 
23a) (R,R)-DACH-Phenyl Trost (I.235) A 2:1 hexane/toluene −10 2 66 
24a) (R,R)-DACH-Phenyl Trost (I.235) B toluene −10 2 64 
25a) (R,R)-DACH-Phenyl Trost (I.235) B 2:1 hexane/toluene −10 2 59 
(A) Pd2(dba)3独CHCl3
or 
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26a)b) (R,R)-DACH-Phenyl Trost (I.235) B toluene −10 2 64 
25a)c) (R,R)-DACH-Phenyl Trost (I.235) B toluene −10 2 17 
a) Tsuji allylation after passage of the preformed catalyst through a plug of glass filter paper; recrystallized ligand used. 
b) Pd2dba3 to ligand ratio of 1:2.2 
c) Pd2dba3 to ligand ratio of 1:2.2 
 
Procedure C: The reaction was carried out at given concentrations in a glovebox under nitrogen 
atmosphere. To tris(dibenzylideneacetone)dipalladium(0) and ligand (3.30 µmol, 11.0 mol%) a 
solvent was added and the catalyst was stirred for 30 min at 25 °C. A solution of carbonate I.228 
(10.0 mg, 0.030 mmol, 1 eq.) in solvent was added to the preformed catalyst and the reaction was 
stirred at the designated temperature for the designated time, prior to dilution of the sample with 
hexanes and ether and analysis of the %ee by chiral HPLC. 
 
Entry Conc. (M) Pd2(dba)3 Solvent T (°C) t (h) %ee 
1a) 0.03 5 mol% toluene −10 2 64 
2a) 0.03 5 mol% 2:1 hexane/toluene −10 2 59 
3a) 0.01 5 mol% toluene −10 2 66 
4a) 0.01 5 mol% 2:1 hexane/toluene −10 2 58 
5a) 0.001 5 mol% toluene −10 2 66 
6a) 0.001 5 mol% 2:1 hexane/toluene −10 2 62 
7a) 0.03 1 mol% toluene −10 2 60 
8a) 0.03 1 mol% 2:1 hexane/toluene −10 2 66 
9a) 0.03 5 mol% toluene −30 2 50 
10a) 0.03 5 mol% 2:1 hexane/toluene −30 2 64 
a) Tsuji allylation after passage of the preformed catalyst through a plug of glass filter paper; recrystallized ligand used. 
 
Procedure D: The reaction was carried out at a concentration of 0.18 M in a glovebox under 
nitrogen atmosphere. Ketone I.226 (38 mg, 0.16 mmol, 1 eq.) and Cs2CO3 (51 mg, 0.16 mmol, 
1 eq.) were dissolved in degassed DME (0.5 mL) and stirred at room temperature for 15 min. 
before being cooled to −78 °C. In a second flask, allylpalladium (II) chloride dimer 
[(η3-C3H5)PdCl]2 (1.4 mg, 3.9 µmol, 2.5 mol%) and ligand (7.8 µmol, 5.0 mol%) were dissolved in 
Pd2(dba)3 : (R,R)-DACH 
Phenyl Trost ligand (1.0 : 2.2)
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DME (0.4 mL) and stirred at room temperature for 15 min. before allyl acetate (18 µL, 0.17 µmol, 
1.1 eq.) was added. Stirring was continued for another 5 min., then the preformed catalyst was 
slowly added via syringe into the enolate solution at −78 °C. The mixture was slowly allowed to 
warm to 0 °C and stirred at this temperature for 12 h, prior to dilution of the sample with hexanes 
and ether and analysis of the %ee by chiral HPLC. 
 
Entry Ligand Solvent T (°C) t (h) %ee 
1 (R,R)-DACH-Phenyl Trost (I.235) DME 0 12 7 
2 (R,R)-DACH-Naphthyl Trost (I.236) DME 0 12 5 
3 (R,R)-ANDEN-Phenyl Trost (I.237) DME 0 12 2 
 
Procedure E: The reaction was carried out at a concentration of 0.025 M in a glovebox under 
nitrogen atmosphere. [Ir(cod)Cl]2 (1.0 mg, 1.5 µmol, 5 mol%), ligand I.240 (1.4 mg, 3.0 µmol, 
10 mol%), and TBD (0.84 mg, 6.0 µmol , 20 mol%) were dissolved in degassed THF (0.3 mL) and 
stirred at 25 °C for 10 min, generating an orange solution. In a second vial, LiOt-Bu (3.6 mg, 
45 µmol, 1.5 eq.) was dissolved in 0.3 mL of THF, then ketone I.228 (10 mg, 30 µmol, 1.0 eq.) was 
added. After stirring for 10 min, the preformed catalyst solution was transferred to this vial, 
followed by cinnamyl carbonate (12 mg, 60 µmol, 2.0 eq.). The vial was sealed and stirred at 25 °C 
for 48 h outside the glovebox prior to dilution of the sample with hexanes and ether and analysis of 
the %ee by chiral HPLC. 
 
 
[(!3-C3H5)PdCl]2 (2.5 mol%)
ligand (5.5 mol%) 
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Allyl (7,8-dimethoxy-3,4-dihydronaphthalen-2-yl) carbonate (I.242) 
 
To a solution of ketone I.219 (300 mg, 1.45 mmol, 1.0 eq.) in THF (15 mL) was added sodium 
hydride (60 wt% in mineral oil, 64.0 mg, 1.60 mmol, 1.1 eq.) at 0 °C and the mixture was stirred for 
1 h at this temperature. Allyl chloroformate (10 v% in THF, 175 mg, 1.45 mmol, 1.0 eq.) was added 
and the reaction was stirred at 0 °C for an additional 30 min. The reaction was quenched with H2O 
(100 mL), extracted with EtOAc (3 × 100 mL) and the combined organic layers were washed with 
saturated aqueous NaCl solution (200 mL), dried (MgSO4) and concentrated under reduced 
pressure. Flash column chromatography [PE/EtOAc, 9:1 to 3:1] afforded carbonate I.242 (286 mg, 
0.985 mmol, 68% ) as a colorless oil. 
Rf = 0.55 [PE/EtOAc, 5:1].  
 1H NMR (400 MHz, CDCl3): δ = 6.81 (d, J = 8.2 Hz, 1H, H-5), 6.68 (d, 
J = 8.2 Hz, 1H, H-4), 6.65 (s, 1H, H-10), 5.98 (ddt, J = 16.5, 10.3, 5.8 Hz, 
1H, H-15), 5.41 (dq, J = 17.2, 1.4 Hz, 1H, H-16a), 5.32 (dt, J = 10.4, 1.2 Hz, 
H-16b), 4.70 (dt, J = 5.9, 1.3 Hz, 2H, H-14), 3.83 (s, 3H, H-12), 3.79 (s, 3H, 
H-11), 2.93 (t, J = 8.2 Hz, 2H, H-7), 2.53 (t, J = 8.1Hz, 2H, H-8) ppm.  
13C NMR (101 MHz, CDCl3): δ = 152.7 (C-13), 151.3 (C-3), 151.3 (C-2), 144.8 (C-15), 131.1 (C-6), 
126.8 (C-1), 126.2 (C-9), 122.4 (C-5), 119.3 (C-16), 110.2 (C-4), 109.2 (C-10), 68.9 (C-14), 61.1 (H-
11), 55.8 (H-12), 28.1 (C-7), 26.0 (C-8) ppm. 
IR (ATR): ṽ = 2940 (w), 2835 (w), 1754 (s), 1665 (w), 1604 (w), 1577 (w), 1485 (m), 1456 (m), 1422 
(m), 1362 (w), 1333 (w), 1313 (w), 1294 (w), 1222 (s), 1159 (m), 1090 (s), 1058 (m), 1032 (m), 978 
(m), 940 (m), 872 (m), 802 (m), 778 (m), 752 (m), 679 (m), 668 (m) cm‒1.  
HRMS (ESI): calcd. for C16H22O4N+:   308.1492 [M+NH4]+  
found:     308.1492 [M+NH4]+. 
 
NaH, THF, 0 °C → allyl 
chloroformate, 0°C
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1-Allyl-7,8-dimethoxy-3,4-dihydronaphthalen-2(1H)-one (I.243) 
 
Tris(dibenzylideneacetone)dipalladium(0) (7.89 mg, 8.61 µmol, 2.5 mol%) and PPh3 (5.65 mg, 
21.5 µmol, 6.25 mol%) were dissolved in degassed THF (3 mL, 3 × freeze-pump-thaw) and stirred 
for 30 min. at room temperature. A solution of carbonate I.242 (100 mg, 0.344 mmol, 1.0 eq.) 
dissolved in degassed THF (2 mL, 3 × freeze-pump-thaw) was added to the preformed catalyst and 
the reaction was stirred at room temperature for 16 h, prior to concentrating the reaction mixture 
under reduced pressure. Flash column chromatography [PE/EtOAc, 9:1] afforded 
allylcyclohexanone I.243 (84.2 mg, 0.342 mmol, 99%) as a colorless oil. 
Rf = 0.57 [PE/EtOAc 3:1]. 
1H NMR (400 MHz, CDCl3): δ = 6.90 (d, J = 8.3 Hz, 1H, H-5), 6.79 (d, J = 8.2 Hz, 1H, H-4), 
5.75–5.63 (m, 1H, H-12), 4.98–4.89 (m, 2H, H-13), 3.86 (s, 3H, H-15), 3.83 (s, 
4H, H-10, H-14), 3.13 (ddd, J = 16.8, 12.3, 5.3 Hz, 1H, H-7a), 2.86 (ddd, 
J = 15.6, 6.5, 3.1 Hz, 1H, H-7b), 2.73–2.60 (m, 2H, H-8a, H-11b), 2.55 (dt, 
J = 14.1, 7.3 Hz, 1H, H-11a), 2.42 (ddd, J = 17.0, 12.4, 6.5 Hz, 1H, H-8b) ppm. 
 
13C NMR (101 MHz, CDCl3): δ = 212.8 (C-1), 151.4 (C-3), 146.7 (C-2), 135.0 (C-12), 131.1 (C-1), 
129.5 (C-6), 123.1 (C-5), 117.3 (C-11), 111.0 (C-4), 60.9 (C-14), 55.9 (C-15), 48.4 (C-10), 38.4 (C-8), 
38.1 (C-11), 27.3 (C-7) ppm.  
IR (ATR): 2940 (w), 1709 (s), 1605 (w), 1491 (s), 11456 (m), 1344 (m), 1276 (s), 1221 (m), 1084 
(m), 1053 (s), 998 (m), 916 (m), 806 (m) cm‒1. 
HRMS (ESI): calcd. for C15H19O3+:   247.1329 [M+H]+  
found:     257.1329 [M+H]+. 
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Methyl-4-(1-(cyanomethyl)-7,8-dimethoxy-2-oxo-1,2,3,4-tetra-hydronaphthalen-1-yl)but-2-
enoate (I.218) 
 
To a solution of α-allylcyclohexanone I.227 (500.0 mg, 1.75 mol, 1.0 eq.) and methyl acrylate 
(2.16 mL, 26.0 mmol, 15 eq.) in toluene (20 mL) was added Hoveyda−Grubbs catalyst 2nd 
generation (104 mg, 123 µmol, 7 mol%) and the reaction was stirred for 48 h at room temperature. 
The reaction was diluted with H2O (40 mL) and extracted with EtOAc (3 × 40 mL). The combined 
organic layers were washed with saturated aqueous NaCl solution (60 mL), dried (MgSO4) and 
concentrated under reduced pressure. Flash column chromatography [PE/EtOAc, 6:1] afforded 
conjugated ester I.218 (539 mg, 1.57 mmol, 90%) as a colorless solid. 
E/Z -ratio: 27:1 (determined by integrals of H-13 in 1H NMR). 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[PE/EtOAc, 15:1] at 0 °C. 
Rf = 0.24 [PE/EtOAc, 3:1].  
mp: 78–81 °C. 
1H NMR (600 MHz, CDCl3) of the E-isomer: δ = 6.93–6.87 (m, 2H, H-4, H-
5), 6.46 (ddd, J = 15.5, 9.3, 6.2 Hz, 1H, H-16), 5.72 (ddd, J = 15.5, 1.6, 1.0 Hz, 
1H, H-17), 3.96 (s, 3H, H-13), 3.88 (s, 3H, H-14), 3.65 (s, 3H, H-19), 3.32 (d, 
J = 16.4 Hz, 1H, H-11a), 3.09 (d, J = 16.4 Hz, 1H, H-11b), 3.07–3.01 (m, 2H, 
H-15a, H-7a), 2.92 (ddd, J = 15.8, 7.4, 5.5 Hz, 1H, H-7b), 2.82 (ddd, J = 0.9, 
9.3, 13.8 Hz, 1H, H-15b), 2.73 (ddd, J = 13.7, 7.6, 5.2 Hz, 1H, H-8a), 2.63 (ddd, J = 13.9, 9.6, 
5.5 Hz, 1H, H-8b) ppm. 
13C NMR (150 MHz, CDCl3) of the E-isomer: δ = 210.3 (C-9), 166.1 (C-18), 151.5 (C-3), 147.8 (C-
2), 142.5 (C-16), 129.8 (C-6), 128.3 (C-1), 124.6 (C-17), 123.8 (C-5), 117.4 (C-12), 113.0 (C-4), 60.6 
(C-13), 55.8 (C-14), 53.4 (C-10), 51.5 (C-19), 40.6 (C-15), 39.2 (C-8), 28.1 (C-7), 25.5 (C-11) ppm. 
IR (ATR): ṽ = 2948 (w), 1719 (s), 1657 (w), 1488 (m), 1438 (m), 1438 (w), 1347 (w), 1277 (s), 1214 
(w), 1171 (m), 1111 (w), 1027 (w), 982 (w), 807 (w) cm‒1.  
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HRMS (EI): calcd. for C19H25N2O5+:  361.1758 [M+NH4]+ 
found:    361.1760 [M+NH4]+. 
 
(3R ,3aS ,9bR)-Methyl 8,9-dimethoxy-11-oxo-2,3,4,5-tetrahydro-1H-3a,9b-(epoxyethano)-
cyclopenta-[a]naphthalene-3-carboxylate (I.254) 
 
A solution of Cu(OAc)2·H2O (28.9 mg, 146 µmol, 0.5 eq.) and rac-BINAP (90.0 mg, 146 µmol, 
0.5 eq.) in deg. THF (3 mL) was stirred for 15 min. before TMDS (39.1 mg, 291 µmol, 1 eq.) was 
added. After additional 15 min. a solution of unsaturated ester I.218 (100 mg, 291 µmol, 1 eq.) in 
deg. THF (1 mL + 0.5 mL rinse) was added rapidly and the reaction stirred for 24 h at room 
temperature. The reaction was quenched by the addition of aqueous 1 M HCl (2 mL) and the 
mixture stirred for 1 h before it was diluted by the addition of aqueous saturated NH4Cl (20 mL) 
and TMEDA (0.1 mL). The mixture was extracted with EtOAc (3 × 20 mL) and the combined 
organic layers were washed with saturated aqueous NaCl solution (40 mL), dried (MgSO4) and 
concentrated under reduced pressure. Flash column chromatography [pent/Et2O, 3:1] afforded 
teracyclic lactone I.254 (60.6 mg, 176 µmol, 60%) as colorless crystals. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[PE/EtOAc, 20:1] at 0 °C. 
Rf = 0.24 [PE/EtOAc, 3:1].  
1H NMR (400 MHz, CDCl3) δ = 6.86–6.76 (m, 2H, H-4, H-5), 3.89 (s, 3H, H-
13), 3.85 (s, 3H, H-14), 3.77 (s, 3H, H-19), 3.21 (d, J = 18.7 Hz, 1H, H-11a), 
2.94 (dd, J = 6.8, 11.4 Hz, 1H, H-17), 2.86–2.77 (m, 2H, H-11b, H-7a), 2.72 (dd, 
J = 10.0, 21.8 Hz, 1H, 8a), 2.60 (dd, J = 4.4, 13.4 Hz, 1H, H-7b), 2.52 (ddd, 
J = 13.7, 7.5, 1.8 Hz, 1H, H-8b), 2.30–2.14 (m, 1H, H-15a), 2.01–1.87 (m, 2H, H-16), 1.82 (dddd, 
J = 13.2, 12.1, 7.3, 0.8 Hz, 1H, H-16a) ppm. 
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13C NMR (101 MHz, CDCl3): δ = 177.7 (C-12), 170.7 (C-18), 151.5 (C-2 or C-3), 147.0 (C-2 or 
C.3), 136.0 (C-1), 126.9 (C-6), 123.2 (C-5), 111.5 (C-4), 95.1 (C-9), 60.5 (C-13), 55.9 (C-14), 52.1 (C-
19), 50.6 (C-17), 50.2 (C-10), 44.1 (C-11), 40.3 (C-15), 30.4 (C-7), 26.0 (C-8), 25.4 (C-16) ppm. 
IR (ATR): ṽ = 2927 (m), 2850 (w), 1772 (s), 1735 (s), 1603 (w), 1489 (s), 1455 (m), 1418 (w), 1355 
(w), 1279 (s), 1207 (m), 1192 (m), 1062 (s), 1026 (m) cm-1. 
HRMS (EI): calcd. for C20H27NO5+:   346.1651 [M+H]+  
found:    346.1649 [M+H]+. 
 
 
Methyl 4-(1-(cyanomethyl)-7,8-dimethoxy-2-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)-butane-
ate (I.251) 
 
To a solution of crude  α,β-unsaturated ester I.218 (2.00 g, 5.82 mmol, 1.0 eq.) in EtOAc (50 mL), 
Pd/C (10 wt%, 200 mg) was added. The flask was purged with H2 five times and stirred under H2 
atmosphere (1 atm) at room temperature for 12 h. The catalyst was removed by filtration through a 
pad of silica, which was washed with EtOAc (100 mL) to afforded saturated ester I.251 (1.90 g, 
5.50 mmol, 95%) as a colorless solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 20 °C. 
Rf = 0.24 [PE/EtOAc, 3:1]. 
mp: 85–88 °C. 
1H NMR (400 MHz, CDCl3): δ = 6.97–6.79 (m, 2H, H-4, H-5), 3.92 (s, 3H, H-13), 3.85 (s, 3H, H-
14), 3.58 (s, 3H, H-7), 3.31 (d, J = 16.4 Hz, 1H, H-11a), 3.16–2.91 (m, 3H, H-11b, H-19), 2.75 (t, 
J = 7.0 Hz, 2H, H-8), 2.17 (dt, J = 7.9, 6.6 Hz, 2H, H-17), 2.05 (dt, J = 11.0, 4.9 Hz, 2H, H-15), 
1.43–1.25 (m, 1H, H-16a), 1.28–1.12 (m, 1H, H-16b) ppm. 
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13C NMR (101 MHz, CDCl3): δ = 211.4 (C-9), 173.2 (C-18), 151.6 (C-3), 
147.9 (C-2), 129.9 (C-6), 129.5 (C-12), 123.7 (C-4), 118.0 (C-1), 112.6 (C-5), 
60.6 (C-13), 55.8 (C-14), 53.7 (C-19), 51.5 (C-10), 39.2 (C-8), 37.6 (C-15), 33.8 
(C-17), 28.4 (C-7), 25.7 (C-11), 20.8 (C-16) ppm. 
IR (ATR): ṽ = 2948 (m), 2842 (w), 1733 (s), 1712 (s), 1601 (w), 1577 (w), 1486 (s), 1453 (m), 1438 
(m), 1415 (m), 1345 (m), 1275 (s), 1232 (m), 1210 (m), 1169 (s), 1106 (s), 1049 (s), 1012 (m), 982 
(m) cm‒1. 
HRMS (EI): calcd. for C19H24NO5+:   346.1649 [M+H]+  
found:    346.1651 [M+H]+.  
 
(3R ,3aS ,9bR)-Methyl 8,9-dimethoxy-11-oxo-2,3,4,5-tetrahydro-1H-3a,9b-(epiminoethano)-
cyclopenta-[a]naphthalene-3-carboxylate (I.260) 
 
Na (96.0 mg, 4.17 mmol, 1.3 eq.) was dissolved in MeOH (60 mL), containing a small amount of 
molecular sieves (3Å). A solution of saturated ester I.251 (1.11 g, 3.21 mmol, 1.0 eq.) in MeOH 
(20 mL) was added and the mixture was heated to 75 °C for 16 h. Aqueous saturated NH4Cl 
solution (60 mL) and H2O (120 mL) were added and the aqueous layer was extracted with EtOAc 
(3 × 250 mL). The combined organic layers were washed with saturated aqueous NaCl solution 
(250 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column chromatography 
[PE/EtOAc, 2:1 to 0:1] afforded lactams I.260 and I.261 (1.10 g, 3.18 mmol, 99%) as a colorless 
solid with a d.r. of 10:1.  
Both enantiomers were separated and crystals suitable for single-crystal X-ray analysis (Section 9.1) 
were obtained from recrystallization [i-Hex/EtOAc, 20:1] at 0 °C. 
Full characterization of the major diastereomer (I.260):  
Rf = 0.41 [EtOAc].  
m.p.: 160–162°C (decomposition). 
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1H NMR (400 MHz, CDCl3) δ = 6.81–6.71 (m, 2H, H-4, H-5), 6.47 (s, 1H, H-
13), 3.86 (s, 3H, H-14), 3.82 (s, 3H, H-15), 3.71 (s, 3H, H-20), 2.98 (d, 
J = 17.7 Hz, 1H, H-11a), 2.87 (dd, J = 11.8, 6.4 Hz, 1H, H-18), 2.74 (dt, J = 16.5, 
4.8 Hz, 1H, H-7a), 2.67 (dd, J = 11.8, 4.3 Hz, 1H, H-7b), 2.58 (d, J = 17.7 Hz, 
1H, H-11b), 2.49 (dd, J = 12.7, 7.4 Hz, 1H, H-16a), 2.21 (dt, J = 13.6, 4.4 Hz, 
1H, H-8a), 2.05 (td, J = 11.2, 10.5, 6.8 Hz, 1H, H-17a), 2.12–1.82 (m, 3H, H-17b, 
H-16b, H-8b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 175.8 (C-12), 173.3 (C-19), 151.5 (C-3), 147.2 (C-2), 137.6 (C-1), 
126.7 (C-6), 123.2 (C-5), 111.1 (C-4), 69.2 (C-9), 60.5 (C-14), 55.8 (C-15), 52.0 (C-20), 49.6 (C-18), 
49.3 (C-10), 46.5 (C-11), 41.9 (C-16), 31.6 (C-8), 26.9 (C-17), 26.0 (C-7) ppm. 
IR (ATR): ṽ = 3185 (w), 2952 (m), 2363 (w), 2334 (w), 1734 (m), 1693 (s), 1488 (m), 1416 (m), 
1351 (w), 1279 (m), 1214 (m), 1098 (m), 1059 (w), 1023 (w), 984 (w), 797 (w) cm-1. 
HRMS (EI): calcd. for C19H23NO5+:   345.1576 [M+H]+  
found:    345.1581 [M+H]+. 
 
Characterization of the minor diastereomer (I.261):  
Rf = 0.39 [EtOAc]. 
1H NMR (400 MHz, CDCl3) δ = 6.80–6.72 (m, 2H, H-4, H-5), 6.04 (s, 1H, H-
13), 3.92 (s, 3H, H-14), 3.84 (s, 3H, H-15), 3.75 (s, 3H, H-20), 3.13 (dd, J = 11.1, 
8.4 Hz, 1H, H-18), 2.93 (d, J = 18.1 Hz, 1H, H-11a), 2.86–2.71 (m, 2H, H-8a, H-
11b), 2.58 (dt, J = 16.1, 4.3 Hz, 1H, H-8b), 2.46 (dt, J = 14.0, 9.2 Hz, 1H, H-
17a), 2.21–2.10 (m, 1H, H-17b), 2.10–1.95 (m, 2H, H-16), 1.76 (dd, J = 8.4, 
4.3 Hz, 2H, H-7) ppm. 
13C NMR (101 MHz, CDCl3): δ = 176.3 (C-12), 172.7 (C-19), 151.4 (C-3), 147.2 (C-2), 136.2 (C-1), 
127.4 (C-6), 122.7(C-5), 111.5 (C-4), 77.0 (C-9), 69.7 (C-14), 60.5 (C-), 55.9 (C-15 or C-18), 55.8 (C-
15 or C-18), 51.9 (C-20), 50.6 (C-10), 48.1 (C-11), 39.1 (C-17), 26.2 (C-7), 25.6 (C-16), 24.5 (C-
8) ppm. 
IR (ATR): ṽ = 3210 (w), 2945 (w), 1732 (m), 1693 (s), 1489 (m), 1453 (m), 1437 (w), 1415 (w), 1361 
(w), 1280 (m), 1217 (m), 1171 (w), 1102 (w), 1072 (w), 1031 (w), 988 (w), 801 (w), 760 (w) cm-1. 
HRMS (EI): calcd. for C19H23NO5+:   345.1576 [M]+  
found:    345.1571 [M]+. 
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t e r t-Butyl (R ,E)-4-(1-(cyanomethyl)-7,8-dimethoxy-2-oxo-1,2,3,4-tetrahydronaphthalen-1-
yl)but-2-enoate (I.265) 
 
To a solution of α-allylcyclohexanone I.227 (30.0 mg, 105 µmol, 1.0 eq.) and tert-butyl acrylate 
(230 µL, 1.58 mmol, 15 eq.) in toluene (2 mL) was added Grubbs catalyst 2nd generation (6.24 mg, 
7.35 µmol, 7 mol%) and the reaction was stirred for 96 h at room temperature. The reaction 
mixture was concentrated under reduced pressure. Flash column chromatography [PE/EtOAc, 9:1 
to 3:1] afforded conjugated ester I.265 (34.8 mg, 90.3 µmol, 86%) as a colorless solid. 
E/Z-ratio: 12:1 (determined by integrals of H-13 in 1H NMR). 
Rf = 0.70 [PE/EtOAc, 2:1].  
1H NMR (400 MHz, CDCl3) of the E-isomer: δ = 6.89 (s, 2H, H-4, H-5), 
6.34 (ddd, J = 15.3, 9.4, 5.8 Hz, 1H, H-17), 5.69–5.61 (m, 1H, H-16), 3.96 (s, 
3H, H-13), 3.88 (s, 3H, H-14), 3.33 (d, J = 16.4 Hz, 1H, H-11a), 3.09 (d, 
J = 16.4 Hz, 1H, H-11b), 3.05–2.96 (m, 2H, H-7a, H-15a), 2.96–2.88 (m, 1H, 
H-7b), 2.82–2.74 (m, 1H, H-15b), 2.74–2.59 (m, 2H, H-8), 1.40 (s, 9H, H-
20) ppm. 
13C NMR (101 MHz, CDCl3) of the E-isomer: δ = 210.4 (C-9), 165.0 (C-18), 151.5 (C-3), 147.7 (C-
2), 140.9 (C-17), 129.8 (C-6), 128.4 (C-1), 126.6 (C-16), 123.8 (C-5), 117.6 (C-12), 112.9 (C-4), 80.5 
(C-19), 77.0 (C-10), 60.6 (C-13), 55.8 (C-14), 53.4 (C-15), 40.5 (C-8), 39.2 (C-7), 28.1 (C-20), 25.4 
(C-11) ppm. 
IR (ATR): ṽ = 2977 (m), 2940 (m), 2841 (w), 1713 (s), 1653 (w), 1602 (w), 1577 (w), 1487 (s), 1455 
(m), 1416 (w), 1367 (m), 1346 (m), 1277 (s), 1247 (w), 1232 (s), 1221 (w), 1154 (s), 1110 (m), 1067 
(w), 1054 (w), 1024 (w), 983 (m), 928 (w), 872 (w), 850 (w), 830 (w), 808 (m) cm‒1.  
HRMS (EI): calcd. for C22H27NO5+:   385.1884 [M]+  
found:    385.1879 [M]+.  
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t e r t-Butyl (R)-4-(1-(cyanomethyl)-7,8-dimethoxy-2-oxo-1,2,3,4-tetrahydronaphthalen-1-
yl)butanoate (I.266) 
 
To a solution of crude  α,β-unsaturated ester I.265 (34.8 mg, 90.3 mmol, 1.0 eq.) in EtOAc 
(1.2 mL), Pd/C (10 wt%, 3.48 mg) was added. The flask was purged with H2 five times and stirred 
under H2 atmosphere (1 atm) at room temperature for 20 h. The catalyst was removed by filtration 
through a pad of silica, which was washed with EtOAc (5 mL) to afford saturated ester I.266 
(28.9 mg, 74.6 mmol, 83%) as a colorless oil. 
Rf = 0.69 [PE/EtOAc, 2:1]. 
1H NMR (400 MHz, CDCl3): δ = 6.88 (s, 2H, H-4, H-5), 3.93 (s, 3H, H-13), 
3.87 (s, 3H, H-14), 3.33 (d, J = 16.4 Hz, 1H, H-11a), 3.15–2.92 (m, 3H, H-
11b, H-7), 2.77 (t, J = 7.0 Hz, 2H, H-8), 2.15–1.98 (m, 4H, H-15, H-17), 1.38 
(s, 9H, H-20), 1.34–1.23 (m, 1H, H-16a), 1.23–1.08 (m, 1H, H-16b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 211.4 (C-9), 172.1 (C-18), 151.5 (C-3), 
147.8 (C-2), 129.8 (C-1 or C-6), 129.6 (C-1 or C-6), 123.7 (C-5), 118.0 (C-12), 112.5 (C-4), 80.4 (C-
19), 60.5 (C-13), 55.7 (C-14), 53.8 (C-10), 39.2 (C-8), 37.7 (C-15), 35.2 (C-17), 28.4 (C-7), 28.0 (C-
20), 25.6 (C-11), 20.8 (C-16) ppm. 
IR (ATR): ṽ = 2975 (m), 2940 (m), 2841 (w), 1717 (s), 1602 (w), 1578 (w), 1487 (s), 1455 (m), 1416 
(m), 1392 (w), 1367 (m), 1346 (m), 1274 (s), 1153 (s), 1107 (m), 1051 (m), 984 (w), 925 (w), 874 (w), 
946 (w), 808 (w), 756 (w) cm‒1.  
HRMS (EI): calcd. for C22H27NO5+:   387.2040 [M]+  
found:    387.2043 [M]+.  
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t e r t-Butyl (3R ,3aR ,9bR)-8,9-dimethoxy-11-oxo-2,3,4,5-tetrahydro-1H-3a,9b-(epiminoetha-
no)cyclo-penta[a]naphthalene-3-carboxylate (I.267) 
 
Saturated ester I.266 (10.0 mg, 25.8 µmol, 1.0 eq.) was dissolved in t-BuOH (1 mL) and KOt-Bu 
(3.76 mg, 33.5 µmol, 1.3 eq.) was added. The mixture was heated to 60 °C for 12 h. H2O (5 mL) 
was added and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic 
layers were washed with saturated aqueous NaCl solution (10 mL), dried (MgSO4) and concentrated 
under reduced pressure. Flash column chromatography [PE/EtOAc, 2:1 to 0:1] afforded the lactam 
I.267 (8.3 mg, 21.4 µmol, 83%) as a colorless oil. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 20 °C. 
Rf = 0.41 [EtOAc/PE, 2: 1]. 
1H NMR (400 MHz, CDCl3) δ = 6.84–6.71 (m, 2H, H-5 and H-5), 6.45 (s, 1H, 
H-13), 3.88 (s, 3H, H-14), 3.84 (s, 3H, H-15), 3.02 (d, J = 17.8 Hz, 1H, H-11a), 
2.80 (dt, J = 12.0, 5.8 Hz, 1H, H-18), 2.76–2.67 (m, 1H, H-7), 2.62 (d, 
J = 17.9 Hz, 1H, H-11b), 2.47 (dd, J = 12.7, 7.4 Hz, 1H, H-16a), 2.25 (dt, 
J = 13.6, 4.3 Hz, 1H, H-8a), 2.07–1.80 (m, 3H, H-8b, H-16b, H-17), 1.47 (s, 9H, 
H-21) ppm. 
13C NMR (101 MHz, CDCl3): δ = 176.0 (C-19), 172.1 (C-12), 151.4 (C-3), 147.2 (C-2), 137.8 (C-1), 
126.7 (C-6), 123.2 (C-5), 111.0 (C-4), 81.5 (C-20), 69.2 (C-9), 60.5 (C-14), 55.8 (C-15), 50.1 (C-18), 
49.7 (C-10), 46.3 (C-11), 41.7 (C-16), 31.0 (C-8), 28.2 (C-21), 26.9 (C-17), 26.1 (C-7) ppm. 
IR (ATR): ṽ = 2974 (w), 2359 (m), 2338 (w), 2180 (w), 1718 (m), 1697 (s), 1654 (m), 1636 (m), 
1617 (m), 1576 (w), 1559 (m), 1540 (m), 1522 (w), 1507 (w), 1457 (w), 1489 (m), 1419 (w), 1368 (w), 
1280 (w), 1155 (w), 668 (w) cm-1. 
HRMS (EI): calcd. for C22H30NO5+:   388.2118 [M+H]+  
found:    388.2120 [M+H]+.  
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12-(t e r t-Butyl) 3-methyl (3R ,3aR ,9bR)-8,9-dimethoxy-11-oxo-2,3,4,5-tetrahydro-1H-3a,9b-
(epiminoethano)cyclopenta[a]naphthalene-3,12-dicarboxylate (I.269) 
 
Amide I.260 (10.4 mg, 30.0 µmol, 1eq.) was dissolved in THF (1 mL) and NEt3 (3.64 mg, 
5.00 µmol, 1.2 eq.) followed by Boc2O (7.86 mg, 36.0 µmol, 1.2 eq.) and DMAP (4.40 mg, 
36.0 µmol, 1.2 eq.) were added. The reaction mixture was heated to 85 °C for 15 h. Afterwards the 
reaction was cooled to room temperature and diluted with EtOAc (50 mL). The organic phase was 
washed with 1 M aqueous HCl solution (3 × 20 mL), H2O (3 × 20 mL) and saturated aqueous NaCl 
solution (20 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column 
chromatography [PE/EtOAc, 1:3 + 1% NEt3] afforded Boc-protected amide I.269 (5.60 mg, 
12.6  µmol, 42%) as a yellow oil. 
Rf = 0.77 [EtOAc/PE, 2:1]. 
1H NMR (400 MHz, CDCl3) δ = 6.80–6.70 (m, 2H, H-4, H-5), 3.89 (s, 3H, H-
22), 3.83 (s, 3H, H-23), 3.67 (s, 3H, H-21), 3.12 (d, J = 18.1 Hz, 1H, H-11a), 3.02 
(t, J = 8.7 Hz, 1H, H-19), 2.70–2.58 (m, 5H, H-11b, H-7, H-8a, H-17a), 2.14 (td, 
J = 10.0, 8.8, 6.7 Hz, 2H, H-18), 1.98–1.82 (m, 2H, H-8b, H-17b), 1.52 (s, 9H, H-
16) ppm. 
13C NMR (101 MHz, CDCl3): δ = 174.5 (C-12), 174.2 (C-20), 151.3 (C-3), 150.6 (C-14), 147.6 (C-
2), 135.2 (C-1), 127.9 (C-6), 123.2 (C-5), 111.6 (C-4), 83.1 (C-15), 74.6 (C-9), 60.5 (C-22), 55.9 (C-
23), 52.9 (C-19), 52.0 (C-21), 49.5 (C-10), 44.3 (C-11), 36.3 (C-17), 30.9 (C-8), 29.3 (C-18), 28.0 (C-
16), 25.6 (C-7) ppm. 
IR (ATR): ṽ = 2980 (w), 2949 (w), 1784 (m), 1730 (s), 1603 (w), 1578 (w), 1489 (m), 1455 (m), 1436 
(m), 1416 (w), 1394 (w), 1368 (m), 1301 (s), 1278 (s), 1284 (m), 1216 (w), 1195 (w), 1168 (s), 1100 
(m), 1062 /m), 1014 (w), 981 (w), 968 (w), 927 (w), 885 (w), 848 (w), 800 (w), 749 (w), 734 (w) cm-1. 
HRMS (ESI): calcd. for C24H31NO7Na+:  468.1993 [M+Na]+  
found:    468.1997 [M+Na]+. 
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(3R ,3aS ,9bR)-Methyl 8,9-dimethoxy-12-methyl-11-oxo-2,3,4,5-tetrahydro-1H-3a,9b-(epimi-
noethano)-cyclopenta[a]naphthalene-3-carboxylate (I.259) 
 
Amide I.260 (2.71 g, 7.85 mol) was dissolved in DMF (125 mL) and NaH (60 wt% in mineral oil, 
377 mg, 9.42 mmol, 1.2 eq.) was added to the stirring solution at 0 °C. The reaction mixture was 
kept at 0 °C and MeI (586 µL, 9.42 mmol, 1.2 eq.) was added slowly. The reaction was heated to 
30 °C and after 14 h it was stopped by the addition of saturated aqueous NH4Cl solution (10 mL). 
A solution of 10% LiCl in H2O (300 mL) was added and the aqueous layer was extracted with 
EtOAc (3 × 500 mL). The combined organic layers were washed with saturated aqueous NaCl 
solution (500 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column 
chromatography [PE/EtOAc, 1:1 to 2:1] afforded N-methyl amide I.259 (2.21 g, 6.15 mmol, 78%) 
as a bright yellow solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 0 °C. 
Full characterization of the major diastereomer (I.259):  
Rf = 0.25 [EtOAc/PE, 2:1]. 
 1H NMR (400 MHz, CDCl3) δ = 6.76 (s, 2H, H-4, H-5), 3.89 (s, 3H, H-13), 
3.84 (s, 3H, H-14), 3.73 (s, 3H, H-19), 3.05 (d, J = 17.7 Hz, 1H, H-11a), 2.80 (dd, 
J = 11.2, 6.7 Hz, 1H, H-17), 2.70 (s, 3H, H-20), 2.55 (m, 2H, 11-b, ), 2.55 (d, 
J = 17.7 Hz, 1H), 2.30 (ddd, J = 13.6, 7.7, 4.4 Hz, 1H), 2.20 – 2.07  (m, 1H), 2.00 
(td, J = 8.6, 4.1 Hz, 1H), 1.95 – 1.87 (m, 1H), 1.81 (ddd, J = 13.6, 11.6, 7.4 Hz, 
1H). 
13C NMR (101 MHz, CDCl3): δ = 176.9 (C-12), 172.7 (C-18), 151.5 (C-2 or C-3), 147.4 (C-2 or 
C.3), 137.2 (C-1), 127.2 (C-6), 123.06 (C-5), 111.2 (C-4), 74.9 (C-9), 60.5 (C-13), 55.8 (C-14), 52.0 
(C-19), 51.0 (C-17), 49.2 (C-10), 45.8 (C-11), 39.5 (C-15), 29.5 (C-7), 25.9 (C-8), 25.8 (C-16) ppm. 
IR (ATR): ṽ = 2949 (bm), 1733 (m), 1688 (s), 1487 (m), 1452 (w), 1417 (w), 1389 (w), 1279 (m), 
1211 (w), 1169 (w), 1099 (1), 1062 (m), 981 (w), 803 (w) cm-1. 
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HRMS (EI): calcd. for C20H25NO5+:   359.1727 [M]+  
found:    359.1719 [M]+. 
 
 
(3R ,3aS ,9bR)-methyl 8,9-dimethoxy-12-methyl-11-thioxo-2,3,4,5-tetrahydro-1H-3a,9b-(epi-
minoethano)cyclopenta[a]naphthalene-3-carboxylate (I.272) 
 
Lactame I.259 (110 mg, 0.300 mmol, 1 eq) was dissolved in toluene (5 mL) and Lawesson’s reagent 
(121 mg, 0.300 mmol, 1 eq.) was added to the stirring solution. The reaction was heated to 110 °C 
for 3 h in a pressure tube. The solvent was removed under reduced pressure and purification via 
flash column chromatography [PE/EtOAc, 6:1 to 1:1] afforded thionolactame I.272 (98.5 mg, 
0.262 mmol, 87%) as a bright yellow solid. 
Rf = 0.77 [EtOAc/PE, 2:1].   
1H NMR (400 MHz, CDCl3) δ = 6.76 (s, 2H, H-4, H-5), 3.91 (s, 3H, H-14), 3.84 
(s, 3H, H-15), 3.75 (s, 3H, H-20), 3.65 (dd, J = 18.7, 1.2 Hz, 1H, H-11a), 3.18 (d, 
J = 18.7 Hz, 1H, H-11b), 3.09 (d, J = 1.1 Hz, 3H, H-13), 2.85 (dd, J = 11.2, 
6.7 Hz, 1H, H-18), 2.74 (dd, J = 8.8, 4.3 Hz, 1H, H-7a), 2.67 – 2.57 (m, 2H, H-
7b, H-16a), 2.36 (ddd, J = 13.7, 7.6, 4.2 Hz, 1H, H-8a), 2.13 – 1.99 (m, 2H, H-8b, 
17-a), 1.93 (dtd, J = 13.0, 7.1, 1.9 Hz, 1H, H-17b), 1.81 (ddd, J = 13.6, 11.6, 
7.4 Hz, 1H, H-16b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 202.4 (C-12), 172.1 (C-19), 151.6 (C-3), 147.3 (C-2), 136.4 (C-1), 
126.7 (C-6), 123.0 (C-5), 111.4 (C-4), 82.9 (C-9), 60.6 (C-14), 58.3 (C-11), 55.9 (C-15), 52.3 (C-20), 
51.3 (C-10), 51.0 (C-18), 39.5 (C-16), 32.1 (C-13), 29.3 (C-8), 26.4 (C-17), 25.9 (C-7) ppm. 
IR (ATR): ṽ = 2945 (m), 2838 (w), 1732 (s), 1595 (w), 1488 (s), 1454 (m), 1417 (m), 1393 (m), 1355 
(w), 1305 (m), 1278 (s), 1214 (m), 1166 (m), 1097 (m), 1062 (m), 979 (w), 934 (w), 802 (w) cm-1. 
HRMS (ESI): calcd. for C20H26NO4S+:  376.1577 [M+H]+  
found:    376.1573 [M+H]+. 
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(3R ,3aS ,9bR)-methyl 8,9-dimethoxy-12-methyl-2,3,4,5-tetrahydro-1H-3a,9b-(epiminoetha-
no)cyclo-penta[a]naphthalene-3-carboxylate (I.273) 
 
To a solution of thionoamide I.272 (96.3 mg, 0.257 mmol, 1.0 eq) in MeOH (5 mL), Raney-Ni 
(about 10 wt%, 0.2 mL Raney-Ni in MeOH) was added. The flask was purged with H2 five times 
and stirred under H2 atmosphere (1 atm) at room temperature for 5 h. The catalyst was removed by 
filtration through a pad of Celite®, which was washed with MeOH (100 mL). The filtrate was 
concentrated under reduced pressure and gave tertiary amine I.273 (78.4 mg, 0.226 mmol, 88%) as 
a colorless oil. 
Rf = 0.78 [DCM/MeOH, 10:1].   
1H NMR (400 MHz, CDCl3) δ = 6.79–6.75 (m, 1H, H-5), 6.75–6.70 (m, 1H, H-4), 
3.88 (s, 3H, H-13), 3.84 (s, 3H, H-14), 3.72 (s, 3H, H-19), 2.99 (ddd, J = 9.0, 7.8, 
2.6 Hz, 1H, H-12a), 2.67 (dd, J = 12.8, 6.6 Hz, 2H, H-7), 2.58 (dd, J = 12.3, 6.0 Hz, 
1H, H-17), 2.54–2.41 (m, 2H, H-15a, H-12b), 2.29 (m, 2H, H-16a, H-11a), 2.25 (s, 
3H, H-20), 2.15–2.06 (m, 1H, H-11b), 1.99 (q, J = 7.1, 6.2 Hz, 2H, H-8), 1.68 (dt, 
J = 12.1, 6.2 Hz, 1H, H-16b), 1.56 (td, J = 12.5, 6.9 Hz, 1H, H-15b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 174.11 (C-18), 151.61 (C-2), 147.63 (C-3), 140.24 (C-1), 128.88 
(C-6), 122.73 (C-5), 110.48 (C-4), 75.04 (C-9), 60.63 (C-14), 56.23 (C-10), 55.96 (C-13), 54.76 (C-
12), 51.51 (C-19), 51.19 (C-17), 41.13 (C-15), 40.63 (C-11), 35.50 (C-20), 27.26 (C-7), 25.83 (C-8), 
25.66 (C-16) ppm. 
IR (ATR): ṽ = 2926 (s), 1733 (s), 1486 (s), 1454 (m), 1208 (m), 1064 (m) 806 (m) cm-1.  
HRMS (ESI): calcd. for C20H28NO4+:   346.2013 [M+H]+  
found:    346.2010 [M+H]+. 
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Methyl (3R ,3aR ,9bR)-8,9-dimethoxy-12-methyl-11-oxo-2,3-dihydro-1H-3a,9b-(epiminoetha-
no)cyclopenta[a]naphthalene-3-carboxylate (I.280) 
 
Lactam I.259 (30.0 mg, 86.9 µmol, 1.0 eq.) was dissolved in DCE (3 mL) and 4Å MS followed by 
DDQ (197 mg, 869 µmol, 10 eq.) and AcOH (50.0 µL, 869 µmol, 10 eq.) were added. The mixture 
was heated to 75 °C for 5 h and after cooling to room temperature it was diluted with H2O 
(100 mL). The mixture was extracted with EtOAc (3 × 100 mL) and the combined organic layers 
were washed with aqueous saturated NaCl solution (200 mL), dried (MgSO4) and concentrated 
under reduced pressure. Flash column chromatography [PE/EtOAc, 1:1 to 2:1] afforded styrene 
derivative I.280 (15.4 mg, 43.1 µmol, 50%) as a colorless solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 20 °C. 
Rf = 0.40 [EtOAc /PE, 3:1]. 
1H NMR (400 MHz, CDCl3) δ = 6.86–6.72 (m, 2H, H-4 and H-5), 6.38 (d, 
J = 10.0 Hz, 1H, H-7), 6.23 (d, J = 10.0 Hz, 1H, H-8), 3.91 (s, 3H, H-14), 3.87 (s, 
3H, H-15), 3.76 (s, 3H, H-20), 2.98 (d, J = 18.1 Hz, 1H, H-11a), 2.80–2.63 (m, 
6H, H-11b, H-13, H-16a, H-18), 2.02–1.86 (m, 1H, H-17a), 1.86–1.70 (m, 2H, 
H-16b, H-17b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 174.6 (C-12), 172.2 (C-19), 153.2 (C-3), 146.7 (C-2), 135.2 (C-1), 
125.8 (C-6), 123.0 (C-5), 122.2 (C-8), 110.8 (C-4), 73.4 (C-9), 60.6 (C-14), 56.6 (C-18), 55.7 (C-15), 
52.0 (C-20), 47.9 (C-10), 46.8 (C-11), 42.0 (C-16), 26.5 (C-13), 23.1 (C-17) ppm. 
IR (ATR): ṽ = 2946 (w), 1733 (m), 1687 (s), 1490 (m), 1454 (m), 1390 (m), 1274 (s), 1213 (m), 1138 
(m), 1071 (m), 961 (w), 818 (w) cm-1. 
HRMS (EI): calcd. for C20H24NO5+:   358.1649 [M+H]+  
found:    358.1650 [M+H]+. 
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2-(7,8-Dimethoxy-2-oxo-1-(4-oxobutyl)-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile (I.281) 
 
To α-allylcyclohexanone I.227 (100 mg, 351 µmol, 1.0 eq.) and Hoveyda−Grubbs catalyst 2nd 
generation (11.0 mg, 17.5 µmol, 5.0 mol%) was added degassed DCM (3 mL). Then, freshly 
distilled crotonaldehyde (369 mg, 450 µL, 5.26 mmol, 15 eq) was added and the reaction mixture 
stirred at room temperature for 16 h. After concentrating under reduced pressure, flash column 
chromatography [PE/EtOAc, 9:1] yielded unsaturated aldehyde I.281 (82.7 mg, 264 µmol, 75%) as 
a colorless solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[PE/EtOAc, 15:1] at 0 °C. 
Rf = 0.57 [PE/EtOAc, 1:1]. 
1H NMR (400 MHz, CDCl3): δ = 9.32 (d, J = 7.7 Hz, 1H, H-18), 6.96–6.86 
(m, 2H, H-4, H-5), 6.33 (ddd, J = 15.3, 8.6, 6.6Hz, 1H, H-16), 5.97 (ddt, 
J = 15.6, 7.7, 1.3 Hz, 1H, H-17), 3.99 (s, 3H, H-13), 3.89 (s, 3H, H-14), 3.36 
(d, J = 16.4Hz, 1H, H-11a), 3.17–2.99 (m, 4H, H-11b, H-15, H-7a), 2.92 (ddd, 
J = 15.8, 8.1, 5.3Hz, 1H, H-7b), 2.80 (ddd, J = 13.5, 8.1, 5.2 Hz, 1H, H-8a), 
2.66 (ddd, J = 14.1, 9.0, 5.3 Hz, 1H, H-8b) ppm. 
13C NMR (100 MHz, CDCl3): δ = 210.0 (C-9), 193.1 (C-18), 151.6 (C-3), 151.0 (C-16), 147.7 (C-2), 
135.7 (C-17), 129.6 (C-6), 128.1 (C-1), 123.9 (C-5), 117.3 (C-12), 113.1 (C-4), 60.7 (C-13), 55.8 (C-
14), 53.3 (C-10), 40.4 (C-15), 39.1 (C-8), 28.2 (C-7), 25.7 (C-11) ppm. 
IR (ATR): ṽ = 2943 (w), 2840 (w), 1716 (s), 1690 (s), 1487 (s), 1455 (m), 1415 (m), 1347 (w), 1275 
(s) cm-1. 
HRMS (ESI): calcd. for C18H20O4N+:   314.1387 [M+H]+ 
found:     314.1390 [M+H]+. 
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2-(7,8-Dimethoxy-2-oxo-1-(4-oxobutyl)-1,2,3,4-tetrahydronaphthalen-1-yl)acetonitrile 
(I.284) 
  
A solution of the unsaturated aldehyde I.281 (200 mg, 0.639 mol, 1.0 eq) in dry EtOAc (7.0 mL) 
was added to palladium on activated charcoal (10 wt%, 20.0 mg, 2.9 mol%). The round bottom 
flask was purged with H2 five times and the suspension was stirred under H2 atmosphere at room 
temperature for 16 h. After removing the catalyst with a pad of celite, the pad was washed with 
EtOAc (50 mL) and the filtrate was concentrated under reduced pressure. The crude saturated 
aldehyde (185 mg crude yield) was immediately used in the next step. To a stirring solution of crude 
aldehyde (185 mg, assumed 0.587 mmol, 1.0 eq) in dry methanol (10 mL), NaOMe (41.2 mg, 763 
µmol, 1.3 eq) was added. The solution was stirred at 75 °C for 3.5 h. After terminating the reaction 
with saturated aqueous NH4Cl solution (25 mL), H2O (100 mL) was added. The reaction mixture 
was extracted with with EtOAc (3 × 100 mL) and the combined organic layers washed with 
saturated aqueous NaCl solution, dried (MgSO4) and concentrated under reduced pressure. Cascade 
product I.284 (172 mg, 0.545 mmol, 85%, dr = 0.17:1.00) was obtained as a colorless oil.  
Rf = 0.38 [EtOAc, 5% NEt3].   
1H NMR (400 MHz, CHCl3): δ = 9.80 (d, J = 0.9 Hz, 1H, H-18), 6.87–6.69 (m, 
2H, H-4, H-5), 6.22 (s, 1H, H-19), 3.89 (s, 3H, H-13), 3.85 (s, 3H, H-14), 3.05–
2.87 (m, 2H, H-11a, H-17), 2.81–2.63 (m, 2H, H-7), 2.63–2.53 (m, 2H, H-11b, H-
15a), 2.26 (dt, J = 13.5, 4.3 Hz, 1H, H-8a), 2.14–1.93 (m, 3H, H-15b, H-16), 1.87 
(td, J = 12.8, 4.8 Hz, 1H, H-8b) ppm. 
13C NMR (100 MHz, CHCl3): δ = 202.6 (C-12), 176.6 (C-18), 151.7 (C-3), 147.3 (C-2), 137.5 (C-1), 
126.8 (C-6), 123.4 (C-5), 111.3 (C-4), 69.5 (C-9), 60.6 (C-13), 57.1 (C-17), 55.9 (C-14), 50.3 (C-10), 
46.1 (C-11), 42.0 (C-15), 32.2 (C-8), 26.1 (C-7), 24.7 (C-16) ppm.  
IR (ATR): ṽ = 3230 (w), 2937 (w), 1686 (s), 1601 (w), 1487 (m), 1454 (m), 1415 (m), 1277 (m), 
1099 (m), 1061 (m) cm-1. 
HRMS (EI): calcd. for C18H21O4N+:   315.1471 [M]+ 
found:     315.1470 [M]+. 
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8,9-Dimethoxy-1,2,4,5-tetrahydro-3H-3a,9b-(epimenoethano)cyclopenta-[a]naphthalene-
3,11-dione (I.285) 
 
Aldehyde I.284 (9.4 mg, 30 µmol, 1.0 eq.) was dissolved in dry toluene (0.94 mL) and 3,4,5-
trimethoxyaniline (5.5 mg, 30 µmol, 1.0 eq.) was added. The mixture was stirred in an autoclave 
(purged 3 × with O2) under O2 presssure (5 bar) at room temperature for 48 h. The reaction was 
stopped by addition of saturated, aqueous NH4Cl solution (50 mL), the aqueous layer extracted 
with EtOAc (3 × 50 mL) and the combined organic layers washed with saturated, aqueous NaCl 
solution (70 mL), dried (MgSO4) and concentrated under reduced pressure. Subsequently, the 
obtained product was dissolved in 1 M HCl (30 mL) and the aqueous layer was extracted with 
EtOAc (30 mL) and washed with saturated, aqueous NaCl solution (20 mL). The combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. Flash column chromatography 
[PE/EtOAc, 5% NEt3 3:1 to 1:2] afforded ketone I.285 (2.9 mg, 0.01 mmol, 32%) as a pale brown 
oil.  
Rf = 0.77 [EtOaA:PE, 3:1 + 5% NEt3]. 
 1H NMR (400 MHz, CDCl3): δ = 87–6.75 (m, 2H, H-4, H-5), 5.72 (s, 1H, H-21), 
3.95 (s, 3H, H-13), 3.87 (s, 3H, H-14), 3.08 (d, J = 17.6 Hz, 1H, H-11a), 2.782.71 
(m, 1H, H-7), 2.68 (d, J = 17.6 Hz, 1H, H-11b), 2.56–2.41 (m, 3H, H-16a, H-15), 
2.30–2.09 (m, 2H, H-16b, H-8a), 1.73 (ddd, J = 13.1, 11.0, 4.5 Hz, 1H, H-
8b) ppm.  
13C NMR (101 MHz, CDCl3): δ = 215.8 (C-17), 175.6 (C-12), 151.5 (C-3), 147.6 (C-2), 133.3 (C-1), 
128.1 (C-6), 123.4 (C-5), 111.8 (C-4), 68.2 (C-9), 60.6 (C-13), 55.8 (C-14), 47.5 (C-10), 44.7 (C-11), 
37.0 (C-16), 33.4 (C-15), 27.4 (C-8), 25.7 (C-7) ppm.  
IR (ATR): v ̃ = 3206 (w), 2930 (w), 2849 (w), 2361 (w), 1746 (m), 1691 (s), 1488 (m), 1456 (m), 1417 
(m), 1350 (w), 1277 (m), 1089 (m), 1065 (m), 1026 (m), 800 (m) cm-1.  
HRMS (EI):  calcd. for C17H19O4N+:  301.1314 [M-H]+ 
found:    301.1324 [M-H]+. 
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3-(Dimethoxymethyl)-8,9-dimethoxy-2,3,4,5-tetrahydro-1H-3a,9b-(epiminoethano)-
cyclopenta[a]-naphthalen-11-one (I.292) 
 
To a solution of crude cascade product I.284 (168 mg, 532 µmol, 1.0 eq.) in dry MeOH (5.5 mL) 
was added tosic acid (658 mg, 3.46 mmol, 6.5 eq.) and HC(OMe)3 (0.300 mL, 2.74 mmol, 5.2 eq.) at 
0 °C. After stirring a room temperature for 14 h, the reaction was quenched with saturated NaOMe 
solution in MeOH (6.0 mL), concentrated under reduced pressure and redissolved in Et2O 
(50 mL). The organic layer was washed with saturated aqueous NaHCO3 solution (50 mL), which 
was then extracted with Et2O (4 × 50 mL). The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure to obtain the crude protected cascade product I.292 as a 
colorless oil. 
The crude product could be used in the next step immediately. For analytical purposes, a sample of 
the product I.292 was purified by preparative TLC [EtOAc, 5% NEt3]. 
d.r .= 1:6.7 (determined by integrals of H-19 in 1H NMR). 
 Rf = 0.38 [EtOAc, 5% NEt3].   
 1H NMR (400 MHz, CHCl3): δ = 6.81–6.74 (m, 2H, H-4, H-5), 5.75 (s, 1H, H-
13), 4.36 (d, J = 7.6 Hz, 1H, H-19), 3.87 (s, 3H, H-14), 3.84 (s, 3H, H-15), 3.39 (s, 
3H, H-20 or H-21), 3.37 (s, 3H, H-20 or H-21), 2.90 (d, J = 17.9 Hz, 1H, H-11a), 2.74 (ddd, 
J = 16.2, 7.4, 4.7 Hz, 1H, H-7a), 2.63 (ddd, J = 11.8, 8.3, 4.3 Hz, 1H, H-7b), 2.52 (d, J = 17.9 Hz, 
1H, H-11b or H-16a), 2.49–2.44 (m, 1H, H-11b or H-16a), 2.20 (dt, J = 9.8, 7.5 Hz, 1H, H-19), 
2.03–1.81 (m, 3H, H-6, H-16b), 1.76–1.66 (m, 2H, H-17) ppm.  
13C NMR (100 MHz, CHCl3) δ = 176.6 (C-12), 151.5 (C-3), 147.4 (C-2), 137.1 (C-1), 128.3 (C-6), 
123.0 (C-5), 111.4 (C-4), 106.0 (C-19), 69.2 (C-9), 60.5 (C-14), 55.8 (C-15), 54.3 (C-20 or C-21), 53.3 
(C-20 or C-21), 51.1 (C-10), 48.5 (C-19), 45.7 (C-11), 39.3 (C-16), 33.6 (C-6), 26.4 (C-17), 25.8 (C-
7) ppm. 
IR (ATR):  = 3205 (br, w), 2925 (s), 2854 (m), 1690 (s), 1602 (w), 1487 (m), 1455 (m), 1415 (w), 
1352 (w), 1277 (m), 1058 (m), 802 (w) cm‒1. 
HC(OMe)3, tosic acid
MeOH, r.t., 14 h
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HRMS (EI):  calc. for C20H28O5N+:  362.1962 [M+H]+ 
                found:    362.1964 [M+H]+. 
 
 
(3R ,3aR ,9bR)-3-(Dimethoxymethyl)-8,9-dimethoxy-12-methyl-2,3,4,5-tetrahydro-1H-3a,9b-
(epimino-ethano)cyclopenta[a]naphthalen-11-one (I.293) 
 
Crude protected aldehyde I.292 (147 mg, assumed 405 µmol, 1.0 eq) was dissolved in DMF (5 mL), 
cooled to 0 °C, and NaH (60 wt% suspension in mineral oil, 24.3 mg, 608 µmol, 1.5 eq) was added. 
After 20 min. iodomethane (37.6 µL, 608 µmol, 1.5 eq) was added, the reaction mixture was heated 
to 60 °C and stirred for 3 h at this temperature. After stopping the reaction with saturated, aqueous 
NaHCO3 solution (5 mL), 10% aqueous LiCl solution (20 mL) was added and the aqueous layer 
was extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with 10 wt% 
aqueous LiCl solution (500 mL) and saturated aqueous NaCl solution (300 mL), dried (MgSO4) and 
concentrated under reduced pressure. The methylation product I.293 (148 mg, 0.394 mmol, 74% 
over 2 steps) was obtained as a colorless oil.  
d.r .= 10:1 (determined by integrals of H-19 in 1H NMR). 
 Rf = 0.60 [EtOAc, 5% NEt3]. 
1H NMR (400 MHz, CDCl3) of the major diastereomer: δ = 6.80–6.68 (m, 2H, 
H-6, H-7), 4.30 (d, J = 8.4 Hz, 1H, H-14), 3.88 (s, 3H, H-15), 3.83 (s, 3H, H-16), 
3.35 (s, 3H, H-20 or H-21), 3.31 (s, 3H, H-20 or H-21), 2.95–2.84 (m, 4H, H- 
17a, H-19), 2.62 – 2.42 (m, 4H, H-17b, H-11a, H-4), 2.26–2.11 (m, 2H, H-3a, H-
13), 1.93 (ddd, J = 14.1, 10.4, 4.1 Hz, 1H, H-3b), 1.79 (dt, J = 13.0, 7.2 Hz, 1H, 
H-12a), 1.75–1.65 (m, 2H, H-12b, H-11b) ppm.  
13C NMR (100 MHz, CDCl3) of the major diastereomer: δ = 207.0 (C-12), 176.1 (C-18), 151.5 (C-
8), 147.5 (C-9), 137.4 (C- 10), 128.2 (C-5), 122.9 (C-6), 110.9 (C-7), 104.4 (C-14), 73.5 (C-2), 60.4 
(C-15), 55.8 (C- 16), 53.5 (C-20 or C-21), 51.7 (C-20 or C-21), 50.4 (C-1), 46.0 (C-17), 38.2 (C-11), 
31.2 (C-3), 30.9 (C-13), 27.8 (C-19), 26.2 (C-12), 15.8 (C-4) ppm.  
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IR (ATR): ν = 2927(s), 2854(m),1682(s),1602(w),1488(s),1454(m),1418(m),1392 (m), 1277 (s), 1098 
(m), 1068 (s), 1052 (s), 802 (w) cm‒1. 
HRMS (EI):  calc. for C21H29O5N+:   375.2046 [M]+ 
found:     375.2055 [M]+. 
 
 
(3R ,3aR ,9bR)-8,9-Dimethoxy-12-methyl-11-oxo-2,3,4,5-tetrahydro-1H-3a,9b-
(epiminoethano)cyclo-penta[a]naphthalene-3-carbaldehyde (I.290) 
Procedure A: 
 
Protected aldehyde I.293 (52.5 mg, 140 µmol, 1.0 eq) was dissolved in acetone (3 mL) and iodine 
(3.55 mg, 14.0 µmol, 0.1 eq) was added. After 2 h, the reaction was stopped by the addition of 
saturated, aqueous Na2S2O7 solution (10 mL) and the aqueous layer was extracted with DCM 
(3 × 100 mL). The combined organic layers were washed with saturated aqueous NaCl solution 
(300 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column chromatography 
[PE/EtOAc, 2:1→1:2, +1% NEt3] afforded aldehyde I.290 (31.4 mg, 95.3 mmol, 68%) as a 
colorless oil. 
Procedure B: 
 
A solution of methylated lactam I.259 (50.0 mg, 0.139 mmol, 1.0 eq.) in dry DCM (5 mL) was 
cooled to –78 °C. After 15 min. DIBAL-H (350 µL, 0.348 mmol, 2.5 eq.) was added and the 
reaction mixture was stirred at – 78 °C for 3 h. Then, the reaction was quenched with EtOAc 
(5 mL) and stirred for another 15 min at –78 °C. Aqueous 10% NaOH solution (5 mL) was added 
and the mixture was allowed to warm up to room tempreature. The aqueous layer was extracted 
with EtOAc (3 × 50 mL) and the combined organic layers were washed with aqueous saturated 
I2, acetone 
r.t., 4 h
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NaCl solution (100 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column 
chromatography on DAVISIL® [CHCl3/acetone, 1:0 to 1:2] afforded aldehyde I.290 (38.5 mg, 
0.117 mmol, 84%) as a yellow oil. 
d.r .= 1:1.3 (determined by integrals of H-13 in 1H NMR). 
Rf = 0.28 [DCM/MeOH, 10:1]. 
1H NMR (400 MHz, CDCl3): δ = 9.86 (d, J = 2.6 Hz, 1H), 9.78 (d, J = 3.5 Hz, 
1H), 6.79–6.74 (m, 4H), 3.91 (s, 5H), 3.91 (s, 3H), 3.84 (s, 7H), 3.01 (t, 
J = 18.0 Hz, 2H), 2.92 (s, 3H), 2.85 (td, J = 8.5, 2.7 Hz, 1H), 2.74 (s, 3H), 2.71–
2.58 (m, 5H), 2.58–2.35 (m, 4H), 2.25–2.09 (m, 3H), 2.09–1.87 (m, 6H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 202.4, 201.9, 174.6, 173.3, 151.5, 151.5, 147.4, 
147.3, 136.4, 135.5, 127.8, 127.0, 123.1, 122.8, 111.4, 111.3, 75.7, 75.4, 60.6, 60.5, 59.9, 59.0, 55.8, 
49.7, 49.4, 45.8, 45.5, 39.6, 38.7, 30.0, 27.3, 26.5, 25.7, 25.4, 25.4, 25.1, 25.0 ppm. 
IR (ATR): v ̃ = 3854 (w), 2938 (m), 2838 (w). 2731 (w), 1714 (m), 1685 (s), 1602 (w), 1576 (w), 1488 
(s), 1453 (m), 1471 (m), 1392 (m), 1355 (w), 1277 (s), 1250 (w), 1208 (w), 1100 (w), 1058 (m), 982 
(w), 934 (w), 800 (w), 748 (w), 665 (w) cm-1.  
HRMS (ESI): calculated for C19H24NO4+ : 330.1700 [M+H]+ 
  found:     330.1699 [M+H]+. 
 
During the optimization prozess of the DIBAL-H reduction, the side product (3R,3aS,9bR)-3-
(hydroxymethyl)-8,9-dimethoxy-12-methyl-2,3,4,5-tetrahydro-1H-3a,9b-(epiminoethano)-cyclopen-
ta[a]naph-thalen-11-one (I.294) and its epimer were isolated and characterized:  
Crystals suitable for single-crystal X-ray analysis (Section 9.1) of both diastereomers were obtained 
from recrystallization [CHCl3] at 0 °C. 
d.r .= 1:5.5 
Rf = 0.36 [CHCl3/acetone, 1:1] 
1H NMR (400 MHz, CDCl3) of the major diastereomer: δ = 6.76–6.74 (m, 2H, 
H-6, H-7), 3.88 (s, 3H, H-14), 3.83 (s, 3H, H-15), 3.82–3.65 (m, 2H, H-19), 2.92 
(s, 3H, H-13), 2.91–2.84 (m, 1H, H-11a), 2.65–2.55 (m, 3H, H-7, H-16a), 2.54–
2.50 (m, 1H, H-11b), 2.28–2.17 (m, 1H, H-8a), 2.16–2.06 (m, 1H, H-18), 1.98–
1.90 (m, 1H, H-8b), 1.89–1.82 (m, 1H, H-17a), 1.81–1.71 (m, 1H, H-16b), 1.55–
1.48 (m, 1H, H-17b) ppm.  
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13C NMR (101 MHz, CDCl3) of the major diastereomer: δ = 175.8 (C-12), 151.7 (C-3), 147.7 (C-2), 
137.6 (C-1), 128.3 (C-6), 123.1 (C-4), 111.1 (C-5), 73.9 (C-9), 63.3 (C-19), 60.6 (C-14), 56.0 (C-15), 
52.2 (C-17), 50.1 (C-10), 46.4 (C-11), 38.7 (C-16), 31.3 (C-8), 27.7 (C-18 or C-13), 27.5 (C-18 or C-
13), 26.0 (C-7) ppm. 
IR (ATR): ṽ = 3384 (m), 2937 (m), 2361 (w), 2340 (w), 2183 (vw), 2150 (vw), 2114 (vw), 2016 (vw), 
2002 (vw), 1951 (vw), 1663 (vs), 1603 (vw), 1487 (s), 1453 (m), 1417 (m), 1398 (m), 1352 (w), 1276 
(s), 1210 (w), 1099 (w), 1055 (s), 973 (w), 859 (vw), 800 (w), 747 (vw), 668 (w) cm-1.  
HRMS (ESI): calculated for C19H26NO4+:  332.1856 [M+H]+ 
found:     332.1861 [M+H]+. 
 
 
(3aR ,9bR)-3,3-Bis(hydroxymethyl)-8,9-dimethoxy-12-methyl-2,3,4,5-tetrahydro-1H-3a,9b-
(epiminoethano)cyclopenta[a]naphthalene-11-one (I.300) 
 
To a solution of aldehyde I.290 (11 mg, 33 µmol, 1 eq.) in MeOH (0.9 mL) was added KOH 
(20 mg, 0.33 mmol, 10 eq.) dissolved in MeOH (0.1 mL) followed by formaldehyde (37% in H2O, 
24 µL, 0.33 mmol, 10 eq.). The reaction mixture stirred for 48 h at 50 °C. Then, the mixture was 
neutralized with conc. AcOH to pH = 6 and diluted with H2O (50 mL). The aqueous layer was 
extracted with Et2O (2 × 50 mL) and CHCl3 (2 x 50 mL) and the combined organic layers were 
washed with aqueous saturated NaCl solution (100 mL), dried (MgSO4) and concentrated under 
reduced pressure. Flash column chromatography [DCM/acetone, 1:0 to 1:2] afforded diol I.300 
(8.8 mg, 24 µmol, 73%) as a colorless solid.  
Rf = 0.21 [CHCl3/acetone, 1:1]  
1H NMR (400 MHz, CDCl3): δ = 6.76–6.69 (m, 2H, H-4, H-5), 3.91 (s, 3H, H-
13), 3.82 (s, 3H, H-14), 3.80–3.60 (m, 4H, H-18, H-19), 2.98–2.94 (m, 1H, H-11a), 
2.93 (s, 3H, H-20), 2.62–2.57 (m, 1H, H-11b), 2.57–2.54 (m, 1H, H-7a), 2.53–2.47 
(m, 1H, H-15a), 2.47–2.40 (m, 1H, H-8a), 2.39–2.33 (m, 1H, H-7b), 2.11 (ddd, 
J = 14.3, 9.2, 4.2 Hz, 1H, H-15b), 1.81 (ddd, J = 17.6, 8.5, 4.3 Hz, 1H, H-16a), 
HCHO, KOH 
MeOH,  50 °C, 48 h
I.300
N
OMe
MeO
O
OH
HO
(73%)N
OMe
MeO
O
H
O H
I.290
I.300
N
O
O
O
OH
HO
14
13
3
2 4
5
6
1
789
1011
12
18
17
15
16
20 19
EXPERIMENTAL 
169  
1.72 (dd, J = 13.7, 3.9 Hz, 1H, H-8b), 1.52–1.39 (m, 1H, H-16b) ppm.  
13C NMR (101 MHz, CDCl3) δ = 175.3 (C-12), 151.7 (C-3), 147.4 (C-2), 138.3 (C-1), 127.4 (C-6), 
122.5 (C-4), 111.5 (C-5), 76.0 (C-9), 65.1 (C-18, C-19), 60.7 (C-13), 55.2 (C-17), 55.0 (C-14), 50.2 
(C-10), 50.5 (C-11), 38.0 (C-15), 30.7 (C-16), 27.6 (C-20), 25.6 (C-8), 24.7 (C-7) ppm. 
C-2 is most likely superimposed with other signals and could therefore not be assigned in the 13C 
NMR spectrum.  
IR (ATR): ṽ = 3396 (m), 2941 (m), 2361 (m), 2341 (m), 1654 (vs), 1489 (s), 1456 (m), 1400 (m), 
1278 (s), 1086 (m), 1063 (m), 986 (w) cm-1. 
HRMS (ESI): calculated for C20H28NO5+:  362.19620 [M+H]+ 
    found:    362.19633 [M+H]+. 
 
 
(7S)-4-(Hydroxymethyl)-10,11-dimethoxy-3-methyl-4,5-dihydro-1H ,7H-4,11b-ethano-3a,7-
methanobenzo[6,7]oxocino[4,5-b]pyrrol-2(3H)-one (I.308) 
 
Diol I.300 (217 mg, 0.601 mmol, 1 eq.) was suspended in dichloroethane (10 mL). DDQ (1.36 g, 
6.01 mmol, 10 eq.), concentrated AcOH (344 µL, 6.01 mmol, 10 eq.) and 4 Å molecular sieves were 
added to the suspension and the reaction mixture was stirred at 75 °C for 5 h. The reaction mixture 
was allowed to cool to room temperature and 200 mL DCM were added. The organic phase was 
washed with 10% aqueous NaOH solution (3 × 100 mL) and aqueous saturated NaCl solution 
(100 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column chromatography 
[DCM/acetone, 1:0 to 0:1] afforded cyclic ether I.308 (141 mg, 0.393 mmol, 71%) as a white solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 0 °C. 
Rf = 0.36 [CHCl3/acetone, 1:1].   
1H NMR (400 MHz, CDCl3): δ = 6.95 (d, J = 8.3 Hz, 1H, H-5), 6.86 (d, J = 8.4 Hz, 1H, H-4), 4.98 
(dd, J = 4.3, 1.7 Hz, 1H, H-7), 4.09–3.99 (m, 1H, H-18a), 3.92 (s, 3H, H-13), 3.88 (s, 3H, H-14), 
DDQ/AcOH,DCE 
4Å MS, 75 °C, 5 h
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3.86 – 3.77 (m, 1H, H-18b), 3.69–3.63 (m, 1H, H-19a), 3.46–3.40 (m, 1H, H-
19b), 3.23 (d, J = 17.3 Hz, 1H, H-11a), 3.08 (s, 3H, H-20), 3.04–2.95 (m, 1H, H-
8a), 2.49–2.43 (m, 1H, H-11b), 2.35–2.25 (m, 2H, H-15), 1.60–1.51 (m, 1H, H-
16a), 1.50–1.47 (m, 1H, H-10b), 1.23–1.14 (m, 1H, H-16b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 176.4 (C-12), 153.7 (C-3), 146.0 (C-2), 140.8 
(C-1), 124.9 (C-6), 124.8 (C-5), 111.3 (C-4), 73.2 (C-7), 73.1 (C-9), 69.4 (C-18), 67.1 (C-19), 60.7 (C-
13), 55.9 (C-14), 51.2 (C-17), 49.4 (C-10), 45.6 (C-11), 40.9 (C-15), 30.6 (C-8), 30.3 (C-16), 29.1 (C-
20) ppm. 
 
IR (ATR): ṽ = 3421 (m), 2943 (m), 2360 (w), 2340 (w), 1734 (w), 1671 (vs), 1602 (w), 1576 (w), 
1559 (w), 1541 (w), 1487 (s), 1456 (m), 1421 (m), 1394 (m), 1355 (m), 1313 (m), 1275 (s), 1229 (m), 
1176 (w), 1130 (w), 1103 (m), 1086 (m), 1068 (m), 1040 (m), 983 (m), 960 (w), 931 (w), 814 (w), 749 
(w), 668 (w) cm-1.  
 
HRMS (ESI): calculated for C20H26NO5+:   360.1805 [M+H]+ 
found:      360.1805 [M+H]+. 
 
(7S)-10,11-Dimethoxy-3-methyl-2-oxo-2,3-dihydro-1H ,7H-4,11b-ethano-3a,7-methanoben-
zo[6,7]oxocino[4,5-b]pyrrole-4(5H)-carbaldehyde (I.310) 
 
To a solution of primary alcohol I.308 (141 mg, 0.393 mmol, 1.0 eq.) in DCM (10 mL) was added 
4Å MS followed by NMO (460 mg, 3.93 mmol, 10 eq.) and TPAP (6.70 mg, 19.7 µmol, 0.05 eq.). 
The reaction mixture stirred at room temperature for 1 h. The oxidant was removed by filtration 
through a pad of silica that was washed with DCM/acetone (1:1, 10 mL) to afford aldehyde I.310 
(97.6 mg, 0.273 mmol, 70%) as a colorless solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CDCl3] at room temperature. 
Rf = 0.79 [DCM/acetone, 2:1].   
TPAP, NMO, DCM 
4Å MS, 1 h, r.t.
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1H NMR (400 MHz, CDCl3) δ = 10.20 (s, 1H, H-18), 6.92 (d, J = 8.3 Hz, 1H, 
H-5), 6.82 (d, J = 8.3 Hz, 1H, H-4), 5.02 (dd, J = 4.1, 1.9 Hz, 1H, H-7), 3.87 (s, 
3H, H-13), 3.82 (s, 3H, H-14), 3.54 (d, J = 13.1 Hz, 1H, H-19a), 3.32 (d, 
J = 13.1 Hz, 1H, H-19b), 3.17 (d, J = 17.2 Hz, 1H, H-11a), 2.84 (dd, J = 12.9, 
4.0 Hz, 1H, H-6a), 2.67 (s, 3H, H-20), 2.39 (d, J = 17.2 Hz, 1H, H-11b), 2.36–
2.20 (m, 2H, H-15), 2.15–2.03 (m, 1H, H-16a), 1.63–1.55 (m, 1H, H-8b), 1.37–
1.28 (m, 1H, H-16b) ppm.  
13C NMR (101 MHz, CDCl3): δ = 202.8 (C-18), 174.3 (C-12), 153.6 (C-3), 145.8 (C-2), 139.3 (C-1), 
124.8 (C-5), 124.1 (C-6), 111.5 (C-4), 72.6 (C-7), 72.5 (C-9), 62.8 (C-19), 60.6 (C-13 or C-17), 60.5 
(C-13 or C-17), 55.7 (C-14), 48.9 (C-10), 44.6 (C-11), 40.0 (C-15), 29.3 (C-8), 27.5 (C-16 or C-20), 
27.3 (C-16 or C-20) ppm. 
IR (ATR): ṽ = 2943 (m), 2360 (w), 2339 (w), 1716 (s), 1684 (s), 1601 (w), 1576 (w), 1559 (w), 1540 
(w), 1488 (m), 1456 (m), 1421 (w), 1394 (w), 1356 (w), 1311 (w), 1275 (s), 1230 (w), 1126 (w), 1102 
(w), 1083 (m), 1067 (m), 1048 (w), 1030 (w), 986 (w), 951 (w), 913 (w), 813 (m), 750 (w), 668 
(m) cm‒1.  
HRMS (EI): calcd. for C20H24NO5+:  358.1649 [M+H]+ 
found:    358.1648 [M+H]+. 
 
(7S)-10,11-Dimethoxy-3-methyl-2-oxo-2,3-dihydro-1H ,7H-4,11b-ethano-3a,7-methanoben-
zo[6,7]oxocino[4,5-b]pyrrole-4(5H)-carboxylic acid (I.309) 
 
To a solution of aldehyde I.310 (83.6 mg, 234 µmol, 1.0 eq.) and 2-methyl-2-butene (0.84 mL) in t-
BuOH (3.66 mL) was added a solution of NaClO2 (80% purity, 243 mg, 2.15 mmol, 9.2 eq.) and 
NaH2PO4 (336 mg, 2.15 mmol, 9.2 eq.) in H2O (1.24 mL). After 3 h, the reaction mixture was 
diluted with an aqueous 10% NaOH solution (2 mL) and the aqueous phase was extracted with 
hexanes (10 mL). The aqueous phase was acidified with aqueous 1 M HCl solution (20 mL) and 
extracted with DCM (3 × 40 mL). The combined DCM layers were dried (MgSO4) and 
NaClO2, 
NaH2PO4, H2O      
t-BuOH, r.t., 3 h
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concentrated under reduced pressure to give carboxylic acid I.309 (85.5 mg, 229 µmol, 98%) as a 
colorless solid. 
Rf = 0.51 [acetone/DCM 1:3 + 1% AcOH]. 
1H NMR (400 MHz, CDCl3) δ = 6.90 (d, J = 8.3 Hz, 1H, H-5), 6.80 (d, J = 8.3 Hz, 
1H, H-4), 5.00 (dd, J = 4.2, 1.7 Hz, 1H, H-7), 3.86 (s, 3H, H-14), 3.82 (s, 3H, H-13), 3.58 
(d, J = 13.0 Hz, 1H, H-19a), 3.35 (d, J = 13.0 Hz, 1H, H-19b), 3.23–3.07 (m, 2H, H-8a, H-
11a), 2.80 (s, 3H, H-20), 2.40 (d, J = 17.2 Hz, 1H, H-11b), 2.36–2.17 (m, 3H, H-15), 1.56–
1.39 (m, 3H, H-8b, H-16). 
13C NMR (150 MHz, CDCl3): δ = 176.8 (C-18), 174.9 (C-12), 153.4 (C-3), 145.6 
(C-2), 139.5 (C-6), 124.5 (C-5), 124.2 (C-1), 111.4 (C-4), 76.7 (C-17 or C-10), 72.6 (C-9), 72.0 (C-7), 
64.0 (C-19), 60.5 (C-14), 55.7 (C-13), 54.4 (C-10 or C-17), 48.6 (C-16), 44.7 (C-11), 39.6 (C-15), 29.2 
(C-8), 25.9 (C-20) ppm. 
IR (ATR): ṽ = 3267 (w), 2946 (m), 1758 (s), 1674 (m), 1596 (w), 1490 (m), 1455 (m), 1423 (w), 
1390 (m), 1277 (s), 1217 (m), 1147 (w), 1090 (m), 1048 (m), 820 (w), 762 (w) cm‒1.  
HRMS (EI): calcd. for C20H22NO6-:  372.1453 [M−H]− 
found:    372.1456 [M−H]-. 
 
(7S)-4-Isocyanato-10,11-dimethoxy-3-methyl-4,5-dihydro-1H ,7H-4,11b-ethano-3a,7-
methanobenzo[6,7]oxocino[4,5-b]pyrrol-2(3H)-one (I.311) 
 
Carboxylic acid I.309 (7.4 mg, 20 µmol, 1.0 eq.) was dissolved in benzene (1 mL) and 
diphenylphosphoryl azide (6.4 µL, 30 µmol, 1.5 eq.) and NEt3 (6.0 µL, 60 µmol, 3 eq.) were added. 
The reaction was stirred at room temperature for 1 h and then heated to 100 °C for another 1 h. 
After cooling to room temperature, t-BuOH (3.5 µL, 60 µmol, 3 eq.) was added and the reaction 
was heated to 100 °C for additional 22 h. The reaction mixture was diluted with saturated aqueous 
NH4Cl solution (5 mL) and extracted with DCM (3 × 5 mL). The combined organic layers were 
washed with saturated aqueous NaCl solution (5 mL), dried (MgSO4) and concentrated under 
DPPA, NEt3, benzene  
r.t., 1 h → 100 °C, 1 h → 
t-BuOH 100 °C, 22 h
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reduced pressure. Flash column chromatography [DCM/acetone, 1:0 to 2:1] afforded isocyanate 
I.311 (4.3 mg, 12 µmol, 60%) as a colorless solid. 
Rf = 0.62 [PE/EtOAc, 1:2].  
1H NMR (600 MHz, CDCl3): δ = 6.97 (d, J = 8.3 Hz, 1H, H-5), 6.87 (d, J = 8.3 Hz, 1H, H-4), 5.00 
(dd, J = 3.9, 2.0 Hz, 1H, H-7), 3.92 (s, 3H, H-13), 3.88 (s, 3H, H-14), 3.57–3.45 
(m, 2H, H-19), 3.19 (d, J = 17.1 Hz, 1H, H-11a), 3.03 (s, 3H, H-20), 2.68 (dd, 
J = 13.0, 3.9 Hz, 1H, H-8a), 2.46 (d, J = 17.1 Hz, 1H, H-11b), 2.34 (ddd, 
J = 15.0, 10.8, 1.7 Hz, 1H, H-15a), 2.26–2.11 (m, 1H, H-15b), 2.08–1.93 (m, 
1H, H-16a), 1.73–1.61 (m, 1H, H-16b), 1.54–1.47 (m, 1H, H-8b) ppm. 
13C NMR (150 MHz, CDCl3): δ = 174.4 (C-12), 153.6 (C-3), 145.9 (C-2), 138.9 
(C-1), 124.9 (C-5), 124.7 (C-18), 123.8 (C-6), 111.6 (C-4), 72.9 (C-7), 70.6 (C-9), 69.0 (C-19), 66.6 
(C-17), 60.6 (C-13), 55.7 (C-14), 45.8 (C-10), 45.6 (C-11), 39.6 (C-15), 33.1 (C-16), 27.8 (C-8), 27.4 
(C-20) ppm. 
Note: No coupling to C-18 was observed, assignment to the last remaining carbon is in agreement 
with the literature value for isocyanates.[398] 
HRMS (EI): calcd. for C20H23N2O5+:  371.1601 [M+H]+ 
found:    371.1602 [M+H]+. 
 
Methyl ((7S)-10,11-dimethoxy-3-methyl-2-oxo-2,3-dihydro-1H ,7H-4,11b-ethano-3a,7-metha-
nobenzo-[6,7]oxocino[4,5-b]pyrrol-4(5H)-yl)carbamate (I.312) 
 
Carboxylic acid I.309 (50.0 mg, 134 µmol, 1.0 eq.) was dissolved in toluene (2.5 mL) and 
diphenylphosphoryl azide (44.0 µL, 201 µmol, 1.5 eq.) and NEt3 (56.0 µL, 402 µmol, 3 eq.) were 
added. The reaction was stirred at room temperature for 1 h and then heated to 100 °C for another 
1 h. After cooling to room temperature, MeOH (500 µL, 12.3 mmol, 92 eq.) was added and the 
reaction was heated to 100 °C for additional 20 h. The reaction mixture was diluted with saturated 
DPPA, NEt3, toluene
 r.t., 1 h → 100 °C, 1 h 
→ MeOH 100 °C, 20 h
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aqueous NH4Cl solution (50 mL) and extracted with DCM (3 × 100 mL). The combined organic 
layers were washed with saturated aqueous NaCl solution (200 mL), dried (MgSO4) and 
concentrated under reduced pressure. Flash column chromatography [DCM/acetone, 1:0 to 2:1] 
afforded methyl carbamate I.312 (43.3 mg, 108 µmol, 81%) as a colorless solid. 
Rf = 0.50 [DCM/acetone, 2:1].  
1H NMR (400 MHz, CDCl3): δ = 6.94 (d, J = 8.3 Hz, 1H, H-5), 6.85 (d, 
J = 8.3 Hz, 1H, H-4), 5.46 (s, 1H, H-18), 4.97–4.89 (m, 1H, H-7), 3.92 (s, 3H, 
H-21), 3.87 (s, 3H, H-22), 3.64 (d, J = 10.7 Hz, 4H, H-20, H-17a), 3.33 (d, 
J = 12.9 Hz, 1H, H-17b), 3.22 (d, J = 17.2 Hz, 1H, H-11a), 2.98 (s, 3H, H-13), 
2.57 (dd, J = 13.2, 4.1 Hz, 1H, H-8a), 2.44 (d, J = 17.2 Hz, 1H, H-11b), 2.41–
2.31 (m, 1H, H-14a), 2.31–2.12 (m, 3H, H-14b, H-15), 1.53 (dd, J = 13.2, 
1.8 Hz, 1H, H-8b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 174.6 (C-12), 155.5 (C-19), 153.6 (C-3), 145.8 (C-2), 139.2 (C-6), 
124.5 (C-5), 123.9 (C-1), 111.4 (C-4), 72.5 (C-7), 71.0 (C-9), 66.3 (C-17), 63.7 (C-16), 60.5 (C-21), 
55.7 (C-22), 52.0 (C-20), 46.0 (C-10), 45.3 (C-11), 40.5 (C-14), 30.7 (C-15), 28.1 (C-8), 27.6 (C-
13) ppm. 
IR (ATR): ṽ = 3313 (w), 2945 (m), 2840 (w), 1717 (m), 1676 (s), 1602 (w), 1576 (w), 1528 (m), 1488 
(m), 1456 (m), 1422 (w), 1393 (w), 1356 (w), 1340 (w), 1312 (w), 1274 (s), 1251 (s), 1153 (w), 1130 
(w), 1107 (w), 1074 (s), 1049 (w), 1028 (w), 1016 (w), 1002 (w), 979 (s), 1016 (w), 961 (w), 815 (m), 
753 (m), 667 (w) cm‒1.  
HRMS (EI): calcd. for C21H27N2O6+:  403.1867 [M+H]+ 
found:    403.1869 [M+H]+. 
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Benzyl ((7S ,11bR)-10,11-dimethoxy-3-methyl-2-oxo-2,3-dihydro-1H ,7H-4,11b-ethano-3a,7-
methano-benzo[6,7]oxocino[4,5-b]pyrrol-4(5H)-yl)carbamate (I.313) 
 
Carboxylic acid I.309 (94.7 mg, 254 mmol, 1.0 eq.) was dissolved in toluene (3 mL) and 
diphenylphosphoryl azide (82.0 µL, 380 µmol, 1.5 eq.) and NEt3 (106 µL, 762 µmol, 3 eq.) were 
added. The reaction was stirred at room temperature for 1 h and then heated to 100 °C for another 
1 h. After cooling to room temperature, benzyl alcohol (132 µL, 1.27 mmol, 5 eq.) was added and 
the reaction was heated to 100 °C for additional 14 h. The reaction mixture was diluted with H2O 
(200 mL) and extracted with DCM (3 × 200 mL). The combined organic layers were washed with 
saturated aqueous NaCl solution (100 mL), dried (MgSO4) and concentrated under reduced 
pressure. Flash column chromatography [PE/EtOAc, 1:1 to 0:1] afforded Cbz-protected amine 
I.313 (86.4 mg, 181 mmol, 71%) as a colorless solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 20 °C. 
Rf = 0.76 [DCM/acetone, 1:1].  
1H NMR (600 MHz, CDCl3) δ = 7.41–7.30 (m, 5H, H-22, H-23, H-24), 6.94 (d, 
J = 8.3 Hz, 1H, H-5), 6.86 (d, J = 8.3 Hz, 1H, H-4), 5.52 (s, 1H, H-18), 5.07 (d, 
J = 3.0 Hz, 2H, H-20), 4.97–4.89 (m, 1H, H-7), 3.92 (s, 3H, H-25), 3.87 (s, 3H, 
H-26), 3.64 (d, J = 12.9 Hz, 1H, H-17a), 3.34 (d, J = 12.9 Hz, 1H, H-17b), 3.22 
(d, J = 17.2 Hz, 1H, H-11a), 2.94 (s, 3H, H-13), 2.55 (dd, J = 13.2, 4.1 Hz, 1H, 
H-11b), 2.44 (d, J = 17.2 Hz, 1H, H-8a), 2.39–2.11 (m, 4H, H-14, H-15), 1.56–
1.49 (m, 1H, H-8b) ppm. 
13C NMR (150 MHz, CDCl3): δ = 174.5 (C-12), 154.8 (C-19), 153.6 (C-3), 145.8 (C-2), 139.3 (C-1), 
136.2 (C-21), 128.6 (C-22 or C-23), 128.3 (C-25), 128.2 (C-22 or C-23), 124.5 (C-5), 123.9 (C-6), 
111.4 (C-4), 72.5 (C-7), 71.0 (C-9), 66.8 (C-20), 66.5 (C-17), 63.8 (C-16), 60.5 (C-25), 55.7 (C-26), 
46.0 (C-10), 45.3 (C-11), 40.5 (C-14), 30.6 (C-15), 28.1 (C-8), 27.5 (C-13) ppm. 
IR (ATR): ṽ = 3298 (w), 2942 (m), 2838 (w), 1721 (m), 1673 (s), 1601 (w), 1576 (w), 1526 (m), 1487 
(s), 1454 (m), 1421 (m), 1391 (m), 1372 (w), 1356 (w), 1340 (w), 1311 (w), 1273 (s), 1247 (s), 1172 
DPPA, NEt3, toluene, r.t., 1 h 
→ 100 °C, 1 h 
→ BnOH, 100 °C, 14 h
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(w), 1151 (w), 1129 (w), 1107 (m), 1080 (s), 1070 (s), 1028 (w), 1015 (w), 1002 (w), 977 (m), 959 
(m), 927 (w), 891 (w), 863 (w), 834 (w), 814 (m), 751 (s), 697 (m), 665 (m) cm‒1.  
HRMS (ESI): calcd. for C19H25N2O5+:  479.2177 [M+H]+ 
found:    479.2178 [M+H]+. 
 
(3a'S ,4R ,9b'R)-8',9'-Dimethoxy-12'-methyl-1',2'-dihydrospiro[oxazolidine-4,3'-[3a,9b](epi-
minoethano)cyclopenta[a]naphthalene]-2,11'-dione (I.329) 
 
Cbz-protected amine I.313 (22.9 mg, 47.8 mmol, 1 eq.) was dissolved in Ac2O (1 mL) and cooled 
to 0 °C. After 15 min., BF3OEt2 (150 µL, 1.42 mmol, 30 eq.) was added slowly. After 6.5 h, the 
reaction was quenched and diluted with wet EtOAc (1 mL) and H2O (1 mL) followed by aqueous 
10% NaOH solution (5 mL). The mixture was extracted with DCM (3 × 10 mL). The combined 
organic layers were washed with saturated aqueous NaCl solution (10 mL), dried (MgSO4) and 
concentrated under reduced pressure. Flash column chromatography [DCM/acetone, 2:1 to 0:1] 
afforded oxazolidinone I.329 (17.4 mg, 47.0 µmol, 98%) as a colorless solid. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystalization 
[CHCl3] at 20 °C. 
Rf = 0.65 [DCM/acetone, 1:3]. 
1H NMR (600 MHz, CDCl3) δ = 6.86 (d, J = 8.4 Hz, 1H, H-5), 6.80 (d, 
J = 8.4 Hz, 1H, H-4), 6.62 (d, J = 10.1 Hz, 1H, H-7), 5.98 (d, J = 10.1 Hz, 1H, 
H-8), 5.61 (d, J = 11.2 Hz, 1H, H-19), 4.31 (d, J = 9.0 Hz, 1H, H-17a), 3.90 (m, 
4H, H-17b, H-20), 3.88 (s, 3H, H-21), 2.99 (m, 4H, H-11a, H-13), 2.71 (d, 
J = 18.2 Hz, 1H, H-11b), 2.66–2.56 (m, 1H, H-14a), 2.03 (td, J = 13.3, 12.0, 6.8 Hz, 2H, H-15a), 
1.74 (m, 2H, H-14b, H-15b). 
13C NMR (100 MHz, CDCl3): δ = 175.5 (C-12), 158.1 (C-18), 153.6 (C-3), 146.6 (C-2), 134.5 (C-1), 
130.0 (C-7), 123.6 (C-5), 122.1 (C-6), 117.4 (C-8), 111.1 (C-4), 73.4 (C-17), 73.2 (C-9), 70.9 (C-16), 
60.6 (C-20), 55.7 (C-21), 48.1 (C-11), 45.6 (C-10), 39.1 (C-14), 32.2 (C-15), 28.7 (C-13) ppm. 
BF3⋅OEt2, Ac2O
0 °C → r.t., 6.5 h
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IR (ATR): ṽ = 3266 (w), 2946 (w), 1758 (s), 1674 (s), 1596 (w), 1490 (m), 1455 (m), 1422 (m), 1390 
(m), 1277 (s), 1217 (w), 1147 (w), 1090 (m), 1049 (m), 810 (w), 762 (w) cm‒1.  
HRMS (ESI): calcd. for C20H23N2O5+:  371.1601 [M+H]+ 
found:    371.1602 [M+H]+. 
 
t e r t-butyl (3a'S ,4R ,9b 'R)-8',9'-dimethoxy-12'-methyl-2,11'-dioxo-1',2'-dihydrospiro[oxazoli-
dine-4,3'-[3a,9b](epiminoethano)cyclopenta[a]naphthalene]-3-carboxylate (I.330) 
 
Oxazolidinone I.320 (12 mg, 32 µmol, 1.0 eq.) was dissolved in THF (2 mL) and Boc2O (14 mg, 
64 µmol, 2 eq.) followed by NEt3 (22 µL, 0.61 mmol, 2 eq.) and DMAP (0.40 mg, 3.2 µmol, 
0.1 eq.) were added and the reaction stirred at room temperature for 17 h. Afterwards, the reaction 
mixture was concentrated under reduced pressure and flash column chromatography 
[DCM/acetone, 1:0 to 1:1] afforded Boc-protected oxazolidonone I.330 (12 mg, 26 µmol, 81%) as 
a colorless oil. 
Rf = 0.65 [DCM/acetone, 5:1]. 
1H NMR (400 MHz, CDCl3): δ = 6.85 (d, J = 8.3 Hz, 1H, H-5), 6.80 (d, 
J = 8.4 Hz, 1H, H-4), 6.58 (d, J = 10.1 Hz, 1H, H-7), 5.95 (d, J = 10.1 Hz, 1H, H-
6), 4.22 (d, J = 8.9 Hz, 1H, H-17a), 3.92 (s, 3H, H-22), 3.87 (s, 3H, H-23), 3.76 (d, 
J = 9.0 Hz, 1H, H-17b), 3.18 (ddd, J = 14.7, 12.7, 6.7 Hz, 1H, H-15a), 3.00 (d, 
J = 18.4 Hz, 1H, H-11a), 2.87–2.80 (m, 4H, H-11b, H-13), 2.73 (dd, J = 13.4, 
6.6 Hz, 1H, H-14a), 1.56 (s, 10H, H-21, H-15b), 1.45 (dd, J = 8.0, 6.1 Hz, 1H, H-
14b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 174.7 (C-12), 153.6 (C-3), 153.4 (C-18), 149.30 (C-19), 146.5 (C-
2), 134.3 (C-1), 129.7 (C-7), 123.6 (C-5), 121.7 (C-6), 117.6 (C-8), 111.2 (C-4), 85.0 (C-20), 74.2 (C-
9), 73.4 (C-16), 72.7 (C-17), 60.6 (C-22), 55.7 (C-23), 48.0 (C-11), 46.0 (C-10), 38.3 (C-14), 28.3 (C-
15), 28.1 (C-13), 27.9 (C-21) ppm. 
IR (ATR): ṽ = 2979 (w), 2939 (w), 1813 (s), 1734 (m), 1681 (s), 1596 (w), 1569 (w), 1490 (m), 1455 
Boc2O, DMAP
NEt3, THF, r.t., 17 h
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(m), 1421 (w), 1393 (w), 1370 (w), 1329 (m), 1302 (s), 1276 (s), 1257 (s), 1150 (s), 1073 (s), 1060 (s), 
964 (w), 819 (w), 774 (w), 754 (m) cm‒1.  
HRMS (ESI): calcd. for C25H31N2O7+:  471.2126 [M+H]+ 
found:    471.2136 [M+H]+. 
 
t e r t-Butyl ((3R ,3aS ,9bR)-3-formyl-8,9-dimethoxy-12-methyl-11-oxo-2,3-dihydro-1H-3a,9b-
(epimino- ethano)cyclopenta[a]naphthalen-3-yl)carbamate (I.331) 
 
Boc-protected oxazolidonone I.330 (12 mg, 24 µmol, 1.0 eq.) was dissolved in MeOH (1 mL), then 
Cs2CO3 (3.9 mg, 12 µmol, 0.5 eq.) was added and the reaction stirred at room temperature for 12 h. 
The reaction mixture was diluted with H2O (10 mL) and extracted with DCM (3 × 10 mL). The 
combined organic layers were washed with saturated aqueous NaCl solution (10 mL), dried 
(MgSO4) and concentrated under reduced pressure. Flash column chromatography [DCM/acetone, 
1:0 to 0:1] afforded aminoalcohol I.331 (9.1 mg, 20 µmol, 83%) as a colorless oil. 
Rf = 0.88 [acetone/DCM, 2:1]. 
1H NMR (400 MHz, CDCl3) δ = 6.76 (m, 2H, H-4, H-5), 6.42 (d, J = 10.1 Hz, 
1H, H-8), 6.16 (d, J = 10.2 Hz, 1H, H-7), 4.64 (s, 1H, H-18), 4.25 (d, J = 12.2 Hz, 
1H, H-17a), 3.90 (s, 3H, H-22), 3.86 (s, 3H, H-23), 3.39 (d, J = 12.2 Hz, 1H, H-
17b), 3.04 (d, J = 18.4 Hz, 1H, H-11a), 2.97 (s, 3H, H-13), 2.77 (d, J = 18.4 Hz, 
1H, H-11b), 2.46 (ddd, J = 13.5, 6.7, 4.2 Hz, 1H, H-14a), 2.0–2.00 (m, 1H, H-
14b), 1.95 (ddd, J = 11.3, 6.5, 4.2 Hz, 1H, H-15a), 1.65 (td, J = 11.5, 7.2 Hz, 1H, 
H-15b), 1.45 (s, 9H, H-21) ppm. 
13C NMR (101 MHz, CDCl3): δ = 175.7 (C-12), 155.2 (C-19), 153.3 (C-3), 146.3 (C-2), 135.4 (C-1), 
128.1 (C-7), 122.9 (C-5), 122.4 (C-6), 119.9 (C-8), 110.9 (C-4), 80.3 (C-20), 75.9 (C-9), 70.7 (C-16), 
60.6 (C-22), 60.4 (C-17), 55.7 (C-23), 48.8 (C-11), 47.7 (C-10), 39.9 (C-14), 30.5 (C-15), 28.4 (C-21), 
28.3 (C-13) ppm. 
IR (ATR): ṽ = 3356 (w), 2976 (w), 2939 (w), 1711 (m), 1669 (s), 1597 (w), 1570 (w), 1530 (w), 1490 
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(m), 1455 (m), 1421 (w), 1393 (m), 1366 (m), 1274 (s), 1249 (m), 1166 (s), 1116 (w), 1052 (m), 962 
(w), 867 (w), 917 (w), 754 (m), 678 (w) cm‒1.  
HRMS (ESI): calcd. for C24H33N2O6+:  445.2333 [M+H]+ 
found:    445.2338 [M+H]+. 
 
t e r t-Butyl ((3R ,3aS ,9bR)-3-formyl-8,9-dimethoxy-12-methyl-11-oxo-2,3-dihydro-1H-3a,9b-
(epimino-ethano)cyclopenta[a]naphthalen-3-yl)carbamate (I.332) 
 
Alcohol I.331 (10 mg, 23 µmol, 1.0 eq.) was dissolved in DCM (1 mL) and NMO (12 mg, 
0.11 mmol, 4.5 eq.) followed by TPAP (1.2 mg, 4.7 µmol, 0.2 eq.) was added to the solution. The 
reaction stirred at room temperature for 30 min. Afterwards, the reaction mixture was filtered over 
a pad of silica and the silica was washed with DCM (3 mL) and acetone (3 mL) to afford 
aminoaldehyde I.332 (9.8 mg, 22 µmol, 96%) as a colorless oil. 
Rf = 0.75 [DCM/acetone, 2:1].   
1H NMR (400 MHz, CDCl3) δ = 9.55 (s, 1H, H-17), 6.88–6.75 (m, 2H, H-4, H-
5), 6.48 (d, J = 10.0 Hz, 1H, H-7), 5.87 (d, J = 10.0 Hz, 1H, H-8), 5.11 (s, 1H, H-
18), 3.92 (s, 3H, H-22), 3.87 (s, 3H, H-23), 3.07 (d, J = 18.4 Hz, 1H, H-11a), 2.92 
(s, 3H, H-13), 2.82 (d, J = 18.5 Hz, 1H, H-11b), 2.50 (dt, J = 12.9, 5.1 Hz, 1H, 
H-14a), 2.20–2.13 (m, 1H, 15a), 2.13 – 2.03 (m, 1H, H-14b), 1.94 (dt, J = 10.7, 
5.2 Hz, 1H, H-15b), 1.45 (s, 9H, H-21) ppm. 
13C NMR (101 MHz, CDCl3): δ = 198.3 (C-17), 175.2 (C-12), 155.0 (C-19), 153.4 (C-3), 146.4 (C-
2), 134.7 (C-1), 129.0 (C-7), 123.3 (C-5), 122.5 (C-6), 119.1 (C-8), 111.0 (C-4), 81.1 (C-20), 75.6 (C-
9), 74.8 (C-16), 60.6 (C-22), 55.7 (C-23), 47.9 (C-11), 38.8 (C-10), 29.9 (C-14), 29.7 (C-15), 28.2 (C-
21), 27.7 (C-13) ppm. 
IR (ATR): ṽ = 3399 (bw), 2927 (m), 2851 (w), 1734 (w), 1673 (s), 1525 (m), 1490 (m), 1455 (m), 
1421 (w), 1394 (w), 1367 (w), 1276 (s), 1165 (s), 1099 (w), 1066 (m), 1046 (w), 969 (w), 817 (w), 679 
(w) cm‒1.  
TPAP, NMO
DCM, r.t., 30 min
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HRMS (ESI): calcd. for C24H3qN2O6+:  443.2177 [M+H]+ 
found:    443.2179 [M+H]+. 
 
(3aR ,8R ,13R)-13-Iodo-4,5-dimethoxy-1-methyl-1H ,8H ,9aH-3a,12a-ethano-8,12b-methano-
benzo[6,7]-pyrrolo[2',3':4,5]oxocino[3,2-d]oxazole-2,11(3H ,12H)-dione (I.342) 
 
Aminoaldehyde I.332 (3.5 mg, 7.9 µmol, 1.0 eq.) was dissolved in MeCN/H2O (5:1, 2.4 mL) then 
I2 (8.9 mg, 79 µmol, 10 eq.) was added and the reaction stirred at room temperature for 24 h. 
Afterwards, the reaction was stopped by the addition of aqueous saturated Na2S2O7 (1 mL) and 
diluted with H2O (10 mL). Then, the mixture was extracted with DCM (3 × 10 mL) and the 
combined organic layers were washed with saturated aqueous NaCl solution (10 mL), dried 
(MgSO4) and concentrated under reduced pressure. Flash column chromatography [DCM/acetone, 
1:0 to 2:1] afforded hexacyclic oxazolidinone I.342 (3.5 mg, 7.2 µmol, 91%) as a yellow oil. 
Rf = 0.61 [DCM/acetone, 2:1]. 
1H NMR (400 MHz, CDCl3): δ = 7.07 (d, J = 8.4 Hz, 1H, H-5), 6.94 (d, J = 8.4 Hz, 1H, H-4), 5.59 
(d, J = 3.9 Hz, 1H, H-19), 5.19 (d, J = 3.5 Hz, 1H, H-7), 5.13 (s, 1H- H-17), 5.08 
(d, J = 3.6 Hz, 1H, H-8), 3.94 (s, 3H, H-20), 3.91 (s, 3H, H-21), 3.11 (d, 
J = 17.5 Hz, 1H, H-11a), 3.01 (d, J = 17.7 Hz, 1H, H-11b), 2.96 (s, 3H, H-13), 
2.39 (dd, J = 14.8, 9.4 Hz, 1H, H-14a), 2.16–2.06 (m, 1H, H14b), 2.06–1.97 (m, 
1H, H-15a), 1.92 (dd, J = 12.8, 8.7 Hz, 1H, H-15b) ppm. 
13C NMR (101 MHz, CDCl3): δ = 175.3 (C-12), 157.8 (C-18), 154.3 (C-3), 145.7 
(C-2), 135.9 (C-1), 126.2 (C-5), 120.4 (C-6), 112.0 (C-4), 97.4 (C-17), 76.5 (C-7), 72.0 (C-16), 70.6 
(9), 60.6 (C-20), 55.7 (C-21), 47.6 (C-10), 46.3 (C-11), 40.4 (C-14), 32.5 (C-15), 27.1 (C-13), 24.4 (C-
8) ppm.  
IR (ATR): ṽ = 1934 (m), 2362 (w), 1778 (s), 1684 (s), 1601 (w), 1490 (m), 1457 (m), 1423 (w), 1362 
(m), 1278 (s), 1212 (w), 1119 (w), 1089 (m), 1034 (s), 979 (m), 954 (w), 929 (w), 800 (w), 752 (w), 
683 (w) cm‒1.  
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HRMS (ESI): calcd. for C20H22IN2O6: : 513.0517 [M+H]+ 
found:    513.0525 [M+H]+. 
 
Methyl (3R ,3aS ,9bR)-3-((t e r t-butoxycarbonyl)amino)-8,9-dimethoxy-12-methyl-11-oxo-2,3-
dihydro-1H-3a,9b-(epiminoethano)cyclopenta[a]naphthalene-3-carboxylate (I.343) 
 
Aminoaldehyde I.332 (9.8 mg, 22 µmol, 1.0 eq.) was dissolved in MeOH (2 mL), then I2 (28.2 mg, 
0.11 mmol, 10 eq.) was added and the reaction stirred at room temperature for 15 min. Afterwards, 
the reaction was stopped by the addition of aqueous saturated Na2S2O7 solution (0.1 mL) and 
diluted with H2O (10 mL). Then, the mixture was extracted with DCM (3 × 10 mL) and the 
combined organic layers were washed with saturated aqueous NaCl solution (10 mL), dried 
(MgSO4) and concentrated under reduced pressure. Ester I.343 (7.8 mg, 17 µmol, 77%) was 
obtained as a yellow oil. 
Rf = 0.65 [DCM/acetone, 5:1].   
1H NMR (400 MHz, CDCl3) δ = 6.83–6.66 (m, 2H, H-4, H-5), 6.44 (d, 
J = 10.0 Hz, 1H, H-7), 5.52 (d, J = 10.0 Hz, 1H, H-8), 4.95 (s, 1H, H-19), 3.94 (s, 
3H, H-23), 3.86 (s, 3H, H-24), 3.77 (s, 3H, H-18), 3.16 (d, J = 18.4 Hz, 1H, H-
11a), 3.02 (s, 3H, H-13), 2.71 (d, J = 18.4 Hz, 1H, H-11b), 2.40 (dd, J = 12.5, 
5.8 Hz, 1H, H-14a), 2.36–2.27 (m, 1H, H-15a), 2.24 (dd, J = 13.0, 5.1 Hz, 1H, H-
14b), 2.14–2.02 (m, 1H, H-15b), 1.43 (s, 9H, H-22) ppm. 
13C NMR (101 MHz, CDCl3): δ = 175.4 (C-12), 172.2 (C-17), 154.4 (C-20), 153.6 (C-3), 146.2 (C-
2), 134.9 (C-1), 130.1 (C-7), 122.9 (C-5), 122.5 (C-6), 117.4 (C-8), 111.0 (C-4), 80.7 (C-21), 75.9 (C-
9), 72.5 (C-16), 60.6 (C-23), 55.7 (C-24), 52.3 (C-18), 48.0 (C-10), 47.9 (C-11), 41.9 (C-14), 33.1 (C-
15), 28.2 (C-22), 27.0 (C-13) ppm.  
IR (ATR): ṽ = 3297(w), 2978 (w), 2945 (w), 2840 (w), 1789 (w), 1681 (s), 1596 (w), 1572 (w), 1491 
(m), 1455 (s), 1421 (m), 1391 (m), 1367 (m), 1274 (s), 1248 (s), 1213 (m), 1163 (s), 1126 (m), 1089 
(m), 1033 (m), 1063 (m), 1033 (m), 981 (m), 955 (m), 929 (w), 879 (w), 817 (m), 753 (s), 666 (w), 
617 (w) cm‒1.  
I2, MeOH, r.t., 15 min.
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HRMS (ESI): calcd. for C25H33N2O7+:  473.2282 [M+H]+ 
found:    473.2287 [M+H]+. 
 
t e r t-Butyl ((7R ,11bR ,14R)-14-bromo-10,11-dimethoxy-3-methyl-2,5-dioxo-2,3-dihydro-1H , 
7H-4,11b-ethano-3a,7-methanobenzo[6,7]oxocino[4,5-b]pyrrol-4(5H)-yl)carbamate (I.346) 
 
Ester I.343 (13 mg, 28 µmol, 1.0 eq.) was dissolved in THF (1 mL) in a flask covered with 
aluminium foil, then NBS (5.1 mg, 29 mmol, 1.05 eq.) in H2O (1 mL) was added and the reaction 
stirred at 0 °C for 90 minutes followed by room temperature for another 90 minutes. Afterwards, 
the reaction was stopped by the addition of aqueous saturated Na2S2O7 (0.05 mL) and diluted with 
H2O (10 mL). Then, the mixture was extracted with DCM (3 × 10 mL) and the combined organic 
layers were washed with saturated aqueous NaHCO3 solution (5 × 20 mL) and saturated aqueous 
NaCl solution (20 mL), dried (MgSO4) and concentrated under reduced pressure. Flash column 
chromatography [PE/EtOAc, 1:0 to 2:1] afforded bromolactone I.346 (13 mg, 23 µmol, 82%) as a 
colorless solid. 
Rf = 0.61 [DCM/acetone, 3:1].   
The product was accompanied by 30−35% succinimide, which could not be separated at this point. 
1H NMR (400 MHz, CDCl3) δ = 7.06 (d, J = 8.3 Hz, 1H, H-5), 6.87 (d, 
J = 8.4 Hz, 1H, H-4), 6.09 (d, J = 4.7 Hz, 1H, H-8), 5.65 (d, J = 4.6 Hz, 1H, H-7), 
5.04 (s, 1H, H-18), 3.90 (s, 3H, H-22), 3.89 (s, 3H, H-23), 3.16 (d, J = 18.0 Hz, 
1H, H-11a), 3.04 (s, 3H, H-13), 2.88 (d, J = 18.0 Hz, 1H, H-11b), 2.43 – 2.34 (m, 
1H, H-15a), 2.34–2.26 (m, 1H, H-14a), 2.08 (td, J = 11.8, 7.2 Hz, 1H, H-15b), 
1.98 (td, J = 12.1, 6.7 Hz, 1H, H-14b), 1.47 (s, 9H, H-21) ppm. 
13C NMR (101 MHz, CDCl3): δ = 176.0 (C-12), 169.7 (C-17), 155.5 (C-3), 154.5 (C-19), 145.8 (C-
2), 135.2 (C-1), 125.5 (C-5), 122.6 (C-6), 111.2 (C-4), 82.0 (C-20), 78.6 (C-7), 75.6 (C-9), 71.2 (C-16), 
60.6 (C-22), 55.7 (C-23), 49.2 (C-11), 47.4 (C-10), 44.6 (C-8), 39.6 (C-14), 38.0 (C-15), 29.7 (C-13), 
28.3 (C-21) ppm. 
IR (ATR): ṽ = 2928 (w), 1702 (w), 1746 (m), 1699 (s), 1684 (s), 1602 (w), 1589 (w), 1521 (w), 1491 
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(m), 1457 (m), 1426 (w), 1391 (w), 1369 (m), 1274 (s), 1232 (w), 1161 (m), 1121 (m), 1025 (m), 983 
(m), 814 (m), 806 (m) cm‒1.  
HRMS (ESI): calcd. for C24H30N2O7Br+:  537.1231 [M+H]+ 
found:     537.1234 [M+H]+. 
 
t e r t-Butyl ((7S ,11bR)-10,11-dimethoxy-3-methyl-2,5-dioxo-2,3-dihydro-1H ,7H-4,11b-ethano-
3a,7-methanobenzo[6,7]oxocino[4,5-b]pyrrol-4(5H)-yl)carbamate (I.355) 
 
Bromide I.346 (12.5 mg, 23.3 µmol, 1.0 eq.) was dissolved in benzene (1 mL) and AIBN (3.83 mg, 
23.3 µmol, 1 eq.) followed by Bu3SnH (63 µL, 67.7 mg, 0.233 mmol, 10 eq.) were added. The 
reaction mixture was degassed using three freeze-pump-thaw cycles. The reaction was then placed 
in a 90 °C oil bath and stirred at this temperature for 3 h. After cooling to room temperature, the 
solvent was removed under reduced pressure. Flash column chromatography on silica/K2CO3, 9:1 
[DCM/acetone, 10:1→2:1] afforded lactone I.355 (8.8 mg, 19 µmol, 82%) as a colorless solid. 
The compound was accompanied by 30−35% succinimide, which could not be separated at this 
point. 
Crystals suitable for single-crystal X-ray analysis (Section 9.1) were obtained from recrystallization 
[CHCl3] at 20 °C. 
Rf = 0.51 [DCM/acetone, 3:1]. 
1H NMR (400 MHz, CDCl3) δ = 7.04 (d, J = 8.3 Hz, 1H, H-5), 6.83 (d, 
J = 8.4 Hz, 1H, H-4), 5.54 (d, J = 4.5 Hz, 1H, H-7), 5.00 (s, 1H, H-18), 3.89 (s, 
3H, H-22), 3.88 (s, 3H, H-23), 3.77 (dd, J = 13.1, 4.7 Hz, 1H, H-8a), 3.20 (d, 
J = 18.2 Hz, 1H, H-11a), 3.03 (s, 3H, H-13), 2.80 (d, J = 19.9 Hz, 2H, H-11b and 
H-succinimide), 2.33–2.22 (m, 2H, H-14a, H-15a), 2.04–1.93 (m, 2H, H-14b, H-
15b), 1.78 (d, J = 12.9 Hz, 1H, H-8b), 1.46 (s, 9H, H-21) ppm. 
13C NMR (101 MHz, CDCl3): δ = 175.1 (C-12), 171.2 (C-17), 155.4 (C-19), 154.2 (C-3), 146.6 (C-
2), 135.5 (C-1), 126.2 (C-6), 124.4 (C-5), 111.1 (C-4), 81.3 (C-20), 76.2 (C-7), 72.4 (C-9), 69.3 (C-16), 
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60.7 (C-22), 55.8 (C-23), 49.6 (C-10), 45.9 (C-11), 39.1 (C-14), 37.4 (C-15), 29.1 (C-8), 28.3 (C-13 
and C-21) ppm. 
IR (ATR): ṽ = 3339 (w), 2976 (w), 2934 (w), 1683 (s), 1603 (w), 1581 (w), 1526 (w), 1491 (m), 1457 
(m), 1424 (w), 1392 (m), 1368 (m), 1329 (w), 1273 (s), 1244 (m), 1162 (m), 1125 (m), 1072 (m), 1026 
(w), 1004 (w), 987 (w), 974 (w), 950 (w), 922 (w), 816 (w), 754 (m), 685 (m), 667 (w) cm‒1.  
HRMS (ESI): calcd. for C24H31N2O7+:   459.2126 [M+H]+ 
found:     459.2129 [M+H]+. 
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8.3  Experimental data of chapter II 
(2R ,6S ,7R ,8R ,8aR)-2-Phenyl-6-(phenylthio)hexahydropyrano[3,2-d][1,3]dioxine-7,8-diol 
(II.19) 
 
β-D-Galactose pentaacetate (II.17, 2.50 g, 6.40 mmol, 1.0 eq.) was dissolved in DCM (125 mL) and 
thiophenol (2.00 mL, 19.2 mmol, 3.0 eq.) was added. The mixture was cooled to 0 °C and 
BF3⋅OEt2 (2.40 mL, 19.2 mmol, 3.0 eq.) was added dropwise. The mixture was allowed to warm to 
room temperature and stirred for 12 h. Then more DCM (50 mL) was added and the organic layer 
was washed with 10% aqueous NaOH (3 × 50 mL), H2O (50 mL), saturated aqueous NaCl 
(50 mL), dried (MgSO4) and concentrated under reduced pressure.  The crude product was 
immediately redissolved in MeOH (50 mL) and NaOMe was added until pH 9−10. The reaction 
mixture stirred at room temperature and after 4 h, it was stopped by the addition of DOWEX 
50WX 2-100 (H+ form) and stirred for another 30 min at room temperature. All solid material was 
removed by filtration through a pad of Celite®, which was washed with MeOH (20 mL) and the 
filtrate was concentrated under reduced pressure. The crude product was dissolved in MeCN 
(40 mL) at 60 °C. The mixture was allowed to cool to room temperature and benzaldehyde 
dimethyl acetal (2.90 mL, 19.2 mmol, 3.0 eq.) and p-TSA hydrate (121 mg, 0.640 mmol, 0.1 eq.) was 
added. The reaction mixture was stirred at room temperature for 3.5 h, then NEt3 was added (until 
pH = 8−9). The solvent was removed under reduced pressure and flash column chromatography 
on silica gel [DCM/MeOH, 9:1] afforded galactose acetal II.19 (2.08 g, 5.76 mmol, 90% over 3 
steps) as a white powder. 
Rf = 0.21 [PE/EtOAc, 1:2].  
[α]D = −0.25 (c = 0.06, MeOH). 
mp: 155−156 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.71–7.66 (m, 2H, H-Ar), 7.42–7.33 (m, 8H, H-Ar), 5.50 (s, 1H, 
H-7), 4.50 (d, 1H, J = 9.2 Hz, H-1), 4.37 (dd, 1H, J = 12.5, 1.6 Hz, H-6a), 4.19 (dd, 1H, J = 1.2 Hz, 
H-4), 4.02 (dd, 1H, J = 12.5, 1.8 Hz, H-6b), 3.72–3.62 (m, 2H, H-2, H-3), 3.56–3.49 (m, 1H, H-5), 
2.73–2.58 (m, 2H, OH-2, OH-3) ppm.  
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13C NMR (100 MHz, CDCl3): δ = 137.7 (C-Ar), 133.8 (C-Ar), 130.9 (C-Ar), 
129.5 (C-Ar), 129.1 (C-Ar), 128.4 (C-Ar), 128.3 (C-Ar), 126.6 (C-Ar), 101.5 
(C-7), 87.1 (C-1), 75.5 (C-4), 73.9 (C-3), 70.1 (C-5), 69.4 (C-6), 68.8 (C-
2) ppm. 
IR (ATR): ṽ = 3345 (m), 2916 (w), 1584 (w), 1481 (m), 1463 (m), 1440 (m), 
1360 (m), 1264 (w), 1235 (w), 1200 (w), 1135 (m), 1122 (w), 1080 (s), 1050 (s), 1015 (s), 907 (m), 
862 (m), 804 (m), 786 (w), 733 (w), 705 (m), 690 (s) cm‒1. 
HRMS (EI): calcd. for C19H24O5NS+: 378.1370 [M+NH4]+ 
   found:    378.1377 [M+NH4]+. 
 
The analytical data matched those previously described in the literature.[386] 
 
 
(2R ,6S ,7R ,8S ,8aS)-7,8-bis(Benzyloxy)-2-phenyl-6-(phenylthio)hexahydropyrano[3,2-
d][1,3]dioxine (II.20) 
 
Galactose acetal II.19 (2.06 g, 5.70 mmol, 1.0 eq.) was dissolved in DMF (40 mL) and cooled to 
0 °C. After 15 min., NaH (1.64 g, 41.1 mmol, 7.2 eq.) was added and stirred for 20 min at this 
temperature. Then benzyl bromide (2.40 mL, 20.5 mmol, 3.6 eq.) was added and the mixture was 
slowly allowed to warm to room temperature and stirred for 12 h. Ice-cold H2O (30 mL) was added 
and the aqueous layer was extracted with DCM (3 × 50 mL). The organic layer was washed with 
saturated aqueous NaCl solution (50 mL), dried (MgSO4) and concentrated under reduced pressure. 
Flash column chromatography on silica gel [PE/EtOAc, 4:1] afforded fully protected galactose 
II.20 (2.61 g, 4.83 mmol, 85%) as a white powder. 
Rf = 0.49 [PE/EtOAc, 2:1].  
[α]D = −0.12 (c = 0.09, DCM). 
mp: 172−173°C. 
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1H NMR (400 MHz, CDCl3): δ = 7.74–7.68 (m, 2H, H-Ar), 7.56–
7.51 (m, 2H, H-Ar), 7.44–7.27 (m, 13H, H-Ar), 7.24–7.16 (m, 3H, H-
Ar), 5.50 (s, 1H, H-7), 4.72 (d, 2H, J = 2.3 Hz, H-8), 4.70 (d, 2H, 
J = 3.8 Hz, H-9), 4.62 (d, 1H, J = 9.5 Hz, H-1), 4.38 (dd, 1H, 
J = 12.3, 1.6 Hz, H-6a), 4.16 (d, 1H, J = 2.9 Hz, H-4), 3.99 (dd, 1H, 
J = 12.3, 1.6 Hz, H-6b), 3.90 (t, 1H, J = 9.4 Hz, H-2), 3.63 (dd, 1H, 
J = 9.2, 3.4 Hz, H-3), 3.43 (dd, 1H, J = 1.5 Hz, H-5) ppm. 
13C NMR (100 MHz, CDCl3): δ = 138.6 (C-Ar), 138.2 (C-Ar), 138.0 (C-Ar), 132.9 (C-Ar), 132.8 
(C-Ar), 129.2 (C-Ar), 129.0 (C-Ar), 128.6 – 127.6 (C-Ar), 126.8 (C-Ar), 101.5 (C-7), 86.7 (C-1), 81.5 
(C-3), 75.6 (C-9), 75.5 (C-2), 73.9 (C-4), 72.0 (C-8), 70.0 (C-5), 69.6 (C-6) ppm. 
IR (ATR): ṽ = 3368 (br, w), 2863 (w), 1585 (w), 1497 (w), 1482 (w), 1453 (m), 1441 (w), 1398 (w), 
1366 (m), 1355 (w), 1342 (w), 1281 (w), 1250 (w), 1214 (w), 1168 (m), 1130 (m), 1091 (s), 1078 (m), 
1056 (s), 1026 (m), 1000 (m), 898 (w), 867 (w), 814 (m), 730 (s), 695 (s) cm‒1. 
HRMS (ESI): calcd. for C33H36O5NS+: 558.2309 [M+NH4]+ 
 found: 558.2321 [M+NH4]+. 
 
The analytical data matched those previously described in the literature.[399]  
 
 
2,3-Di-O-benzyl-4,6-O-benzylidene-α ,β-D-galactopyranose (II.21) 
 
Protected galactose II.20 (2.61 g, 4.83 mmol, 1.0 eq.) was dissolved in acetone (80 mL). Then H2O 
(7.7 mL) was added and the mixture was cooled to 0 °C. NBS (1.02 g, 8.70 mmol, 1.8 eq.) was 
added and the color of the mixture changed to yellow. After 1 h, the yellow color disappeared and 
saturated aqueous Na2S2O3 solution (40 mL) was added. The aquous layer was extracted with DCM 
(2 × 50 mL) and the combined organic layers were washed with saturated aqueous Na2S2O3 
(40 mL), saturated aqueous NaCl solution (40 mL), dried (MgSO4) and concentrated under reduced 
pressure. Flash column chromatography on silica gel [PE/EtOAc, 1:1] afforded hemiacetal II.21 
(1.93 g, 4.30 mmol, 89%) as a white powder.  
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The compound was obtained as an inseparable mix of diastereomers. Thus NMR signals could not 
be assigned. All signals match the data reported in the literature.[401]  
Rf = 0.35 [PE/EtOAc, 2:1].  
[α]D = +0.50 (c = 0.08, MeOH). 
mp: 154−155°C. 
1H NMR (400 MHz, CDCl3): δ = 7.59–7.51 (m, 4H), 7.45–7.27 (m, 26H), 5.50 (s, 1H), 5.49 (s, 
1H), 5.38–5.35 (m, 1H), 4.91–4.68 (m, 8H), 4.65 (t, 1H, J = 7.4 Hz), 4.31 (d, 1H, J = 12.4 Hz), 
4.25–4.17 (m, 2H), 4.12–4.04 (m, 2H), 4.02–3.95 (m, 3H), 3.84–3.77 (m, 2H), 3.66–3.43 (m, 2H), 
3.32–3.27 (m, 1H), 3.19–3.04 (m, 1H) ppm.   
13C NMR (100 MHz, CDCl3): δ = 138.7, 138.6, 138.4, 138.3, 137.9, 137.8, 129.0, 128.5, 128.4, 
128.3, 128.2, 128.1, 127.9, 127.7, 126.5, 126.4, 101.2, 101.1, 97.6, 92.5, 80.0, 79.4, 75.9, 75.8, 75.3, 
74.4, 73.9, 73.8, 72.0, 71.9, 69.6, 69.4, 66.8, 62.8 ppm. 
IR (ATR): ṽ = 3376 (br, w), 2914 (w), 1454 (m), 1098 (s), 739 (s), 698 (s) cm‒1. 
HRMS (ESI): calcd. for C27H32O6N+: 466.2224 [M+NH4]+ 
 found: 466.2235 [M+NH4]+. 
 
 
(2R ,6R ,7R ,8S ,8aS)-7,8-bis(Benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-6-yl 
2,2,2-trichloroacetimidate (II.15) 
 
Hemiacetal II.21 (750 mg, 1.67 mmol, 1.0 eq.) was dissolved in DCM (13 mL) and CCl3CN 
(1.30 mL, 16.7 mmol, 10 eq.) followed by DBU (100 µL, 0.669 mmol, 0.4 eq.) were added. The 
mixture was stirred at room temperature for 2 h. Then the solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography on silica gel 
[PE/EtOAc, 3:2 + 1% NEt3] to give trichloroacetimidate II.15 (974 mg, 1.64 mmol, 98%) as a 
white powder.  
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Rf = 0.58 [PE/EtOAc, 2:1].  
[α]D = +31.4 (c = 4.3, DCM) 
mp: 137−138 °C.  
1H NMR (400 MHz, CDCl3): δ = 8.58 (s, 1H, H-11), 7.60–7.49 (m, 2H, 
H-Ar), 7.45–7.28 (m, 13H, H-Ar), 6.65 (d, 1H, J = 3.3 Hz, H-1), 5.53 (s, 
1H, H-7), 4.87–4.74 (m, 4H, H-8, H-9), 4.34–4.26 (m, 3H, H-2, H-4, H-
6a), 4.09 (dd, 1H, J = 10.1, 3.3 Hz, H-3), 4.02 (dd, 1H, J = 12.7, 1.8 Hz, 
H-6b), 3.85 (s, 1H, H-5) ppm. 
13C NMR (100 MHz, CDCl3): δ = 161.1 (C-10), 138.5 (C-Ar), 138.4 (C-Ar), 137.7 (C-Ar), 129.1 (C-
Ar), 128.4–127.5 (C-Ar), 126.5 (C-Ar), 101.2 (C-7), 95.7 (C-1), 91.5 (C-12), 75.2 (C-2), 74.8 (C-3), 
74.6 (C-4), 73.2 (C-9), 72.3 (C-8), 69.2 (C-6), 65.4 (C-5) ppm. 
IR (ATR): ṽ = 3344 (w), 2918 (w), 2251 (w), 2163 (w), 1998 (w), 1727 (m), 1497 (w), 1455 (m), 
1364 (w), 1099 (s), 1051 (m), 1028 (m), 824 (m), 739 (m), 698 (s) cm‒1. 
HRMS (ESI): calcd. for C29H29O6Cl3N+: 592.1055 [M+H]+ 
 found: 592.1079 [M+H]+. 
 
The analytical data matched those previously described in the literature.[401]  
 
t e r t-Butyl-((2S ,3S ,4R)-3,4-dihydroxy-1-(trityloxy)octadecan-2-yl)carbamate (II.22) 
 
Boc2O (1.13 g, 5.19 mmol, 1.1 eq.) and phytosphingosine II.18 (1.50 g, 4.72 mmol, 1.0 eq.) were 
dissolved in THF (50 mL) and stirred at room temperature for 12 h. The reaction was stopped by 
the addition of 0.5 M aqueous HCl (50 mL) and the aqueous layer was extracted with EtOAc 
(3 × 100 mL). The combined organic layers were washed with H2O (100 mL) and saturated 
aqueous NaCl solution (100 mL), dried (MgSO4) and concentrated under reduced pressure. The 
residue was dissolved in pyridine (60 mL), and TrCl (1.32 g, 4.72 mmol, 1.0 eq.) followed by 
DMAP (28.8 mg, 0.236 mmol, 0.05 eq.) were added. The mixture was stirred at 80 °C for 12 h. 
Then a second portion of TrCl (395 mg, 1.42 mmol, 0.3 eq.) was added and, after additional 2 h, 
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the solvent was removed under reduced pressure. Flash column chromatography on silica gel 
[PE/EtOAc, 4:1] afforded diol II.22 (2.55 g, 3.87 mmol, 82% over two steps) as a colorless oil.  
Rf = 0.40 [PE/EtOAc, 4:1]. 
[α]D = +0.02 (c = 0.1, MeOH).  
1H NMR (400 MHz, CDCl3): δ = 7.43–7.40 (m, 6H, H-Ar), 
7.34–7.29 (m, 6H, H-Ar), 7.27–7.23 (m, 3H, H-Ar), 5.18 (d, 
1H, J = 8.9 Hz, H-5), 3.95 (q, J = 4.3 Hz, 1H, H-2), 3.60 (dt, 1H, 
J  = 8.2, 5.5 Hz, H-3), 3.40–3.39 (m, 3H, H-1, H-4), 2.80 (d, 
1H, J = 8.1 Hz, OH-3), 2.02 (d, 1H, J = 7.6 Hz, OH-4), 1.67–
1.62 (m, 1H, H-alkyl), 1.46 (m, 10H, H-8, H-alkyl), 1.44–1.05 (m, 25H, H-alkyl), 0.88 (t, J = 6.4 Hz, 
H-alkyl) ppm.  
13C NMR (100 MHz, CDCl3): δ = 155.8 (C-6), 143.4 (C-Ar), 128.6 (C-Ar), 128.2 (C-Ar), 127.5 (C-
Ar), 87.7 (C-Ar), 79.8 (C-7), 76.0 (C-3), 73.3 (C-4), 63.4 (C-1), 51.2 (C-2), 33.2–29.5 (C-alkyl), 28.6 
(C-8), 26.0 (C-alkyl), 22.9 (C-alkyl), 14.3 (C-alkyl) ppm. 
IR (ATR): ṽ = 3441 (w), 1923 (s), 2853 (m), 1692 (m), 1492 (m), 1449 (m), 1392 (w), 1366 (m), 
1319 (w), 1246 (w), 1169 (m), 1058 (m), 1001 (m), 899 (w), 862 (w), 761 (m), 745 (m), 703 (s) cm‒1. 
HRMS (ESI): calcd. for C42H6iNO5Cl-: 694.4244 [M+Cl]- 
 found: 694.4283 [M+Cl]-. 
 
 
(2S ,3S ,4R)-2-((t e r t-Butoxycarbonyl)amino)-1-(trityloxy)octadecane-3,4-diyl dibenzoate 
(II.23) 
 
To a solution of diol II.22 (1.21 g, 1.84 mmol, 1.0 eq.) in pyridine (84 mL) was added benzoyl 
chloride (1.28 mL, 11.0 mmol, 6.0 eq.) and DMAP (17.9 mg, 150 µmol, 0.08 eq.). The mixture was 
stirred at room temperature for 12 h. Then iced-cold H2O (50 mL) was added and the aqueous 
layer was extracted with DCM (3 × 100 mL). The combined organic layers were washed with 
saturated aqueous NaHCO3 (100 mL) and saturated aqueous NaCl (100 mL) and concentrated 
under reduced pressure. Flash column chromatography on silica gel [PE/EtOAc, 10:0→10:1] 
afforded protected phytosphingosine II.23 (1.48 g, 1.70 mmol, 93%) as a colorless oil.  
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Rf = 0.46 [PE/EtOAc, 9:1 + 1% NEt3].  
[α]D = +0.14 (c = 0.08, MeOH). 
 1H NMR (400 MHz, CDCl3): δ = 7.96–7.90 (m, 2H, H-Ar), 7.83 (dd, 2H, J = 8.3, 1.4 Hz, H-Ar), 
7.59–7.51 (m, 2H, H-Ar), 7.43–7.28 (m, 10H, H-21, H-Ar), 7.19–7.08 (m, 9H, H-Ar), 5.72 (dd, 1H, 
J = 9.0, 2.9 Hz, H-3), 5.49 (dt, 1H, J = 9.5, 3.1 Hz, H-4), 5.07 (d, 1H, J = 9.9 Hz, NH-5), 4.33–4.24 
(m, 1H, H-2), 3.32 (dd, 1H, J = 9.6, 3.1 Hz, H-1a), 3.20 (dd, 1H, 
J = 9.6, 4.3 Hz, H-1b), 1.95–1.78 (m, 2H, H-alkyl), 1.48 (s, 9H, 
H-8), 1.43–1.17 (m, 24H, H-alkyl), 0.88 (t, 3H, J = 6.9 Hz, H-
alkyl) ppm.  
13C NMR (100 MHz, CDCl3): δ = 166.3 (C-9), 165.2 (C-10), 
155.5 (C-6), 143.5 (C-Ar), 133.1 (C-Ar), 133.0 (C-Ar), 130.0 (C-
Ar), 129.9 (C-Ar), 129.5 (C-Ar), 128.7 (C-Ar), 128.4 (C-Ar), 127.9 (C-Ar), 127.0 (C-Ar), 86.8 (C-11), 
79.9 (C-7), 73.9 (C-4), 72.9 (C-3), 62.2 (C-1), 50.6 (C-2), 32.1–29.4 (C-alkyl), 28.7 (C-alkyl), 28.5 (C-
8), 25.7–22.8 (C-alkyl), 14.3 (C-alkly) ppm. 
IR (ATR): ṽ = 3352 (br, w), 2925 (m), 2854 (w), 1717 (m), 1602 (w), 1492 (w), 1450 (m), 1367 (m), 
1315 (w), 1262 (m), 1173 (m), 1094 (m), 1068 (m), 1026 (m), 899 (w), 756 (m), 703 (s) cm‒1. 
HRMS (ESI): calcd. for C56H73N2O7+: 885.5412 [M+NH4]+ 
 found: 885.5439 [M+NH4]+. 
 
 
(2S ,3S ,4R)-2-((t e r t-Butoxycarbonyl)amino)-1-hydroxyoctadecane-3,4-diyl dibenzoate 
(II.16)  
 
To a solution of protected phytosphingosine II.23 (1.48 g, 1.70 mmol, 1.0 eq.) in DCM (28 mL) 
and MeOH (28 mL) was added p-TSA (325 mg, 1.70 mmol, 1.0 eq.). The mixture was stirred at 
room temperature for 5 h, then saturated aqueous NaHCO3 (30 mL) was added and the aqueous 
layer was extracted with DCM (3 × 100 mL). The combined organic layers were washed with 
saturated aqueous NaHCO3 solution (100 mL) and saturated aqueous NaCl solution (100 mL), 
dried (MgSO4) and concentrated under reduced pressure. Flash column chromatography 
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[PE/EtOAc, 10:1 to 3:1] afforded primary alcohol II.16 (968 mg, 1.55 mmol, 91%) as a colorless 
oil.  
Rf = 0.54 [PE/EtOAc, 2:1 + 1% NEt3].  
 [α]D = +0.08 (c = 0.09, MeOH). 
1H NMR (400 MHz, CDCl3): δ = 8.08–8.03 (m, 2H, H-Ar), 7.97–7.93 
(m, 2H, H-Ar), 7.63 (tt, 1H, J = 7.4, 1.3 Hz, H-Ar), 7.54–7.47 (m, 3H, 
H-Ar), 7.37 (t, 2H, J = 7.8 Hz, H-Ar), 5.50 (dt, 1H, J = 9.3, 3.1 Hz, H-
4), 5.40 (dd, 1H, J = 9.5, 2.6 Hz, H-3), 5.35 (d, 1H, J = 9.8 Hz, NH-5), 
4.03 (t, 1H, J = 9.6 Hz, H-2), 3.65 (s, 2H, H-1), 2.62 (s, 1H, OH-1), 
2.10–1.93 (m, 2H, H-alkyl), 1.48 (s, 9H, H-8), 1.44–1.11 (m, 24H, H-
alkyl), 0.87 (t, 3H, J = 6.8 Hz, H-alkyl) ppm.  
13C NMR (100 MHz, CDCl3): δ = 167.2 (C-10), 166.3 (C-9), 155.6 (C-Ar), 133.9 (C-6), 133.2 (C-
Ar), 130.1 (C-Ar), 130.1 (C-Ar), 129.8 (C-Ar), 129.3 (C-Ar), 128.8 (C-Ar), 128.5 (C-Ar), 80.2 (C-7), 
74.0 (C-3), 73.9 (C-4), 61.8 (C-1), 51.6 (C-2), 32.1–29.4 (C-alkyl), 28.6 (C-alkyl), 28.5–22.8 (C-alkyl), 
14.3 (C-alkyl) ppm. 
IR (ATR): ṽ = 3377 (br, w), 2924 (s), 2854 (m), 1719 (s), 1602 (w), 1505 (w), 1452 (m), 1392 (w), 
1366 (w), 1315 (m), 1279 (s), 1173 (m), 1108 (m), 1069 (m), 1026 (m), 711 (s) cm‒1. 
HRMS (ESI): calcd. for C37H56NO7+: 626.4052 [M+H]+ 
 found: 626.4072 [M+H]+. 
 
The analytical data matched those previously described in the literature.[365] 
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(2S ,3S ,4R)-1-(((2R ,6S ,7R ,8S ,8aS)-7,8-bis(Benzyloxy)-2-phenylhexahydropyrano[3,2-d][1,3]-
dioxin-6-yl)oxy)-2-((t e r t-butoxycarbonyl)amino)octadecane-3,4-diyl dibenzoate (II.14) 
 
Galactosyl donor II.28 (450 mg, 0.759 mmol, 1.5 eq.) and acceptor II.16 (316 mg, 0.506 mmol, 
1.0 eq.) were combined and co-evaporated with toluene (3 × 5 mL) and with THF (1 × 5 mL), 
dried under high vacuum and then dissolved in Et2O (8.4 mL) and THF (4.2 mL). The mixture was 
stirred with freshly activated 4Å MS at room temperature for 30 min, before the reaction vessel was 
cooled to −30 °C and TMSOTf (5.2 µL, 29 µM, 0.056 eq.) was added. After 2.5 h a second portion 
of trichloroacetimidate II.15 (450 mg, 0.759 mmol, 1.5 eq.) and after 15 min. TMSOTf (5.2 µL, 29 
µM, 0.056 eq.) was added slowly. After 1 h at this temperature, the mixture was allowed to warm to 
−10 °C and after an additional 0.5 h the reaction was stopped by the addition of NEt3 (1 mL). Then 
the reaction mixture was allowed to warm to room temperature and EtOAc (10 mL) was added. All 
solid material was removed by filtration through a pad of Celite®, which was washed with EtOAc 
(20 mL). Saturated aqueous NaHCO3 (10 mL) was added to the filtrate and the aqueous layer was 
extracted with EtOAc (3 × 20 mL). The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure. Flash column chromatography [PE/EtOAc, 100:0 to 0:1] 
afforded protected glycoside II.14 (249 mg, 0.235 mmol, 46%) as a colorless oil. 
Rf = 0.69 [PE/EtOAc, 2:1]. 
[α]D = +0.19 (c = 0.06, MeOH). 
1H NMR (400 MHz, CDCl3): δ = 8.05–7.92 (m, 4H, 
H-Ar), 7.65–7.13 (m, 21H, H-Ar), 5.60 (dd, 1H, 
J = 8.6, 3.2 Hz, H-12), 5.46 (s, 1H, H-7), 5.44–5.38 (m, 
1H, H-13), 5.38–5.32 (m, 1H, NH-14), 4.86 (d, 1H, 
J = 3.6 Hz, H-1), 4.78–4.59 (m, 4H, H-8, H-9), 4.30–
4.19 (m, 2H, H-11, H-6a), 4.16 (d, 1H, J = 3.4 Hz, H-
4), 4.06–3.99 (m, 2H, H-2, H-6b), 3.93–3.88 (m, 1H, 
H-3), 3.86–3.79 (m, 1H, H-10a), 3.77–3.69 (m, 2H, H-
10b, H-5), 2.02–1.79 (m, 2H, H-alkyl), 1.47 (s, 9H, H-17), 1.37–1.18 (m, 24H, H-alkyl), 0.88 (t, 3H, 
J = 6.9 Hz, H-alkyl) ppm.  
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13C NMR (100 MHz, CDCl3): δ = 166.3 (C-19), 165.4 (C-15, C-19), 139.0–126.4 (C-Ar), 101.0 (C-
7), 100.4 (C-1), 80.1 (C-16), 76.0 (C-3), 75.8 (C-2), 74.8 (C-4), 73.9 (C-13), 73.6 (C-9), 73.1 (C-12), 
72.2 (C-8), 69.8 (C-10), 69.6 (C-6), 63.5 (C-5), 50.7 (C-11), 32.1–29.4 (C-alkyl), 28.8 (C-alkyl), 28.5 
(C-17), 25.8–22.8 (C-alkyl), 14.3 (C-alkyl) ppm. 
IR (ATR): ṽ = 2924 (m), 2854 (w), 1715 (m), 1602 (w), 1497 (w), 1452 (m), 1392 (w), 1366 (m), 
1314 (m), 1258 (s), 1173 (m), 1095 (s), 1068 (s), 1064 (s), 1025 (s), 798 (m), 740 (m), 710 (s), 696 
(s) cm‒1. 
HRMS (ESI): calcd. for C64H85O12N2+: 1073.6097 [M+NH4]+ 
 found: 1073.6110 [M+NH4]+. 
 
The analytical data matched those previously described in the literature.[365] 
 
(2R ,3S ,4S ,5R ,6S)-2-(Acetoxymethyl)-6-(((2S ,3S ,4R)-3,4-bis(benzoyloxy)-2-((t e r t-
butoxycarbonyl)-amino)octadecyl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (II.13) 
 
Protected glycoside II.14 (249 mg, 0.235 mmol, 1.0 eq.) was dissolved in ethanol/EtOAc (1:1, 
12.6 mL) and 10% Pd/C (250 mg, 10 wt%, 0.01 eq.) was added. The mixture was stirred vigorously 
under H2-atmosphere at room temperature for 12 h. Then the solution was diluted with 
ethanol/EtOAc (1:1, 10 mL) and all solid material was removed by filtration through a pad of 
Celite®, which was washed with ethanol/EtOAc (1:1, 20 mL). The filtrate was concentrated under 
reduced pressure and immediately dissolved in pyridine/Ac2O (1:1, 5 mL) and DMAP (1.44 mg, 
11.8 µmol, 0.05 eq.) was added. The reaction mixture was stirred at room temperature for 12 h. 
Then the solvent was removed under reduced pressure and the crude product was dissolved in 
EtOAc (20 mL). The organic layer was washed with saturated aqueous NaCl solution (20 mL), 
dried (MgSO4) and the solvent was removed under reduced pressure. Flash column 
chromatography on silica gel (PE/EtOAc, 10:1 to 1:1) afforded acetylated glycoside II.13 (224 mg, 
0.234 mmol, 99% over 2 steps) as a colorless oil. 
Rf = 0.39 [PE/EtOAc, 2:1]. 
[α]D = +0.25 (c  = 0.04, MeOH).  
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1H NMR (400 MHz, acetone-d6): δ = 8.11–8.04 (m, 2H, H-Ar), 8.02–7.95 (m, 2H, H-Ar), 7.71–
7.65 (m, 1H, H-Ar), 7.64–7.59 (m, 1H, H-Ar), 7.54 (t, 2H, J = 7.8 Hz, H-Ar), 7.47 (t, 2H, 
J = 7.8 Hz, H-Ar), 6.84 (d, 1H, J = 9.6 Hz, NH-19), 5.71 (dd, 1H, J = 9.1, 3.0 Hz, H-17), 5.53 (dt, 
1H, J = 10.2, 2.9 Hz, H-18), 5.42 (dd, 1H, J = 3.5, 1.3 Hz, H-4), 5.35 (dd, 1H, J = 10.6, 3.5 Hz, H-
2), 5.03- 4.98 (m, 2H, H-1, H-3), 4.44 (t, 1H, J = 6.5 Hz, 
H-5), 4.37 (tdd, 1H J = 9.0 Hz, 4.8, 2.9 Hz, H-16), 4.14–
4.00 (m, 2H, H-6), 3.96 (dd, 1H, J = 10.4, 2.9 Hz, H-
15a), 3.70 (dd, 1H, J = 10.4, 4.8 Hz, H-15b), 2.09 (s, 3H, 
H-Ac), 2.01-1.96 (m, 2H, H-alkyl), 1.94 (s, 3H, H-Ac), 
1.92 (s, 3H, H-1Ac), 1.91 (s, 3H, H-Ac), 1.47 (s, 9H, H-
22), 1.40–1.08 (m, 24H, H-alkyl), 0.87 (t, 3H, J = 6.8 Hz, 
H-alkyl) ppm.  
13C NMR (100 MHz, acetone-d6): δ = 170.7 (C-9, C-11), 170.4 (C-7), 170.2 (C-13), 166.3 (C-23), 
165.7 (C-24), 156.4 (C-20), 134.2 (C-Ar), 133.9 (C-Ar), 131.1 (C-Ar), 130.9 (C-Ar), 130.5 (C-Ar), 
130.3 (C-Ar), 129.5 (C-Ar), 129.3 (C-Ar), 97.6 (C-1), 79.4 (C-21), 74.5 (C-18), 73.6 (C-17), 68.8 (C-
4), 68.5 (C-15), 68.4 (C-2, C-3), 67.3 (C-5), 62.2 (C-6), 51.1 (C-16), 32.6–29.3 (C-alkyl), 28.7 (C-22), 
26.4–23.3 (C-alkyl), 20.6 (C-12), 20.6 (C-8, C-14), 20.5 (C-10), 14.4 (C-alkyl) ppm.  
IR (ATR): ṽ = 2924 (m), 2854 (w), 1715 (m), 1602 (w), 1497 (w), 1452 (m), 1392 (w), 1366 (m), 
1314 (m), 1258 (s), 1173 (m), 1095 (s), 1068 (s), 1064 (s), 1025 (s), 798 (m), 740 (m), 710 (s), 696 
(s) cm‒1. 
HRMS (ESI): calcd. for C51H77O16N2+: 973.5268 [M+NH4]+ 
 found: 973.5290 [M+NH4]+. 
 
The analytical data matched those previously described in the literature.[365] 
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(2R ,3S ,4S ,5R ,6S)-2-(Acetoxymethyl)-6-(((2S ,3S ,4R)-3,4-bis(benzoyloxy)-2-(4-((E)-(4-
heptylphenyl)-diazenyl)benzamido)octadecyl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
(II.46) 
 
Acetylated glycoside II.31 (66.7 mg, 69.7 µmol, 1.0 eq.) was dissolved in DCM (0.75 mL) and the 
mixture was cooled to 0 °C. TFA (0.75 mL) was added and the mixture was stirred at 0 °C and after 
2 h the solvent was removed under reduced pressure. The crude product was immediately dissolved 
in DCM (3.4 mL) and FAAzo-1 (33.9 mg, 0.105 mmol, 1.5 eq.) followed by HBTU (39.6 mg, 
0.105 mmol, 1.5 eq.) and N-methylmorpholine (97.3 µL, 1.05 mmol, 15 eq.) were added at room 
temperature. After 12 h, the solvent was removed under reduced pressure and the crude product 
was purified by flash column chromatography [PE/EtOAc, 100:0 to 1:1] to give protected 
glycosphingolipid II.46 (60.9 mg, 52.4 µmol, 75% over 2 steps) as a yellow viscous oil. 
Rf = 0.40 [PE/EtOAc, 2:1].   
1H NMR (400 MHz, CDCl3): δ = 8.12 (d, 2H, J = 8.5 Hz, H-22), 8.06–8.00 (m, 4H, H-Bz, H-23), 
7.97–7.93 (m, 2H, H-35), 7.89 (d, 2H, J = 8.3 Hz, H-26), 7.67–7.60 (m, 1H, H-Bz), 7.56–7.52 (m, 
1H, H-Bz), 7.49 (t, 2H, J = 7.7 Hz, H-Bz), 7.39 (t, 2H, J = 7.8 Hz, H-Bz), 7.36–7.31 (m, 2H, H-27), 
5.88 (dd, 1H, J = 9.4, 2.8 Hz, H-17), 5.47–5.42 (m, 1H, H-18), 5.42–5.37 (m, 2H, H-3, H-4), 5.18–
5.12 (m, 1H, H-2), 4.92 (d, 1H, J = 3.6 Hz, H-1), 4.91–
4.84 (m, 1H, H-16), 4.14 (t, 1H, H-5), 4.00–3.93 (m, 2H, 
H-6), 3.92–3.87 (m, 1H, H-15a), 3.66 (dd, 1H, J = 11.0, 
2.8 Hz, H-15b), 2.70 (t, 2H, J = 7.6 Hz, H-29), 2.10 (s, 
3H, H-10 or H-12), 2.02–1.96 (m, 5H, H-10 or H-12, H-
alkyl), 1.94 (s, 3H, H-14), 1.90 (s, 3H, H-8), 1.72–1.62 
(m, 2H, H-alkyl), 1.35–1.10 (m, 30H, H-alkly), 0.92 –
 0.82 (m, 6H, H-alkyl) ppm.  
13C NMR (100 MHz, CDCl3): δ = 170.7 (C-13), 170.5 
(C-7), 170.3 (C-9, C-11), 166.8 (C-30), 166.5 (C-20), 
165.4 (C-31), 154.8 (C-24), 151.0 (C-25), 147.5 (C-28), 135.1 (C-21), 133.7 (C-Bz), 133.3 (C-Bz), 
130.0 (C-Bz, C-Bz), 129.8 (C-Bz), 129.4 (C-Bz), 129.3 (C-27), 128.8 (C-Bz), 128.5 (C-22), 123.3 (C-
26), 123.1 (C-23), 97.6 (C-1), 74.2 (C-18), 72.0 (C-17), 68.1 (C-4), 67.8 (C-15), 67.6 (C-2, C-3), 67.0 
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(C-5), 61.9 (C-6), 49.4 (C-16), 36.1 (C-29), 32.0–31.9 (C-alkyl), 31.4 (C-alkyl), 29.9-29.3 (C-alkyl), 
28.2 (C-alkyl), 22.8 (C-alkyl), 20.8–20.6 (C-8, C-10, C-12, C-14), 14.3 (C-alkyl) ppm.  
IR (ATR): ṽ = 2924 (m), 2854 (w), 1748 (m), 1724 (m), 1663 (m), 1602 (w), 1530 (m), 1492 (w), 
1451 (m), 1370 (m), 1315 (w), 1223 (s), 1177 (m), 1153 (m), 1094 (m), 1068 (s), 1026 (s), 953 (w), 
906 (w), 861 (m), 803 (m), 754 (s), 710 (s) cm‒1. 
HRMS (ESI):  calcd. for C66H91N4O15+: 1179.6475 [M+NH4]+ 
 found: 1179.6491 [M+NH4]+. 
 
 
N-((2S ,3S ,4R)-3,4-Dihydroxy-1-(((2S ,3R ,4S ,5R ,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tet-
rahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)-4-((E)-(4-heptylphenyl)diazenyl)benzamide 
(α-GACe-1, II.25) 
 
Protected glycosphingolipid II.46 (60.9 mg, 52.4 µmol, 1.0 eq.) was dissolved in MeOH (14 mL) 
and NaOMe was added until pH 9−10. The reaction mixture was stirred at room temperature for 
12 h. Then a second portion of NaOMe was added and stirred for additional 4 h at room 
temperature.  The reaction was stopped by the addition of DOWEX 50WX 2-100 (H+ form) and 
stirred for another 30 min at room temperature. All solid material was removed by filtration 
through a pad of Celite®, which was washed with MeOH (20 mL) and the filtrate was concentrated 
under reduced pressure. Flash column chromatography [CHCl3/MeOH, 19:1 to 9:1] afforded α-
GACe-1 (II.25, 29.0 mg, 37.1 µmol, 71%) as yellow viscous oil. 
Compound II.25 was isolated as a 5:1 mixture of trans-/cis-isomers. 
Rf = 0.20 [DCM/MeOH, 9:1].  
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1H NMR (800 MHz, pyridine-d5): δ = 9.05 (d, 1H, 
J = 7.6 Hz, NH-11), 8.41 (d, 2H, J = 8.0 Hz, H-14), 
8.09 (d, 2H, J = 7.9 Hz, H-18), 8.05 (d, 2H, J = H-15), 
7.42 (d, 2H, J = 8.0 Hz, H-19), 7.09 (d, J = 6.8 Hz, 
1H, OH-2), 6.76 (d, 1H, J = 6.6 Hz, OH-9), 6.71–6.63 
(m, 1H, OH-3), 6.59–6.50 (m, 1H, OH-6), 6.40–6.29 
(m, 1H, OH-4), 6.22 (d, 1H, J = 6.8 Hz, OH-10), 5.63 (d, 1H, J = 2.7 Hz, H-1), 5.54–5.45 (m, 1H, 
H-8), 4.84–4.74 (m, 1H, H-7a), 4.73–4.64 (m, 1H, H-2), 4.60–4.29 (m, 8H, H-7b, H-3, H-9, H-4, H-
10, H-5, H-6), 2.64 (t, 2H, J = 7.7 Hz, H-21), 2.38–2.28 (m, 1H, H-alkyl), 1.99–1.86 (m, 2H, H-
alkyl), 1.75–1.66 (m, 1H, H-alkyl), 1.63–1.55 (m, 2H, H-alkyl), 1.49–1.35 (m, 2H, H-alkyl), 1.35–
1.13 (m, 28H, H-alkyl), 0.91–0.83 (m, 6H, H-alkyl) ppm.  
13C NMR (200 MHz, pyridine-d5): δ = 167.5 (C-12), 154.8 (C-16), 151.8 (C-17), 148.1 (C-20), 138.4 
(C-13), 130.2 (C-19), 129.7 (C-14), 124.1 (C-18), 123.4 (C-15), 102.0 (C-1), 76.7 (C-9), 73.6 (C-5), 
73.0 (C-10), 72.1 (C-3), 71.6 (C-4), 70.8 (C-2), 68.6 (C-7), 63.2 (C-6), 53.1 (C-8), 36.5 (C-21), 34.9 
(C-alkyl), 32.6–32.5 (C-alkyl), 31.9 (C-alkyl), 30.8 (C-alkyl), 30.6–29.8 (C-alkyl), 26.9 (C-alkyl), 23.4–
20.2 (C-alkyl), 14.8–14.7 (C-alkyl) ppm. 
IR (ATR): ṽ = 3570 (w), 3458 (m), 3288 (m), 2955 (m), 2920 (s), 2850 (m), 1635 (s), 1606 (m), 1538 
(m), 1492 (w), 1468 (m), 1407 (w), 1347 (m), 1294 (m), 1224 (m), 1140 (m), 1065 (s), 1039 (s), 1013 
(m), 974 (m), 950 (w), 892 (w), 858 (m), 804 (m), 772 (m), 720 (s), 696 (m) cm‒1. 
HRMS (ESI):  calcd. for C44H72N3O9+: 786.5263 [M+H]+ 
 found: 786.5285 [M+H]+. 
 
 
(2R ,3S ,4S ,5R ,6S)-2-(Acetoxymethyl)-6-(((2S ,3S ,4R)-3,4-bis(benzoyloxy)-2-(3-(4-((E)-(4-
pentylphe-nyl)diazenyl)phenyl)propanamido)octadecyl)oxy)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (II.47) 
 
Acetylated glycoside II.31 (66.7 mg, 69.7 µmol, 1.0 eq.) was dissolved in DCM (0.75 mL) and the 
mixture was cooled to 0 °C Then TFA (0.75 mL) was added and the mixture was stirred at 0 °C 
and after 2 h the solvent was removed under reduced pressure. The crude product was dissolved in 
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
II.47
1) TFA, DCM, 0 °C, 2 h
2) FAAzo-3, HBTU, NMM
    DCM, r.t., 12 h
(86% over 2 steps)
O
AcO
AcO
AcO
OAc
O
C14H29
NHBoc
OBz
OBz
II.31
O N
N
C5H11
9
8 107
HN
OH
α-GACe-1 (II.25)
11
12 13
14
OH
12
3
4 5
6
O
HO
HO
HO
OH
H
OH
H
H
H
15
16
17
18
19
20 21
N
N
O
EXPERIMENTAL 
199  
DCM (3.4 mL) and FAAzo-3 (21.0 mg, 64.7 µmol, 0.93 eq.) followed by HBTU (39.6 mg, 
0.105 mmol, 1.5 eq.) and N-methylmorpholine (97.3 µL, 1.05 mmol, 15 eq.) were added and stirred 
at room temperature for 12 h. Afterwards, the solvent was removed under reduced pressure and 
the crude product was purified via flash column chromatography [PE/EtOAc, 100:0 to 1:1] to give 
protected glycosphingolipid II.47 (69.9 mg, 60.1 µmol, 86% over 2 steps) as yellow viscous oil. 
Rf = 0.29 [PE/EtOAc = 2:1].  
1H NMR (400 MHz, CDCl3): δ = 8.01–7.95 (m, 2H, H-
Bz), 7.93–7.88 (m, 2H, H-Bz), 7.85 (d, 2H, J = 8.2 Hz, 
H-25), 7.78 (d, 2H, J = 8.2 Hz, H-28), 7.59 (t, 1H, 
J = 7.4 Hz, Bz), 7.52 (t, 1H, J = 7.4 Hz, H-Bz), 7.49–
7.41 (m, 4H, H-24, H-Bz), 7.36 (t, 2H, J = 7.6 Hz, H-
Bz), 7.28 (d, 2H, J = 8.2 Hz, H-29), 6.72 (d, 1H, 
J = 9.7 Hz, NH-19), 5.66 (dd, 1H, J = 9.8, 2.4 Hz, H-
17), 5.41 (d, 1H, J = 3.3 Hz, H-4), 5.32 (dd, 1H, J = 10.9, 
3.4 Hz, H-3), 5.24–5.19 (m, 1H, H-18), 5.13 (dd, 1H, 
J = 10.9, 3.6 Hz, H-2), 4.77 (d, 1H, J = 3.6 Hz, H-1), 
4.66–4.56 (m, 1H, H-16), 4.08–4.01 (m, 1H, H-5), 4.01-3.91 (m, 2H, H-6), 3.67 (dd, 1H, J = 11.0, 
2.9 Hz, H-15a), 3.48 (dd, 1H, J = 11.3, 2.8 Hz, H-15b), 3.14 (t, 2H, J = 7.7 Hz, H-22), 2.80–2.71 
(m, 2H, H-21), 2.66 (t, 3H, J = 7.7 Hz, H-31), 2.09 (s, 3H, H-10), 1.99 (d, 6H, J = 2.6 Hz, H-8, H-
12), 1.92 (s, 3H, H-14), 1.88 (d, 2H, J = 6.7 Hz, H-alkyl), 1.65 (p, 2H, J = 7.4 Hz, H-alkyl), 1.45–
1.10 (m, 30H, H-alkyl), 0.97–0.77 (m, 8H, H-alkyl) ppm. 
13C NMR (100 MHz, CDCl3): δ = 171.8 (C-20), 170.7 (C-13), 170.5 (C-7), 170.3 (C-11), 170.2 (C-
9), 166.6 (C-32), 165.1 (C-33), 151.4 (C-26), 151.0 (C-27), 146.4 (C-30), 143.7 (C-23), 133.6 (C-Bz), 
133.2 (C-Bz), 130.0 (C-Bz), 129.9 (C-Bz), 129.7 (C-Bz), 129.4 (C-Bz), 129.2 (C-24), 129.1 (C-29), 
128.7 (C-Bz), 128.4 (C-Bz), 123.1 (C-25), 122.9 (C-28), 97.4 (C-1), 74.3 (C-18), 71.6 (C-17), 68.1 (C-
4), 67.6 (C-3), 67.2 (C-2), 66.9 (C-5), 62.0 (C-6), 48.4 (C-16), 37.8 (C-21), 35.9 (C-31), 32.0 (C-alkyl), 
31.6 (C-alkyl), 31.4 (C-22), 31.1 (C-alkyl), 29.8–29.4 (C-alkyl), 28.1 (C-alkyl), 25.7 (C-alkyl), 22.8 (C-
alkyl), 22.6 (C-alkyl), 20.8 (C-8, C-12), 20.7 (C-10), 20.6 (C-14), 14.2 (C-alkyl), 14.1 (C-alkyl) ppm. 
IR (ATR): ṽ = 2925 (w), 2854 (w), 1748 (m), 1728 (m), 1674 (w), 1602 (w), 1529 (w), 1451 (w), 
1370 (w), 1315 (w), 1222 (s), 1176 (w), 1156 (w), 1095 (m), 1068 (m), 1026 (m), 953 (w), 907 (w), 
848 (w), 803 (w), 752 (s), 710 (s), 666 (m) cm‒1. 
HRMS (ESI): calcd. for C66H88O15N3+: 1162.6210 [M+H]+ 
 found: 1162.6223 [M+H]+. 
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N-((2S ,3S ,4R)-3,4-Dihydroxy-1-(((2S ,3R ,4S ,5R ,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tet-
rahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)-3-(4-((E)-(4-pentylphenyl)diazenyl)phenyl)-
propanamide (α-GACe-3, II.26) 
 
Protected glycosphingolipid II.47 (69.9 mg, 60.1 µmol, 1.0 eq.) was dissolved in MeOH (14 mL) 
and NaOMe was added until pH 9−10. The reaction mixture was stirred at room temperature for 
12 h. Afterwards, it was stopped by the addition of DOWEX 50WX 2-100 (H+ form) and stirred 
for another 30 min at room temperature. All solid material was removed by filtration through a pad 
of Celite®, which was washed with MeOH (20 mL) and the filtrate was concentrated under reduced 
pressure. Flash column chromatography [CHCl3/MeOH, 9:1] afforded α-GACe-3 (II.26, 40.6 mg, 
51.7 µmol, 86%) as yellow viscous oil. 
Compound was obtained as a 10:1 mixture of trans-/cis-isomers. 1H NMR signal of H-1 underneath 
solvent signal; conformation at the anomeric center was confirmed by coupling of H-2 to H-1 
(J = 3.8 Hz). 
Rf = 0.17 [DCM/MeOH, 9:1]. 
1H NMR (800 MHz, CD3OD): δ = 7.88–7.82 (m, 4H, H-17, H-20), 7.43 (d, 2H, J = 8.4 Hz, H-16), 
7.37 (d, 2H, J = 8.2 Hz, H-21), 4.90–4.88 (m, 1H, H-1), 4.22 (dt, 1H, J = 6.3, 4.6 Hz, H-8), 3.90–
3.86 (m, 2H, H-4, H-7a), 3.83 (t, 1H, J = 6.1 Hz, H-5), 3.80 (dd, 1H, J = 10.0, 3.8 Hz, H-2), 3.76–
3.68 (m, 4H, H-3, H-6, H-7b), 3.56 (t, 1H, J = 6.1 Hz, H-9), 3.51–3.48 (m, 1H, H-10), 3.09–3.01 
(m, 2H, H-14), 2.72 (t, 2H, J = 7.8 Hz, H-23), 1.94 (td, 2H, J = 7.5, 3.5 Hz, H-13), 1.70 (p, 2H, 
J = 7.5 Hz, H-alkyl), 1.42–1.16 (m, 30H, H-alkyl), 
0.94 (t, 3H, J = 7.0 Hz, H-alkyl), 0.91 (t, 3H, 
J = 7.2 Hz, H-alkyl) ppm.  
13C NMR (200 MHz, CD3OD ): δ = 1.74.5 (C-12), 
152.6 (C-18), 152.3 (C-19), 147.9 (C-22), 145.7 (C-
15), 130.3 (C-16), 130.2 (C-21), 123.9-123.8 (C-17, C-20), 101.1 (C-1), 75.5 (C-9), 72.9 (C-10), 72.6 
(C-5), 71.5 (C-3), 71.1 (C-4), 70.2 (C-2), 68.2 (C-13), 62.8 (C-6), 52.0 (C-2), 38.4 (C-13), 36.8 (C-23), 
33.1 (C-alkyl), 32.6 (C-alkyl), 32.6 (C-14), 31.4–23.7 (C-alkyl), 23.6 (C-alkyl), 14.5 (C-alkyl), 14.4 (C-
alkyl) ppm. 
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IR (ATR): ṽ = 3386 (br, w), 2955 (s), 2922 (s), 2854 (m), 1653 (w), 1558 (w), 1458 (m), 1378 (m), 
1155 (w), 1058 (m), 721 (m) cm‒1. 
HRMS (ESI): calcd. for C44H72N3O9+: 789.5263 [M+H]+ 
 found: 789.5283 [M+H]+. 
 
 
(2R,3S ,4S ,5R ,6S)-2-(Acetoxymethyl)-6-(((2S ,3S ,4R)-3,4-bis(benzoyloxy)-2-(4-(4-((E)-(4-
butylphe-nyl)diazenyl)phenyl)butanamido)octadecyl)oxy)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (II.24) 
 
Acetylated glycoside II.31 (73.4 mg, 76.8 µmol, 1.0 eq.) was dissolved in DCM (0.75 mL) and 
cooled to 0 °C. Then TFA (0.75 mL) was added and the reaction mixture stirred at 0 °C for 2 h. 
Afterwards, the solvent was removed under reduced pressure and the crude product was 
immediately redissolved in DCM (3.7 mL). FAAzo-4 (37.4 mg, 0.115 mmol, 1.5 eq.) followed by 
HBTU (43.7 mg, 0.115 mmol, 1.5 eq.) and N-methylmorpholine (110 µL, 1.15 mmol, 15 eq.) were 
added and the reaction stirred at room temperature for 12 h. The solvent was removed under 
reduced pressure and the crude product was purified via flash column chromatography 
[PE/EtOAc, 100:0→1:1] to give protected glycosphingolipid II.24 (82.5 mg, 71.0 µmol, 92% over 
2 steps) as a yellow oil. 
Compound II.24 was isolated as an 8:1 mixture of trans-/cis-isomers. 
Rf = 0.34 [PE/EtOAc, 2:1]. 
1H NMR (400 MHz, CDCl3): δ = 8.02–7.97 (m, 2H, H-Bz), 7.94–7.89 (m, 2H, H-Bz), 7.86–7.80 
(m, 4H, H-26, H-29), 7.64–7.58 (m, 1H, H-Bz), 7.56–7.50 (m, 1H, H-Bz), 7.47 (t, 2H, J = 7.7 Hz, 
H-Bz), 7.41–7.34 (m, 4H, H-25, H-Bz), 7.31 (d, 2H, J = 8.4 Hz, H-30), 6.60 (d, 1H, J = 9.6 Hz, 
NH-19), 5.69 (dd, 1H, J = 9.7, 2.6 Hz, H-17), 5.43–5.40 (m, 1H, H-4), 5.36–5.29 (m, 2H, H-3, H-
18), 4.81 (d, 1H, J = 3.6 Hz, H-1), 4.10 (t, 1H, J = 6.4 Hz, H-5), 4.06–3.93 (m, 2H, H-6), 5.14 (dd, 
1H, J = 10.9, 3.6 Hz, H-2), 4.67–4.59 (m, 1H, H-16), 3.74 (dd, 1H, J = 10.8, 2.9 Hz, H-15a), 3.50 
(dd, 1H, J = 10.9, 2.7 Hz, H-15b), 2.83–2.77 (m, 2H, H-23), 2.68 (t, 2H, J = 7.8 Hz, H-32), 2.42 (t, 
2H, J = 7.5 Hz, H-21), 2.14–2.07 (m, 5H, H-10, H-22), 1.99 (s, 3H, H-12), 1.97 (s, 3H, H-8), 1.94–
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1.87 (m, 5H, H-14, H-alkyl), 1.67–1.60 (m, 2H, H-
33), 1.42–1.35 (m, 2H, H-34), 1.31–1.09 (m, 24H, 
H-alkyl), 0.94 (t, 3H, J = 7.4 Hz, H-alkyl), 0.89–
0.84 (m, 3H, H-alkyl) ppm. 
13C NMR (100 MHz, CDCl3): δ = 172.6 (C-20), 
170.8 (C-13), 170.6 (C-7), 170.4 (C-11), 170.3 (C-
9), 166.7 (C-36), 165.2 (C-37), 151.4 (C-27), 151.1 
(C-28), 146.4 (C-31), 144.8 (C-24), 133.7 (C-Bz), 
133.3 (C-Bz), 130.0 (C-Bz), 129.9 (C-Bz), 129.8 (C-Bz), 129.4 (C-Bz), 129.3 (C-25), 129.2 (C-30), 
128.8 (C-Bz), 128.5 (C-Bz), 123.0 (C-26), 122.9 (C-29), 97.5 (C-1), 74.3 (C-18), 71.7 (C-17), 68.1 (C-
4), 67.7 (C-3), 67.5 (C-15), 67.3 (C-2), 66.9 (C-5), 61.9 (C-6), 48.5 (C-16), 36.1 (C-21), 35.7 (C-32), 
35.3 (C-23), 33.6 (C-33), 32.1 – 29.5 (C-alkyl), 28.1 (C-alkyl), 27.2 (C-22), 25.9 – 22.8 (C-alkyl), 22.5 
(C-34), 20.8-20.7 (C-8, C-10, C-12, C-14), 14.3 (C-alkyl), 14.1 (C-alkyl) ppm. 
IR (ATR): ṽ = 2925 (m), 2363 (w), 1753 (m), 1260 (s), 1070 (m), 799 (m), 712 (w) cm‒1. 
HRMS (ESI): calcd. for C66H88O15N3+: 1162.6210 [M+H]+ 
 found: 1162.6249 [M+H]+. 
 
 
4-(4-((E)-(4-Butylphenyl)diazenyl)phenyl)-N-((2S ,3S ,4R)-3,4-dihydroxy-1-(((2S ,3R ,4S ,5R , 
6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecan-2-yl)bu-
tanamide (α-GACe-4, II.12) 
 
Protected glycosphingolipid II.24 (82.5 mg, 71.0 µmol, 1.0 eq.) was dissolved in MeOH (14 mL) 
and NaOMe was added until pH 9−10 and reaction mixture was stirred at room temperature for 
12 h. The reaction was stopped by the addition of DOWEX 50WX 2-100 (H+ form) and stirred for 
another 30 min at room temperature. All solid material was removed by filtration through a pad of 
Celite®, which was washed with MeOH (20 mL) and the filtrate was concentrated under reduced 
pressure. Flash column chromatography [DCM/MeOH, 9:1] afforded (α-GACe-4 (II.12, 48.0 mg, 
61.1 µmol, 86%) as yellow viscous oil. 
1) TFA, DCM, 0 °C, 2 h
2) FAAzo-4-Cl, HBTU, NMM
    DCM, r.t., 12 h
3) NaOMe, MeOH, r.t., 12 h
(56% over 3 steps)
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Compound II.12 was isolated as a 14:1 mixture of trans-/cis-isomers. 
Rf = 0.15 [DCM/MeOH, 9:1]. 
 1H NMR (800 MHz, CD3OD ): δ = 7.83–7.80 
(m, 4H, H-18, H-21), 7.39 (d, 2H, J = 8.3 Hz, 
H-17), 7.35 (d, 2H, J = 8.3 Hz, H-22), 4.87 (d, 
1H, J = 3.8 Hz, H-1), 4.23–4.21 (m, 1H, H-8), 
3.90 (dd, 1H, J = 10.6, 4.1 Hz, H-7a), 3.87 (d, 
1H, J = 2.5 Hz, H-4), 3.84–3.83 (m, 1H, H-5), 3.79 (dd, 1H, J = 10.0, 3.9 Hz, H-2), 3.74 (dd, 1H, 
J = 10.1 Hz, 3.3 Hz, H-3), 3.73–3.66 (m, 3H, H-7b, H-6), 3.63 (t, 1H, J = 6.2 Hz, H-9), 3.58–3.55 
(m, 1H, H-4), 2.74 (t, 2H, J = 7.8 Hz, H-15), 2.71 (t, 2H, J = 7.8 Hz, H-24), 2.31 (td, 2H, J = 7.4, 
3.8 Hz, H-13), 1.99 (td, 2H, J = 7.6, 3.7, H-14), 1.69–1.64 (m, 2H, H-25), 1.42–1.38 (m, 2H, H-26), 
1.36–1.19 (m, 26H, H-alkyl), 0.97 (t, 3H, J = 7.4 Hz, H-27), 0.88 (t, 3H, J = 7.2 Hz, H-alkyl) ppm.  
13C NMR (200 MHz, CD3OD): δ = 175.3 (C-12), 152.5 (C-19), 152.3 (C-20), 147.8 (C-23), 146.6 
(C-16), 130.3 (C-17), 130.2 (C-22), 123.9–123.8 (C-18, C-21), 101.2 (C-1), 75.4 (C-9), 72.9 (C-10), 
72.7 (C-5), 71.5 (C-3), 71.1 (C-4), 70.2 (C-2), 68.3 (C-7), 62.8 (C-6), 52.0 (C-8), 36.6 (C-13), 36.5 (C-
24), 36.2 (C-15), 34.8 (C-25), 33.07–30.5 (C-alkyl), 28.7 (C-14), 27.1–23.7 (C-alkyl), 23.4 (C-26), 14.5 
(C-alkyl), 14.3 (C-27) ppm. 
IR (ATR): ṽ = 3790 (w), 3663 (w), 3288 (m), 2921 (s), 2851 (m), 1725 (w), 1658 (m), 1642 (m), 
1564 (w), 1551 (w), 1468 (m), 1151 (m), 1031 (m) cm‒1. 
HRMS (ESI): calcd. for C44H72O9N3+: 786.5263 [M+H]+ 
 found: 786.5287 [M+H]+. 
 
 
4-(4-((E)-(4-Butyl-2,6-dichlorophenyl)diazenyl)-3,5-dichlorophenyl)-N-((2S ,3S ,4R)-3,4-
dihydroxy-1-(((2S ,3R ,4S ,5R ,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)octadecan-2-yl)butanamide (α-GRACe-4, II.27) 
 
1) TFA, DCM, 0 °C, 2 h
2) FAAzo-4-Cl, HBTU, NMM
    DCM, r.t., 12 h
3) NaOMe, MeOH, r.t., 12 h
(56% over 3 steps)
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Acetylated glycoside II.31 (66.7 mg, 69.7 µmol, 1.0 eq.) was dissolved in DCM (0.75 mL) and the 
mixture was cooled to 0 °C. Then TFA (0.75 mL) was added and the reaction stirred at 0 °C for 
2 h. The solvent was removed under reduced pressure and the crude product was immediately 
redissolved in DCM (3.4 mL). Red FAAzo-4 (48.3 mg, 0.105 mmol, 1.5 eq.) followed by HBTU 
(39.6 mg, 0.105 mmol, 1.5 eq.) and N-methylmorpholine (97.3 µL, 1.05 mmol, 15 eq.) were added 
and the reaction stirred at room temperature for 12 h. The solvent was removed under reduced 
pressure and the crude product (Rf = 0.29 [PE/EtOAc, 2:1]) was filtered over a plug of silica and 
directly used in the next step. The crude material was dissolved in MeOH (14 mL) and NaOMe was 
added until pH 9−10. The reaction mixture stirred at room temperature for 12 h. Afterwards, it was 
stopped by the addition of DOWEX 50WX 2-100 (H+ form) and stirred for another 30 min at 
room temperature. All solid material was removed by filtration through a pad of Celite®, which was 
washed with MeOH (20 mL), and the filtrate was concentrated under reduced pressure. Flash 
column chromatography [CHCl3/MeOH, 19:1 to 9:1] afforded α-GRACe-4 (II.27, 36.1 mg, 
39.1 µmol, 56% over 3 steps) as a yellow viscous oil. 
Compound II.27 was isolated as a 1.7:1 mixture of trans-/cis-isomers, thus NMR signals could not 
be assigned. 
Rf = 0.17 [DCM/MeOH, 9:1]. 
1H NMR (800 MHz, CD3OD): δ = 7.46 (s, 2H), 7.42 (s, 2H), 7.27 (s, 1H), 7.23 (s, 1H), 4.90 (dd, 
J = 9.1, 3.8 Hz, 2H), 4.26 (ddt, J = 8.0, 6.2, 4.7 Hz, 2H), 3.96–3.89 (m, 4H), 3.87 (dddd, J = 14.1, 
6.7, 5.2, 1.3 Hz, 2H), 3.81 (ddd, J = 10.1, 6.3, 3.8 Hz, 2H), 3.80–3.69 (m, 7H), 3.64 (dt, J = 23.4, 
6.1 Hz, 2H), 3.58 (dddd, J = 18.1, 9.8, 6.0, 2.4 Hz, 2H), 2.74 (td, J = 7.5, 2.5 Hz, 2H), 2.73–2.70 (m, 
2H), 2.66–2.60 (m, 3H), 2.34 (td, J = 7.3, 4.5 Hz, 2H), 2.29 (td, J = 7.3, 3.1 Hz, 1H), 2.01 (p, 
J = 7.6 Hz, 2H), 1.95–1.90 (m, 1H), 1.71–1.65 (m, 3H), 1.63–1.55 (m, 4H), 1.47–1.39 (m, 3H), 
1.39–1.24 (m, 45H), 1.01 (t, J = 7.4 Hz, 3H), 0.96 (t, J = 7.4 Hz, 2H), 0.92 (dt, J = 11.8, 7.2 Hz, 
6H) ppm. 
13C NMR (200 MHz, CD3OD ): δ = 175.0, 174.9, 147.6, 147.5, 147.3, 147.1, 146.8, 146.5, 146.5, 
130.7, 130.6, 130.4, 130.4, 128.3, 128.3, 126.8, 126.7, 101.2, 101.1, 75.4, 72.9, 72.6, 71.5, 71.1, 70.2, 
70.2, 68.3, 68.3, 62.8, 52.0, 49.0, 36.3, 35.8, 35.5, 35.4, 35.2, 34.2, 33.1, 32.9, 30.9, 30.8, 30.8, 30.5, 
28.2, 28.1, 27.0, 27.0, 23.7, 23.3, 23.2, 14.5, 14.2 ppm. 
IR (ATR): ṽ = 3396 (br, m), 2924 (m), 2853 (w), 1641 (m), 1591 (w), 1548 (w), 1466 (w), 1401 (w), 
1149 (m), 1030 (m), 844 (s) cm‒1. 
HRMS (ESI):  calcd. for C44H68Cl4N3O9+: 922.3704 [M+H]+ 
 found: 922.3723 [M+H]+. 
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(2S ,3S ,4R)-2-((t e r t-Butoxycarbonyl)amino)-1-(((2S ,3R ,4S ,5R ,6S)-3,4,5-tris(benzyloxy)-6-
(fluoromethyl)tetrahydro-2H-pyran-2-yl)oxy)octadecane-3,4-diyl dibenzoate (II.29) 
 
Fluorinated galactosyl donor II.28 (72 mg, 119 mmol, 1.5 eq.) and acceptor II.16 (50 mg, 80 mmol, 
1.0 eq.) were combined and co-evaporated with toluene (3 × 5 mL) and with THF (1 × 5 mL), 
dried under high vacuum and then dissolved in THF (8.0 mL) under argon. The mixture was stirred 
with freshly activated 4Å MS at room temperature for 30 min, before the reaction vessel was 
cooled to −40 °C. TMSOTf (4.4 mL, 24 mmol, 0.3 eq.) was added and the reaction mixture was 
stirred at −40 °C for 1 h. The reaction mixture was diluted with THF (10 mL), quenched by the 
addition of NEt3 and filtered through a pad of celite. The solvents were removed under reduced 
pressure and the crude product was purified by flash chromatography on silica (PE/EtOAc, 6:1) to 
give II.29 (54 mg, 51 mmol, 64%) as a colorless oil. 
Rf = 0.76 [PE:EtOAc, 2:1].  
[α]D20 = + 0.47 (c = 2.9, DCM). 
1H NMR (599 MHz, CDCl3) δ = 8.05–7.95 (m, 4H, 
H-Ar), 7.60–7.16 (m, 21H, H-Ar), 5.62 (dd, J = 8.7, 
3.2 Hz, 1H, H-12), 5.48 (d, J = 9.8 Hz, 1H, H-13), 
5.33 (d, J = 9.9 Hz, 1H, NH-14), 4.93 (d, J = 11.5 Hz, 
1H, -CH2-Ph), 4.83–4.78 (m, 1H, H-1), 4.69 (d, 
J = 11.7 Hz, 1H, -CH2-Ph), 4.64 (d, J = 3.4 Hz, 2H, -
CH2-Ph), 4.57 (d, J = 11.4 Hz, 1H, -CH2-Ph), 4.50–
4.21 (m, 3H, H-6, H-11), 4.13–4.05 (m, 1H, H-5), 4.00 
(dd, J = 9.5, 3.6 Hz, 1H, H-2), 3.92–3.87 (m, 2H, H-3, H-4), 3.79–3.71 (m, 2H, H-10), 1.98–1.79 
(m, 1H, H-alkyl), 1.47 (s, 9H, H-17), 1.42 – 1.18 (m, 19H, H-alkyl), 0.89 (t, J = 6.9 Hz, 3H, H-alkyl).  
13C NMR (151 MHz, CDCl3) δ = 166.2 (C-18), 165.4 (C-19), 155.5 (C-14), 138.9 (C-Ar), 138.6 (C-
Ar), 138.3 (C-Ar), 133.4 (C-Ar), 133.0 (C-Ar), 130.3 (C-Ar), 123.0 (C-Ar), 129.9 (C-Ar), 128.6 (C-
Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.2 (C-Ar), 127.9 (C-Ar), 127.6 (C-Ar), 99.3 (C-1), 82.3 (d, 
J = 167.8 Hz, C-6), 80.0 (C-16), 78.5 (C-3), 76.6 (C2), 74.8 (CH2-Ph), 74.6 (C-4), 73.8 (C-13), 73.6 
(CH2-Ph), 73.3 (CH2-Ph), 73.2 (C-12), 69.7 (d, J = 23.0 Hz, C-5), 69.1 (C-10), 50.6 (C-11), 32.1 (C-
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alkyl), 29.8 (C-alkyl), 29.7 (C-alkyl), 29.5 (C-alkyl), 28.9 (C-alkyl), 28.5 (C-17), 27.1 (C-alkyl), 25.8 (C-
alkyl), 22.8 (C-alkyl), 14.3 (C-alkyl) ppm. 
19F NMR (377 MHz, CDCl3) δ = −229.50 (td, J = 46.8, 12.3 Hz, F-6). 
IR (ATR): ṽ = 2925 (s), 2854 (m), 1718 (s), 1602 (w), 1585 (w), 1497 (m), 1453 (m), 1392 (w), 
1366 (m), 1343 (w), 1315 (m), 1263 (s), 1159 (m), 1097 (s), 1069 (s), 1042 (m), 1027 (s), 913 (w), 866 
(w), 736 (m), 712 (s), 698 (m) cm‒1. 
HRMS (ESI): calcd. for C64H86FN2O11+: 1077.6210 [M+NH4]+ 
  found:    1077.6237 [M+NH4]+. 
 
 
(2S ,3R ,4S ,5R ,6S)-2-(((2S ,3S ,4R)-3,4-bis(Benzoyloxy)-2-((tert-butoxycarbonyl)amino)octa-
decyl)oxy)-6-(fluoromethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (II.30) 
 
Protected glycoside II.29 (28.6 mg, 27.0 µmol, 1.0 eq.) was dissolved in EtOH/EtOAc (1:1, 2 mL) 
and 10% palladium on activated charcoal (28.6 mg, 100 wt%, 0.1 eq.) was added. The mixture was 
stirred vigorously under H2-atmosphere at room temperature for 12 h. Then the solution was 
diluted with EtOH/EtOAc (1:1, 10 mL) and all solid material was removed by filtration through a 
pad of Celite®, which was washed with EtOH/EtOAc (1:1, 20 mL) and the filtrate was 
concentrated under reduced pressure. The crude product was dissolved in pyridine (1 mL) and 
Ac2O (0.2 mL) and DMAP (0.165 mg, 1.35 µmol, 0.05 eq.) were added. The reaction mixture was 
stirred at room temperature for 12 h, then the solvent was removed under reduced pressure and the 
crude product was dissolved in EtOAc (10 mL). The organic layer was washed with saturated 
aqueous NaCl solution (20 mL), dried (MgSO4) and the solvent was removed under reduced 
pressure. Flash column chromatography on silica gel [PE/EtOAc, 10:1 to 1:1] afforded acetylated 
glycoside II.30 (15 mg, 0.0164 mmol, 61% over 2 steps) as a colorless oil. 
Rf = 0.31 [PE/EtOAc, 4:1]. 
[α]D20 = +0.74 (c = 1, DCM). 
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2) Ac2O, DMAP, pyridine
    r.t., 12 h
(61% over 2 steps)
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1H NMR (400 MHz, acetone-d6): δ = 8.01−7.96 (m, 2H, 
H-Bz), 7.92 (dd, J = 8.0, 1.4 Hz, 2H, H-Bz), 7.63−7.56 
(m, 1H, H-Bz), 7.56−7.49 (m, 1H, H-Bz), 7.46 (t, 
J = 7.8 Hz, 2H, H-Bz), 7.37 (t, J = 7.6 Hz, 2H, H-Bz), 
5.63 (dd, J = 9.5, 2.7 Hz, 1H, H-15), 5.55–5.47 (m, 1H, 
H-4), 5.43 (dt, J = 10.0, 3.0 Hz, 1H, H-16), 5.30 (dd, 
J = 10.9, 3.3 Hz, 1H, H-2), 5.21–5.13 (m, 1H, NH-17, H-
3), 4.84 (d, J = 3.7 Hz, 1H, H-1), 4.45–4.35 (m, 2H, H-6), 4.35–4.17 (m, 2H, H-5, H-14), 3.80 (dd, 
J = 10.9, 3.0 Hz, 1H, H-13a), 3.53–3.42 (m, 1H, H-13b), 2.10 (s, 3H, H-Ac), 1.99 (s, 3H, H-Ac), 
1.97 (s, 3H, H-Ac), 1.51 (s, 9H, H-20), 1.32−17 (m, 25H, H-alkyl), 0.87 (dp, J = 5.7, 3.1 Hz, 6H, H-
alkyl) ppm.  
13C NMR (100 MHz, acetone-d6): δ = 170.8 (C-Ac), 170.3 (C-Ac), 170.2 (C-Ac), 166.3 (C-21), 
165.2 (C-22), 155.3 (C-Bz), 133.6 (C-Bz), 133.1 (C-Bz), 130.1 (C-Bz), 129.9 (C-Bz), 129.8 (C-Bz), 
129.6 (C-Bz), 128.7 (C-Bz), 128.5 (C-Bz), 125.7 (C-Bz), 97.5 (C-1), 81.3 (d, J = 171.8 Hz, C-6), 80.5 
(C-16), 77.4 (C-15), 77.2 (C-4), 76.8 (C-13), 72.1 (C-2), 68.0 (C-3), 67.45 (d, J = 22.8 Hz, C-5), 50.9 
(C-14), 34.3 (C-alkyl), 32.1 (C-alkyl), 30.5 (C-alkyl), 29.8−29.4 (C-alkyl), 28.5 (C-alkyl), 28.4 (C-alkyl), 
25.9 (C-alkyl), 22.8 (C-alkyl), 22.5 (C-alkyl), 20.8 (C-Ac), 20.7 (C-Ac), 20.7 (C-Ac), 15.4 (C-alkyl), 
14.3 (C-alkyl), 14.2 (C-alkyl) ppm. 
19F NMR (377 MHz, acetone-d6) δ = −231.07 (td, J = 46.4, 14.2 Hz, F-6). 
IR (ATR): ṽ = 3369 (bw), 2925 (s), 2854 (m), 1750 (s), 1717 (s), 1602 (w), 1507 (w), 1452 (m), 1369 
(m), 1315 (w), 1279 (s), 1248 (s), 1226 (s), 1173 (m), 1096 (m), 1069 (s), 1026 (m), 951 (w), 712 
(m) cm‒1. 
HRMS (ESI): calcd. for C49H74O14N2F+: 933.5119 [M+NH4]+ 
 found: 933.5149 [M+NH4]+. 
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(2S ,3R ,4S ,5R ,6S)-2-(((2S ,3S ,4R)-3,4-Bis(benzoyloxy)-2-(3-(4-((E)-(4-pentylphenyl)diaze-
nyl)phenyl)-propanamido)octadecyl)oxy)-6-(fluoromethyl)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (II.49) 
 
Acetylated glycoside II.30 (22.0 mg, 23.0 µmol, 1.0 eq.) was dissolved in DCM (1 mL) and the 
mixture was cooled to 0 °C. Then TFA (1 mL) was added and after 2 h, the solvent was removed 
under reduced pressure. The crude product was dissolved in DCM (1.3 mL), and FAAzo-1 
(11.2 mg, 34.5 µmol, 1.5 eq.) followed by HBTU (13.1 mg, 34.5 µmol, 1.5 eq.) and N-
methylmorpholine (38.0 µL, 34.5 µmol, 1.5 eq.) were added at room temperature. After 12 h the 
solvent was removed under reduced pressure and the crude product was purified via flash column 
chromatography [PE/EtOAc, 100:0 to 1:1] to give protected glycosphingolipid II.49 (18.3 mg, 
16.3 µmol, 71% over 2 steps) as a yellow viscous oil. 
Rf = 0.63 [PE/EtOAc, 2:1]. 
1H NMR (800 MHz, CD3OD ): δ = 8.08–8.04 (m, 4H), 8.03–8.00 (m, 2H), 7.99–7.97 (m, 2H), 7.90 
– 7.88 (m, 2H), 7.62 (tt, J = 7.4, 1.3 Hz, 1H), 7.55 (tt, J = 7.4, 1.3 Hz, 1H), 7.51–7.48 (m, 2H), 7.42–
7.39 (m, 2H), 7.35–7.33 (m, 2H), 5.77 (dd, J = 8.9, 3.1 Hz, 1H), 5.50–5.44 (m, 2H), 5.33 (dd, 
J = 10.9, 3.4 Hz, 1H), 5.16 (dd, J = 10.9, 3.7 Hz, 1H), 4.95 (d, J = 3.7 Hz, 1H), 4.87 (tt, J = 9.1, 
3.4 Hz, 1H), 4.40–4.22 (m, 3H), 3.90 (dd, J = 11.4, 3.5 Hz, 1H), 3.73 (dd, J = 11.4, 3.4 Hz, 1H), 
2.70 (t, J = 7.8 Hz, 2H), 2.10 (s, 3H), 1.99 (s, 3H), 1.98–1.94 (m, 1H), 1.93 (s, 3H), 1.70–1.64 (m, 
2H), 1.40–1.12 (m, 21H), 0.88 (dt, J = 20.3, 7.1 Hz, 6H) ppm. 
13C NMR (200 MHz, CD3OD): δ = 170.7, 170.2, 166.7, 166.5, 165.5, 154.9, 151.1, 147.5, 135.2, 
133.7, 133.3, 130.0, 129.9, 129.4, 129.3, 128.8, 128.6, 128.4, 123.3, 123.2, 97.9, 81.4 (d, 
J = 172.1 Hz),  77.2, 74.1, 72.7, 68.4, 68.1, 68.2, 67.9 (d, J = 22.3 Hz), 67.5, 67.5, 49.5, 36.1, 32.1, 
32.0, 31.4, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.4, 29.3, 28.7, 25.6, 22.8, 20.8, 20.7, 20.7, 14.3, 
1.3 ppm. 
19F NMR (377 MHz, CD3OD) δ = –231.07 (td, J = 46.5, 14.2 Hz). 
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IR (ATR): ṽ = 2926 (s), 2854 (m), 1752 (s), 1726 (s), 1666 (m), 1602 (w), 1531 (w),1492 (w), 1452 
(m), 1372 (m), 1316 (w), 1254 (s), 1227 (s), 1177 (w), 1153 /w), 1108 (w), 1070 (s), 1027 (m), 948 
(w), 861 (w), 712 (m) cm‒1. 
HRMS (ESI): calcd. for C64H88FN4O13+: 1139.6326 [M+NH4]+ 
 found: 1139.6350 [M+HH4]+. 
 
 
N-((2S ,3S ,4R)-1-(((2S ,3R ,4S ,5R ,6S)-6-(Fluoromethyl)-3,4,5-trihydroxytetrahydro-2H-
pyran-2-yl)oxy)-3,4-dihydroxyoctadecan-2-yl)-3-(4-((E)-(4-pentylphenyl)diazenyl)phenyl)-
propanamide (α-6F-GACe-1, II.33) 
 
Protected glycosphingolipid II.49 (18.3 mg, 16.5 µmol, 1.0 eq.) was dissolved in MeOH (1 mL) and 
NaOMe was added at room temperature until pH 9−10. After 12 h, it was stopped by the addition 
of DOWEX 50WX 2-100 (H+ form) and stirred for another 30 min. at room temperature. All solid 
material was removed by filtration through a pad of Celite®, which was washed with MeOH (5 mL) 
and the filtrate was concentrated under reduced pressure. Flash column chromatography 
[DCM/MeOH, 9:1] afforded 6F-α-GACe-1 (II.33, 12.5 mg, 15.8 µmol, 96%) as a yellow viscous 
oil.  
Rf = 0.50 [DCM/MeOH, 10:1].  
1H NMR (800 MHz, CD3OD): δ = 8.02–8.00 (m, 2H), 7.98–7.96 (m, 2H), 7.90–7.87 (m, 2H), 
7.40−7.38 (m, 2H), 4.96 (d, J = 3.6 Hz, 1H), 4.59–4.44 (m, 3H), 4.11 (dtd, J = 12.8, 6.1, 5.4, 2.7 Hz, 
1H), 4.03 (dd, J = 10.8, 4.3 Hz, 1H), 3.67 (ddd, J = 9.9, 5.7, 2.4 Hz, 1H), 3.35–3.33 (m, 2H), 3.29 (p, 
J = 1.7 Hz, 1H), 2.75–2.70 (m, 2H), 1.73–1.66 (m, 3H), 1.58–1.51 (m, 1H), 1.51–1.43 (m, 1H), 
1.41–1.18 (m, 33H), 0.91 (t, J = 7.1 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H) ppm. 
13C NMR (200 MHz, CD3OD): δ = 169.1, 155.8, 152.3, 148.8, 137.6, 130.4, 129.6, 124.2, 123.6, 
101.2, 83.9 (d, J = 167.0 Hz), 75.0, 72.8, 71.1, 71.0 (d, J = 22.1 Hz), 70.5, 70.5, 70.1, 68.2, 52.9, 36.9, 
33.1, 33.0, 32.7, 32.5, 30.9–30.7, 30.6, 30.5, 30.4, 30.3, 26.7, 23.8, 23.7, 14.5, 14.4 ppm. 
19F NMR (377 MHz, CD3OD) δ = –231.33–(–231.69) (m).  
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IR (ATR): ṽ = 3284 (bw), 2924 (s), 2853 (s), 2362 (w), 2168 (m), 1734 (w), 1635 (m), 1540 (m), 
1458 (m), 1025 (s), 859 (m), 727 (m), 668 (m) cm‒1. 
HRMS (ESI): calcd. for C44H71N3O8F+: 788.5220 [M+H]+ 
 found: 788.5244 [M+H]+. 
 
 
(2S ,3R ,4S ,5R ,6S)-2-(((2S ,3S ,4R)-3,4-bis(Benzoyloxy)-2-(4-(4-((E)-(4-butylphenyl)diaze-
nyl)phenyl)-butanamido)octadecyl)oxy)-6-(fluoromethyl)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (II.31) 
 
Acetylated glycoside II.30 (15.0 mg, 16.4 µmol, 1.0 eq.) was dissolved in DCM (0.5 mL) and cooled 
to 0 °C. Then TFA (0.5 mL) was added and the reaction mixture was stirred at 0 °C and after 2 h 
the solvent was removed under reduced pressure. The crude product was dissolved in DCM (1 mL) 
and FAAzo-4 (7.97 mg, 24.6 µmol, 1.5 eq.) followed by HBTU (9.33 mg, 24.6 µmol, 1.5 eq.) and 
N-methylmorpholine (27.0 µL, 246 µmol, 15 eq.) was added and the reaction stirred at room 
temperature. After 12 h the solvent was removed under reduced pressure and the crude product 
was purified via flash column chromatography [PE/EtOAc, 100:0 to 1:1] to give protected 
glycosphingolipid II.31 (16.4 mg, 14.6 µmol, 89% over 2 steps) as yellow viscous oil. 
Rf = 0.53 [PE/EtOAc, 2:1]. 
1H NMR (600 MHz, CDCl3): δ = 8.00 (dd, J = 8.4, 1.3 Hz, 2H), 7.96–7.92 (m, 2H), 7.86–7.80 (m, 
4H), 7.60 (ddt, J = 8.7, 7.2, 1.3 Hz, 1H), 7.53 (ddt, J = 8.8, 7.1, 1.3 Hz, 1H), 7.49–7.44 (m, 2H), 
7.41–7.35 (m, 4H), 7.33–7.29 (m, 2H), 6.40 (d, J = 9.5 Hz, 1H), 5.65 (dd, J = 9.2, 2.8 Hz, 1H), 5.45 
(dd, J = 3.4, 1.3 Hz, 1H), 5.37–5.29 (m, 2H), 5.15 (dd, J = 10.9, 3.7 Hz, 1H), 4.86 (d, J = 3.7 Hz, 
1H), 4.64 (ddt, J = 9.5, 6.3, 3.0 Hz, 1H), 4.40–4.23 (m, 2H), 4.22–4.16 (m, 1H), 3.76 (dd, J = 11.2, 
3.1 Hz, 1H), 3.60 (dd, J = 11.2, 3.1 Hz, 1H), 2.83–2.77 (m, 2H), 2.72–2.66 (m, 2H), 2.39 (t, 
J = 7.5 Hz, 2H), 2.09 (s, 4H), 1.99 (s, 3H), 1.93 (s, 3H), 1.69–1.60 (m, 2H), 1.39 (dtt, J = 14.7, 9.3, 
5.4 Hz, 3H), 1.34–1.16 (m, 30H), 0.94 (t, J = 7.4 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (201 MHz, CDCl3): δ = 172.5, 170.7, 170.2, 170.2, 166.6, 165.3, 151.4, 151.1, 146.4, 
144.8, 133.7, 133.2, 130.1, 130.0, 129.8, 129.5, 129.3, 129.2, 128.8, 128.5, 126.7, 123.0, 122.9, 97.8, 
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81.5 (d, J = 171.9 Hz), 74.1, 72.2, 68.3, 68.1, 68.0, 67.8 (d, J = 22.3 Hz), 67.6, 67.3, 48.6, 36.1, 35.7, 
35.3, 33.6, 32.1, 29.8, 29.8, 29.8, 29.7, 29.7, 29.5, 28.4, 27.1, 25.8, 22.8, 22.5, 20.8, 20.7, 14.3, 
14.1 ppm. 
19F NMR (377 MHz, CHCl3) δ = –230.43 (td, J = 46.5, 14.7 Hz). 
IR (ATR): ṽ = 3370 (w), 2925 (s), 2854 (m), 1726 (s), 1751 (s), 1679 (m), 1602 (w), 1529, 1452, 
1372, 1315, 1279 (s), 1249 (s), 1226 (s), 1177 (w), 1156 (), 1109 (m), 1096 (m), 1070 (s), 1026 (w), 
951 (w), 845 (w), 712 (m) cm‒1. 
HRMS (ESI): calcd. for C64H85FN3O13+: 1122.6061 [M+H]+ 
 found: 1122.6100 [M+H]+. 
 
 
4-(4-((E)-(4-Butylphenyl)diazenyl)phenyl)-N-((2S,3S,4R)-1-(((2S ,3R ,4S ,5R ,6S)-6-(fluoro-
methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxyoctadecan-2-
yl)butanamide (α-6F-GACe-4, II.32) 
 
Protected glycosphingolipid II.31 (16.4 mg, 14.6 µmol, 1.0 eq.) was dissolved in MeOH (1 mL) and 
NaOMe was added until pH 9−10. The reaction mixture was stirred at room temperature and after 
12 h, it was stopped by the addition of DOWEX 50WX 2-100 (H+ form) and stirred for another 
30 min. at room temperature. All solid material was removed by filtration through a pad of Celite®, 
which was washed with MeOH (5 mL), and the filtrate was concentrated under reduced pressure. 
Flash column chromatography [CHCl3/MeOH, 9:1] afforded α-6F-GACe-4 II.32 (10.3 mg, 
13.1 µmol, 90%) as yellow viscous oil. 
Rf = 0.47 [DCM/MeOH, 10:1].  
1H NMR (800 MHz, CD3OD): δ = 7.84–7.81 (m, 4H), 7.40–7.34 (m, 4H), 4.60–4.44 (m, 2H), 4.21 
(dt, J = 6.8, 4.2 Hz, 1H), 4.09 (dddd, J = 14.8, 6.2, 4.8, 1.2 Hz, 1H), 3.90–3.84 (m, 2H), 3.82–3.76 
(m, 2H), 3.74–3.69 (m, 1H), 3.65 (dd, J = 6.8, 5.6 Hz, 1H), 3.57 (ddd, J = 10.0, 5.7, 2.4 Hz, 1H), 
3.34 (dq, J = 4.5, 1.6 Hz, 1H), 2.73 (dt, J = 19.6, 7.8 Hz, 4H), 2.34–2.27 (m, 2H), 2.02–1.96 (m, 
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2H), 1.71–1.60 (m, 4H), 1.47–1.36 (m, 3H), 1.36–1.18 (m, 17H), 0.97 (t, J = 7.4 Hz, 3H), 0.89 (t, 
J = 7.2 Hz, 3H) ppm.  
 13C NMR (200 MHz, CD3OD): δ = 175.2, 152.5, 152.3, 147.8, 146.6, 131.2, 130.3, 130.2, 128.7, 
123.9, 123.8, 101.0, 84.0 (d, J = 167.2 Hz), 75.1, 70.9 (d, J = 21.6 Hz), 70.6, 70.5, 70.1, 68.3, 51.8, 
36.6, 36.5, 36.2, 34.8, 33.1, 32.7, 30.9, 30.8, 30.8, 30.5, 28.7, 27.1, 23.7, 23.4, 14.5, 14.3 ppm.  
19F NMR (377 MHz, CD3OD) δ = –231.30 (td, J = 47.4, 14.9 Hz).  
IR (ATR): ṽ = 3302 (bw), 2922 (s), 2852 (s), 2362 (w), 2168 (m), 2138 (w), 1647 (m), 1601 (w), 
1545 (m), 1476 (m), 1379 (m), 1260 (w), 1156 (m), 1076 (s), 1028 (s), 840 (m), 798 (m), 727 (m), 716 
(w), 668 (w) cm‒1. 
HRMS (ESI): calcd. for C44H71N3O8F+: 788.5220 [M+H]+ 
 found: 788.5244 [M+H]+. 
 
 
 (2S ,3R ,4S ,5R ,6S)-2-(((2S ,3S ,4R)-3,4-Bis(benzoyloxy)-2-(4-(4-((E)-(4-butyl-2,6-dichloro-
phenyl)diazenyl)-3,5-dichlorophenyl)butanamido)octadecyl)oxy)-6-(fluoromethyl)tetra-
hydro-2H-pyran-3,4,5-triyl triacetate (II.50) 
 
Acetylated glycoside II.30 (19.0 mg, 19.9 µmol, 1.0 eq.) was dissolved in DCM (1.0 mL) and the 
mixture was cooled to 0 °C Then TFA (1.0 mL) was added and the reaction was stirred for 2 h at 
this temperature. Afterwards the solvent was removed under reduced pressure and the crude 
product was immediately dissolved in DCM (1.3 mL). FAAzo-4-Cl (13.7 mg, 29.8 µmol, 1.5 eq.) 
followed by HBTU (11.3 mg, 29.8 mmol, 1.5 eq.) and N-methylmorpholine (32.0 µL, 1.5 mmol, 
15 eq.) were added and the reaction stirred at room temperature. After 12 h the solvent was 
removed under reduced pressure and the crude product was purified via flash column 
chromatography [PE/EtOAc, 10:1→1:1] to give protected glycosphingolipid II.50 (19.2 mg, 
15.2 µmol, 76% over 2 steps) as yellow viscous oil. 
Compound II.50 was isolated as a 2.2:1 mixture of trans-/cis-isomers. 
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
II.50
1) TFA, DCM, 0 °C, 2 h
2) FAAzo-4-Cl, HBTU, NMM
    DCM, r.t., 12 h
(76% over 2 steps)
O
AcO
AcO
AcO
F
O
C14H29
NHBoc
OBz
OBz
II.30
O
N
N
C4H9Cl
Cl
Cl
Cl
EXPERIMENTAL 
213  
Rf = 0.50 [PE/EtOAc, 2:1].  
1H NMR (800 MHz, CDCl3): δ = 8.01 (ddd, J = 8.4, 5.1, 1.4 Hz, 2H), 7.95 (ddd, J = 10.0, 8.4, 
1.4 Hz, 2H), 7.63–7.59 (m, 1H), 7.56–7.52 (m, 1H), 7.49–7.46 (m, 2H), 7.41–7.37 (m, 2H), 7.34 (s, 
1H), 6.45–6.40 (m, 1H), 5.62 (ddd, J = 11.3, 9.0, 2.9 Hz, 1H), 5.45 (ddd, J = 8.2, 3.4, 1.3 Hz, 1H), 
5.32 (dddt, J = 17.9, 10.5, 7.0, 3.3 Hz, 2H), 5.15 (ddd, J = 11.0, 7.3, 3.7 Hz, 1H), 4.87 (dd, J = 6.2, 
3.7 Hz, 1H), 4.66–4.59 (m, 1H), 4.39–4.33 (m, 1H), 4.33–4.26 (m, 1H), 4.26–4.19 (m, 1H), 3.76 
(ddd, J = 17.8, 11.2, 3.1 Hz, 1H), 3.65 (ddd, J = 10.7, 7.2, 3.3 Hz, 1H), 2.74 (dt, J = 8.6, 6.3 Hz, 
1H), 2.66–2.59 (m, 2H), 2.56–2.51 (m, 1H), 2.39 (t, J = 7.3 Hz, 2H), 2.36 (t, J = 7.4 Hz, 1H), 2.10 
(s, 3H), 2.10 (s, 3H), 1.99 (s, 3H), 1.93 (s, 2H), 1.92 (s, 1H), 1.65–1.60 (m, 1H), 1.60–1.54 (m, 1H), 
1.39 (dt, J = 15.0, 7.4 Hz, 1H), 1.36–1.30 (m, 1H), 1.28–1.16 (m, 25H), 0.94 (dt, J = 25.7, 7.4 Hz, 
3H), 0.87 (td, J = 7.2, 5.2 Hz, 3H) ppm. 
13C NMR (201 MHz, CDCl3): δ = 172.2, 170.7, 170.2, 166.6, 165.3, 146.4, 146.1, 145.8, 145.7, 
145.5, 145.3, 144.3, 143.9, 133.7, 133.3, 130.0, 130.0, 129.9, 129.6, 129.5, 129.4, 129.2, 129.1, 128.8, 
128.5, 127.5, 127.5, 97.9, 81.5 (d, J = 171.7 Hz), 77.2, 74.1, 72.4, 72.3, 68.4, 68.0, 67.9 (d, 
J = 22.3 Hz), 67.6, 67.4, 48.7, 35.8, 35.0, 34.8, 34.6, 34.4, 33.1, 32.9, 32.1, 30.5, 29.8, 29.8, 29.8, 29.7, 
29.7, 29.5, 28.5, 26.4, 25.8, 22.8, 22.3, 20.8, 20.7, 14.3, 14.0 ppm. 
19F NMR (377 MHz, CDCl3) δ = –230.25 (td, J = 46.2, 14.3 Hz). 
IR (ATR): ṽ = 2926 (s), 2854 (m), 1751 (m), 1726 (m), 1679 (w), 1588 (w), 1530 (w), 1452 (w), 1372 
(w), 1315 (w), 1250 (s), 1227 (s), 1177 (w), 1155 (w), 1070 (s), 1026 (m), 953 (w), 807 (w), 712 
(m) cm‒1. 
HRMS (ESI): calcd. for C64H84Cl4FN4O13+: 1275.4768 [M+NH4]+ 
 found: 1275.4798 [M+NH4]+. 
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4-(4-((E)-(4-Butyl-2,6-dichlorophenyl)diazenyl)-3,5-dichlorophenyl)-N-((2S ,3S ,4R)-1-(((2S , 
3R ,4S ,5R ,6S)-6-(fluoromethyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-3,4-
dihydroxyoctadecan-2-yl)butanamide (α-6F-GRACe-4, II.34) 
 
Protected glycosphingolipid II.50 (17.3 mg, 15.2 µmol, 1.0 eq.) was dissolved in MeOH (1 mL) and 
NaOMe was added at room temperature until pH 9−10. After 12 h, the reaction was stopped by 
the addition of DOWEX 50WX 2-100 (H+ form) and stirred for another 30 min. at room 
temperature. All solid material was removed by filtration through a pad of Celite®, which was 
washed with MeOH (20 mL) and the filtrate was concentrated under reduced pressure. Flash 
column chromatography [CHCl3/MeOH, 9:1] afforded α-6F-GRACe-4 (II.34, 11.4 mg, 12.3 µmol, 
81%) as yellow viscous oil. 
Compound II.34 was isolated as a 2.2:1 mixture of trans-/cis-isomers. 
Rf = 0.45 [DCM/MeOH, 10:1]. 
1H NMR (800 MHz, CD3OD): δ = 7.45 (s, 1H), 7.41 (d, J = 0.7 Hz, 1H), 4.63–4.47 (m, 2H), 4.23 
(tt, J = 6.8, 4.3 Hz, 1H), 4.16–4.08 (m, 1H), 3.94–3.86 (m, 2H), 3.85–3.77 (m, 2H), 3.72 (ddd, 
J = 15.7, 10.5, 4.6 Hz, 1H), 3.66 (dd, J = 6.8, 5.7 Hz, 1H), 3.57 (dddd, J = 18.2, 9.9, 5.8, 2.4 Hz, 
1H), 2.72 (dt, J = 15.7, 7.4 Hz, 2H), 2.62 (dt, J = 11.8, 7.8 Hz, 1H), 2.32 (ddd, J = 10.3, 6.6, 2.9 Hz, 
1H), 2.00 (dtd, J = 15.2, 8.5, 7.9, 4.1 Hz, 1H), 1.97–1.88 (m, 1H), 1.72–1.52 (m, 2H), 1.47–1.39 (m, 
2H), 1.39–1.22 (m, 26H), 0.98 (dt, J = 35.1, 7.4 Hz, 2H), 0.94–0.88 (m, 3H) ppm.   
13C NMR (200 MHz, CD3OD): δ = 174.9, 174.9, 147.7, 147.5, 147.3, 147.1, 146.8, 146.5, 146.5, 
146.4, 130.7, 130.6, 130.4, 130.4, 128.3, 128.3, 126.8, 126.7, 101.0, 84.4, 84.4, 83.6, 83.6, 75.2, 75.1, 
72.9, 71.1, 71.0, 70.9, 70.6, 70.5, 70.1, 68.3, 51.9, 51.8, 49.0, 36.3, 36.2, 35.8, 35.5, 35.4, 35.2, 34.3, 
34.1, 33.1, 32.9, 32.8, 30.9, 30.8, 30.5, 28.2, 28.0, 27.0, 23.8, 23.3, 23.2, 14.5, 14.2 ppm. 
19F NMR (377 MHz, CD3OD) δ = –231.18 (td, J = 48.3, 47.7, 15.3 Hz). 
IR (ATR): ṽ = 3308 (bm), 2922 (s), 2852 (s), 1643 (m), 1591 (m), 1549 (m), 1466 (m), 1401 (m), 
1379 (m), 1347 (m), 1260 (m), 1207 (m), 1153 (m), 1079 (s), 1028 (s), 1004 (s), 979 (s), 858 (m), 802 
(m), 726 (m), 692 (m) cm‒1. 
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HRMS (ESI): calcd. for C44H65N3O8F-: 922.3515 [M−H]- 
 found: 922.3531 [M−H]-. 
 
 
4-(4-((E)-(4-Butylphenyl)diazenyl)phenyl)-N-((2S ,3S ,4R)-1,3,4-trihydroxyoctadecan-2-
yl)butanamide (PACe-1, II.35) 
 
Phytosphingosine II.18 (4.3 mg, 14 µmol, 1.0 eq.) was dissolved in DCM (1 mL) and FAAzo-4 
(4.4 mg, 14 µmol, 1 eq.) followed by HBTU (7.7 mg, 21 µmol, 1.5 eq.) and N-methylmorpholine 
(22 µL, 0.20 mmol, 15 eq.) were added and the reaction stirred at room temperature. After 12 h the 
solvent was removed under reduced pressure and the crude product was purified via flash column 
chromatography [DCM/MeOH, 10:0 to 10:1] to give PACe-1 II.35 (8.3 mg, 13 µmol, 93%) as 
yellow viscous oil. 
Rf = 0.82 [DCM/MeOH, 10:1]. 
1H NMR (400 MHz, CDCl3): δ = 7.82 (d, J = 8.1 Hz, 4H, H-26 and H-29), 7.31 (d, J = 8.1 Hz, 
4H, H-25 and H-30), 6.39 (d, J = 7.6 Hz, 1H, H-19), 4.14 (td, J = 5.4, 2.9 Hz, 1H, H-2), 3.90 (dd, 
J = 11.5, 2.7 Hz, 1H, H-1a), 3.71 (dd, J = 11.6, 5.5 Hz, 1H, H-1b), 3.61 (dt, J = 8.8, 4.8 Hz, 1H, H-
4), 3.55 (dd, J = 6.8, 3.1 Hz, 1H, H-3), 2.73 (t, J = 7.4 Hz, 2H, H-23), 2.68 (t, J = 7.7 Hz, 2H, H-
32), 2.26 (t, J = 7.4 Hz, 2H, H-21), 2.02 (p, J = 7.5 Hz, 2H, H-22), 1.69 – 1.59 (m, 2H, H-33), 1.37 
(dt, J = 14.8, 7.5 Hz, 2H, H-34), 1.24 (s, 24H, H6−17), 0.94 (t, J = 7.4 Hz, 3H, H-35), 0.87 (t, 
J = 7.1 Hz, 3H, H-18) ppm.    
13C NMR (100 MHz, CDCl3): δ = 173.8 (C-20), 151.3 
(C-27 or C-28), 150.9 (C-27 or C-28), 146.4 (C-31), 144.4 
(C-24), 129.2 (C-25), 129.1 (C-30), 122.8 (C-26 and C-
29), 76.6 (C-3), 72.6 (C-4), 61.8 (C-1), 53.1 (C-2), 35.6 (C-
21 and C-32), 35.0 (C-23), 33.5 (C-33), 33.3 − 29.4 (C-
6 − C-17), 26.8 (C-22), 25.6 (C-5), 22.7 (C-6 − C-17), 22.3 (C-34), 14.1 (C-18), 13.9 (C-35) ppm. 
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IR (ATR): ṽ = 3295 (bm), 2956 (m), 1919 (s), 2851 (s), 1636 (m), 1603 (w), 1542 (w), 1498 (w), 
1468 (m), 1481 (w), 1378 (w), 1156 (w), 1068 (w), 840 (w), 721 (w) cm‒1. 
HRMS (ESI): calcd. for C38H62N3O4+: 624.4735 [M+H]+ 
 found: 624.4738 [M+H]+. 
 
 
(2R ,3S ,4S ,5R ,6R)-2-(Acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (II.39) 
 
β-D-Galactose pentaacetate (II.38, 1.00 g, 2.56 mmol, 1.0 eq.) was dissolved in DMF (25 mL), 
hydrazine acetate (295 mg, 3.20 mmol, 1.25 eq.) was added and the reaction was heated to 50 °C. 
After 1 h, the reaction was allowed to cool to room temperature. EtOAc (200 mL) was added and 
the organic phase was washed with H2O (3 × 100 mL), 0.2 M aqueous HCl (100 mL), saturated 
NaHCO3 (100 mL), saturated aqueous NaCl (100 mL) and dried (MgSO4) and concentrated under 
reduced pressure. The crude reaction mixture was dissolved in DCM (20 mL) and cooled to 0 °C. 
CCl3CN (2.9 mL, 25.6 mmol, 10 eq.) was added and after 1 h, DBU (77 µL, 0.512 mmol, 0.2 eq.) 
was added and the reaction stirred for 2 h. Then the solvent was removed under reduced pressure 
and the crude product was purified by flash column chromatography on silica gel [PE/EtOAc, 1:1] 
to give trichloroacetimidate (II.39, 974 mg, 1.98 mmol, 77% over two steps) as white foam.  
1H NMR (400 MHz, CDCl3): δ = 8.67 (s, 1H), 6.60 (d, J = 3.4 Hz, 1H), 5.61–5.54 (m, 1H), 5.45–
5.31 (m, 2H), 4.51–4.40 (m, 1H), 4.17 (dd, J = 11.3, 6.6 Hz, 1H), 4.12–4.05 (m, 1H), 2.17 (s, 3H), 
2.03 (s, 3H), 2.02 (s, 3H), 2.02 (s, 3H) ppm. 
HRMS (ESI): calcd. for C14H24N2O10Cl3 +:        509.0461 [M+H]+ 
found:     509.0499 [M+H]+. 
 
The analytical data matched those previously described in the literature.[402] 
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(2S ,3R ,E)-2-Azidooctadec-4-ene-1,3-diol (II.40) 
   
D-erythro-sphingosine (II.1, 275 mg, 0.920 mmol, 1 eq.), NaHCO3 (312 mg, 3.72 mg, 4 eq.) and 
CuSO4•H2O (8.80 mg, 40.0 µmol, 5 mol%) were dissolved in H2O (1.2 mL). The emulsion was 
cooled to 0 °C and freshly prepared TfN3[403] (2 M in toluene, 2.00 mL, 4.00 mmol, 4.3 eq.) was 
added. MeOH (2 mL) was added and the reaction was slowly allowed to warm to r.t. After 24 h, 
H2O (20 mL) was added and the reaction mixture was extracted with EtOAc (3 × 20 mL), dried 
(MgSO4) and concentrated under reduced pressure. Flash column chromatography 
[PE/EtOAc, 10:1 to 0:1] afforded azidosphingosine (II.40, 263 mg, 0.806 mmol, 88%) as a yellow 
oil. 
Rf = 0.66 [PE/EtOAc, 1:1]. 
[α]D20 = −0.14 (c = 1, DCM). 
1H NMR (400 MHz, CDCl3): δ = 5.86–5.78 (m, 1H, H-5), 5.53 (ddt, 
J = 15.4, 7.4, 1.5 Hz, 1H, H-4), 4.27–4.23 (m, 1H, H-3), 3.78 (dd, 
J = 5.2, 3.9 Hz, 2H, H-1), 3.51 (q, J = 5.4 Hz, 1H, H-2), 2.14–2.00 (m, 
2H, H-6), 1.47–1.32 (m, 2H, H-alkyl), 1.32–1.19 (m, 21H, H-alkyl), 0.88 (t, J = 6.8 Hz, 3H, H-
alkyl) ppm. 
13C NMR (101 MHz, CDCl3): δ = 136.1 (C-5), 127.9 (C-4), 73.8 (C-3), 66.7 (C-2), 62.6 (C-1), 32.3 
(C-6), 31.9 (C-alkyl), 29.7 − 29.2 (C-alkyl), 28.9 (C-7), 14.1 (C-alkyl) ppm. 
IR (ATR): ṽ = 3351 (w), 2919 (s), 2851 (s), 2100 (m), 1669 (w), 1467 (m), 1379 (m), 1266 (m), 1235 
(m), 1195 (m), 1154 (m), 1003 (m), 971 (m), 704 (w) cm-1. 
HRMS (EI): calcd. for C18H34O2N3−:  324.2657 [M−H]− 
found:    324.2658 [M−H]−. 
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(2S ,3R ,E)-2-Azido-1-(trityloxy)octadec-4-en-3-ol (II.41) 
   
Azide II.40 (263 mg, 0.806 mmol, 1eq.) was dissolved in pyridine (3 mL) and TrCl (274 mg, 
0.887 mmol, 1.1 eq.) followed by DMAP (4.92 mg, 40.3 µmol, 0.05 eq.) were added. The mixture 
was stirred at 50 °C for 12 h. Afterwards, the solvent was removed under reduced pressure. The 
crude product was purified by flash column chromatography on silica gel [PE/EtOAc, 10:1 to 3:1] 
to give protected alcohol II.41 (437 mg, 0.771 mmol, 95%) as a colorless oil. 
Rf = 0.65 [PE/EtOAc, 7:1].  
[α]D20 = 0.01 (c = 1, DCM). 
1H NMR (400 MHz, CD3CN): δ = 7.37–7.32 (m, 6H, H-Ar), 
7.21 (q, J = 6.8, 6.1 Hz, 6H, H-Ar), 7.16 (t, J = 7.1 Hz, 3H, H-
Ar), 5.46 (dt, J = 14.3, 6.8 Hz, 1H, H-5), 5.22 (dd, J = 15.5, 
7.1 Hz, 1H, H-4), 3.97 (t, J = 6.2 Hz, 1H, H-3), 3.49 (dt, 
J = 8.6, 4.4 Hz, 1H, H-2), 3.14–3.06 (m, 1H, H-1a), 3.01 (dd, J = 9.9, 7.7 Hz, 1H, H-1b), 3.14–3.06 
(m, 2H), 3.01 (dd, J = 9.9, 7.7 Hz, 1H), 1.83 (dq, J = 5.2, 2.6 Hz, 2H, H-6), 1.01−1.21 (d, 
J = 13.9 Hz, 22H, H-alkyl), 0.77 (t, J = 6.6 Hz, 3H, H-alkyl) ppm. 
13C NMR (101 MHz, CD3CN): δ = 144.8 (C-Ar), 134.7 (C-5), 129.9 (C-4), 129.6 (C-Ar), 129.4 (C-
Ar), 128.1 (C-Ar), 87.8 (C-alkyl), 73.0 (C-3), 67.2 (C-2), 64.2 (C-1), 32.7 (C-6), 32.6−29.7 (C-alkyl), 
23.3 (C-alkyl), 14.4 (C-alkyl) ppm.  
IR (ATR): ṽ = 3422 (bw), 3059 (w), 3033 (w), 2924 (s), 2954 (m), 2362 (w), 2098 (m), 1669 (w), 
15098 (w), 1491 (w=, 1448 (m), 1271 (w), 1221 (w), 1184 (w), 1155 (w), 1077 (m), 1033 (w), 1015 
(w), 972 (w), 989 (w), 764 (m), 746 (m), 702 (s) cm-1.  
HRMS (EI): calcd. For C37H48N3O2- : 566.3752 [M−H]−  
found:    : 566.3746 [M−H]−. 
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(2S ,3R ,E)-2-Azido-1-(trityloxy)octadec-4-en-3-yl benzoate (II.42) 
   
To a solution of secondary alcohol II.41 (437 mg, 0.771 mmol, 1 eq.) in pyridine (12 mL) were 
added benzoylchloride (0.187 mL, 1.54 mmol, 2 eq.) and DMAP (4.71 mg, 38.6 µmol, 0.05 eq.). 
The mixture was stirred at room temperature for 12 h. The solvent was removed under reduced 
pressure and flash column chromatography on silica gel [PE/EtOAc, 1:0 to 2:1] afforded protected 
D-erythro-sphingosine II.42 (383 mg, 0.570 mmol, 74%) as a colorless oil. 
Rf = 0.79 [PE/EtOAc, 7:1] 
[α]D = −0.003 (c = 1, DCM). 
1H NMR (400 MHz, CDCl3): δ = 7.91−7.85 (m, 2H, H-Ar), 
7.53−7.45 (m, 1H, H-Ar), 7.39−7.32 (m, 6H, H-Ar), 7.24−7.17 
(m, 6H, H-Ar), 7.17−7.11 (m, 3H, H-Ar), 5.74 (dt, J = 15.4, 
6.7 Hz, 1H, H-5), 5.56 (dd, J = 7.9, 4.8 Hz, 1H, H-3), 5.35 
(ddt, J = 15.4, 7.9, 1.5 Hz, 1H, H-4), 3.79 (dt, J = 6.8, 5.0 Hz, 
1H, H-2), 3.22 (dd, J = 9.8, 6.8 Hz, 1H, H-1a), 3.12 (dd, J = 9.8, 5.2 Hz, 1H, H-1b), 1.89 (qt, 
J = 7.0, 1.7 Hz, 2H, H-6), 1.29–1.06 (m, 22H, H-alkyl), 0.86–0.74 (m, 3H, H-alkyl) ppm. 
13C NMR (101 MHz, CDCl3): δ = 165.3 (C-8), 143.6 (C-5), 138.5 (C-Ar), 133.2 (C-Ar), 129.9 (C-
Ar), 129.8 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.2 (C-Ar), 128.0 (C-Ar), 127.3 (C-Ar), 123.2 (C-4), 
87.3 (C-7), 74.9 (C-3), 64.6 (C-2), 63.0 (C-1), 32.4 (C-alkyl), 32.1 (C-alkyl), 29.9-29.3 (C-alkyl), 28.8 
(C-alkyl), 22.9 (C-alkyl), 14.3 (C-alkyl) ppm.  
IR (ATR): ṽ = 2924 (m), 2853 (m), 2098 (m), 1723 (m), 1602 (w), 1491 (w), 1466 (w), 1450 (m), 
1315 (w), 1263 (s), 1177 (w), 1154 (w), 1092 (m), 1069 (m), 1026 (m), 970 (m), 899 (w), 774 (w), 764 
(m), 741 (m), 703 (s) cm-1.  
HRMS (ESI): calcd. for C44H57N4O3+   689.4425 [M+NH4+] 
found:    689.4442 [M+NH4+]. 
 
 
BzCl, DMAP
py, r.t., 12 h
N3
OH
TrO C13H27
N3
OBz
TrO C13H27
(74%)
II.41 II.42
32
4
5 61
N3
O
O
II.42
7
O8
EXPERIMENTAL 
 
 220 
(2S ,3R ,E)-2-Azido-1-hydroxyoctadec-4-en-3-yl benzoate (II.43) 
   
To a solution of protected D-erythro-sphingosine (II.42, 72.6 mg, 0.108 mmol, 1 eq.) in DCM 
(1 mL) and MeOH (1 mL) was added p-toluenesulforic acid hydrate (20.5 mg, 0.108 mmol, 1.0 eq.). 
The mixture was removed under reduced pressure and the crude product was purified by flash 
column chromatography [PE/EtOAc, 10:1 to 3:1] to give primary alcohol (II.43, 27.6 mg, 
85.1 µmol, 79%) as a colorless oil. 
Rf = 0.66 [PE/EtOAc, 4:1].   
[α]D20 = −0.38 (c = 1, DCM). 
1H NMR (400 MHz, CDCl3): δ = 8.06 (d, J = 7.7 Hz, 2H, H-Ar), 7.59 
(t, J = 7.4 Hz, 1H, H-Ar), 7.46 (t, J = 7.6 Hz, 2H, H-Ar), 5.96 (ddd, 
J = 13.8, 8.7, 4.3 Hz, 1H, H-5), 5.68–5.57 (m, 2H, H-4 and H-3), 3.85–
3.70 (m, 2H, H-2 and H-1a), 3.63 (dd, J = 11.6, 7.0 Hz, 1H, H-1b), 2.08 
(q, J = 7.1 Hz, 2H, H-6), 1.57 (bs, 1H, OH), 1.39 (t, J = 7.2 Hz, 2H, H-
alkyl), 1.24 (d, J = 3.7 Hz, 16H, H-alkyl), 0.88 (t, J = 6.7 Hz, 3H, H-alkyl) ppm.  
13C NMR (101 MHz, CDCl3): δ = 165.5 (C-7), 138.7 (C-Ar), 133.4 (C-Ar), 129.8 (C-5), 129.7 (C-
Ar), 128.5 (C-Ar), 123.2 (C-4), 74.6 (C-3), 66.2 (C-2), 62.0 (C-1), 32.4 (C-6), 31.9−28.7 (C-alkyl), 
22.7 (C-alkyl), 14.1 (C-alkyl) ppm.  
IR (ATR): ṽ = 3428 (bw), 2923 (s), 2853 (s), 2168 (w), 2101 (s), 1722 (s), 1602 (w), 1452 (m), 1316 
(m), 1265 (s), 1177 (m), 1110 (s), 1068 (s), 1026 (m), 970 (m), 860 (w), 710 (s), 686 (m) cm-1.  
HRMS (EI): calcd. for C25H43N4O3- 447.3330 [M+NH4+] 
found:    447.3336 [M+NH4+] 
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(2R ,3S ,4S ,5R ,6R)-2-(Acetoxymethyl)-6-(((2S ,3R ,E)-2-azido-3-(benzoyloxy)octadec-4-en-1-
yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (II.44) 
   
Galactosyl donor II.39 (225 mg, 0.456 mmol, 2.3 eq.) and acceptor II.43 (100 mg, 0.198 mmol, 
1.0 eq.) were combined and co-evaporated with toluene (3 × 5 mL) and with THF (1 × 5 mL), 
dried under high vacuum and then dissolved in DCM (0.8 mL). The mixture was stirred with 
freshly activated 4Å MS at room temperature for 30 min, before the reaction vessel was cooled to 
0 °C and TESOTf (0.8 M in DCM, 31.7 µL, 39.6 µmol, 0.2 eq.) were added. After 10 min. the 
reaction was allowed to warm to room temperature and after an additional 30 min. the reaction was 
diluted with DCM and washed with saturated aqueous NaHCO3 solution (10 mL). The aqeous 
layer was extracted with DCM (3 × 20 mL) and the combined organic phases were dried (MgSO4) 
and concentrated under reduced pressure. Flash column chromatography (PE/EtOAc, 100:0 to 
2:1) afforded protected glycoside (II.44, 139 mg, 0.182 mmol, 92%) as a colorless oil. 
Rf = 0.50 [PE/EtOAc, 2:1]. 
[α]D20 = −0.13 (c = 1, DCM) 
1H NMR (600 MHz, CDCl3): δ = 8.08–8.02 (m, 2H, H-
Bz), 7.57 (t, J = 7.4 Hz, 1H, H-Bz), 7.45 (t, J = 7.6 Hz, 
2H, H-Bz), 5.93 (dt, J = 13.6, 6.7 Hz, 1H, H-11), 5.63–
5.51 (m, 2H, H-3, H-10), 5.38 (d, J = 3.4 Hz, 1H, H-4), 
5.23 (dd, J = 10.5, 7.9 Hz, 1H, H-2), 5.01 (dd, J = 10.4, 
3.5 Hz, 1H, H-3), 4.49 (d, J = 8.0 Hz, 1H, H-1), 4.17–
4.04 (m, 2H, H-6), 3.92 (m, 3H, H-5, H-7a, H-8), 3.58 (dd, J = 9.1, 4.8 Hz, 1H, H-7b), 2.15 (s, 3H, 
H-Ac), 2.10 (s, 3H, H-Ac), 2.09–2.03 (m, 3H, H-alkyl), 2.02 (s, 3H, H-Ac), 1.98 (s, 4H, H-Ac, H-
alkyl), 1.37 (q, J = 7.0 Hz, 2H, H-alkyl), 1.24 (d, J = 4.7 Hz, 23H, H-alkyl), 0.87 (t, J = 6.7 Hz, 3H, 
H-alkyl).  
13C NMR (101 MHz, CDCl3): δ = 170.3 (C-Ac), 170.2 (C-Ac), 170.14 (C-Ac), 169.3 (C-Ac), 165.1 
(C-13), 139.1 (C-10), 133.2 (C-Bz), 129.9 (C-Bz), 129.7 (C-Bz), 128.4 (C-Bz), 122.62 (C-11), 101.0 
(C-1), 74.7 (C-9), 70.8 (C-3 and C-5), 68.5 (C-2), 68.0 (C-7), 66.9 (C-4), 63.5 (C-8), 61.1 (C-6), 32.4 
(C-alkyl), 31.9−29.1 (C-alkyl), 28.7 (C-alkyl), 22.7 (C-Ac), 20.7 (C-Ac), 20.7 (C-Ac), 20.6 (C-Ac), 
14.1 (C-alkyl) ppm. 
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IR (ATR): ṽ = 3428 (w), 3353 (w), 3296 (w), 1926 (m), 2854 (m), 2108 (m), 1726 (s), 1726 (s), 1601 
(w), 1452 (w), 1370 (m), 1317 (w), 1252 (s), 1224 (s), 1176 (w), 1070 (m), 1026 (w), 973 (w), 957 (w), 
916 (w), 827 (m), 713 (m) cm-1.  
HRMS (EI): calcd. for C39H61N4O12+:  777.4280 [M+NH4]+ 
found:     777.4297 [M+NH4]+. 
 
 
4-(4-((E)-(4-Butylphenyl)diazenyl)phenyl)-N-((2S ,3R ,E)-3-hydroxy-1-(((2R ,3R ,4S ,5R ,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octadec-4-en-2-
yl)butanamide (II.45) 
   
Glycoside II.44 (23.9 mg, 31.5 µmol, 1 eq.) and FAAzo-4 (15.3 mg, 47.2 µmol, 1.5 eq.) were 
dissolved in DCM (1 mL). Bu3P (11.6 µL, 47.2 µmol, 1.5 eq.) was added and the reaction stirred for 
6 h at room temperature. Then EDCI (22.0 mg, 142 µmol, 3 eq.) was added and the reaction 
mixture stirred at room temperature for another 12 h. The solvent was removed under reduced 
pressure and purification via flash column chromatography [PE/EtOAc, 10:1 to 0:1] afforded 
amide II.45 (14.8 mg, 14.2 µmol, 45%) as a yellow oil. 
Rf = 0.60 [PE/EtOAc, 1:2]. 
1H NMR (600 MHz, CDCl3): δ = 8.05−8.01 (m, 2H, H-Bz), 7.83−7.80 (m, 4H, H-Ar), 7.58−7.53 
(m, 1H, H-Bz), 7.46−7.42 (m, 2H, H-Bz), 7.33−7.29 (m, 4H, H-Ar), 5.89 (dtd, J = 15.2, 6.7, 0.8 Hz, 
1H, H-11), 5.78 (d, J = 9.1 Hz, 1H, NH-14), 5.59−5.54 (m, 1H, H-9), 5.50 (ddt, J = 15.3, 7.6, 
1.5 Hz, 1H, H-10), 5.35 (dd, J = 3.4, 1.2 Hz, 1H, H-4), 5.15 (dd, J = 10.5, 7.8 Hz, 1H, H-2), 4.99 
(dd, J = 10.5, 3.4 Hz, 1H, H-3), 4.54−4.48 
(m, 1H, H-8), 4.44 (d, J = 7.9 Hz, 1H, H-
1), 4.07−4.00 (m, 2H, H-6a and H-7a), 
3.96 (dd, J = 11.3, 6.3 Hz, 1H, H-H-6b), 
3.85 (ddd, J = 7.4, 6.4, 1.3 Hz, 1H, H-5), 
3.68 (dd, J = 10.1, 4.3 Hz, 1H, H-7b), 
II.44
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2.78−2.71 (m, 2H, H-alkyl), 2.71−2.65 (m, 3H, H-Ac), 2.10−2.13 (m, 3H, H-12), 2.07−1.99 (m, 4H, 
H-alkyl), 1.97 (s, 2H, H-Ac), 1.96 (s, 3H, H-Ac), 1.94 (s, 3H, H-Ac), 1.68–1.61 (m, 2H, H-alkyl), 
1.38 (h, J = 7.4 Hz, 3H, H-alkyl), 1.35–1.17 (m, 27H, H-alkyl), 0.94 (t, J = 7.4 Hz, 3H, H-alkyl), 
0.87 (t, J = 7.1 Hz, 3H, H-alkyl) ppm. 
13C NMR (151 MHz, CDCl3): δ = 172.3 (C-15), 170.4 (C-Ac), 170.3 (C-Ac), 170.2 (C-Ac), 169.7 
(C-Ac), 165.4 (C-13), 151.4 (C-Ar), 151.1 (C-Ar), 146.5 (C-Ar), 144.8 (C-Ar), 137.7 (C-11), 133.2 
(C-Bz), 129.8 (C-Bz), 129.3 (C-Ar), 129.2 (C-Ar), 128.6 (C-Bz), 124.8 (C-Ar), 123.0 (C-Ar), 122.9 
(C-Ar), 101.1 (C-1), 74.5 (C-9), 70.9 (C-3 and C-5), 70.8 (C-2), 69.0 (C-7), 67.3 (C-4), 67.0 (C-6), 
61.2 (C-8), 51.0 (C-16), 36.0 (C-alkyl), 35.7 (C-alkyl), 35.2 (C-alkyl), 33.6 (C-alkyl), 32.5 (C-alkyl), 
32.1 (C-alkyl), 29.8 (C-alkyl), 29.6 (C-alkyl), 29.5 (C-alkyl), 29.4 (C-alkyl), 29.1 (C-alkyl), 27.1 (C-12), 
22.8 (C-alkyl), 22.5 (C-alkyl), 20.9 (C-Ac), 20.8 (C-Ac), 20.7 (C-Ac), 14.3 (C-alkyl), 14.1 (C-
alkyl) ppm.  
IR (ATR): ṽ = 2926 (m), 2854 (w), 1753 (s), 1672 (w), 1602 (w), 1531 (w), 1452 (w), 1369 (m), 1224 
(s), 1176 (w), 1071 (m), 968 (w), 846 (w), 714 (m) cm-1.  
HRMS (ESI): calcd. for C59H82N3O13+:  1040.5842 [M+H]+ 
found:     1040.5880 [M+H]+. 
 
 
(2R ,3S ,4S ,5R ,6R)-2-(Acetoxymethyl)-6-(((2S ,3R ,E)-3-(benzoyloxy)-2-(4-(4-((E)-(4-butyl-
phenyl)di-azenyl)phenyl)butanamido)octadec-4-en-1-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (β-GACe-4 , II.36)  
 
Protected glycosphingolipid (II.45, 13.6 mg, 13.1 µmol, 1.0 eq.) was dissolved in MeOH (1.5 mL) 
and NaOMe was added until pH 9−10. The reaction mixture was stirred at room temperature for 
12 h. The reaction was stopped by the addition of DOWEX 50WX 2-100 (H+ form) and stirred for 
another 30 min. at room temperature. All solid material was removed by filtration through a pad of 
Celite®, which was washed with MeOH (5 mL) and the filtrate was concentrated under reduced 
pressure. Flash column chromatography [CHCl3/MeOH, 10:1] afforded β-GACe-4 (II.36, 7.4 mg, 
9.63 µmol, 74%) as yellow viscous oil. 
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Rf = 0.34 [DCM: MeOH 10:1]  
 1H NMR (800 MHz, CD3OD): δ = 7.85–7.80 (m, 4H), 7.42–7.33 (m, 4H), 5.69 (dtd, J = 15.3, 6.7, 
0.9 Hz, 1H), 5.46 (ddt, J = 15.3, 7.8, 1.5 Hz, 1H), 4.23 (d, J = 7.7 Hz, 1H), 4.18 (dd, J = 10.1, 4.9 
Hz, 1H), 4.10 (t, J = 8.1 Hz, 1H), 4.01 (ddd, J = 8.3, 4.9, 3.3 Hz, 1H), 3.83 (dd, J = 3.4, 1.1 Hz, 1H), 
3.77 (dd, J = 11.4, 7.0 Hz, 1H), 3.72 (dd, J = 11.4, 5.2 Hz, 1H), 3.63 (dd, J = 10.2, 3.3 Hz, 1H), 
3.59–3.55 (m, 1H), 3.55–3.51 (m, 1H), 3.48 (dd, J = 9.7, 3.4 Hz, 1H), 2.76–2.68 (m, 4H), 2.26 (t, 
J = 7.5 Hz, 2H), 2.02–1.93 (m, 4H), 1.71–1.64 (m, 2H), 1.41 (dt, J = 15.0, 7.4 Hz, 2H), 1.35–1.16 
(m, 33H), 0.97 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H) ppm. 
13C NMR (101 MHz, CDCl3): δ = 175.5, 152.5, 152.3, 147.8, 146.7, 135.2, 131.3, 130.3, 130.2, 
123.9, 123.8, 105.4 (C-1), 76.8, 74.9, 73.1, 72.7, 70.3, 70.0, 62.6, 54.9, 49.0, 36.8, 36.5, 36.2, 34.8, 
33.4, 33.1, 30.8, 30.8, 30.7, 30.5, 30.4, 30.4, 28.8, 23.8, 23.4, 14.5, 14.3 ppm.  
IR (ATR): ṽ = 3288 (bm), 2924 (s), 2852 (m), 2168 (m), 1745 (m), 1558 (w), 1465 (m), 1003 (s), 727 
(m) cm-1.  
HRMS (EI): calcd. for C44H70N3O8+:  768.5167 [M+H]+ 
found:    768.5157 [M+H]+. 
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9  Appendix 
9.1 Single-crystal X-ray analysis 
All single-crystal X-ray analyses were carried out by Dr. Peter Mayer in the analytic department. 
The data collections were performed on an Oxford Diffraction Xcalibur, Bruker D8Quest or 
Bruker D8Venture diffractometer and MoKα-radiation (λ = 0.71073 Å, graphite monochromator). 
The CrysAlisPro software was applied for the integration, scaling and multi-scan absorption 
correction of the data. The structures were solved by direct methods with SIR97 and refined by 
least-squares methods against F2 with SHELXL-97. All non-hydrogen atoms were refined 
anisotropically. The hydrogen atoms were placed in ideal geometry riding on their parent atoms. 
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Single-crystal X-ray analysis of compound I.224 
 
 
 
net formula C17H22O6 
Mr/g mol−1 322.353 
crystal size/mm 0.131 × 0.084 × 0.027 
T/K 100(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system monoclinic 
space group P21/n 
a/Å 16.8852(14) 
b/Å 12.1795(11) 
c/Å 18.4136(13) 
APPENDIX 
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α/° 90 
β/° 116.451(2) 
γ/° 90 
V/Å3 3390.4(5) 
Z 8 
calc. density/g cm−3 1.26307(19) 
μ/mm−1 0.095 
absorption correction multi-scan 
transmission factor range 0.8543–0.9579 
refls. measured 19953 
Rint 0.0742 
mean σ(I)/I 0.0743 
θ range 2.98–25.04 
observed refls. 3640 
x, y (weighting scheme) 0.0593, 0 
hydrogen refinement mixed 
refls in refinement 5976 
parameters 431 
restraints 0 
R(Fobs) 0.0468 
Rw(F2) 0.1195 
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Single-crystal X-ray analysis of compound I.219 
 
 
net formula  C12H14O3 
Mr/g mol−1  206.23 
crystal size/mm  0.100 × 0.040 × 0.030 
T/K  100(2) 
radiation  MoKα 
diffractometer  'Bruker D8Venture' 
crystal system  monoclinic 
space group  'C c' 
a/Å  4.2298(2) 
b/Å  19.7579(11) 
c/Å  12.2515(6) 
α/°  90 
β/°  97.8156(18) 
γ/°  90 
V/Å3  1014.37(9) 
Z  4 
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calc. density/g cm−3  1.350 
μ/mm−1  0.096 
absorption correction  multi-scan 
transmission factor range  0.8529–0.9585 
refls. measured  6169 
Rint  0.0331 
mean σ(I)/I  0.0308 
θ range  3.940–26.38 
observed refls.  1631 
x, y (weighting scheme)  0.0465, 0.2317 
hydrogen refinement  constr 
refls in refinement  0.1(15) 
parameters  1775 
restraints  139 
R(Fobs)  2 
Rw(F2)  0.0332 
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Single-crystal X-ray analysis of compound I.226. 
 
 
 
 
net formula  C14H15NO3 
Mr/g mol−1  245.274 
crystal size/mm  0.388 × 0.284 × 0.270 
T/K  200(2) 
radiation  'MoKα 
diffractometer  'Bruker D8Quest' 
crystal system  monoclinic 
space group  P21/c 
a/Å  7.2350(2) 
b/Å  11.4719(4) 
c/Å  14.8725(5) 
α/°  90 
β/°  95.298(2) 
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γ/°  90 
V/Å3  1229.13(7) 
Z  4 
calc. density/g cm−3  1.32547(8) 
μ/mm−1  0.094 
absorption correction  ‘multi-scan’ 
transmission factor range  0.8791–0.9144 
refls. measured  19144 
Rint  0.0330 
mean σ(I)/I  0.0212 
θ range  2.75–27.60 
observed refls.  2335 
x, y (weighting scheme)  0.0512, 0.3930 
hydrogen refinement  constr 
refls in refinement  2823 
parameters  165 
restraints  0 
R(Fobs)  0.0438 
Rw(F2)  0.1140 
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Single-crystal X-ray analysis of compound I.227 (racemic). 
 
 
 
 
net formula C17H19NO3 
Mr/g mol−1 285.338 
crystal size/mm 0.17 × 0.14 × 0.12 
T/K 123(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group P212121 
a/Å 7.6671(6) 
b/Å 8.3382(6) 
c/Å 23.4368(18) 
α/° 90 
β/° 90 
γ/° 90 
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V/Å3 1498.3(2) 
Z 4 
calc. density/g cm−3 1.26496(17) 
μ/mm−1 0.087 
absorption correction multi-scan 
transmission factor range 0.9276–0.9585 
refls. measured 17807 
Rint 0.0274 
mean σ(I)/I 0.0202 
θ range 3.17–26.43 
observed refls. 2776 
x, y (weighting scheme) 0.0408, 0.3090 
hydrogen refinement constr 
Flack parameter −0.1(10) 
refls in refinement 3051 
parameters 192 
restraints 0 
R(Fobs) 0.0326 
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Single-crystal X-ray analysis of compound (R)-I.227. 
 
 
net formula C17H19NO3 
Mr/g mol−1 285.33 
crystal size/mm 0.10 × 0.10 × 0.09 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 7.6599(2) 
b/Å 8.3420(2) 
c/Å 23.4353(7) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1497.49(7) 
Z 4 
calc. density/g cm−3 1.266 
μ/mm−1 0.087 
absorption correction Multi-Scan 
transmission factor range 0.8862–0.9634 
refls. measured 49074 
Rint 0.0477 
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mean σ(I)/I 0.0350 
θ range 3.177–36.36 
observed refls. 6781 
x, y (weighting scheme) 0.0488, 0.2654 
hydrogen refinement constr 
Flack parameter −0.1(2) 
refls in refinement 7261 
parameters 192 
restraints 0 
R(Fobs) 0.0425 
 
C3: R 
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Single-crystal X-ray analysis of compound (S)-I.227 
 
 
net formula C17H19NO3 
Mr/g mol−1 285.33 
crystal size/mm 0.100 × 0.100 × 0.090 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 7.6610(2) 
b/Å 8.3423(2) 
c/Å 23.4440(5) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1498.31(6) 
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Z 4 
calc. density/g cm−3 1.265 
μ/mm−1 0.087 
absorption correction Multi-Scan 
transmission factor range 0.9091–0.9666 
refls. measured 66705 
Rint 0.0391 
mean σ(I)/I 0.0270 
θ range 2.997–42.15 
observed refls. 6833 
x, y (weighting scheme) 0.0540, 0.2317 
hydrogen refinement constr 
Flack parameter −0.09(19)  
refls in refinement 7261 
parameters 192 
restraints 0 
R(Fobs) 0.0388 
 
C3: S 
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Single-crystal X-ray analysis of compound I.218. 
 
 
 
net formula C19H21NO5 
Mr/g mol−1 343.374 
crystal size/mm 0.483 × 0.451 × 0.356 
T/K 123(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1 
a/Å 7.6302(6) 
b/Å 8.8519(6) 
c/Å 12.7508(9) 
α/° 87.503(6) 
β/° 87.653(6) 
γ/° 87.251(6) 
V/Å3 858.75(11) 
Z 2 
calc. density/g cm−3 1.32796(17) 
μ/mm−1 0.096 
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absorption correction 'multi-scan' 
transmission factor range 0.97201–1.00000 
refls. measured 4728 
Rint 0.0155 
mean σ(I)/I 0.0340 
θ range 4.57–26.37 
observed refls. 2838 
x, y (weighting scheme) 0.0420, 0.2630 
hydrogen refinement constr 
refls in refinement 3462 
parameters 229 
restraints 0 
R(Fobs) 0.0397 
Rw(F2) 0.1023 
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Single-crystal X-ray analysis of compound I.251. 
 
 
 
net formula C19H23NO5 
Mr/g mol−1 345.38 
crystal size/mm 0.100 × 0.090 × 0.010 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system monoclinic 
space group 'P 21/c' 
a/Å 16.1951(7) 
b/Å 8.3508(4) 
c/Å 13.1442(6) 
α/° 90 
β/° 102.4370(10) 
γ/° 90 
V/Å3 1735.93(14) 
Z 4 
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calc. density/g cm−3 1.322 
μ/mm−1 0.096 
absorption correction multi-scan 
transmission factor range 0.8970–0.9579 
refls. measured 19934 
Rint 0.0461 
mean σ(I)/I 0.0266 
θ range 3.041–25.04 
observed refls. 2472 
x, y (weighting scheme) 0.0407, 0.7699 
hydrogen refinement constr 
refls in refinement 3072 
parameters 229 
restraints 0 
R(Fobs) 0.0353 
Rw(F2) 0.0909 
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Single-crystal X-ray analysis of compound I.254. 
 
 
net formula C19H22O6 
Mr/g mol−1 346.374 
crystal size/mm 0.182 × 0.095 × 0.054 
T/K 173(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system monoclinic 
space group P21/c 
a/Å 8.9536(5) 
b/Å 13.8303(7) 
c/Å 13.3248(6) 
α/° 90 
β/° 94.6825(16) 
γ/° 90 
V/Å3 1644.52(14) 
Z 4 
calc. density/g cm−3 1.39901(12) 
μ/mm−1 0.104 
absorption correction multi-scan 
transmission factor range 0.9257–0.9585 
refls. measured 32974 
Rint 0.0386 
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mean σ(I)/I 0.0186 
θ range 3.21–26.42 
observed refls. 2795 
x, y (weighting scheme) 0.0414, 0.9448 
hydrogen refinement constr 
refls in refinement 3350 
parameters 229 
restraints 0 
R(Fobs) 0.0378 
Rw(F2) 0.0984 
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Single-crystal X-ray analysis of compound I.260.  
 
 
 
net formula C19H23NO5 
C19H23NO5 345.38 
Mr/g mol−1 0.100 × 0.080 × 0.040 
345.38 100(2) 
crystal size/mm MoKα 
0.100 × 0.080 × 0.040 'Bruker D8Venture' 
T/K monoclinic 
100(2) 'C 2' 
radiation 25.0443(7) 
MoKα 6.8179(2) 
diffractometer 10.1504(3) 
'Bruker D8Venture' 90 
crystal system 96.3846(9) 
monoclinic 90 
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space group 1722.43(9) 
'C 2' 4 
a/Å 1.332 
25.0443(7) 0.096 
b/Å multi-scan 
6.8179(2) 0.9095–0.9585 
c/Å 16167 
10.1504(3) 0.0317 
α/° 0.0257 
90 3.098–26.43 
β/° 3359 
96.3846(9) 0.0438, 0.6259 
γ/° mixed 
90 0.2(3) 
V/Å3 3536 
1722.43(9) 233 
Z 1 
4 0.0325 
calc. density/g cm−3 0.0785 
1.332 1.057 
μ/mm−1 0.001 
0.096 0.183 
 
C-H: constr 
N-H: refall 
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Single-crystal X-ray analysis of compound I.261. 
 
 
net formula C19H23NO5 
Mr/g mol−1 345.390 
crystal size/mm 0.110 × 0.070 × 0.050 
T/K 100(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system monoclinic 
space group P21/c 
a/Å 7.6612(4) 
b/Å 20.3093(9) 
c/Å 10.7852(5) 
α/° 90 
β/° 90.6667(15) 
γ/° 90 
V/Å3 1677.99(14) 
Z 4 
calc. density/g cm−3 1.36721(11) 
μ/mm−1 0.099 
absorption correction multi-scan 
transmission factor range 0.9061–0.9585 
refls. measured 19936 
Rint 0.0377 
mean σ(I)/I 0.0301 
θ range 3.33–26.42 
observed refls. 2669 
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x, y (weighting scheme) 0.0396, 0.8950 
hydrogen refinement mixed 
refls in refinement 3432 
parameters 233 
restraints 0 
R(Fobs) 0.0419 
Rw(F2) 0.1013 
S 1.053 
1.062 0.001 
shift/errormax 0.358 
0.001 −0.190 
 
C-H: constr, N-H: refall. 
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Single-crystal X-ray analysis of compound I.259. 
 
Table 9.1 Crystallographic data for lactam I.259. 
net formula C19H22O6 
Mr/g mol−1 359.416 
crystal size/mm 0.294 × 0.153 × 0.092 
T/K 173(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Quest’ 
crystal system orthorhombic 
space group Pbca 
a/Å 11.5962(5) 
b/Å 14.1871(7) 
c/Å 21.2925(9) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 3503.0(3) 
Z 8 
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calc. density/g cm−3 1.36302(12) 
μ/mm−1 0.098 
absorption correction multi-scan 
transmission factor range 0.9079–0.9580 
refls. measured 61699 
Rint 0.0583 
mean σ(I)/I 0.0202 
θ range 2.46–25.41 
observed refls. 2628 
x, y (weighting scheme) 0.0469, 2.1055 
hydrogen refinement constr 
refls in refinement 3203 
parameters 239 
restraints 0 
R(Fobs) 0.0425 
Rw(F2) 0.1077 
S S 
1.062 1.062 
shift/errormax shift/errormax 
0.001 0.001 
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Single-crystal X-ray analysis of compound I.267. 
 
 
net formula C22H29NO5 
C20H23NO5 387.46 
Mr/g mol−1 0.100 × 0.070 × 0.040 
357.39 123.(2) 
crystal size/mm MoKα 
0.100 × 0.040 × 0.030 'Bruker D8 Venture TXS' 
T/K monoclinic 
100.(2) 'P 1 21 1' 
radiation 9.7651(2) 
'Mo Kα 19.5668(5) 
diffractometer 11.8470(3) 
'Bruker D8 Venture TXS' 90 
crystal system 92.1790(10) 
orthorhombic 90 
space group 2261.99(9) 
'P 21 21 21' 4 
a/Å 1.138 
10.8766(6) 0.080 
b/Å Multi-Scan 
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14.6810(9) 0.9358–0.9705 
c/Å 9220 
21.6036(13) 0.0362 
α/° 0.0344 
90 3.374–26.372 
β/° 8053 
90 0.0728, 1.1613 
γ/° H(C) constr, H(N) refall 
90 −0.4(3) 
V/Å3 9220 
3449.6(4) 523 
Z 1 
8 0.0493 
calc. density/g cm−3 0.1458 
1.376 1.087 
μ/mm−1 0.001 
0.099 0.313 
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Single-crystal X-ray analysis of compound I.280. 
 
Table 9.2 Crystallographic data for styrene I.280. 
net formula C20H23NO5 
Mr/g mol−1 357.39 
crystal size/mm 0.100 × 0.040 × 0.030 
T/K 100.(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 10.8766(6) 
b/Å 14.6810(9) 
c/Å 21.6036(13) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 3449.6(4) 
Z 8 
calc. density/g cm−3 1.376 
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μ/mm−1 0.099 
absorption correction Multi-Scan 
transmission factor range 0.89–1.00 
refls. measured 60717 
Rint 0.0886 
mean σ(I)/I 0.0434 
θ range 1.68–25.41 
observed refls. 5493 
x, y (weighting scheme) 0.0750, 7.4803 
hydrogen refinement constr 
Flack parameter 0.500000 
refls in refinement 6329 
parameters 477 
restraints 0 
R(Fobs) 0.0787 
Rw(F2) 0.1963 
S 1.106 
shift/errormax 0.001 
max electron density/e Å−3 0.536 
 
Structure refined as a racemic twin. 
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Single-crystal X-ray analysis of compound I.281. 
 
 
 
net formula C18H19NO4 
Mr/g mol−1 313.348 
crystal size/mm 0.348 ◊ 0.319 ◊ 0.131 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system orthorhombic 
space group 'P n a 21' 
a/Å 8.0956(3) 
b/Å 17.2610(8) 
c/Å 11.5189(5) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1609.63(12) 
Z 4 
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calc. density/g cm−3 1.29305(10) 
μ/mm−1 0.092 
absorption correction 'multi-scan' 
transmission factor range 0.95975–1.00000 
refls. measured 7591 
Rint 0.0305 
mean σ(I)/I 0.0395 
θ range 4.254–25.341 
observed refls. 2437 
x, y (weighting scheme) 0.0336, 0.0140 
hydrogen refinement constr 
refls in refinement 0.3(14) 
parameters 2873 
restraints 211 
R(Fobs) 1 
Rw(F2) 0.0361 
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Single-crystal X-ray Analysis of compounds I.294 and I.295 
 
Figure III.1 Crystal structure of major component I.294. 
 
Figure III.2 Crystal structure of minor component I.295. 
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net formula C19H25NO4 
Mr/g mol−1 331.40 
crystal size/mm 0.100 × 0.070 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorhombic 
space group 'P b c a' 
a/Å 11.022(3) 
b/Å 14.897(4) 
c/Å 20.167(5) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 3311.3(14) 
Z 8 
calc. density/g cm−3 1.330 
μ/mm−1 0.093 
absorption correction Multi-Scan 
transmission factor range 0.8998–0.9457 
refls. measured 53585 
Rint 0.0641 
mean σ(I)/I 0.0254 
θ range 3.401–27.102 
observed refls. 3155 
x, y (weighting scheme) 0.0610, 2.2953 
hydrogen refinement C-H: constr, O-H: noref 
refls in refinement 3621 
parameters 234 
restraints 0 
R(Fobs) 0.0481 
Rw(F2) 0.1303 
S 1.065 
shift/errormax 0.001 
max electron density/e Å−3 0.337 
min electron density/e Å−3 −0.286 
 
Structure disordered, major product 82%, minor product 18%. 
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Single-crystal X-ray analysis of compound I.308. 
 
 
net formula C21H27Cl2NO5 
Mr/g mol−1 444.33 
crystal size/mm 0.090 × 0.060 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 8.3263(5) 
b/Å 11.3620(7) 
c/Å 12.3017(6) 
α/° 69.648(2) 
β/° 83.394(2) 
γ/° 70.160(2) 
V/Å3 1026.36(10) 
Z 2 
calc. density/g cm−3 1.438 
μ/mm−1 0.350 
absorption correction Multi-Scan 
transmission factor range 0.7750–0.9705 
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refls. measured 12197 
Rint 0.0419 
mean σ(I)/I 0.0483 
θ range 3.442–26.372 
observed refls. 3604 
x, y (weighting scheme) 0.0358, 0.7268 
hydrogen refinement H(C) constr, H(O) refall 
refls in refinement 4170 
parameters 269 
restraints 0 
R(Fobs) 0.0403 
Rw(F2) 0.1053 
S 1.035 
shift/errormax 0.001 
max electron density/e Å−3 0.391 
min electron density/e Å−3 −0.447 
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Single-crystal X-ray analysis of compound I.290. 
 
 
net formula C20H23NO5 
Mr/g mol−1 357.39 
crystal size/mm 0.100 × 0.090 × 0.070 
T/K 298.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 7.9677(2) 
b/Å 9.2454(2) 
c/Å 11.7448(3) 
α/° 83.4692(8) 
β/° 88.5722(9) 
γ/° 80.9664(9) 
V/Å3 848.88(4) 
Z 2 
calc. density/g cm−3 1.398 
μ/mm−1 0.100 
absorption correction Multi-Scan 
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transmission factor range 0.9304–0.9590 
refls. measured 16616 
Rint 0.0285 
mean σ(I)/I 0.0301 
θ range 3.112–27.485 
observed refls. 3287 
x, y (weighting scheme) 0.0585, 0.3339 
hydrogen refinement constr 
refls in refinement 3871 
parameters 238 
restraints 0 
R(Fobs) 0.0485 
Rw(F2) 0.1355 
S 1.070 
shift/errormax 0.001 
max electron density/e Å−3 0.232 
min electron density/e Å−3 −0.218 
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Single-crystal X-ray analysis of compound I.313. 
 
 
net formula C27H30N2O6 
Mr/g mol−1 478.53 
crystal size/mm 0.100 × 0.100 × 0.030 
T/K 298.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 13.4422(4) 
b/Å 11.6532(4) 
c/Å 15.2777(5) 
α/° 90 
β/° 99.7940(10) 
γ/° 90 
V/Å3 2358.29(13) 
Z 4 
calc. density/g cm−3 1.348 
μ/mm−1 0.096 
absorption correction Multi-Scan 
transmission factor range 0.9101–0.9590 
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refls. measured 45381 
Rint 0.0405 
mean σ(I)/I 0.0259 
θ range 3.076–27.494 
observed refls. 4408 
x, y (weighting scheme) 0.0640, 1.3189 
hydrogen refinement mixed 
Flack parameter 5391 
refls in refinement 323 
parameters 0 
restraints 0.0575 
R(Fobs) 0.1627 
Rw(F2) 1.072 
S 0.001 
shift/errormax 0.375 
max electron density/e Å−3 −0.187 
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Single-crystal X-ray analysis of compound I.329. 
 
 
net formula C20H22N2O5 
Mr/g mol−1 370.39 
crystal size/mm 0.090 × 0.060 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorhombic 
space group 'P b c a' 
a/Å 8.246(5) 
b/Å 18.285(11) 
c/Å 22.344(15) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 3369.(4) 
Z 8 
calc. density/g cm−3 1.461 
μ/mm−1 0.106 
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absorption correction Multi-Scan 
transmission factor range 0.9167–0.9590 
refls. measured 4372 
Rint 0.0000 
mean σ(I)/I 0.0439 
θ range 3.648–27.483 
observed refls. 3702 
x, y (weighting scheme) 0.0396, 5.2315 
hydrogen refinement C-H: constr, N-H: refall 
refls in refinement 4372 
parameters 252 
restraints 0 
R(Fobs) 0.0614 
Rw(F2) 0.1544 
S 1.098 
shift/errormax 0.001 
max electron density/e Å−3 0.427 
min electron density/e Å−3 −0.285 
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Single-crystal X-ray analysis of compound I.355. 
 
 
net formula C24H32N2O8 
Mr/g mol−1 476.51 
crystal size/mm 0.100 × 0.060 × 0.040 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 10.0419(7) 
b/Å 18.4401(10) 
c/Å 12.5503(7) 
α/° 90 
β/° 93.409(2) 
γ/° 90 
V/Å3 2319.9(2) 
Z 4 
calc. density/g cm−3 1.364 
μ/mm−1 0.103 
absorption correction Multi-Scan 
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transmission factor range 0.9250–0.9705 
refls. measured 20766 
Rint 0.0399 
mean σ(I)/I 0.0339 
θ range 3.252–26.372 
observed refls. 4076 
x, y (weighting scheme) 0.0397, 1.4833 
hydrogen refinement H(C) const, H(N/O) refall 
refls in refinement 4735 
parameters 325 
restraints 0 
R(Fobs) 0.0402 
Rw(F2) 0.1021 
S 1.052 
shift/errormax 0.001 
max electron density/e Å−3 0.360 
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9.2 NMR spectra of chapter I 
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1H NMR (CDCl3, 400 MHz):
OMe
MeO
OH
I.221
C9H12O3
M = 168.19 g/mol
13C NMR (CDCl3, 101 MHz):
OMe
MeO
OH
I.221
C9H12O3
M = 168.19 g/mol
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13C NMR (CDCl3, 101 MHz):
OMe
MeO
Cl
I.359
C9H11ClO2
M = 186.64 g/mol
1H NMR (CDCl3, 400 MHz):
OMe
MeO
Cl
I.359
C9H11ClO2
M = 186.64 g/mol
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OMe
MeO
CN
I.222
C10H11NO2
M = 177.20 g/mol
1H NMR (CDCl3, 400 MHz):
OMe
MeO
CN
I.222
C10H11NO2
M = 177.20 g/mol
13C NMR (CDCl3, 101 MHz):
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OMe
MeO
COOH
I.223
C10H12O4
M = 196.20 g/mol
13C NMR (CDCl3, 101 MHz):
OMe
MeO
COOH
1H NMR (CDCl3, 400 MHz):
I.223
C10H12O4
M = 196.20 g/mol
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HOOC
OMe
MeO
COOt-Bu
I.224
C17H22O6
M = 322.36 g/mol
1H NMR (CDCl3, 300 MHz):
HOOC
OMe
MeO
I.224
C17H22O6
M = 322.36 g/mol
COOt-Bu
13C NMR (CDCl3, 75 MHz):
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MeOOC
OMe
MeO
COOt-Bu
I.225
C18H26O6
M = 338.40 g/mol
1H NMR (CDCl3, 300 MHz):
13C NMR (CDCl3, 75 MHz):
MeOOC
OMe
MeO
COOt-Bu
I.225
C18H26O6
M = 338.40 g/mol
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OMe
MeO
I.219
C12H14O3
M = 206.24 g/mol
O
13C NMR (CDCl3, 75 MHz):
OMe
MeO
O
I.219
C12H14O3
M = 206.24 g/mol
1H NMR (CDCl3, 300 MHz):
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1H NMR (CDCl3, 300 MHz):
MeO
OMe
O
NC
I.226
C14H15NO3
M = 245.28 g/mol
13C NMR (CDCl3, 100 MHz):
MeO
OMe
O
NC
I.226
C14H15NO3
M = 245.28 g/mol
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1H NMR (CDCl3, 400 MHz):
MeO
OMe
O
NC
O O
I.228
C18H19NO5
M = 329.35 g/mol
13C NMR (CDCl3, 101 MHz):
MeO
OMe
O
NC
O O
I.228
C18H19NO5
M = 329.35 g/mol
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OMe
MeO
O
NC
1H NMR (CDCl3, 400 MHz):
I.227
C17H19NO3
M = 285.34 g/mol
13C NMR (CDCl3, 101 MHz):
OMe
MeO
O
NC
I.227
C17H19NO3
M = 285.34 g/mol
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MeO
OMe
O
O O
I.242
C15H18O3
M = 246.31 g/mol
1H NMR (CDCl3, 400 MHz):
MeO
OMe
O
O O
I.242
C15H18O3
M = 246.31 g/mol
13C NMR (CDCl3, 101 MHz):
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OMe
MeO
O
1H NMR (CDCl3, 400 MHz):
I.243
C15H18O3
M = 246.31 g/mol
13C NMR (CDCl3, 101 MHz):
OMe
MeO
O
I.243
C15H18O3
M = 246.31 g/mol
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OMe
MeO
O
NC
O
OMe
1H NMR (CDCl3, 600 MHz):
I.218
C19H21NO5
M = 343.38 g/mol
13C NMR (CDCl3, 150 MHz):
OMe
MeO
O
NC
O
OMe
I.218
C19H21NO5
M = 343.38 g/mol
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O
OMe
MeO
O
H
O OMe
1H NMR (CDCl3, 400 MHz):
I.254
C19H22O6
M = 346.38 g/mol
13C NMR (CDCl3, 101 MHz):
O
OMe
MeO
O
H
O OMe
I.254
C19H22O6
M = 346.38 g/mol
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OMe
MeO
O
NC
O
OMe
I.251
C19H23NO5
M = 345.40 g/mol
1H NMR (CDCl3, 400 MHz):
13C NMR (CDCl3, 101 MHz):
OMe
MeO
O
NC
O
OMe
I.251
C19H23NO5
M = 345.40 g/mol
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N
H
OMe
MeO
O
H
O OMe
1H NMR (CDCl3, 400 MHz):
I.260
C19H23NO5
M = 345.40 g/mol
13C NMR (CDCl3, 101 MHz):
N
H
OMe
MeO
O
H
O OMe
I.260
C19H23NO5
M = 345.40 g/mol
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1H NMR (CDCl3, 400 MHz):
I.261
C19H23NO5
M = 345.40 g/mol
N
OMe
MeO
O
H
H
MeO
O
13C NMR (CDCl3, 101 MHz):
I.261
C19H23NO5
M = 345.40 g/mol
N
OMe
MeO
O
H
H
MeO
O
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13C NMR (CDCl3, 101 MHz):
I.265
C22H27NO5
M = 385.46 g/mol
OMe
MeO
O
NC
O
Ot-Bu
I.265
C22H27NO5
M = 385.46 g/mol
OMe
MeO
O
NC
O
Ot-Bu
1H NMR (CDCl3, 400 MHz):
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I.266
C22H29NO5
M = 387.48 g/mol
OMe
MeO
O
NC
O
Ot-Bu
1H NMR (CDCl3, 400 MHz):
13C NMR (CDCl3, 101 MHz):
I.266
C22H29NO5
M = 387.48 g/mol
OMe
MeO
O
NC
O
Ot-Bu
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I.267
C22H29NO5
M = 387.48 g/mol
N
H
OMe
MeO
O
H
O Ot-Bu
1H NMR (CDCl3, 400 MHz):
13C NMR (CDCl3, 101 MHz):
I.267
C22H29NO5
M = 387.48 g/mol
N
H
OMe
MeO
O
H
O Ot-Bu
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N
OMe
MeO
O
H
O OMe
Boc
1H NMR (CDCl3, 400 MHz):
I.269 
C24H31NO7
M = 445.51 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
H
O OMe
Boc
I.269 
C24H31NO7
M = 445.51 g/mol
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N
OMe
MeO
O
H
O OMe
1H NMR (CDCl3, 400 MHz):
I.259
C20H25NO5
M = 359.42 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
H
O OMe
I.259
C20H25NO5
M = 359.42 g/mol
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1H NMR (CDCl3, 400 MHz):
N
OMe
MeO
S
H
O OMe
I.272
C20H25NO4S
M = 375.48 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
S
H
O OMe
I.272
C20H25NO4S
M = 375.48 g/mol
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N
OMe
MeO
H
O OMe
1H NMR (CDCl3, 400 MHz):
I.273
C20H27NO4
M = 345.44 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
H
O OMe
I.273
C20H27NO4
M = 345.44 g/mol
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N
OMe
MeO
O
H
O OMe
1H NMR (CDCl3, 400 MHz):
I.280
C20H23NO5
M = 357.41 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
H
O OMe
I.280
C20H23NO5
M = 357.41 g/mol
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OMe
MeO
O
NC
O
H
1H NMR (CDCl3, 400 MHz):
I.281
C18H19NO4
M = 313.35 g/mol
13C NMR (CDCl3, 101 MHz):
OMe
MeO
O
NC
O
H
I.281
C18H19NO4
M = 313.35 g/mol
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N
H
OMe
MeO
O
H
O H
1H NMR (CDCl3, 400 MHz):
I.284
C18H21NO4
M = 315.37 g/mol
13C NMR (CDCl3, 101 MHz):
N
H
OMe
MeO
O
H
O H
I.284
C18H21NO4
M = 315.37 g/mol
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13C NMR (CDCl3, 101 MHz):
N
H
OMe
MeO
O
O
I.285
C17H19NO4
M = 301.34 g/mol
N
H
OMe
MeO
O
O
1H NMR (CDCl3, 400 MHz):
I.285
C17H19NO4
M = 301.34 g/mol
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N
H
OMe
MeO
O
H
HMeOMeO
1H NMR (CDCl3, 400 MHz):
I.292
C20H27NO5
M = 361.44 g/mol
13C NMR (CDCl3, 101 MHz):
N
H
OMe
MeO
O
H
HMeOMeO
I.292
C20H27NO5
M = 361.44 g/mol
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N
OMe
MeO
O
H
HMeOMeO
1H NMR (CDCl3, 400 MHz):
I.293
C21H29NO5
M = 375.47 g/mol
N
OMe
MeO
O
H
HMeOMeO
I.293
C21H29NO5
M = 375.47 g/mol
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N
OMe
MeO
O
H
O H
1H NMR (CDCl3, 400 MHz):
I.290
C19H23NO4
M = 329.40 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
H
O H
I.290
C19H23NO4
M = 329.40 g/mol
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1H NMR (CDCl3, 400 MHz):
N
OMe
MeO
O
H
OH
I.294
C19H25NO4
M = 331.41 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
H
OH
I.294
C19H25NO4
M = 331.41 g/mol
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1H NMR (CDCl3, 400 MHz):
N
OMe
MeO
O
OH
HO
I.300
C20H27NO5
M = 361.44 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
OH
HO
I.300
C20H27NO5
M = 361.44 g/mol
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13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
O
H
HO
I.308
C20H25NO5
M = 359.42 g/mol
N
OMe
MeO
O
O
H
HO
1H NMR (CDCl3, 400 MHz):
I.308
C20H25NO5
M = 359.42 g/mol
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N
OMe
MeO
O
O
H
HO
1H NMR (CDCl3, 400 MHz):
I.310
C20H23NO5
M = 357.41 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
O
H
HO
I.310
C20H23NO5
M = 357.41 g/mol
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N
OMe
MeO
O
O
H
OHO
1H NMR (CDCl3, 400 MHz):
I.309
C20H23NO6
M = 373.41 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
O
H
OHO
I.309
C20H23NO6
M = 373.41 g/mol
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N
OMe
MeO
O
O
H
NCO
1H NMR (CDCl3, 400 MHz):
I.311
C20H22N2O5
M = 370.41 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
O
H
NCO
I.311
C20H22N2O5
M = 370.41 g/mol
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N
OMe
MeO
O
O
H
NH
OMe
O
1H NMR (CDCl3, 400 MHz):
I.312
C21H26N2O6
M = 402.45 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
O
H
NH
OMe
O
I.312
C21H26N2O6
M = 402.45 g/mol
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N
OMe
MeO
O
O
H
CbzHN
1H NMR (CDCl3, 400 MHz):
I.313
C27H30N2O6
M = 478.55 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
O
H
CbzHN
I.313
C27H30N2O6
M = 478.55 g/mol
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N
OMe
MeO
O
HN O
O
1H NMR (CDCl3, 400 MHz):
I.329
C20H22N2O5
M = 370.41 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
HN O
O
I.329
C20H22N2O5
M = 370.41 g/mol
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N
OMe
MeO
O
BocN O
O
1H NMR (CDCl3, 400 MHz):
I.330
 C25H30N2O7
M = 470.52 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
BocN O
O
I.330
 C25H30N2O7
M = 470.52 g/mol
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N
OMe
MeO
BocHN
OH
O
1H NMR (CDCl3, 400 MHz):
I.331
C24H32N2O6
M = 444.53 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
BocHN
OH
O
I.331
C24H32N2O6
M = 444.53 g/mol
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N
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MeO
OBocHN
O
H
1H NMR (CDCl3, 400 MHz):
I.332
 C24H30N2O6
M = 442.51 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
OBocHN
O
H
I.332
 C24H30N2O6
M = 442.51 g/mol
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OMe
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HO
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O
I
1H NMR (CDCl3, 400 MHz):
I.342
C20H21IN2O6
M = 512.30 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
HO
HN O
O
I
I.342
C20H21IN2O6
M = 512.30 g/mol
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N
OMe
MeO
OMe
OBocHN
O
1H NMR (CDCl3, 400 MHz):
I.343
C25H32N2O7
M = 472.54 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
OMe
OBocHN
O
I.343
C25H32N2O7
M = 472.54 g/mol
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N
OMe
MeO
O
H
OBocHN
O Br
1H NMR (CDCl3, 400 MHz):
I.346
C24H29BrN2O7
M = 537.41 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
H
OBocHN
O Br
I.346
C24H29BrN2O7
M = 537.41 g/mol
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N
OMe
MeO
O
H
OBocHN
O
1H NMR (CDCl3, 400 MHz):
I.355
C24H30N2O7
M = 458.51 g/mol
13C NMR (CDCl3, 101 MHz):
N
OMe
MeO
O
H
OBocHN
O
I.355
C24H30N2O7
M = 458.51 g/mol
APPENDIX 
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9.3 NMR spectra of chapter II 
  
APPENDIX 
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1H NMR (CDCl3, 400 MHz):
O
OH
HO
O
O
Ph
SPh
II.19
C19H20O5S
M = 360.42 g/mol
13C NMR (CDCl3, 101 MHz):
II.19
C19H20O5S
M = 360.42 g/mol
O
OH
HO
O
O
Ph
SPh
APPENDIX 
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1H NMR (CDCl3, 400 MHz):
O
OBn
BnO
O
O
Ph
SPh
II.20
C33H32O5S
M = 540.67 g/mol
13C NMR (CDCl3, 101 MHz):
O
OBn
BnO
O
O
Ph
SPh
II.20
C33H32O5S
M = 540.67 g/mol
APPENDIX 
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1H NMR (CDCl3, 400 MHz):
O
BnO
BnO
O
O
Ph
OH
II.21
C27H28O6
M = 448.52 g/mol
13C NMR (CDCl3, 101 MHz):
O
BnO
BnO
O
O
Ph
OH
II.21
C27H28O6
M = 448.52 g/mol
APPENDIX 
 
 320 
 
 
 
 
1H NMR (CDCl3, 400 MHz):
O
BnO
BnO
O
O
Ph
O NH
CCl3
II.15
C29H28Cl3NO6
M = 592.89 g/mol
13C NMR (CDCl3, 101 MHz):
O
BnO
BnO
O
O
Ph
O NH
CCl3
II.15
C29H28Cl3NO6
M = 592.89 g/mol
APPENDIX 
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C14H29
BocHN
OH
TrO
OH
II.22
C42H61NO5
M = 659.95 g/mol
1H NMR (CDCl3, 400 MHz):
13C NMR (CDCl3, 101 MHz):
C14H29
BocHN
OH
TrO
OH
II.22
C42H61NO5
M = 659.95 g/mol
APPENDIX 
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C14H29
BocHN
OBz
TrO
OBz
II.23
C56H69NO7
M = 868.17 g/mol
1H NMR (CDCl3, 400 MHz):
13C NMR (CDCl3, 101 MHz):
C14H29
BocHN
OBz
TrO
OBz
II.23
C56H69NO7
M = 868.17 g/mol
APPENDIX 
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C14H29
BocHN
OBz
HO
OBz
1H NMR (CDCl3, 400 MHz):
II.16
C37H55NO7
M = 625.85 g/mol
13C NMR (CDCl3, 101 MHz):
C14H29
BocHN
OBz
HO
OBz
II.16
C37H55NO7
M = 625.85 g/mol
APPENDIX 
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O
BnO
BnO
O
O
Ph
O
C14H29
NHBoc
OBz
OBz
1H NMR (CDCl3, 400 MHz):
II.14
C64H81NO12
M = 1056.35 g/mol
13C NMR (CDCl3, 101 MHz):
O
BnO
BnO
O
O
Ph
O
C14H29
NHBoc
OBz
OBz
II.14
C64H81NO12
M = 1056.35 g/mol
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O
BnO
BnO
O
O
Ph
O
C14H29
NHBoc
OBz
OBz
II.14
C64H81NO12
M = 1056.35 g/mol
1H-13C HSQC (CDCl3):
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O
AcO
AcO
AcO OAc
O
C14H29
NHBoc
OBz
OBz
1H NMR (acetone-d6, 400 MHz):
II.13
C51H73NO16
M = 956.14 g/mol
13C NMR (acetone-d6, 101 MHz):
O
AcO
AcO
AcO OAc
O
C14H29
NHBoc
OBz
OBz
II.13
C51H73NO16
M = 956.14 g/mol
APPENDIX 
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1H-13C HSQC (acetone-d6, 400 MHz):
O
AcO
AcO
AcO OAc
O
C14H29
NHBoc
OBz
OBz
II.13
C51H73NO16
M = 956.14 g/mol
APPENDIX 
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1H NMR (CDCl3, 400 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O
N
N
C7H15
II.46
C66H87N3O15
M = 1162.43 g/mol
13C NMR (CDCl3, 101 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O
N
N
C7H15
II.46
C66H87N3O15
M = 1162.43 g/mol
APPENDIX 
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1H-13C HSQC (CDCl3, 400 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O
N
N
C7H15
II.46
C66H87N3O15
M = 1162.43 g/mol
APPENDIX 
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O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C7H15
1H NMR (pyridine-d5, 800 MHz):
α-GACe-1 (II.25)
C44H71N3O9
M = 786.06 g/mol
13C NMR (pyridine-d5, 200 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C7H15
α-GACe-1 (II.25)
C44H71N3O9
M = 786.06 g/mol
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1H-13C HSQC (pyridine-d5, 800 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C7H15
α-GACe-1 (II.25)
C44H71N3O9
M = 786.06 g/mol
APPENDIX 
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1H NMR (CDCl3, 400 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O N
N
C5H11
II.47
C66H87N3O15
M = 1162.43 g/mol
13C NMR (CDCl3, 101 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O N
N
C5H11
II.47
C66H87N3O15
M = 1162.43 g/mol
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1H-13C HSQC (CDCl3, 400 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O N
N
C5H11
II.47
C66H87N3O15
M = 1162.43 g/mol
APPENDIX 
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O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O N
N
C5H11
1H NMR (CD3OD, 800 MHz):
α-GACe-3 (II.26)
C44H71N3O9
M = 786.06 g/mol
13C NMR (CD3OD, 200 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O N
N
C5H11
α-GACe-3 (II.26)
C44H71N3O9
M = 786.06 g/mol
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1H-13C HSQC (CD3OD, 800 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O N
N
C5H11
α-GACe-3 (II.26)
C44H71N3O9
M = 786.06 g/mol
APPENDIX 
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O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O
N
N
C4H9
1H NMR (CDCl3, 400 MHz):
II.24
C66H87N3O15
M = 1162.43 g/mol
13C NMR (CDCl3, 101 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O
N
N
C4H9
II.24
C66H87N3O15
M = 1162.43 g/mol
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1H-13C HSQC (CDCl3, 400 MHz):
O
AcO
AcO
AcO
OAc
O
C14H29
HN
OBz
OBz
O
N
N
C4H9
II.24
C66H87N3O15
M = 1162.43 g/mol
APPENDIX 
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O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C4H9
1H NMR (CD3OD, 800 MHz):
α-GACe-4 (II.12)
C44H71N3O9
M = 786.06 g/mol
13C NMR (CD3OD, 200 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C4H9
α-GACe-4 (II.12)
C44H71N3O9
M = 786.06 g/mol
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1H-13C HSQC (CD3OD, 800 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C4H9
α-GACe-4 (II.12)
C44H71N3O9
M = 786.06 g/mol
APPENDIX 
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1H NMR (CD3OD, 800 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C4H9Cl
Cl
Cl
Cl
α-GRACe-4 (II.27)
C44H67Cl4N3O9
M = 923.83 g/mol
13C NMR (CD3OD, 200 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C4H9Cl
Cl
Cl
Cl
α-GRACe-4 (II.27)
C44H67Cl4N3O9
M = 923.83 g/mol
APPENDIX 
341  
 
 
 
 
1H-13C HSQC (CD3OD, 800 MHz):
O
HO
HO
HO
OH
O
C14H29
HN
OH
OH
O
N
N
C4H9Cl
Cl
Cl
Cl
α-GRACe-4 (II.27)
C44H67Cl4N3O9
M = 923.83 g/mol
APPENDIX 
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O
BnO
BnO
BnO
F
O
C14H29
NHBoc
OBz
OBz
II.29
C64H82FNO11
M = 1060.35 g/mol
1H NMR (CDCl3, 599 MHz):
13C NMR (CDCl3, 151 MHz):
O
BnO
BnO
BnO
F
O
C14H29
NHBoc
OBz
OBz
II.29
C64H82FNO11
M = 1060.35 g/mol
APPENDIX 
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19F NMR (CDCl3, 377 MHz):
O
BnO
BnO
BnO
F
O
C14H29
NHBoc
OBz
OBz
II.29
C64H82FNO11
M = 1060.35 g/mol
1H-13C HSQC (CDCl3, 599 MHz):
O
BnO
BnO
BnO
F
O
C14H29
NHBoc
OBz
OBz
II.29
C64H82FNO11
M = 1060.35 g/mol
APPENDIX 
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1H NMR (CDCl3, 400 MHz):
O
AcO
AcO
AcO F
O
C14H29
NHBoc
OBz
OBz
II.30
C49H70FNO14
M = 916.09 g/mol
13C NMR (CDCl3, 100 MHz):
O
AcO
AcO
AcO F
O
C14H29
NHBoc
OBz
OBz
II.30
C49H70FNO14
M = 916.09 g/mol
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19F NMR (CDCl3, 377 MHz):
O
AcO
AcO
AcO F
O
C14H29
NHBoc
OBz
OBz
II.30
C49H70FNO14
M = 916.09 g/mol
1H-13C HSQC (CDCl3, 400 MHz):
O
AcO
AcO
AcO F
O
C14H29
NHBoc
OBz
OBz
II.30
C49H70FNO14
M = 916.09 g/mol
APPENDIX 
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O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C7H15
1H NMR (CDCl3, 800 MHz):
II.49
C64H84FN3O13
M = 1122.38 g/mol
13C NMR (CDCl3, 200 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C7H15
II.49
C64H84FN3O13
M = 1122.38 g/mol
APPENDIX 
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19F NMR (CDCl3, 377 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C7H15
II.49
C64H84FN3O13
M = 1122.38 g/mol
1H-13C HSQC (CDCl3, 800 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C7H15
II.49
C64H84FN3O13
M = 1122.38 g/mol
APPENDIX 
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O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C7H15
1H NMR (CD3OD, 800 MHz):
α-6F-GACe-1 (II.33)
C44H70FN3O8
M = 788.06 g/mol
13C NMR (CD3OD, 200 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C7H15
α-6F-GACe-1 (II.33)
C44H70FN3O8
M = 788.06 g/mol
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19F NMR (CD3OD, 377 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C7H15
α-6F-GACe-1 (II.33)
C44H70FN3O8
M = 788.06 g/mol
1H-13C HSQC (CD3OD, 800 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C7H15
α-6F-GACe-1 (II.33)
C44H70FN3O8
M = 788.06 g/mol
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1H NMR (CDCl3, 599 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9
II.31
C64H84FN3O13
M = 1122.38 g/mol
13C NMR (CDCl3, 200 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9
II.31
C64H84FN3O13
M = 1122.38 g/mol
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19F NMR (CDCl3, 377 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9
II.31
C64H84FN3O13
M = 1122.38 g/mol
1H-13C HSQC (CDCl3,599 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9
II.31
C64H84FN3O13
M = 1122.38 g/mol
APPENDIX 
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1H NMR (CD3OD, 800 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9
α-6F-GACe-4 (II.32)
C44H70FN3O8
M = 788.06 g/mol
13C NMR (CD3OD, 200 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9
α-6F-GACe-4 (II.32)
C44H70FN3O8
M = 788.06 g/mol
APPENDIX 
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19F NMR (CD3OD, 377 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9
α-6F-GACe-4 (II.32)
C44H70FN3O8
M = 788.06 g/mol
1H-13C HSQC (CD3OD, 800 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9
α-6F-GACe-4 (II.32)
C44H70FN3O8
M = 788.06 g/mol
APPENDIX 
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O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9Cl
Cl
Cl
Cl
1H NMR (CDCl3, 800 MHz):
II.50
C64H80Cl4FN3O13
M = 1260.15 g/mol
13C NMR (CDCl3, 200 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9Cl
Cl
Cl
Cl
II.50
C64H80Cl4FN3O13
M = 1260.15 g/mol
APPENDIX 
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19F NMR (CDCl3, 377 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9Cl
Cl
Cl
Cl
II.50
C64H80Cl4FN3O13
M = 1260.15 g/mol
1H-13C HSQC (CDCl3 800 MHz):
O
AcO
AcO
AcO
F
O
C14H29
HN
OBz
OBz
O
N
N
C4H9Cl
Cl
Cl
Cl
II.50
C64H80Cl4FN3O13
M = 1260.15 g/mol
APPENDIX 
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1H NMR (CD3OD, 800 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9Cl
Cl
Cl
Cl
α-6F-GRACe-4 (II.34)
C44H66Cl4FN3O8
M = 925.82 g/mol
13C NMR (CD3OD, 200 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9Cl
Cl
Cl
Cl
α-6F-GRACe-4 (II.34)
C44H66Cl4FN3O8
M = 925.82 g/mol
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19F NMR (CD3OD, 377 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9Cl
Cl
Cl
Cl
α-6F-GRACe-4 (II.34)
C44H66Cl4FN3O8
M = 925.82 g/mol
1H-13C HSQC (CD3OD, 800 MHz):
O
HO
HO
HO
F
O
C14H29
HN
OH
OH
O
N
N
C4H9Cl
Cl
Cl
Cl
α-6F-GRACe-4 (II.34)
C44H66Cl4FN3O8
M = 925.82 g/mol
APPENDIX 
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HO
HN
O
OH
OH
N
N
1H NMR (CDCl3, 400 MHz):
PACe-1 (II.35)
 C38H61N3O4
M = 623.92 g/mol
13C NMR (CDCl3, 101 MHz):
HO
HN
O
OH
OH
N
N
PACe-1 (II.35)
 C38H61N3O4
M = 623.92 g/mol
APPENDIX 
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1H NMR (CDCl3, 400 MHz):
N3
OH
HO C13H27
II.40
C18H35N3O2
M = 325.50 g/mol
13C NMR (CDCl3, 101 MHz):
N3
OH
HO C13H27
II.40
C18H35N3O2
M = 325.50 g/mol
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1H NMR (CD3CN, 400 MHz):
N3
OH
TrO C13H27
II.40
C37H49N3O2
M = 567.82 g/mol
13C NMR (CD3CN, 101 MHz):
N3
OH
TrO C13H27
II.40
C37H49N3O2
M = 567.82 g/mol
APPENDIX 
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13C NMR (CDCl3, 101 MHz):
N3
OBz
TrO C13H27
II.42
C44H53N3O3
M = 671.93 g/mol
N3
OBz
TrO C13H27
1H NMR (CDCl3, 400 MHz):
II.42
C44H53N3O3
M = 671.93 g/mol
APPENDIX 
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13C NMR (CDCl3, 101 MHz):
N3
OBz
HO C13H27
II.43
C25H39N3O3
M = 429.61 g/mol
1H NMR (CDCl3, 400 MHz):
N3
OBz
HO C13H27
II.43
C25H39N3O3
M = 429.61 g/mol
APPENDIX 
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C13H27O
N3
OBz
O
OAc
AcO
AcO
AcO
1H NMR (CDCl3, 600 MHz):
II.44
C39H57N3O12
M = 759.89 g/mol
13C NMR (CDCl3, 151 MHz):
C13H27O
N3
OBz
O
OAc
AcO
AcO
AcO
II.44
C39H57N3O12
M = 759.89 g/mol
APPENDIX 
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1H-13C HSQC (CDCl3, 600 MHz):
C13H27O
N3
OBz
O
OAc
AcO
AcO
AcO
II.44
C39H57N3O12
M = 759.89 g/mol
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C13H27O
HN
OBz
O
OAc
AcO
OAc
AcO
O N N
C4H9
1H NMR (CDCl3, 600 MHz):
II.45
C59H81N3O13
M = 1040.31 g/mol
13C NMR (CDCl3, 151 MHz):
C13H27O
HN
OBz
O
OAc
AcO
OAc
AcO
O N N
C4H9
II.45
C59H81N3O13
M = 1040.31 g/mol
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1H-13C HSQC (CDCl3, 600 MHz):
C13H27O
HN
OBz
O
OAc
AcO
OAc
AcO
O N N
C4H9
II.45
C59H81N3O13
M = 1040.31 g/mol
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C13H27O
HN
OH
O
OH
HO
OH
HO
O N N
C3H7
1H NMR (CDCl3, 800 MHz):
β-GACe-4 (II.36)
C43H67N3O8
M = 754.02 g/mol
13C NMR (CDCl3, 200 MHz):
C13H27O
HN
OH
O
OH
HO
OH
HO
O N N
C3H7
β-GACe-4 (II.36)
C43H67N3O8
M = 754.02 g/mol
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1H-13C HSQC (CDCl3, 800 MHz):
C13H27O
HN
OH
O
OH
HO
OH
HO
O N N
C3H7
β-GACe-4 (II.36)
C43H67N3O8
M = 754.02 g/mol
APPENDIX 
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9.4 Chiral HPLC data 
Chiral HPLC of racemic α-allylcyclohexanone I.227  
 
  
 5/12/2017 2:40:10 PM  Page 1 / 1 
 C:\LabSolutions\ERC Data\Nina\NV54-rac_2-5%iPrOH-hept_IB-daicel2.lcd 
Analysis Report
Sample Name : NV54-rac_2-5%iPrOH-hept_IB-daicel
Sample ID : 1
Data Filename : NV54-rac_2-5%iPrOH-hept_IB-daicel2.lcd
Method Filename : 5%iProH-Hept.lcm
Batch Filename : 
Vial # : 1-1 Sample Type : Unknown
Injection Volume : 20 uL
Date Acquired : 11.11.2015 16:01:55 Acquired by : System Administrator
Date Processed : 11.11.2015 16:31:42 Processed by : System Administrator
 
<Chromatogram>
min
mAU
0 5 10 15 20 25
0
100
200
300
400
PDA Multi 3 213nm,4nm
 1
0.
97
3 
 1
2.
42
8 
<Peak Table>
Detector A Channel 1
Peak#
Total
Ret. Time Area Height Conc. Unit Mark Name
PDA Ch3 213nm
Peak#
 1 
 2 
Total
Ret. Time
 10.973 
 12.428 
Area
 12688725 
 12787837 
 25476562 
Height
 445555 
 425553 
 871108 
Conc.
 49.805 
 50.195 
Unit
  
  
Mark
     
     
Name
  
  
<Sample Information>
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Example of a chiral HPLC of α-allylcyclohexanone I.227 synthesized with chiral (S ,S)-
DACH-Phenyl Trost ligand (I.235) 
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 C:\LabSolutions\ERC Data\Nina\NV56A-S-S-DACH_2-5%iPrOH-hept_IB-daicel1.lcd 
Analysis Report
Sample Name : NV56A-S-S-DACH_2-5%iPrOH-hept_IB-daicel
Sample ID : 1
Data Filename : NV56A-S-S-DACH_2-5%iPrOH-hept_IB-daicel1.lcd
Method Filename : 5%iProH-Hept.lcm
Batch Filename : 
Vial # : 1-1 Sample Type : Unknown
Injection Volume : 20 uL
Date Acquired : 11.11.2015 16:34:04 Acquired by : System Administrator
Date Processed : 11.11.2015 16:57:53 Processed by : System Administrator
 
<Chromatogram>
min
mAU
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5
0
100
200
300
400
500
PDA Multi 3 213nm,4nm
 1
0.
97
7 
 1
2.
44
2 
<Peak Table>
Detector A Channel 1
Peak#
Total
Ret. Time Area Height Conc. Unit Mark Name
PDA Ch3 213nm
Peak#
 1 
 2 
Total
Ret. Time
 10.977 
 12.442 
Area
 15714567 
 5482158 
 21196725 
Height
 540261 
 183836 
 724096 
Conc.
 74.137 
 25.863 
Unit
  
  
Mark
     
  V  
Name
  
  
<Sample Information>
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Chiral HPLC of (R)−I.227 synthesized with chiral (S ,S)-DACH-Phenyl Trost ligand (I.235) 
 
 
 5/12/2017 2:32:27 PM  Page 1 / 1 
 C:\LabSolutions\ERC Data\Nina\NVI-236_E1_2-5%iPrOH-hept_IB-daicel1.lcd 
Analysis Report
Sample Name : NVI-236_E1_2-5%iPrOH-hept_IB-daicel
Sample ID : 1
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